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Development of effective and affordable HIV vaccines is one of the best and cost-effective strategies for 
controlling the HIV epidemic and a top priority in endemic areas. Successful future candidate HIV vaccines 
are expected to elicit effective antibody and T cell-mediated responses. This is envisaged to be attained 
through induction of potent T cell-mediated immune responses to control viral replication in the tissues and 
disease progression as well as a durable antibody immune response which comprises of broadly 
neutralizing antibodies to block virus entry at the mucosal sites. Both types of immune responses are 
influenced by a T helper cell type 1 (Th1) immune response. In developing worlds such as Sub-Saharan 
Africa co-infections of HIV and schistosomiasis are common. Helminth infections such as schistosomiasis 
induce strong Th2 biased immune responses that have been reported to alter HBV, BCG, Tetanus toxoid 
and some candidate HIV vaccine-specific immune responses. Because Th1 and Th2 are almost mutually 
exclusive, it is suggested that, in the presence of chronic helminthic infections, Th1 responses elicited by 
HIV vaccine may be attenuated, hence, reduce vaccine efficiency. On the other hand, vaccination with an 
effective HIV vaccine might shift the immune bias towards a Th1 response, resulting in worsening of the 
helminth-associated pathology, thus, making the vaccine unsafe to the recipients.  
 
This study aimed at investigating if chronic helminth infection (Schistosoma mansoni: Sm) has a negative 
impact on the immunogenicity of HIV vaccine candidates (SAAV DNA-C2, SAAVI MVA-C, and Env gp140 
protein) previously shown to induce cellular, mixed and antibody immune responses in mice. The objectives 
of this study were to (i) infect mice with live Schistosoma mansoni infection in order to induce a 
predominantly Th2 immune response in a mouse model; (ii) evaluate if helminth-induced Th2 immune 
biasing negatively affects responses to candidate HIV vaccines; (iii) evaluate the ability of antihelminthic 
chemotherapy in restoring normal responses to HIV vaccines in helminth infected mice; (iv) evaluated if 
HIV vaccine that predominantly induces strong cellular immune responses result in worsening of the 
helminth-associated pathology and (v) evaluate if helminth eggs in the absence of live helminth infection 
drives a Th2-dominant response that can affect HIV vaccine responses.  
 
The BALB/c mouse model has been used extensively at the University of Cape Town for studying the Sm-
associated immunology as well as for initial evaluation of candidate HIV vaccines. Female BALB/c mice 
were either chronically infected with Sm cercariae or inoculated with Sm eggs (SmE) before being 
subsequently vaccinated twice, 4 weeks apart with three vaccination regimes that elicit cellular (SAAVI 
DNA-C2 prime + MVA-C boost denoted: DNA+MVA), antibody (gp140 Env protein) and mixed cellular and 
antibody (SAAVI MVA-C prime + gp140 Env protein boost denoted: MVA+gp140) responses. Some groups 
of mice infected with live Sm were treated twice with praziquantel (PZQ) prior to vaccination. Spleens, blood 
and livers were harvested for analysis of vaccine-specific T cell, antibody responses and histological studies 




Our findings demonstrated that in a mouse model, chronic Sm-infection induces a predominantly Th2 
immune biased response marked with elevated parasite-specific IL-4; IL-6 and IL-10 as well as elevated 
total IgG1 and IgM, while resulting in decreased Th1 markers. Furthermore, chronic infection significantly 
inhibited cellular responses to the MVA+gp140 vaccine regimen shown by IFN-γ and IL-2 ELISpot; CBA 
and ICS staining. Similarly, in DNA+MVA vaccinated mice, a significant reduction in vaccine-specific 
responses was observed in Sm-infected groups compared to uninfected vaccinated groups shown by IFN-
γ and IL-2 ELISpot; CBA and ICS against HIV immunogens. antihelminthic treatment with PZQ resulted in 
the partial restoration of Th1-Th2 balance in the Sm-infected hosts, with the levels of vaccine-induced IFN-
γ; TNF-α and IL-2 being partially restored despite the presence of elevated Th2 cytokines after treatment 
with PZQ. A significant overall decrease in Env gp140 specific IgG, IgG1, IgG2a and IgG2b antibody 
responses was observed in the Sm-infected mice vaccinated with gp140 or MVA+gp140 vaccine regimen 
compared to uninfected vaccinated controls. Surprisingly, antihelminthic treatment did not restore vaccine-
induced antibody responses. Our histology data showed that DNA+MVA vaccinated mice develop 
increased liver pathology during chronic schistosomiasis compared to unvaccinated Sm-infected groups 
shown by larger livers; spleen and enlarged granuloma formation. However, no significant difference in 
collagen content (a marker of fibrosis) measured by hydroxyproline assay in both vaccinated and 
unvaccinated infected groups was observed. Our findings further demonstrated that in a mouse model, 
inoculation with SmE also induces a predominantly Th2 immune biased response marked with elevated 
parasite-specific IL-4; IL-6 and IL-10 while resulting in decreased Th1 markers. No significant impact on 
cellular responses evaluated by ELISpot and CBA were observed. However, gp140 specific IgG, IgG1 
IgG2a and IgG2b antibody responses were significantly reduced in groups challenged with SmE.  
 
Overall, these findings show that chronic helminthiasis in the mouse model induces a strong Th2 biasing 
which is associated with attenuation of both T cell and antibody response to HIV vaccines. Elimination of 
helminths by chemotherapy may partially restore T cell responses, but not necessarily antibody responses. 
These findings further suggest that vaccinating helminth infected individuals with HIV vaccines that induce 
strong cellular responses may increase the pathology induced by the parasites, rendering the vaccine 
unsafe in helminth endemic areas. Furthermore, this study suggested that in the absence of an active 
chronic Sm-infection, SmE left trapped in the tissues following antihelminthic treatment, may continue to 
induce strong Th2 responses which are capable of downregulating vaccine-specific responses, especially 
the antibody-mediated responses. This study strongly recommends that development of HIV vaccines 










CHAPTER 1  
1. BACKGROUND INFORMATION AND LITERATURE REVIEW 
1.1. Global burden of HIV/AIDS 
The high prevalence of human immunodeficiency virus (HIV) infection continues to pose a global health 
problem. In 2015, the joint United Nations Program on HIV/AIDS (UNAIDS) and the World Health 
Organization (WHO) published data showing that there were an estimated 36.7 million people living with 
HIV/AIDS globally, end of 2015 (WHO, 2015, UNAIDS, 2016). Sub-Saharan Africa (SSA) remains the 
region most heavily affected by HIV and accounts for more than two-thirds (about 25.8 million) of infections 
worldwide. In addition, the UNAIDS reported that 70% of the 1.5 million new HIV infections worldwide 
occurred in SSA (UNAIDS, 2015). Furthermore, South Africa has the highest number of HIV-positive people 
in the world; with an estimated 7.0 million people living with HIV (UNAIDS, 2016) (Fig 1.1). Only 37% of 
HIV-infected individuals in sub-Saharan Africa are receiving life-saving antiretroviral therapy (ART) 
(UNAIDS, 2014). Because of the major disproportionate burden of disease inflicted by HIV in SSA, there is 
substantial potential for improvement of HIV prevention and diagnosis. Disease management could be 
further optimized. 
 
Figure 1.1: Adult HIV prevalence: adapted from Kaiser-Family Foundation, based on UNAIDS, 
AIDS information.  Accessed on 28 July 2016: http://kff.org/global-health-policy/fact-sheet/the-global-




1.2. Background on HIV 
1.2.1. The origin and history of HIV 
Human Immunodeficiency Virus (HIV) is an RNA virus belonging to the Retroviridae family, subfamily 
Lentiviridae (Nye and Parkin, 2003). It was first isolated in 1983, (Barre-Sinoussi et al., 1983) and soon 
discovered to be associated with weakening of the immune system leading to what today is termed the 
acquired immunodeficiency syndrome (AIDS) (Gallo et al., 1984, Groopman, 1984, Walgate, 1986). The 
origin of HIV is believed to be the Congo River area in central Africa and was transfected from primates to 
humans during the late 19th or early 20th century (Keele et al., 2006, Worobey et al., 2008). The transmission 
was most likely through hunting and handling uncooked meat infected with simian immunodeficiency 
viruses (SIV) (Peeters et al., 2002). HIV type 1 (HIV-1) and type 2 (HIV-2) are the two known lineages of 
HIV with the former being distributed worldwide and the latter found primarily in West Africa (Romieu et al., 
1990, Marlink et al., 1994, Popper et al., 1999, Sharp and Hahn, 2011). HIV-1, comprising of groups M, N, 
O, and P, is by far the most virulent of the two lineages with group M being responsible for the current global 
HIV pandemic (Robertson et al., 2000, Hemelaar et al., 2011). Group M is further subdivided into ten 
recognised phylogenetic subtypes (A, B, C, D, F, G, H, J, K, and L) (Robertson et al., 2000, Buonaguro et 
al., 2007, Hemelaar et al., 2011). HIV-2 is made up of groups A to H and unlike HIV-1; it is closely related 
to the SIV with cases reported mostly in West Africa (Franchini and Bosch, 1989, Marlink et al., 1994, 
Popper et al., 1999, de Silva et al., 2008, Sharp and Hahn, 2011, Campbell-Yesufu and Gandhi, 2011). 
Although the degree of virulence may be less for HIV-2 (Rowland-Jones and Whittle, 2007, Campbell-
Yesufu and Gandhi, 2011, Thiébaut et al., 2011), both HIV-1 and HIV-2 infects helper CD4 T cells resulting 
in their gradual decline and consequent immune-suppression, thus associated with AIDS (Clavel et al., 
1987, Campbell-Yesufu and Gandhi, 2011, Reeves and Doms, 2002). 
 
1.2.2. HIV-1 structure and genomic organization 
The HIV-1 virion is on average ~120nm wide and is roughly spherical in structure. It comprises of the 
external envelope-glycoprotein complex made up of the external surface membrane (SU, also called gp120) 
and transmembrane part (TM, also called gp41) of the envelope (Env), the inner membrane (matrix) and 
the core capsid (CA, also called p24). The core CA contains viral genomic RNA, reverse transcriptase (RT, 
also called p18), integrase (p32), protease (PR) (p11) and other enzymes needed for the replication cycle 
(Fig 1.2 B) (Gelderblom, 1997, Rubbert A, 2011, Foley et al., 2013).   
The HIV-1 genome consists of three structural genes namely; gag, encoding for the matrix enclosing a 
nucleocapsid (p24); pol, encoding enzymes responsible for PR, RT, and integration; and env, encoding 
Env-glycoproteins of the viral membrane (Fig 1.2 A). Six other genes (trans-activator of transcription (tat), 




encode proteins responsible for host cell regulation, immune evasion, and viral gene expression. Though 
Nef, vif, vpr and vpu were classified as accessory genes in the past, as they were not absolutely required 
for replication in vitro, their proteins have been studied and characterized in more detail over the past few 
years (Girard et al., 2011). The accessory genes nef, tat, and rev are all produced early in the viral 
replication cycle (Shum et al., 2013, Christian, 2015, Altfeld; et al., 2015).  
 
 
Figure 1.2: (A) HIV-1 genome and (B) HIV-1 virion and potential antiviral targets. Taken from 









1.2.3. HIV-1 replication cycle 
HIV-1 replication cycle occurs in 7 major steps. First, the transmembrane protein gp120 on the surface of 
the virus interacts with the CD4+ of the T helper cell as well as the monocytes. With a help of co-receptor 
(CXCR4 and CCR5) fusion of the plasma membrane with the virus capsid to the host cell surface occurs. 
Then the viral genome (HIV RNA, reverse transcriptase, integrase and other viral proteins) along with the 
enzyme machinery enter the cell leaving the coat outside. After entering the cell, reverse transcriptase 
begins to make viral RNA-cDNA hybrid from the information of ssRNA template, which is turned into viral 
DNA. The viral DNA is then transported to the nucleus and integrates into the host DNA by 
the integrase enzyme forming a provirus stage. The viral transcription factors now stimulate the host cell 
transcription and make ssRNA followed by the translation to make necessary proteins to make new viral 
RNA and proteins. The new viral RNA and proteins assemble with other proteins including gp41 and gp120, 
which moves to the cell surface and buds out forming viral coat and a new immature HIV. The virus finally 
matures by protease releasing individual HIV proteins which will seek healthy cells to infect to keep the 
infection cycle going (Fig 1.3) (Freed, 2001, Korber et al., 2001, Miyauchi et al., 2009, NIAID, 2012, 





Figure 1.3: HIV replication cycle. Taken from (NIAID, 2012). 
 
1.2.4. HIV-1 infection and pathogenesis 
HIV-1 is mainly spread by heterosexual people, men who have sex with men (MSM); infection among 
injection drug users (IDUs) and mother to child transmission occurring in the form of cell-free or cell-
associated virus via vaginal secretions, semen, rectal sections, or blood (Royce et al., 1997, Shaw and 
Hunter, 2012). However, sexual transmission of HIV-1 remains most common route (Royce et al., 1997, 




After transmission of the HIV-1 virus into a new host, progressive immunodeficiency is established from a 
depletion of T lymphocytes that express a cell surface molecule called CD4 (the main target cells for 
infection by HIV) and from general chronic immune activation brought about by active viral replication, which 
causes cell death (Ho et al., 1995, Berges et al., 2008, Douek et al., 2009, McMichael et al., 2010, Girard 
et al., 2011, Xu et al., 2013). A pathophysiological event within days after primary infection determines the 
course of the disease (Douek et al., 2009). With waning CD4 cell numbers, the adaptive immune system 
collapses, as a result, a specific immunodeficiency emerges, which permits infection with a range of virulent 
diseases and opportunistic infections (those capable of disease in immuno-compromised individuals) 
(Moore and Chaisson, 1996, Okoye and Picker, 2013, Luo et al., 2016). 
 
The first signal of an immune response to HIV-1 is an appearance of an acute phase which is characterized 
by high plasma viral loads in the first few weeks paired with a decline in CD4+ T cells, followed by an 
increase in HIV-specific CD8+ CTLs (Cohen et al., 2011b, Maartens et al., 2014). Continuous loss of CD4+ 
T lymphocytes and systemic immune activation leads to a chronic HIV-1 infection, when untreated, leads 
to disease progression and sustained viral replication (Grossman et al., 2006, Haas et al., 2011). Stages 





Figure 1.4: Clinical HIV-1 Infection: Plasma viraemia (A) and the changes in the CD4 + T-lymphocyte 
compartments (B). Primary infection is characterised by high plasma viraemia (red line, A), low CD4 cells 
(green line, B, and absence of HIV-1 specific antibodies (orange line, B). Plasma viraemia drops as 
cytotoxic CD8+ T-lymphocytes (CTL) develop (blue line, B) and an individual viral-load set point is reached 
during chronic infection. Viral set points differ greatly among individuals (eg, red dotted line, A) and predict 
disease progression. Viral diversity increases throughout the disease (closed circles, A). The risk of 
transmission is highest in the first weeks when viraemia peaks (closed circles, A). GALT=gut-associated 






Symptoms of acute HIV-1 infection arise 2-4 weeks post-transmission, often last 3-4 weeks and resemble 
influenza-like or mononucleosis-like symptoms, which may include fever, headache, sore throat, swollen 
lymph nodes, joint or muscle pain, malaise, rash, and weight loss (Tindall et al., 1988, Daar et al., 2001, 
Hecht et al., 2002, Daar et al., 2008, Hoenigl et al., 2016). During chronic HIV infection, immune dysfunction 
causes some individuals to experience fatigue, weight loss, night sweats, oral lesions (hairy leukoplakia), 
oral and vaginal candidiasis, and symptoms associated with herpesvirus reactivation (Kuritzkes, 2007). In 
addition, muscle wasting, dermatological conditions, neurological complications, and multiple organ 
dysfunctions, including cardiovascular disease, are also observed (Coopman et al., 1993, Nahlen et al., 
1993, Simpson and Tagliati, 1994, Wanke et al., 2000, Kuritzkes, 2007). 
 
There is minimal change in viral load and CD4+ T cell counts at the beginning of the chronic phase of 
infection, however over time, a slow and quasi-steady increase in viral load is in conjunction with a 
progressive and gradual decrease in the CD4+ T cell population (Fig 1.4) (Simon et al., 2006, Coffin and 
Swanstrom, 2013). 
 
In the GALT, the depletion of the CD4+ T cell compartment is maintained during chronic HIV-1 infection 
(Fig 1.4). HIV-1 preferentially infects and causes profound depletion in the Th17 and Th22 CD4+ T cell 
subsets, which defend against microbes and play a role in maintaining the integrity of the gastrointestinal 
(GI) tract mucosal barrier, by preventing microbial translocation from the GI tract to the periphery (Brenchley 
et al., 2008, Raffatellu et al., 2008, Prendergast et al., 2010, Dandekar et al., 2010, Kaul et al., 2011, Kim 
et al., 2012). When these cells are depleted, the guts permeability becomes enhanced, allowing for 
microbial translocation, which in turn leads to increased and sustained systemic immune activation, a 
hallmark of chronic HIV-1 infection (Brenchley et al., 2006a, Raffatellu et al., 2008, Okoye and Picker, 
2013). 
 
Multiple factors that promote the widespread production of pro-inflammatory factors and increased viral 
replication in activated T cells are associated with chronic immune activation (Moir et al., 2011). This cellular 
hyperactivity leads to persistent high T cell, B cell, and NK cell turnover, which further contributes to 
increased immune dysfunction marked by cellular exhaustion, senescence, and limited renewal capacity 
(Mohri et al., 1998, Lempicki et al., 2000, McCune et al., 2000, De Boer et al., 2003, Moir et al., 2011, 
Wherry, 2011). In this regard, chronic systemic immune activation has a poor prognosis for survival and is 
associated with a more rapid progression to AIDS (Giorgi et al., 1999, Hazenberg et al., 2003, Brenchley 
et al., 2006b), the immunosuppression stage that allows infections to surface, which can include oral 
candidiasis, pneumococcus, tuberculosis, and the reactivation of latent herpesviruses, such as herpes 





1.2.5. Immune responses to HIV Infection 
The early stages of HIV infection are characterized by a short-lived symptomatic illness in most cases and 
are associated with high levels of virus replication (Perreau et al., 2013). The source of infection is 
commonly from transmission of a single virus variant (Keele et al., 2008, Perreau et al., 2013). Symptoms 
at this stage are not specific to HIV but typical of an acute viral syndrome which may be followed by wide 
range of illnesses (Tindall et al., 1988, Daar et al., 2001, Hecht et al., 2002, Daar et al., 2008, Hoenigl et 
al., 2016). The symptomatic phase persists for 2–4 weeks at a normal rate of disease progression while 
prolonging in rapid disease progression (Perreau et al., 2013). Once chronic HIV infection is established, 
the outcome of the infection will be affected by hosts genetic,  immunological and virological factors (O'Brien 
and Nelson, 2004).  
 
Ever since the discovery of HIV, the host immune responses to HIV have been extensively studied and the 
immune correlates of protection have been extensively explored (Tomaras and Plotkin, 2017). It is now 
known that the immune system mounts a robust response to HIV infection; however, the immune response 
to HIV differs among infected individuals, with the course of the infection determined by several factors 
including viral fitness or virulence, the host genetic factors such as the association between the different 
HLA alleles (Liu et al., 1996, Carrington and O'Brien, 2003) and CCR-5 mutation (Schmitz et al., 1999) with 
resistance, as well as a predominance of type-1 cytokine production. 
 
The immune responses to virus infection are mainly innate, cellular, and/or humoral responses, however,  
not all contribute to protective immunity (Tomaras and Plotkin, 2017). The first line of immune responses 
to the virus is mediated by innate immunity (Freed and Gale, 2014) encompassed by (i) natural killer cells 
(NK cels), which have been shown to control HIV-1 infection of macrophages through soluble factors and 
cellular contacts in the human decidua in pregnant women, and also playing an important role in viral 
clearance (Quillay et al., 2016, Lam and Lanier, 2017), (ii) plasmacytoid dendritic cells (pDCs), which are 
indirectly impaired by HIV through suppression of IFN-α production induced by TLR-7 agonist (Dhamanage 
et al., 2017). (iii) Cellular restriction factors such as APOBECs and Trim5α (Rehwinkel, 2014, Simon et al., 
2015), SAMHD1 which act by hampering the induction of an efficient immune response directed against 
HIV-1,(iv) myeloid dendritic cells (mDCs), which function as antiviral restriction factors (Herrmann et al., 
2016) as well as inhibitor of HIV-1 reverse transcription in some cell types (Ayinde et al., 2012); and (v) 
antiviral cytokines such as type I interferons, IL-15 and IL-18 (McMichael et al., 2010, Desimmie et al., 
2014, Rustagi and Gale, 2014, Dhamanage et al., 2017). Despite the fact that the innate control of infection 
is important, it is facilitated by inflammation, which also recruits HIV target cells during acute infection, 
impairs CD4+ T cell recovery, and promotes disease progression (Tomalka et al., 2016). 
   
The second line of defence is the adaptive immune response, which is a specialized form of defences 




immune system depends on the generation of a diverse repertoire of antigen receptors on T and B 
lymphocytes and subsequent activation as well as the clonal expansion of infected or activated cells. The 
induction of adaptive immunity not only depends on direct antigen recognition by the antigen receptors but 
also relies on essential signals that are delivered by the innate immune system. This type of immune 
responses is capable of clearing bacterial and viral infection (Schenten and Medzhitov, 2011). However, 
despite the induction of both humoral and cellular immune responses, infection with HIV does not get 
eliminated (Jones and Walker, 2016). Virus-specific CD8+ T cells play a role in the elimination of viruses, 
which occurs by recognition of processed viral proteins (Jones and Walker, 2016). A cascade of activation 
events is initiated by recognition through T cell receptor (TCR) leads to the release of granzymes and 
perforin and killing of the infected cell, which can occur before infectious progeny virions are produced 
(Yang et al., 1997, Voskoboinik et al., 2015). Furthermore, TCR activation leads to the release of a variety 
of effector cytokines including IFN-γ, TNF-α, macrophage inflammatory proteins 1α and 1β (MIP-1α and 
MIP-1β), and RANTES (regulated upon activation, normal T cell expressed and secreted [also known as 
CCL5]), which have antiviral effects (Jones and Walker, 2016). 
A number of studies agree that HIV-specific CD8+ T cells exert potent antiviral effects and have shown that 
the magnitude and rapidity of HIV-specific CD8+ T cell activation inversely correlates with viral load set 
point in a hyper-acute infection (Ndhlovu et al., 2015), thus mediating an antiviral pressure during peak 
viremia (Borrow et al., 1994, Koup et al., 1994). The evidence for an antiviral effect of these cells has been 
demonstrated using In vitro models and showed that the cells are potently capable of inhibiting viral 
replication (Yang et al., 1997, Chen et al., 2009). This further explains why depletion of CD8+ T cells 
following acute infection leads to high-level viremia that decreases as CD8+ T cells reappear (Schmitz et 
al., 1999). Taking together genetic studies, which indicate that HLA class I alleles are associated with 
differences in set-point viremia (Fellay et al., 2007); studies of viral fitness, which suggest that CD8+ T cell-
induced mutations can diminish viral fitness, the conclusion is that CD8+ T cells are capable of potent 
antiviral function and provide a strong rationale for enlisting these responses in eradication strategies such 
as vaccines (Jones and Walker, 2016).  
Another arm of the immune system that mounts during primary HIV infection is the humoral responses to 
HIV through the induction of binding and or neutralising antibodies (Moir and Fauci, 2017). The large 
majority of these antibodies are produced during the first months of natural HIV-1 infection and are generally 
either non-neutralizing or strain-specific neutralizing antibodies (Wei et al., 2003, Richman et al., 2003, 
Gray et al., 2007, Tomaras et al., 2011, Mikell et al., 2011). It is only after 2-4 years after primary infection 
that the emergence of broadly neutralising antibodies (bNabs) occurs, with just about 20% of infected 
individuals developing these antibodies (Doria-Rose et al., 2010, Walker et al., 2010, Gray et al., 2011). 
However, a minority of infected individuals (1–2%)  develop a more potent form of bNabs capable of 
neutralizing a large proportion (>70%) of virus isolates (Noto and Pantaleo, 2017). A small percentage of 




counts, and able to maintain viral replication below 1000 HIV RNA copies/ml for an extended period of time 
in the absence of antiretroviral therapy (ART) (Noel et al., 2016). Such individuals are referred to as long-
term non-progressors (LTNPs) (Sáez‐Cirión and Pancino, 2013). They make up between 2 and 5 % of all 
HIV-seropositive individuals and maintain low levels of viraemia with elevated CD4+ T-cell levels in contrast 
to rapid progressor HIV-1 subjects who quickly develop AIDS in the absence of ART (Noel et al., 2016). 
Furthermore, another group of infected individuals called Elite controllers can suppress HIV infection below 
50 HIV RNA copies/ml in the absence of treatment for an unspecified period of time ranging from months 
to years (Joglekar et al., 2016). However, Elite controllers can undergo immunodeficiency and opportunistic 
infections as a result of CD4+ T-cell depletion (Hunt, 2009).  A better understanding of the mechanisms 
underlying this viral control is important in the development of therapeutic interventions capable of achieving 
HIV-1 remission in other patients (Noel et al., 2016). 
It is unclear whether these bNabs exert any protective effect during HIV chronic infection since HIV-1 is 
capable of escaping antibody responses during natural infection, considering the fact that bNabs only 
appear later on during infection (Noto and Pantaleo, 2017). It is also not clear why bNabs generation is 
delayed during infection (Noto and Pantaleo, 2017). 
Little is known concerning initial responses of B cells during an acute phase. This is due to the fact that it 
is difficult to access patients with acute HIV infection since most do not come to medical attention until the 
acute phase has passed (Moir and Fauci, 2017). During the course of HIV infection, 
hypergammaglobulinemia, which reflects systemic immune-activating effects of HIV on B cell differentiation 
is common as well as defects in memory B cells, which also reflect defects in CD4+ T cell help (Lane et al., 
1983, Buckner et al., 2013). To determine the development and regulation of B cells during early HIV 
diagnosis, it is clinically important to track seroconversion (Fiebig et al., 2003). During a typical viral 
infection, short-lived plasmablasts elicited prior to germinal centre (GC) formation and T cell help is the 
most likely source of this initial antibody response (Fink, 2012). This is also true for HIV, HIV-specific IgM 
in the first week of infection can be detected (Tomaras et al., 2008). Furthermore, an enrichment of IgG3 
antibodies [strongly associated with protection in the RV144 trial (Yates et al., 2014, Chung et al., 2015) 
occur during this time (Yates et al., 2011) and are also thought to derive from GC-independent class 
switching of B cells that have not undergone affinity maturation (Wirths and Lanzavecchia, 2005, Fecteau 
et al., 2006, Budeus et al., 2015). Although these early responses reflect an inadequate T cell help 
response, marked by rapid lymphoid tissue damage in environment where cognate B and T cell interact 
(Levesque et al., 2009), HIV-specific IgG3 antibodies also decline rapidly in early HIV-infected individuals 
(Yates et al., 2011) including in vaccines of the RV144 trial [reviewed in (Haynes, 2015)]. 
The transmembrane glycoprotein gp41 is one of the earliest targets of the antibody response following HIV 
infection (Tomaras et al., 2008). Circulating plasmablasts have been identified as a source of these 




are highest in early HIV infection, despite a large portion of these are not specific for HIV (Buckner et al., 
2013). Nonetheless, HIV-specific antibodies cloned from these cells were shown to recognize gp41 (Liao 
et al., 2011). Epitopes within the membrane proximal region (MPER) of gp41 have been shown to elicit 
bNAbs (Stiegler et al., 2001, Huang et al., 2012). Generally, such antibodies may be very difficult to induce 
following vaccination in normal, non-immunocompromised individuals due to compromise of immune 
tolerance caused by self-reactive antibodies (Verkoczy and Diaz, 2014). Nonetheless, a study by Huang et 
al., showed that potent gp41 MPER-specific neutralizing antibodies can arise in HIV-infected individuals in 
the absence of autoreactivity (Huang et al., 2012). The chronic phase of HIV, triggered mostly in the majority 
of HIV-infected individuals not taking antiretroviral therapy (ART) during the early phase of infection has 
been associated with a broadening of the B-cell response, with a minor percentage of individuals developing 
a response that is both broad and potent (Burton and Mascola, 2015). The forces involved in driving breath 
of B cells of these infected individuals is often referred to as elite neutralizers and have been considered 
as a pathway to the “holy grail” of immunogen design for an effective vaccine (Moir and Fauci, 2017). 
However, elite neutralizers are not particularly elite in their HIV disease status (Doria-Rose et al., 2010) as 
there are few virologic and clinical factors that influence this. This includes increased neutralization breadth 
with high viral load in early infection (Piantadosi et al., 2009, Gray et al., 2011) or later in infection (Doria-
Rose et al., 2010); decline in CD4+ T cells (Gray et al., 2011); HIV subtype and host genotype (Landais et 
al., 2016) and the quality of CD4+ T cell responses against HIV (Ranasinghe et al., 2016). However, CD4+ 
T cell studies suggest that a strong cellular response may be beneficial for humoral immunity in HIV-infected 
individuals.  
 
Apart from bNabs, non-neutralizing (nonNab) against HIV Env viable domain 1 and 2 (V1V2) have been 
associated with modest protection from HIV infection in the RV144 trial (Rerks-Ngarm et al., 2009). The 
outcomes of this trial demonstrated that vaccine-induced IgG antibody responses to the V1V2 region of HIV 
Env inversely correlated with lower risk of HIV infection in the absence of bNabs (Montefiori et al., 2012, 
Tomaras and Plotkin, 2017). Furthermore, V1V2 specific IgG antibodies have been associated with the 
induction of ADCCs, which have been shown to plays a role in SIV control and protection in nonhuman 
primate models (Gómez-Román et al., 2005, Barouch et al., 2012, Smalls-Mantey et al., 2012). ADCC cells 
have been known to occurs when antibody forms a bridge between a target cell bearing foreign antigens 
on its surface and an effector cell expressing Fc receptors, leading to lysis or apoptosis of the target cell 
(Forthal et al., 2001). Like CTL activity, ADCC could eliminate infected cells and thereby reduce viral 
burden. These antibodies have been shown to appear at the same time as CTLs became detectable in 
acutely infected patients (CONNICK et al., 1996). These findings taken all into account suggested that at 
least partial protection observed in the RV144 trial was also due to ADCC-mediated antibodies. However, 
these observations were only in vaccinees of low IgA antibodies to the Env, suggesting that Env specific 





In a number of nonhuman primate (NHP) studies, protection against SIV acquisition in the absence of bNab 
has been reported (Letvin et al., 2011, Barouch et al., 2012, Barouch et al., 2013), thus, further supporting 
the fact that functional vaccine-induced Env-specific antibodies may provide protection against HIV 
acquisition even in the absence of bNab.  
Furthermore, these studies demonstrate that nonNab can result in increased antiviral activity, through 
recognition of virus-infected cells, infectious virion capture and ADCC (Pollara et al., 2014). Taken together, 
studies on natural infections demonstrate that the body is principally capable of controlling virus replication 
through effective CTL and antibody responses. Developing combination therapies that bring together both 
the cellular and humoral arms of adaptive immunity with innate immune mechanisms is of great importance 
in order to understand how to trigger immune responses in healthy individuals, therefore, providing a way 
to control or prevent subsequent HIV infection. 
1.3. Need for HIV-1 vaccine 
The introduction of anti-retroviral drugs and highly active antiretroviral therapy (HAART) brought a 
significant decline in morbidity and mortality (WHO, 2013, HIV/AIDS, 2016), and have been shown to 
prevent HIV transmission (Grant et al., 2010, Cohen et al., 2011a, Baeten et al., 2012). However, the 
persistence of a latent viral reservoir during HIV infection makes it difficult for treatment to eradicate HIV 
infection (Finzi et al., 1999, Siliciano et al., 2003). Thus, a continuous need for ART is inevitable, however, 
the cost is substantial (UNAIDS, 2014, Granich et al., 2015) and may be difficult to sustain (Deeks et al., 
2016). Furthermore, adherence to treatment across different populations is critical, as it affects the efficacy 
and efficiency of biomedical preventive interventions (Doblecki-Lewis et al., 2015). However, the use of 
ARTs for HIV treatment and prevention can be compromised by HIV-1 drug resistance mutations (DRMs), 
especially in resource-limited settings where virological monitoring is not routinely performed as part of 
clinical management (Gupta et al., 2009, Hosseinipour et al., 2009, Sigaloff et al., 2011). High levels of drug 
resistance have been reported in individuals with prolonged first-line ART failure, including complex 
nucleoside reverse transcriptase inhibitor (NRTI) resistance profiles (Marconi et al., 2008, Hosseinipour et 
al., 2009, Wallis et al., 2010, Sigaloff et al., 2011). Also, antiretroviral agents can be responsible for a wide 
range of toxicities that may present anything from negligible to life-threatening side effects (Organization, 
2010). To date, a full spectrum of ARV toxicities observed in adults has also been reported in children as 
well. Thus, the development of an effective HIV vaccine remains one of the best hopes for controlling the 
HIV pandemic and is essential as a more sustainable solution (Cohen and Dolin, 2013, Fauci and Marston, 
2014). Undoubtedly, the ultimate goal for an HIV vaccine would be to elicit sterilizing immunity, thus 





1.3.1. HIV vaccines  
To date, designing a universal effective HIV vaccine remains an exceptionally difficult biomedical challenge. 
Ideally, an effective HIV vaccine is expected to be capable of inducing both potent T cell-mediated immune 
responses as well as a durable humoral immune response through antibody production (Chhatbar et al., 
2011, Haynes and McElrath, 2013, Cohen and Dolin, 2013, McMichael and Koff, 2014). However, there 
are few important factors that make it difficult to develop an effective HIV vaccine. First, there is insufficient 
knowledge of causal mechanisms of protection against HIV infection (Pantaleo and Koup, 2004, Letvin, 
2006, Johnston and Fauci, 2011); second, the extreme diversity between HIV strains and subtypes can 
differ by up to 35% in their envelope (Env) proteins (Korber et al., 2001, Gaschen et al., 2002). To generate 
an efficacious global vaccine, immunogens capable of generating protective innate, cellular, and/or humoral 
responses covering most major strains are required. However, not all responses contribute to protective 
immunity (Tomaras and Plotkin, 2017). Correlates of protection (CoP) for most pathogens is generally 
difficult to determine, but research efforts have contributed knowledge of what constitutes protective 
immunity for many of these infectious pathogens (Tomaras and Plotkin, 2017).    
 
Immunological correlates of protection are immune parameters that measure responses to vaccination that 
predicts vaccine efficacy for a given clinical outcome and are usually complex (Plotkin, 2010, Plotkin, 2013). 
To date, the RV144 vaccine efficacy trial remains the only trial in which correlates of HIV-1 risk involving 
multiple immune responses have been identified. However, these responses are not yet accepted to be 
CoP until they have been confirmed in another vaccine efficacy trial (Tomaras and Plotkin, 2017). 
Nonetheless, follow-up studies for determining if RV144 correlates of HIV risk are protective or not are 
underway. 
 
Currently licenced vaccines induce immune responses that associated with correlates of protection (Plotkin, 
2008, Plotkin, 2010, Thakur et al., 2012, Iwasaki, 2016) (Table 1.1). These immune responses include 
binding antibody responses, functional antibody responses (ie neutralization/pathogen inhibition, 
opsonophagocytosis) and cellular immunity (CD4+ T cell, lymphoproliferation). Nevertheless, prevention of 
infection correlates with the induction of antibodies in most vaccines (Plotkin, 2008, Thakur et al., 2012) 
with exception to BCG, Zoster and Malaria which act through T cell responses or with both reviewed in 






Table 1.1: Types of immune responses associated/correlated with protection/infection risk: Taken from 
(Tomaras and Plotkin, 2017). 
 
Immune response  Vaccine 
Antibody binding Hepatitis A, Hepatitis B, Human Papilloma 
Virus, Measles, Pertussis, Rubella, Varicella, 
Zoster#, HibPolysaccharides/Conjugate, 
Lyme disease, Tick borne encephalitis, 
Pneumococcus#, HIV-1# (not licensed) 
Antibody function Neutralization or Pathogen/Toxin inhibition 
Anthrax, Diphtheria, Influenza, Japanese 
Encephalitis, Measles, Meningococcal, 






Cellular response CD4 T cell, Lymphoproliferation 
Zoster#, BCG 
CD4+ T-Cell polyfunctionality 
HIV-1#  
Categories of identified immune correlates for licensed vaccines, identified correlates of risk for HIV-1 are also shown. 
#Both antibody and cellular correlates, Italics: not licensed vaccines. 
 
This was thought to be the case with initial HIV-1 vaccine approach during the VAX003 and VAX004 clinical 
trial which focused primarily on the generation of neutralizing antibodies (nAb) (Berman et al., 1990, El-
Amad et al., 1995, Berman et al., 1996).  
 
VAX003 and VAX004 were double-blind, randomized trials which used a bivalent vaccine composed of 
rgp120 from subtype B, conducted in injecting drug users (IDU) in Thailand and among men who have sex 
with men (MSM) and women at high risk for heterosexual transmission of HIV-1 in North America and The 
Netherlands respectively (Flynn et al., 2005, Pitisuttithum et al., 2006). Both vaccines did not demonstrate 
protection; however, they showed an association of higher nAb to HIV-1MN, CD4 blocking Ab and antibody-
dependent cell-mediated viral inhibition (ADCVI) and reduced infection rates among vaccine recipients in 
VAX004 (Gilbert et al., 2005, Forthal et al., 2007). Furthermore, these trials also highlighted supported the 
importance of cell-mediated immunity in controlling viral replication in rhesus macaques (RM) (Jin et al., 




2006). This turned attention to the use of T-cell vaccines to induce HIV-specific cellular immune responses 
which were implemented in the STEP and the Phambili vaccine trial.  
 
The STEP and the Phambili trial focused on eliciting HIV-1 gag/pol/nef sub-type B cellular responses aimed 
to reduce viral load in breakthrough infections (Buchbinder et al., 2008, Gray et al., 2014). These vaccine 
induced antigen-specific T-cell responses, however, did not prevent HIV-1 infection and had no effect on 
plasma viral load (Buchbinder et al., 2008). Instead, it was associated with an increased incidence of HIV-
1 acquisition in male recipients who were Ad5 seropositive pre-vaccination or were uncircumcised 
[reviewed in (Gray et al., 2010)]. thus, was stopped after the first interim analysis (Buchbinder et al., 2008).   
 
In 2003, the field was reinvigorated by the optimistic results of the RV144 trial published in 2009, following 
the failures of the Step and Phambili trial. The RV144 trial was a large Phase III double-blinded randomized 
study comprised 16,395 HIV negative participants in a multicenter study with enrolment in Thailand (Rerks-
Ngarm et al., 2009). The trial was a collaborative effort between trial site (Thailand: Thailand Ministry of 
Public Health) and the sponsor (United States: US Army, and National Institute of Allergy and Infectious 
Disease [NIAID]). The trial enrolled Men and women between 18-30 years of age who were at community 
risk for acquiring HIV. In an effort to induce both a cellular and humoral immune response, the vaccine was 
given in a prime-boost vaccination (Lu, 2009) with a recombinant canarypox vector expressing HIV Gag, 
Pol, and Env proteins (ALVAC-HIV) delivered as a prime and the VaxGen recombinant gp120 subtype B 
and E bivalent protein (AIDSVAX B/E®) was given as a boost (Nitayaphan et al., 2004). The vaccination 
regimen included four priming inoculations with ALVAC-HIV at weeks 0, 4, 12 and 24, and two booster 
inoculations with AIDSVAX B/E® at weeks 12 and 24 which took place over 6 months. HIV infections were 
monitored every semester for 3 years. The primary endpoints for the study included prevention of HIV-1 
infection, and upon infection, the impact of the vaccine on HIV-1 viral load (Rerks-Ngarm et al., 2009). 
To date, HVTN 505 trial is the last efficacy trial to be conducted. This was  a randomized, placebo-controlled 
trial of a prime-boost, DNA/rAd5 vaccine consisting of a 6-plasmid DNA vaccine (expressing clade B Gag, 
Pol, and Nef, and Env proteins from clades A, B, and C) with rAd5 vector boost (expressing clade B Gag-
Pol fusion protein and Env glycoproteins from clades A, B, and C) (Hammer et al., 2013). The trial was 
brought prematurely to a stop due to lack of efficacy. Albeit the vaccine-induced both cellular and humoral 
responses, these were not associated with protection (Hammer et al., 2013). To date, none of the 
completed vaccine efficacy trials managed to induce strong bnAb responses. However, CD8+ T cell 
responses in STEP, Phambili and HVTN505 studies was induced, despite not associated with protection. 
Only one trial, RV144 demonstrated efficacy and protection were associated with functional binding 
antibodies such as vaccine-induced IgG antibody binding to the V1V2 of Env and thus inversely correlated 
with associated with of HIV infection but IgA against Env was directly linked to greater risk of infection 
(Rerks-Ngarm et al., 2009, Tomaras and Plotkin, 2017). Despite the V1V2-specific IgG not being broadly 




Tomaras and Plotkin, 2017). When Env-specific IgA levels are low, these ADCCs are suggested to confer 
protection, particularly those belonging to IgG1 and IgG3 subclasses (Montefiori et al., 2012, Tomaras and 
Plotkin, 2017, Pollara et al., 2011). However, efficacy was of a suboptimal magnitude and was not durable. 
 
In summary, the current major goal in HIV vaccine design is to elicit a protective immune response mediated 
primarily by antibodies that are able to recognize a range of diverse strains. Such type of antibodies includes 
broadly neutralizing antibodies (bnAb) with activities against major strains that are common in human 
transmission. Another approach is the induction of protective functional antibodies as well as T cell 
responses through prime-boost strategies (Chhatbar et al., 2011, Haynes and McElrath, 2013, Cohen and 
Dolin, 2013, McMichael and Koff, 2014, Zolla-Pazner, 2014, Safrit et al., 2016, Stephenson et al., 2016). 
 
1.3.2. Challenges in vaccine research and development 
Although there is continuous progress in vaccine design and development, as well as advanced 
methodologies for selection of candidate antigens and new technologies for vaccine delivery put in place, 
fully effective vaccines against widespread infectious diseases including HIV-AIDS, malaria, and 
tuberculosis remains unachieved. The complexity of the infection/life cycles of these pathogens makes it 
difficult to determine when during the pathogen’s life cycle to intervene, and how to target vaccine delivery 
such that protective immune responses are induced (Taylor-Robinson, 2002, Good and Doolan, 2010, 
Douradinha and Doolan, 2011, Stanisic et al., 2013, Schiffner et al., 2013, Chowdhury and Silvestri, 2013, 
Excler et al., 2014).  
 
Previous clinical studies have shown that humoral immunity plays a role in preventing infection by HIV as 
well as influencing certain stages of malaria infection, making it an important immune correlate of protection 
(Mascola et al., 2000, Moorthy and Ballou, 2009, da Silva et al., 2012). However, Th1 cells, CD8+ T cells, 
or both, also been demonstrated to play a critical role in preventing and controlling these infections (López 
et al., 2011, Killian et al., 2011, O'Connell et al., 2011, Hansen et al., 2011, Krzych et al., 2012, Mudd et 
al., 2012, Killian et al., 2013, Zarling et al., 2013, Yan et al., 2013, Chuang et al., 2013).  
 
One of the challenges to vaccines success in target populations is the fact that the human immune system 
matures during early childhood and then begins to senesce around 60 years of age. Therefore, a question 
of how to immunize neonates, young children, and the elderly arises. Children younger than 6 months old 
and preterm infants have immature immune responses (Morein et al., 2002, Morein et al., 2007, Pastoret, 
2007, Siegrist, 2007, Pichichero, 2014). This goes for adults over the age of 65 who will have an aging 
immune system that could result in defects in immune response to vaccinations (Lefebvre and Haynes, 
2013, Lowery et al., 2013, Scholz et al., 2013, Shaw et al., 2013, Wong and Goldstein, 2013). Vaccines 




systems can be compromised or suppressed by an infection, as consequence, failure to mount desirable 
vaccine responses. As most vaccines rely on the bodies infection pathway, their form of infection does not 
cause illness, but it does cause the immune system to produce T-lymphocytes and antibodies. In some 
instances, minor symptoms such as a fever can be observed following vaccination. Such minor symptoms 
are normal and usually expected as the body builds immunity. It is at this stage that cellular or humoral 
responses are activated. Once the imitation infection is cleared, memory T-lymphocytes, as well as B-
lymphocytes that will remember how to fight that disease in the future, are generated (Schenten and 
Medzhitov, 2011). Immune-compromised individuals usually have challenges in building up these memory 
responses to vaccination, since most of the resources required will be depleted or exhausted (Schenten 
and Medzhitov, 2011, Gisbert et al., 2012, Guan et al., 2013). Helminth infections, found in a large 
percentage of humans, may also suppress immune responses to vaccines as previously suggested (Actor 
et al., 1993, Sabin et al., 1996). These attenuated responses to vaccines have serious complications for 
HIV vaccine development in areas where helminth infections are prolific. Challenges posed by helminth 
infections to vaccine development will be discussed further in section 1.4.1 
 
1.3.3. Helminth infection  
 
Helminths affect one-quarter of the world’s population, where the majority of these infections are chronic 
and occur in the developing world (WHO, 2016). Helminth parasites cause a significant morbidity as they 
compete with the host for nutrients, causing damage as they migrate through host tissues, but rarely 
resulting in the death of their host. In particular, schistosomes and the filarial nematodes are associated 
with severe pathology (McSorley and Maizels, 2012). Protective immunity and clearance of helminths are 
mediated by Th2 cells, type 2 (M2) macrophages, type 2 innate lymphoid cells (ILC2) and eosinophils 
(Pearce, 2016). Infected individuals usually develop immunopathology mediated by Th1 or Th17 cells as a 
result of failure to mount type 2 immune responses against the parasites(Maizels and McSorley, 2016). 
Over time, helminths have found a way to escape host immune system and prolong their survival in the by 
a wide variety of approaches for immune suppression, especially the generation of regulatory T cells and 
anti-inflammatory cytokines IL-10 and TGF-β. This ability has the bystander effect of modulating immune 
responses to unrelated antigens (Maizels and Yazdanbakhsh, 2008). Epidemiology studies in humans have 
shown that infection with helminth parasites is associated with a low incidence of allergy and autoimmune 
diseases in developing countries. They do this by suppressing Th2 and Th1/Th17 responses which are 
mediators of allergy and autoimmunity respectively. Their ability to suppress immune system have been 
associated with impairment of vaccinations (Piessens et al., 1981, Colley et al., 1986, Grogan et al., 1996, 








1.4. Helminth co-infection with HIV/AIDS 
 
Helminth infections are common in tropical and subtropical areas of the globe and affect the poorest and 
most deprived communities living in regions with substandard water, sanitation, and hygiene services 
(Worrell et al., 2016, WHO, 2016). Worldwide, more than 2 billion people are infected with at least one 
helminth species (Hotez et al., 2008, Walson et al., 2010, WHO, 2016). A significant geographic overlap 
exists between HIV-1 and helminth infection exists in sub-Saharan Africa and other developing counties 
(Hotez et al., 2008, Borkow and Bentwich, 2008, Means et al., 2016). More than 22.5 million people in sub-
Saharan Africa alone are estimated are estimated to be co-infected with HIV-1 and at least one species of 
helminth (Fig 1.5) (De Silva et al., 2003, Walson et al., 2009, Pullan et al., 2014, UNAIDS, 2016). 
 
 
Figure 1.5: Soil-transmitted helminthiases and HIV epidemics in Africa. 
The interaction between chronic helminth and HIV-1 coinfection as well as their ability to have a profound 
effect on the host immune system and has sparked research interest in the virology field. Most soil-
transmitted helminth infections are asymptomatic, especially in adults. In children, they are a cause of 
physical and intellectual growth retardation and malnutrition. Helminths induce tissue reactions, such as 
granuloma, and provokes intestinal obstruction or rectal prolapses, especially in children (Aranzamendi et 
al., 2013). Some studies have also shown that soil-transmitted helminth infection has profound effects on 
school performance and attendance and future economic productivity (Brooker et al., 2000, Anderson et 
al., 2013). Despite all these consequences, helminth infection is an area which remains largely neglected.  
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A typical helminth infection induces a dominant type 2 T-helper–cell systemic immune system response, 
accompanied by an induction of regulatory T cells; activation of immunosuppressive cytokines, including 
interleukin (IL)-4, IL-5, and IL-10; increased production of immunoglobulin IgE; and degranulation of mast 
cells (Webb et al., 2012, Siegel and Simon, 2012, Lankowski et al., 2014). On the other hand, HIV-1 is 
controlled by natural killer (NK) cells, CD8 T cells, and antibodies and destroys the host immune system by 
direct CD4 T cells infection (Siegel and Simon, 2012). Continuous depletion of CD4 T cells leads to 
immunodeficiency and down-regulation of type 1 helper T cells that are important for modulating the 
progression to AIDS (Siegel and Simon, 2012, Webb et al., 2012). The intense loss of Th1 immune cells 
during the AIDS phase is balanced with minimal reduction of Th2-associated cytokine activity (Webb et al., 
2012). This immunologic shift from Th1 to Th2 cytokine response in patients with HIV may serve as a 
marker of HIV progression (Webb et al., 2012). Also, shifting the balance between Th1 and Th2 activation, 
during coinfection with HIV and different helminth species can influence the likelihood of pathogen 
establishment, growth, replication, and clearance; disease severity; and transmission (Fenton, 2013) 
especially since both HIV and chronic helminth infections significantly alter the host immune system. Data 
on Interactions between chronic helminth infections and HIV infection remains inconclusive.  
Coinfection with helminths in patients with HIV infection has been shown to increase cellular susceptibility 
to HIV-1 infection, which increases the susceptibility to HIV transmission, and downregulating control of 
HIV-1 replication, which can increase viral replication and accelerate disease progression (Kjetland et al., 
2006, Mayer et al., 2007, Walson et al., 2009, Mbabazi et al., 2011, Downs et al., 2012, Fenton, 2013, 
Lankowski et al., 2014, Colley et al., 2014). Furthermore, a link between helminth infection and increased 
risk of mother-to-child transmission of HIV has been previously shown (Mayer et al., 2007, Webb et al., 
2012). Conversely, the depletion of CD4 T-cells from HIV-1 infection could also increase susceptibility to or 
reduced clearance of helminth infection (Webb et al., 2012). However, some studies have found no effect 
of helminth infection such as S. mansoni on the risk of HIV transmission (Sanya et al., 2015). A study in an  
HIV-1-seropositive adult cohort from Uganda, also showed that there was no correlation between helminth 
infection and exacerbated HIV infection (Elliott et al., 2003).  
In addition, helminths can also sabotage host defences against other major pathogens, such 
as Mycobacterium tuberculosis (Salgame et al., 2013, Mishra et al., 2014). Ironically, in the case of malaria, 
however, the consequences of helminth infection are more different, with evidence of increased 
susceptibility combined with moderated inflammatory responses and hence attenuated disease severity 
(Hartgers et al., 2009, Dolo et al., 2012). Also, in a baboon study, chronic S. mansoni was shown to 
attenuate the severity of Plasmodium knowlesi, suggesting that infection with S. mansoni may provide 




T cell up-regulation in the intestinal mucosa has been shown to be capable of inhibiting the ability of CD8 
cells to control HIV viral replication, increasing HIV progression in concurrency with schistosomiasis 
(Bustinduy et al., 2014). In patients with intense HIV infection with low CD4 counts, it has been 
demonstrated that the excretion efficiency of eggs is suppressed even with heavy schistosomiasis burden 
is suppression of egg excretion efficiency (Karp and Auwaerter, 2007, Ndeffo Mbah et al., 2013, Bustinduy 
et al., 2014). 
As CD4 counts decline due to a progressive HIV infection, the granulomatous response to Schistosoma 
eggs stops and migration of the eggs through the mucosa becomes inhibited (Karp and Auwaerter, 
2007).This, in turn, reduces egg excretion in HIV-1 infected individuals with low CD4 counts, leading to a 
gross underestimate of schistosomiasis prevalence when conventional stool egg count methods are used 
for detection (Webb et al., 2012). 
Certain anthelminthic treatment regimens have been shown to be less effective in clearing helminth 
infections in HIV-1 infected persons with low CD4 counts (Kallestrup et al., 2006) compared to HIV-1 
uninfected patients. Reinfection has also been shown to be more common after anthelminthic treatment in 
HIV-infected persons with low CD4 counts (Webb et al., 2012). Highly active antiretroviral therapy (HAART) 
has been shown to significantly reduce the prevalence of ascariasis, trichuris, hookworm infection, and 
strongyloidiasis, suggesting that HAART improves immunologic protection and control of helminth infection 
(Walson et al., 2010).  
Despite these associations, it remains unclear whether the overall relationship between helminths and HIV 
vary with helminth burden and the specific helminth pathogen (Fenton, 2013). It is, therefore, paramount to 
acquire better understanding of the interactions between helminths and HIV could influence HIV-1 
acquisition, disease progression, interaction with helminth vaccination, and eradication of helminth infection 
(Webb et al., 2012, Downs and Fitzgerald, 2016, Kroidl et al., 2016). 
 
1.4.1. Helminth infection reduces vaccine efficacy 
Vaccine development is essential to the control and prevention of chronic health challenges such as HIV-1 
and helminth infections in endemic areas worldwide (Maizels and McSorley, 2016, Tomaras and Plotkin, 
2017). Clinical trials and animal experiments indicate that a protective vaccine against HIV-1 will be able to 
protect a large helminth-coinfected population (Webb et al., 2012). However, the effects of helminths on 
vaccine-induced immune responses remain an area of uncertainty (Maizels and McSorley, 2016). 
Elimination of helminths in the host, such as albendazole treatment of ascariasis enhanced the response 
to oral cholera vaccine in children (Cooper et al., 2000a), and treatment of S. mansoni-infected mice with 
praziquantel had enhanced interferon gamma response to an HIV-1 clade C DNA vaccine (Da'dara and 




immunogenicity. Furthermore, it has been suggested that helminth vaccination may be impeded in people 
with poorly controlled HIV infection, depending on the type of vaccine. Vaccinations in children with HIV 
has been shown to be less immunogenic than in children without HIV and protective antibody titres, and 
they have rapid waning of vaccine-induced immunity (Bustinduy et al., 2014). 
A neglected challenge to the development of vaccines for use in developing countries is helminth infection 
in the human host. Studies show that populations with the highest prevalence of malaria, tuberculosis, and 
HIV-1 mainly reside in regions of SSA and South America (Haynes et al., 2012). Unfortunately, these same 
populations are also often endemic for one or more helminth parasites (Hotez et al., 2008, Obuku et al., 
2016). Failure to mount efficient immune responses to oral vaccines such as those for cholera, polio and 
rotavirus in developing countries, initiated the hypothesis that the presence of helminths in the 
gastrointestinal tract might have affected efficient uptake of these vaccines (Cooper et al., 2000b). In an 
oral cholera vaccine study, it was found that A. lumbricoides, “giant roundworm" of humans, decreased 
seroconversion, hence impairing vaccine efficiency (Cooper et al., 2000b, Cooper et al., 2001). 
In Ethiopia, helminth infections have been shown to negatively impact the response to vaccines such as 
Bacille Calmette Guérin (BCG) vaccine (Elias et al., 2008). One study showed an improved PPD-specific 
Interferon gamma (IFN-γ) production and T-cell proliferation from peripheral blood mononuclear cells 
(PBMCs) in albendazole (ALB) treated healthy subjects with intestinal helminths compared to controls 
vaccinated with BCG (Elias et al., 2001). It was further shown that BCG-vaccinated mice with prior S. 
mansoni infection had significantly higher tuberculosis (TB) bacillary load as measured by viable count after 
challenge with TB (Elias et al., 2005a). In addition, lower levels of IFN-γ and nitric oxide together with 
increased levels of IL-4 and IL-5 were observed in mice with prior S. mansoni infection (Elias et al., 2005a). 
 
Considerable amount of literature demonstrates that population infected with helminth, have an impaired 
ability to respond to infections with other pathogens, especially those that require cytotoxic effector cells 
(Kullberg et al., 1992, Actor et al., 1993, Sabin et al., 1996, Cooper et al., 1999, Gopinath et al., 2000, La 
Flamme et al., 2002, Chenine et al., 2005, Su et al., 2005). Similarly, immune responses to vaccines 
designed to drive Th1-type CD4+ and CD8+ T cell responses, have been shown to be diminished in 
helminth-infected populations (Kullberg et al., 1992, Actor et al., 1993, Sabin et al., 1996, Cooper et al., 
1999, Cooper et al., 2001, Chen et al., 2012). 
A study by La Flamme et al. (La Flamme et al., 2002) showed that mice co-infected with the protozoan 
parasite Leishmania and S. mansoni had reduced Leishmania-specific IFN-γ, TNF-α and nitric oxide 
production concurrent with increased production of IL-4. In terms of the ability to respond to unrelated 
antigens, Kullberg et al. (Kullberg et al., 1992) demonstrated that schistosome-infected mice had 
significantly reduced production of sperm whale myoglobin-specific interleukin (IL)-2 and IFN-γ per CD4+ 
T cell coincident with a three-fold increase in CD4+ T cell IL-4 compared to responses from non-infected 




Litomosoides sigmodontis at different life stages on the efficacy of an experimental vaccine against 
Plasmodium, it was demonstrated that the helminth infection was able to attenuate accessory T helper 
cells, resulting in the suppression of antibody-producing B cells, thus suppressing antibody production to 
the vaccine (Haben et al., 2014).  
 
With regards to the effect of helminth infection on immune responses to HIV-1 antigens, significant 
downregulation of virus-specific cytotoxic CD8+ T cell responses in schistosome-infected mice have been 
demonstrated in several studies. In a study by Actor et al., examining immune responses to vaccinia 
expressing HIV-1 gp160 in schistosome-infected vs non-infected mice, a significant decrease in the 
frequency of vaccinia and HIV-1 gp160-specific cytotoxic CD8+ T cells in schistosome-infected mice 
compared to vaccinia infected naïve mice was demonstrated (Actor et al., 1993). Similarly, Da’dara et al. 
also demonstrated that vaccination of S. mansoni infected mice with naked plasmid DNA encoding the 
TD158 HIV-1 antigens failed to induce significant viral-specific CTL responses (Da'Dara et al., 2006). The 
lack of gp160-specific cytotoxic CD8+ T cells and response to the TD158 vaccine in helminth-infected 
vaccine recipients is in agreement with multiple studies suggesting the negative effects of helminth infection 
on tetanus, BCG and viral vaccines (Sabin et al., 1996, Cooper et al., 1999, Cooper et al., 2001, Elias et 
al., 2001, Elias et al., 2005a). 
 
1.5. Schistosomiasis 
1.5.1. History, causative agents, geographical distribution, and life cycle 
 
Schistosomiasis is a helminth-associated disease caused by digenetic trematodes of the genus 
Schistosoma primarily infecting man. During the mid-1800s, Egyptian pharaohs wrote of urinary 
disturbances (haematuria) which became common in classically young boys and was once thought to be a 
sign of puberty. In 1851, came along a young German pathologist, Theodore Bilharz who discovered the 
causative parasite; Schistosoma (El Khoby et al., 1998) following which he described the worm “Distoma 
haematobium” (subsequently S. haematobium) and published his findings together with his teacher, 
Professor Siegbold in Breslau. The connection to urinary disease (haematuria) with the presence of eggs 
in urine was made later on. There are three main species that infect human being; S. haematobium, S. 
mansoni, S. japonicum, and two minor species: S. intercalatum, and S. mekongi. Schistosomes are unique 
amongst platyhelminth parasites as they are not hermaphroditic.  
Urogenital schistosomiasis such as S. haematobium is a water-borne parasitic blood fluke, that has been 
reported to cause ulcerative lesions and inflammation of the cervix and vagina in females, and 
leukocytospermia and gross hematospermia in males (Barsoum et al., 2013). It has also been shown that 




risk of HIV transmission by three to four times (Karp and Auwaerter, 2007, Webb et al., 2012, Ndeffo Mbah 
et al., 2013, Kleppa et al., 2014). The distribution of Urogenital Schistosomiasis species is common in areas 
of high prevalence of HIV throughout the world. Of the 220 million people in sub-Saharan Africa who are 
infected with the parasite, 112 million are infected with S. haematobium (Ndeffo Mbah et al., 2013). In 
endemic areas, up to 75% of infected individuals have genital schistosomiasis, acquired primarily during 
childhood (Ndeffo Mbah et al., 2013).  
Hepatic and intestinal schistosomiasis, S. mansoni, is most prevalent in certain tropical and subtropical 
areas of sub-Saharan Africa, the Middle East, South America and the Caribbean (Elbaz and Esmat, 2013). 
Characterised by liver and gut damaging through inflammatory inducing egg deposition (Elbaz and Esmat, 
2013). Its ability to modulate immune responses has been shown to have effects on the immune modulation 
of HIV (Bustinduy et al., 2014). 
However, geographical distribution is dependent on the distribution of the appropriate snail vectors 
(Gryseels et al., 2006), normally in warm climatic conditions mainly developing worlds. Schistosoma 
haematobium primarily transmitted by aquatic pulmonate snails of the genus Bulinus is distributed mainly 
in Africa and the Middle East. On the other hand, S. mansoni (intestinal schistosomiasis) primarily 
transmitted by aquatic snails of the genus Biomphalaria has a wide distribution including Africa, the 
Caribbean, South America and the middle East (Gryseels et al., 2006). Similar in transmission S. japonicum 
is mainly dominant in China, Indonesia, and the Philippines while the minor S. intercalatum and S. mekongi 
are found in limited areas of SSA and Southeast Asia, respectively (Gryseels et al., 2006). Schistosomiasis 
is typically an infection of the rural dwellers; however, urban schistosomiasis is an increasing problem in 
many countries especially in Africa (Steinmann et al., 2006). However, man-made ecological changes such 
as irrigation and the migration of infected populations further contribute to the epidemiology of 
schistosomiasis (Jordan and Webbe, 1993). Transmission is linked to poor hygiene, human water contact 
patterns and the presence of the snail vector which can only breed. This involves multiple developmental 
stages, both in the snail intermediate host and in the human definitive host (Fig 1.6). Schistosome eggs, 
excreted into fresh water, hatch to release miracidium larvae that seek snail hosts, where they replicate 
asexually to produce multiple generations of sporocysts (Gryseels et al., 2006, CDC, 2012). Sporocysts 
mature into cercariae with a characteristic bifurcated tail and are then released from snails into fresh water 
to seek their definitive host. At this time, cercariae typically live for 24-48 hours (hrs) and can penetrate 
unbroken skin, shed its tail and transform into a Schistosomulae, which then migrate through tissue into the 
host bloodstream, the lung, and ultimately the portal vein, resulting in human infection (Lawson and Wilson, 
1980, Gryseels et al., 2006). They will mature in the portal vein for 4-6 weeks into adult worms and, migrate 
preferentially to venules of the urinary and genital tracts (S. haematobium) or the gastrointestinal tract (S. 
mansoni, S. japonicum). Once they reach the adult stage, they will form reproductive male-female pairs, 
producing hundreds to thousands of eggs per day and living an average of 3-5 years (Macedonia and 




arrive at the lumen of the bladder or intestine and are excreted in urine or stool (Wynn et al., 1994); the 
remaining eggs are trapped in the tissues or are embolized to distant organs (Gryseels and Nkulikyinka, 
1988). To complete the cycle, the eggs must again hatch into miracidium which must penetrate a freshwater 
snail (intermediate host) and develop into cercariae that are shed into the fresh water. Repeated exposure 
of the host to schistosome-infected fresh water will maintain the life cycle (CDC, 2012) and progressively 
increases the number of worms and eggs as well as the severity of the infection (Utzinger et al., 2001). 
Each species has its own specific snail host, which explains why the disease follows the distribution of the 
respective snails (Sturrock, 1993). 
 
 
    
 
 
Figure 1.6: The Schistosomiasis life cycle. Taken from 





1.5.2. Pathogenesis and immune responses  
 
Helminths are extracellular eukaryotic parasites from an evolutionarily ancient and diverse group (Garnier 
et al., 2013), but show species independent modes of immune modulation in clinical and experimental 
studies. This gives them the ability to escape the host defence system through suppression of both Th1 
and Th2 associated host immunity and establishing chronic infections (Aranzamendi et al., 2013, Maizels 
and McSorley, 2016). Usually, parasitism leads to complications caused by the blockage of internal organs 
or the effects of pressure exerted by growing parasites. Parasite eggs migrating through body tissues also 
cause direct tissue damage, as well as initiate hypersensitivity reactions leading to indirect tissue damage 
(La Flamme et al., 2002, Borkow and Bentwich, 2004). Immune modulation due to helminth infection results 
in general immune hyporesponsiveness and anergy of the host (Borkow and Bentwich, 2004). Helminths 
induce a strong Th2-type immune response characterized by production of cytokines such as IL- 4, IL-5, 
IL-9, and IL-13 and increased levels of circulating IgE antibodies, eosinophils, and mast cells (Kamal and 
El Sayed Khalifa, 2006, Moreau and Chauvin, 2010, Ortiz et al., 2011, Aranzamendi et al., 2013), creating 
an ideal environment for chronic infection. The polarized Th2 response, in turn, down-regulates Th1 
responses along with associated cell and cytokine subsets (Kamal and El Sayed Khalifa, 2006). CD4+ Th2-
lymphocytes and T-reg cells are the central players in the helminth-induced immune response by the 
production of cytokines and chemokines such as CCR3.  
Previous studies showed that depletion of CD4+ T-cells discouraged mounting of a protective immune 
response following vaccination, and lacked the ability to expel the intestinal helminths (Koyasu et al., 2010, 
Saenz et al., 2010). IL-10 and TGF-β mediated suppression of competing Th1 and Th17 cell populations 
play a critical role in the maintenance of Th2 dominance in many forms of helminth infections (Elias et al., 
2008). This has been shown in a mouse filariasis model using L. sigmodontis where the chronic phase of 
infection is marked by T-cell anergy, loss of proliferative responses to parasite antigen challenge, reductions 
in effector cytokine levels, and elevated expression of inhibitory immune molecules and cells such as IL-
10, TGF-β and Tregs. In some animal models, the infective stage of the parasite stimulates a Th1-like 
response, and it is only after the infection is established and adult worms are present that a switch to Th2 
occurs (Maizels and Yazdanbakhsh, 2003). However, this observation is not observed in all animals.  
Helminths use proteins as an important product to interact with host innate immune responses (Table 1.2). 
Their interaction can occur through dendritic cells, toll-like receptors, and costimulatory receptors to trigger 
Th2 and T regulatory responses. Dendritic cells (DC) are key players in the polarization of T cell 
development towards Th1, Th2, or T-regs through their signaling and antigen presenting. Helminths and 
helminth products modulate DC function, such as DC maturation, as well as those involved in signaling 
through TLRs, such as TLR-2,3, and 4. TLRs mostly associated with signaling Th1 responses are activated 
by helminth products to signal Th2 and regulatory responses (van Riet et al., 2007). Furthermore, helminth 




in immature antigen presenting cells (APC) and decreased pro-inflammatory cytokines (Harnett and 
Harnett, 2010). The use of helminth products to stimulate anti-inflammatory immune responses is being 





Table 1.2: Immunomodulatory products of helminths: Taken from Harnett and Harnett (Harnett and 
Harnett, 2010) 
Product  Helminth  Mechanism of action  
Lysophospha-
tidylserine  




S. mansoni and A. 
lumbricoides  
TLR2-dependent activation of DCs promotes TH 2-type anti-
inflammatory responses  
LNFPIII  S. mansoni  Production of IL-10 and prostaglandin E2 by B-1 B cells; 
TLR4- and C-type lectin-dependent activation of APCs 
promotes TH 2-type anti-inflammatory responses  
ES62  A. viteae  Inhibition of B-2 B cell proliferation and induction of B-1 B 
cell-dependent IL-10 secretion; TLR4-dependent activation 
of APCs promotes TH 2-type anti-inflammatory responses; 
TLR4-dependent inhibition of mast cell degranulation and 
inflammatory mediator production  
dsRNA  S. mansoni  Modulates DC function, through TLR3, to suppress TH2 cell 




S. mansoni and F. 
hepatica  
Inhibits LPS-induced nitric oxide, IL-6, IL-12 and TNF 
production by macrophages by inhibition of TRIF signalling 
through endosomal degradation of TLR3  
smCKBP  S. mansoni  Blocks CXCL8-induced migration and infiltration of 
neutrophils in a mouse air pouch model and in a chemotaxis 
model  
IPSE  S. mansoni  IgE-binding factor that induces IL-4 production from 
basophils  
Omega-1  S. mansoni  T2 ribonuclease that matures DCs to prime TH2 cell 
responses in an MYD88- and TRIF-independent manner  
Peroxiredoxin  F. hepatica and S. 
mansoni  
Promotes TH2 cell responses through induction of 
alternatively activated macrophages  
Cystatin  A. viteae and O. 
volvulus  
Inhibition of T cell responses by macrophage-derived IL-10  
Calreticulin  H. polygyrus  Promotes TH2 cell-responses by interacting with scavenger 
receptor A  






1.5.3. Acute and chronic infection  
Schistosomiasis morbidity depends on the schistosome species involved, the intensity of infection, the 
topographic site affected by sequestered eggs and the immune responsiveness of the host (Harms and 
Feldmeier, 2002, Vennervald and Dunne, 2004). Acute schistosomiasis is a systemic hypersensitivity 
reaction against migrating schistosomula which occur 3 to 5 weeks after cercarial penetration (Akhiani, 
1996, Bottieau et al., 2006). The clinical manifestations reflect developmental stages of the parasite and 
host responses to toxic or antigenic substances derived from the parasite and eggs. During this early stage 
of intestinal schistosomiasis (caused by S. mansoni and S. japonicum), the schistosomula grow into adult 
worms that lay eggs, which then pass through the intestinal walls. Only about 50% of the eggs are trapped 
in the walls and mediate an immune reaction that cause mucosal granulomatous inflammation and 
formation of pseudopolyps and scars around the trapped eggs (Vennervald and Dunne, 2004, Gryseels et 
al., 2006) leading to an inflammatory reaction that causes a sudden feverish syndrome with severe systemic 
illness referred to as Katayama fever (Gryseels et al., 2006). This is accompanied by malaise, weight loss, 
gastrointestinal symptoms, intermittent abdominal pains, high eosinophilia, headache, localised oedema, 
unproductive irritating cough, loss of appetite, nausea, vomiting, bloody diarrhea and muscular pains 
(Cheever et al., 2000, van der Werf et al., 2003, Danso‐Appiah et al., 2004, Gryseels et al., 2006, Booth et 
al., 2006). Acute schistosomiasis is short-term conditions that usually resolve without treatment 
(Lambertucci, 1993).  
In mice, the acute phase of infection is also associated with the antigen-specific production of Th1 cytokines 
(IFN-γ, IL-2, and TNF-a) (Grzych et al., 1991), but this switches to a Th2 dominated response, in which 
there is an underlying Th1 response as soon as eggs are produced (Rutitzky et al., 2001). Failure to develop 
a Th2 response to regulate the initial pro-inflammatory response associated with acute schistosomiasis has 
been shown to be is lethal. This was first observed when C57BL/6 IL-4 deficient mice were infected with S. 
mansoni. These mice suffered from cachexia and significant mortality on the onset of parasite egg 
production (Brunet et al., 1997) even though they developed relatively normal hepatic granulomas.  
Continuous egg deposition and retaining of eggs that are carried to the liver via the portal circulation where 
they get trapped in the presinusoidal periportal spaces in the liver trigger a chronic infection (Pearce and 
MacDonald, 2002, Gryseels et al., 2006). This is characterized by hepatosplenomegaly, although the 
development of polyps or mucosal proliferation of the intestine is observed in most cases. The eggs contain 
a developing miracidium, which releases proteolytic enzymes, which give rise to typical eosinophilic 
inflammatory and granulomatous reactions that result in granuloma formation (Mitchell, 1990, Gryseels et 
al., 2006). In about 6-8 weeks, the miracidium in the egg dies, decreasing the antigen load, which 
sometimes leads to shrinking of the granuloma. Egg granulomas are replaced by fibrotic tissues which are 
prominent in the periportal areas that lead to the development of periportal fibrosis (Rumbley and Phillips, 
1999, Oliveira and Andrade, 2001). The granulomatous reactions and the fibrotic lesions may result in 




these symptoms is associated with the intensity of infection and related to the type of immune responses 
generated by the infected individual (Pearce and MacDonald, 2002, Vennervald and Dunne, 2004, Gryseels 
et al., 2006). Hepatosplenic schistosomiasis is more common in children and adolescents than in adults 
(Gryseels and Polderman, 1991, Vennervald and Dunne, 2004). 
 
1.5.4. The egg granuloma 
 
Granuloma formation is a result of a delayed type hypersensitivity reaction against schistosome egg 
antigens. The egg antigens induce CD4+ T cell-dependent response which orchestrates the development 
of granulomatous lesions, composed of collagen fibers and cells, including macrophages, eosinophils and 
CD4+ T cells around the individual eggs (Dunne and Pearce, 1999, Layland et al., 2005, Wilson et al., 
2007, Layland et al., 2010) (Fig 1.7). The granulomas usually resolve as the eggs die, leaving fibrotic 
plaques. In S. mansoni infection, the schistosomal granuloma is a dynamic process in which suppressor T 
lymphocytes drive the granulomatous reaction, closely regulated by mononucleated cells (Perrin and 
Phillips, 1989, Elliott et al., 1990, Lundy and Lukacs, 2013, Pearce, 2016). Both T and B cells have been 
shown to play a major role in immune responses against S. mansoni ova (Chensue and Boros, 1979, 
Bentley et al., 1982, Pearce, 2016), and plasma cells may produce antibodies targeted at S. mansoni 
antigens (Lichtenberg, 1964). A severe consequence of infection with S. mansoni is the result of an increase 
in portal blood pressure as the liver becomes fibrotic, congested and harder to perfuse (Silva et al., 2000, 





Figure 1.7: Major components of the granulomatous response to Schistosome eggs in the host liver and 
the main cytokines and chemokines that regulate this response. Taken from Burke et al., (Burke et al., 
2009). 
 
1.5.5. Th1/Th2 responses to Schistosome eggs 
 
Most of the immune responses in schistosomiasis have been deduced from studies of murine S. mansoni 
infection (Burke et al., 2009). A closely regulated immune response against schistosomes acts to suppress 
the parasites’ virulent effects, and may further be essential for host survival (Brunet et al., 1997, Fallon and 
Dunne, 1999). In murine S. mansoni infection model, the first 4-6 weeks of infection are characterised by a 
moderate T helper 1 cell (Th1) dominated immune response characterized by increased levels of circulating 
pro-inflammatory cytokines including TNF-α, IL-1, IL-6 and IFN-γ (La Flamme et al., 2002, Wynn et al., 
2004, Bartley et al., 2006, Wilson et al., 2007). These Th1 cells are recruited in response to schistosomula 
and immature adult worms and produce cytokines involved in macrophage activation (La Flamme et al., 
2002). This is then followed by a shift to a T helper 2 cell (Th2) dominated immune reaction reviewed in 
(Burke et al., 2009). Th2 cells, are activated in response to ova deposition and produce interleukins such 
as IL-4, IL-5 and IL-13 involved in establishing eosinophilic and granulomatous reactions and in generating 




as the secretion of immunoglobulin (Ig)E and IgG4 isotypes by plasma cells (Hagan et al., 1991, Mulu et 
al., 2015). Following a peak at around 8 weeks post-infection (p.i), the Th2 dominant response is then 
downmodulated towards the chronic stage of infection (Burke et al., 2009). Regulatory T lymphocytes (T 
regs or CD4+CD25+ T cells) by IL-10 production, regulates the shift from Th1 to Th2 dominant immune 
responses, preventing severe pathology due to excessively polarised responses (Burke et al., 2009). 
Previous studies suggest that the immune profile in chronic helminth infections could protect against 
diseases such as asthma, allergy and autoimmunity (van den Biggelaar et al., 2000, Weinstock et al., 2004, 
Zaccone et al., 2006). The Th1/Th2-CD4+ T cell biased immune response is well represented in a mouse 
model by Pearce and MacDonald in Fig 1.8 below.  
 
 
Figure 1.8: The development of immune response in schistosomiasis in a mouse model. Taken from 
(Pearce and MacDonald, 2002). 
 
1.5.6. Control of schistosomiasis by anti-helminth chemotherapy 
 
Despite the abundance and spread of helminth infections, helminth infections are easily eliminated by drug 
treatment, praziquantel (PZQ) and Oxamniquine for schistosomiasis (Shaheen et al., 1989, Utzinger and 
Keiser, 2004, Tallima and El Ridi, 2007) and ivermectin or mebendazole for geohelminths (Cañete et al., 
2009, Churcher et al., 2009, Geary, 2012). In a mouse model, once treated, the host immunity will usually 
return to a normal mixed Th1-Th2 system within four to six weeks post-treatment, however, this depends 




2010, Shollenberger et al., 2013b). One of the ways in which treatment (Oxamniquine) works is by causing 
the worms to shift from the mesenteric veins to the liver, where the male worms are retained. Here the 
cellular host responses finally eliminate the male worms. On the other hand, PZQ works by increasing the 
permeability of the membranes of schistosome cells towards calcium ions. This causes contractions of the 
parasites, leading to paralysis in this contracted state. Therefore, the parasites dislodge from their active 
site, and are released into the systemic circulation or are destroyed by phagocytosis. There is always 
caution to be taken since it has been shown that treatment using PZQ was associated with increased viral 
replication in Ugandan population (Brown et al., 2005). Furthermore, the antifibrotic properties of PZQ have 
been shown to be inferior compared to Paeoniflorin, a novel experimental drug used for treating 
schistosomiasis and been shown to reduce and prevent liver fibrosis following liver injury due to 
Schistosoma mansoni (Abd El-Aal et al., 2017).  
 
1.6. Problem statement 
 
Helminthiasis and HIV infections are co-endemic in many regions of sub-Saharan Africa (SSA). Globally, 
soil-transmitted helminths (STH) and schistosome infections are estimated to infect over 1 billion people 
(Lustigman et al., 2012) with a third of STH infections and over 90% of schistosomiasis cases occurring in 
Africa (WHO, 2014). In addition, the geographical distribution of these infections vastly overlaps with 
regions with high HIV prevalence in SSA (Webb et al., 2012). Therefore, it is very likely that successful 
future HIV vaccines will be administered to people who already have ongoing helminthiasis or have been 
previously infected and treated. Helminths are potent modulators of host immune response that drives Th2-
dependent pathways to mediate their protection from the host (Anthony et al., 2007, Allen and Maizels, 
2011). Chronic helminth Infection can result in altered response to non-parasite antigens (Kullberg et al., 
1992), and has been previously shown to impair specific immunity induced by a number of vaccines 
including Tetanus toxoid (Sabin et al., 1996), cholera (Cooper et al., 2000a), Salmonella typhi (Muniz-
Junqueira et al., 1996), BCG (Buck et al., 1970, Kilian and Nielsen, 1989, Stewart et al., 1999, Elias et al., 
2008) and two HIV vaccines, including a DNA-based vaccine construct (Actor et al., 1993, Da'Dara et al., 
2006). However, there is lack of consistent scientific data to inform how candidate HIV vaccines would 
perform in the presence of ongoing helminthiasis given that some studies show that helminthic infections 
down-regulate vaccine-specific Th1 immune responses to HIV (Da'Dara et al., 2006), while other studies 
show the opposite is true (Shollenberger et al., 2013a). 
Preventive chemotherapy is recommended by WHO and partner organizations for the control of 
schistosomiasis in many endemic countries. Although effective antihelminthic drugs are available (such as 
PZQ for schistosomiasis and ALB for gastrointestinal helminths), re-infection after treatment is possible and 
frequent in endemic areas, thus, vaccinees in developing countries will already have an ongoing chronic 




continue to pose a significant problem for the development of HIV-1 vaccines designed to induce viral-
specific Th1- type CD4+ and cytotoxic CD8+ T cell responses (Colley et al., 2014).  
However, there is a lack of consistency in data to inform the effect of helminth treatment on the recovery of 
vaccine-specific responses. Some studies show that anthelminthic treatment restores vaccine responses 
(Da'dara and Harn, 2010, Chen et al., 2012), while others show that there is no difference between treated 
and untreated individuals (Walson et al., 2012, Lankowski et al., 2014). Furthermore, because both HIV-1 
and S. mansoni rely on mutually exclusive T helper responses, it is not known whether immunization in 
infected individuals may contribute to helminth-induced pathogenesis or vice versa. There is therefore, a 
lack of scientific data to inform how candidate HIV vaccines would perform in the presence of ongoing 
chronic helminthiasis or whether the integration of helminthic control programmes with future HIV 
vaccinations would result in beneficial vaccination outcomes. 
 
1.7. Rationale of the study 
 
Schistosomiasis and HIV-1 are endemic to sub-Saharan Africa and co-infection with both is common. 
Although no effective vaccines are available for both HIV-1 and Schistosomiasis, effective anti-helminthic 
drugs such as praziquantel are available for schistosomiasis. However, re-infection after successful 
treatment is very common in endemic areas. Therefore, it is likely that vaccinees will already have an 
ongoing chronic schistosomiasis or have previous exposure to schistosomiasis during future successful 
HIV immunization. Typical helminth infections are characterized by an induction of a strong T helper 2 (Th2) 
immune responses, increased levels of regulatory cells and the induction of specific and generalized 
immune hyporesponsiveness (anergy) (Borkow et al., 2000, Hoerauf et al., 2005). The performance of HIV 
vaccines in an ongoing chronic helminthiasis has not been clearly documented and scientific data on 
whether the integration of helminthic treatment with future HIV vaccinations would result in beneficial 
vaccination outcomes remains to be elucidated. It is thus important to investigate if whether Schistosomiasis 
could have an impact on the protective features of HIV vaccines.    
At the University of Cape Town (UCT), two candidates HIV vaccines (SAAVI DNA-C2, SAAVI modified 
vaccinia Ankara [MVA-C]) have been developed (Burgers et al., 2006, Burgers et al., 2008) and have been 
demonstrated to generate robust T-cell immune responses in mice and NHP when given as a prime-boost 
vaccination regimen (Shephard et al., 2008, Burgers et al., 2009). It has been further shown that a prime-
boost vaccination with SAAVI MVA-C and HIV gp140 protein vaccines induces strong mixed T-cell and 
antibody immune responses in NHP (Chege et al., 2017). The current study sought out to evaluate whether 
the immunogenicity of these candidate HIV vaccines are impacted by helminth-induced immune responses 




being well established in BALB/c mice (Actor et al., 1993, Da'Dara et al., 2006, du Plessis et al., 2013) and 
its availability and established protocols in our collaborator's facility.  
Findings from this study will describe the potential impact of chronic helminth infection on the 
immunogenicity of candidate HIV vaccines as well as inform whether the integration of helminths control 
programs will be beneficial to mass vaccination programmes in endemic areas. Also, this study will further 
demonstrate if HIV vaccinations are safe for helminth-infected people. Such outcomes would have a major 
impact on health policy regarding the current vaccines in clinical use and future HIV vaccines. In addition, 
this study is likely to provide justification for further investigations using a nonhuman primate model aimed 
at providing further information on the impact of schistosomiasis and future HIV vaccinations. The study 
hypotheses are:  
1: Chronic schistosomiasis reduces the quantity and quality of HIV vaccine-induced responses to 
vaccination. 
2: Effective HIV vaccination worsens the schistosome worm-induced pathology. 
3: Chemotherapeutic elimination of schistosome worms restores normal responses to HIV vaccination. 
 
1.8.  Aims of the study 
The aim of the study was to investigate the effects of S. mansoni infection (schistosomiasis) on the 
immunogenicity of candidate HIV vaccines in mice and to determine if chemotherapeutic elimination of 
schistosome worms using praziquantel reverses these effects. In addition, this study aimed to examine if 





CHAPTER 2  
2. An investigation of cellular and humoral HIV vaccine-induced responses in Sm-infected mice: a 
preliminary study.  
2.1. Introduction 
The aim of this objective was to conduct a preliminary study to confirm successful reproducibility of the 
mouse model of chronic schistosomiasis in order to validate the HIV vaccination outcomes and to give an 
indication of whether candidate HIV vaccine responses elicited by different vaccination regimens are 
affected by chronic schistosomiasis. As reviewed in Chapter 1, section 1.4, both HIV and parasitic 
helminthic worm infections are prevalent and geographically overlap each other considerably in Sub 
Saharan Africa (SSA), with a large number of inhabitants harboring at least one or more species of parasitic 
helminth infection (De Silva et al., 2003, WHO and UNAIDS, 2009, UNICEF and WHO, 2011) whilst over 
50% of the chronically infected individuals are co-infected with HIV (Bustinduy et al., 2014). It is likely that 
once successful future HIV-1 vaccine(s) are developed, they will target populations in developing country 
populations, where the HIV epidemic is higher. However, it is most likely that vaccine recipients will be 
already infected with parasitic helminthics before they receive HIV immunization during such future mass 
vaccinations. 
Several clinical and animal studies have shown that chronic helminthic worm infections play an important 
role in modulating host immune responses towards a predominantly Th2 type as a parasite survival 
mechanism (Urban et al., 1996, Fincham et al., 2003, van Riet et al., 2007). On the other hand, the trend 
in vaccine design is towards targeting the virus at their most vulnerable sites by robust and timely immune 
responses to various epitopes (Da'Dara et al., 2006, Rappuoli, 2011, Walker and McMichael, 2012). Most 
often, they target multiple epitopes at the same time to induce robust T cell responses (Da'Dara et al., 2006, 
Gray et al., 2016, Chege et al., 2017, Wee et al., 2017, Korber et al., 2017). Also, antibody responses to 
envelope protein are the essential target of current vaccine design (Rerks-Ngarm et al., 2009, Joseph et 
al., 2017, Chege et al., 2017).  
Th1 and Th2 are almost mutually exclusive, meaning that if a strong Th1 response dominates, a Th2 
response will be at a minimal level and vice versa. Thus, the immunological consequence of host immune 
response modulation by helminths may adversely impact standard immunizations, by suppressing immune 
responses to Th1-type vaccine and impairing the expansion of pathogen-specific cytotoxic T lymphocyte 
(CTL) responses (Elias et al., 2005a, Kamal and El Sayed Khalifa, 2006, Elias et al., 2008, Labeaud et al., 
2009, Wammes et al., 2010). 
As previously described in Chapter 1, section 1.3.3, several vaccine studies have suggested that helminth 
infections are capable of impairing vaccine efficiency and efficacy (Actor et al., 1993, Elias et al., 2005a, 




infection in mice has been shown to down-regulate both HIV-1 gp160 specific CD8+ cytotoxic T 
lymphocytes and Th1 (IFN-γ and IL-2) responses, resulting in delayed clearance of vaccinia virus in the 
liver, spleen and lungs (Actor et al., 1993). Similarly, S. mansoni-infected mice had a poor IFN-γ response 
to an HIV-1 DNA vaccine compared to uninfected group (Da'Dara et al., 2006). However, a recent study 
showed that HIV-specific responses generated in mice by an attenuated live L. monocytogenes expressing 
HIV-1 Gag were not statistically different between schistosome-free and chronically infected animals 
(Shollenberger et al., 2013b, Shollenberger et al., 2013a). Furthermore, some studies go as far as showing 
that the host immune balance is not affected by helminths (Obuku et al., 2016). 
 
Albeit each of the studies has empirical support and opposition, it remains unclear whether or not helminth 
infection will confound the immunogenicity and efficacy of future HIV vaccination. A number of studies that 
show no effect of helminth infections have major limitations such as the manner of evaluating vaccine 
responses and consideration of critical variables that may not render justice to the full evaluation of helminth 
impact on vaccination if excluded. For example, in mouse study by Shollenberger et al., showed that 
helminth infections do not affect vaccination with a Listeria HIV vaccine, however, immune responses were 
only observed for one dominant peptide (i.e gag protein responses: Lm-gag) (Mata et al., 2001, 
Shollenberger et al., 2013a). In another study that evaluated the effect of Schistosoma mansoni infection 
on innate and HIV-specific T cell immune responses in HIV-infected Ugandan fisherfolk, contradicted the 
theory that S. mansoni downregulated HIV-specific Th1 responses in HIV and S. mansoni-coinfected 
human hosts. However, the status of chronic infection was not confirmed as only the egg counts from feaces 
were used to demonstrate Schistosoma infection without the determination of Th1 and Th2 cytokine profiles 
(Obuku et al., 2016, Storey et al., 2017). An acute and early chronic infection with schistosomes is 
characterised by elevated Th1 cytokine responses before processing to late chronic infection which is 
characterised by the dominant Th2 response (Pearce and MacDonald, 2002, Da'dara and Harn, 2010, 
Shollenberger et al., 2013a, Shollenberger et al., 2013b). Furthermore, a study by Storey et al., suggested 
that soil-transmitted helminth infections were not associated with compromised antibody responses to 
previously administered measles and tetanus vaccines among HIV-1 infected Kenya adults who were not 
on ARTs. However, the measured responses reported in this study were of unstimulated cells, which may 
not speak to the impact of these helminths on Th1 cytokine responses (Storey et al., 2017). This is because, 
for an active secretion of antibodies, memory B cells need to be stimulated (Amanna and Slifka, 2010). 
   
At UCT, two candidate HIV vaccines (SAAVI DNA‐C2 and SAAVI MVA‐C) have been developed (Burgers 
et al., 2006, Burgers et al., 2008) and demonstrated to generate robust T-cell immune responses in mice 
and NHP (Shephard et al., 2008, Burgers et al., 2009) following a prime-boost vaccination regimen. 
Furthermore, a prime-boost vaccination with SAAVI MVA-C and HIV gp140 protein vaccines was shown to 
induce strong mixed T-cell and antibody immune responses in guinea pigs and NHP in pre-clinical 




The aim of the present study was to determine whether chronic helminthiasis attenuates the 
immunogenicity of candidate HIV vaccines in the mouse model. Mice are the most widely used animal 
models in pre-clinical investigation of vaccine and drug development. In this study, BALB/c strain of mice 
was chosen because of its well-studied immune system. Despite having a less complex immune system 
than that of human, they make a suitable animal model for evaluating HIV vaccines. For example,  
BALB/c mice have both H-2Kd MHC class I and class II molecules which bind to several epitopes present 
in HIV-1 Gag, RT and Env and have been shown to activate corresponding CD8+ and CD4+ T cells (Mata 
et al., 1998, Mata and Paterson, 1999, Casimiro et al., 2002). This makes it possible to use synthetic 
peptides in T cell assays to assessed HIV-specific CD4+ and CD8+ T cell responses in these mice. 
Furthermore, both SAAVI DNA and MVA vaccines were designed to contain a peptide sequence, 
RGPGRAFVTI, which is dominant BALB/c Env CD8+ T cell epitope within HIV-1 gp120 Env (Burgers et al., 
2008). Logistically, they are small, have a short gestation period, required small space and are relatively 
cost-effective. Apart from assessing HIV vaccine responses, BALB/c mice have been used to evaluate 
immune responses to parasitic infections. Most research in schistosomiasis has focused on S. mansoni as 
a prototype in mice, wherein the entire life cycle can be recapitulated (Fu et al., 2012). Based on the 
versatility of the BALB/c, this animal model was therefore chosen to assess and compare the results to 
those previously obtained by our group and others. 
Helminth infections have been suggested to negatively affect immune responses to unrelated antigens, 
particularly Th1 cellular responses. There is little scientific data to inform how candidate HIV vaccines would 
perform in the presence of ongoing helminthiasis, especially to vaccines that elicit humoral responses to 
HIV. In this study, three HIV vaccination regimens were selected to elicit either (i) a predominant T cell-
mediated response (SAAVI DNA-C2 prime + MVA-C boost denoted DNA+MVA); (ii) a predominant 
antibody-mediated response (Env-gp140 protein alone) or (iii) mixed cellular and antibody (SAAVI MVA-C 
prime + Env-gp140 protein boost denoted MVA+gp140) responses. The aims were to investigate whether 
chronic helminthiasis attenuate either or both types of responses differently or equally. These vaccines 
regimens were then evaluated in mice chronically infected with Schistosoma mansoni. Splenocytes and 
blood serum were harvested for analysis of vaccine-specific T cell and antibody responses using ELISpot, 
ELISA, CBA and ICS staining. Data generated from these vaccine regimens was necessary to determine 








2.2. Materials and methods 
2.2.1. Parasites 
Biomphalaria glabrata snails infected with the Puerto Rican strain of S. mansoni (Sm) were maintained in 
the laboratory or Prof Frank Brombacher at IDM. To induce shedding of infectious Sm cercariae, 10-15 
snails were put in a glass beaker containing Lipper buffered water (water containing CaCl2; MgSO4; K2SO4; 
NaHCO3 and FeCl3.6H2O) and placed under a heat lamp (250-Watt) for 30-50 minutes. The harvested 
cercariae were counted under a dissecting microscope. Three independent counts were taken to get an 
average dose of 30-35 cercariae per mouse. 
 
2.2.2. Vaccines 
The following three candidate HIV vaccines were used:  
1. SAAVI DNA‐C2: composed of two DNA plasmids, pVRCgrttnC, and pVRCgp150CT expressing a 
human immunodeficiency virus subtype C (HIV-1C) polyprotein comprising gag, reverse 
transcriptase, tat and nef (grttnC) and an HIV-1C truncated env (gp150CT) respectively mixed at 
equimolar concentrations (1mg/ml) (Burgers et al., 2006).  
2. SAAVI MVA‐C: which expresses the same immunogens as the DNA vaccine with grttnC, is a 
recombinant MVA virus under the control of the vaccinia virus 40K promoter inserted into the Del 
III region, and gp150CT, under the control of the vaccinia virus 13 promoter inserted into the 49/50 
region (Burgers et al., 2008).  
Both the DNA and MVA were developed at UCT and have been shown to generate robust T-cell immune 
responses in mice (Shephard et al., 2008) and NHP (Burgers et al., 2009, Chege et al., 2017) when given 
in a prime-boost vaccination regime. These vaccines were manufactured by Therion Biologics Corporation 
(Cambridge, MA, USA; now defunct) under Good Manufacturing Practices (GMP).  
3. HIV-1 gp140 Env protein: The gp140 (TV-1)(HIV-1/Clade C) was purchased from Immune 
Technology, USA. The Env amino acid consequences were derived from a South African subtype 
C primary isolate, TV1 (Lian et al., 2005). This vaccine is similar to the Novartis protein subunit 
vaccine (GSK, Cambridge, MA), an oligomeric V2 loop deleted glycoprotein 140 (gp140ΔV2.TV1) 
derived from the same HIV isolate, TV1, and shown to induce Env-specific humoral responses in 
rabbits and mice (Lian et al., 2005). 
The above vaccines were manufactured for a clinical trial in South Africa (Williamson et al., 2012). They 
were demonstrated in a pre-clinical and clinical trial to be safe and to elicit strong CD4+ responses and 





Female BALB/c mice (6–8 weeks old) were purchased from South African Vaccine Producers (SAVP) 
(Johannesburg, South Africa), housed in Animal Biosafety Level 2 and maintained in accordance with the 
South African national guidelines for Use of Animals for Scientific Purposes (SANS Code 10386: 2008). 
Mice were allowed to acclimate for one week before commencing any experimentation. The experimental 
protocols performed in this study were reviewed and approved by the Animal Ethics Committee of the 
University of Cape Town (UCT AEC: protocol number: 014/026).  
 
2.2.4. Experimental design 
2.2.4.1. Immunization schedule 
Three pre-clinical experiments were conducted as a preliminary study to indicate if chronic schistosomiasis 
in mice can be reproduced and whether immune responses elicited by different vaccination regimes are 
differently affected by schistosomiasis. Briefly, BALB/c mice were divided into two groups of 5 mice (Sm-
free) or two groups of 8 mice (Sm-infected). Mice were infected with Sm cercariae at week 0 and 
subsequently vaccinated twice, four weeks apart with appropriate vaccines at week 10 and 14 respectively. 
Twelve days after last vaccination (week 16), mice were euthanised, and samples (blood; spleen and liver) 






Figure 2.1: Immunisation schedules: A) Representation of infection and immunization strategy. B): 
experiment 1 (mixed cellular and antibody response vaccine regimen); experiment 2 (cellular response 
vaccine regimen) and experiment 3 (antibody response vaccine regimen). 
2.2.4.2. Infection of mice with Sm-cercariae 
Mice were anaesthetized by intraperitoneal injection of a mixture of ketamine hydrochloride (120mg/kg body 
weight) and xylazine (16mg/kg body weight) in saline. Mouse abdomen was shaved and a metal ring (1 cm 
in diameter) was placed on the wet shaved area. 30-35 live Sm cercariae parasite were placed in water 
held inside the metal ring for 20 min to allow natural skin penetration. 
 
2.2.4.3. Vaccination of mice with SAAVI DNA-C2; SAAVI MVA and HIV Env-gp140 
Vaccinations with SAAVI DNA-C2 and SAAVI MVA-C were given intramuscularly while vaccination with the 
Env-gp140 protein was given intraperitoneally. The Env-gp140 vaccine protein was administered at a dose 
of 10ug protein in 100µl PBS containing 1µg Gag VLPs (per mouse). Gag VLPs were included in the protein 
vaccine to provide adjuvant properties as has been observed (Gerald Chege; personal communication). All 
intramuscular vaccinations were performed under anaesthesia with ketamine and xylazine mixture. The 
DNA vaccine (100µg per mouse) was administered intramuscularly in a total volume of 100µl PBS by needle 
injection, 50μl in the tibialis muscle of each hind leg. The MVA vaccine (106 plaque forming units [pfu] per 
mouse) in a total volume of 100µl 1mM Tris (Sigma Aldrich, USA) per mouse was administered by needle 
Groups: n=5-8 Infection Vaccine 1 Vaccine 2 End point
Week - 0 10 14 16
Experiment 1 MVA+gp140 -   
Sm+MVA+gp140    
Sm  - - 
Naïve - - - 
Experiment 2 DNA+MVA -   
Sm+DNA+MVA    
Sm  - - 
Naïve - - - 
Experiment 3 Gp140 -   
Sm+gp140    
Sm  - - 






injection, 50µl in the tibialis muscle of each hind leg. Administration of vaccines was according to the 
immunisation schedule (Fig 2.1). 
 
2.2.5. Preparation of splenocytes and serum 
Spleens harvested from animals of the same group were pooled for the preparation of a single cell 
suspension of splenocytes as previously described (Shen, 2010). Red blood cells were removed by lysing 
them with Red Blood Cell Lysing Buffer (Sigma-Aldrich, USA). The resulting splenocytes were used in IFN-
γ / IL-2 ELISpot (section 2.2.6), flow cytometry and intracellular cytokine staining (ICS) (section 2.2.7) and 
cytometric bead array (CBA) assay (section 2.2.8). Serum was separated by spinning down mouse blood 
at 2000 g for 10 minutes and stored at -22°C until analysed for antibodies using an antibody ELISA assay 
(section 2.2.9). 
 
2.2.6. Interferon (IFN)-γ and interleukin-2 (IL-2) ELISpot assay 
To measure the number of IFN-γ and IL-2 secreting CD4+ and CD8+ T cells, in response to re-stimulation 
with HIV-1 peptides or S. mansoni soluble egg antigen (SEA) and concanavalin A (Con A: Sigma-Aldrich, 
USA), IFN-γ and IL-2 ELISpot were carried out according to an established and optimised protocol in the 
lab (Shephard et al., 2008). Briefly, freshly isolated splenocytes were plated in triplicates at half a million 
cells per well previously coated with either IFN-γ or IL-2 capture antibody. Two micrograms per millilitre 
(2µg/ml) of an individual peptide (Bachem, Switzerland) was used for in vitro stimulation of cells followed 
by detecting responding cells (Table 2.1). As for the Gag CD4 peptides, MRC13 and MRC17 were pooled 
together. (The Env CD8 peptide (V3 CTL) was not available for use in the preliminary study but it was used 
in succeeding assays described in Chapters 3 and 4). BALB/c mice express the H-2Kd gene in their major 
histocompatibility complex (MHC) which allows them to bind and respond to specific HIV-1 epitopes. Cells 
were also stimulated with 2µg/ml of an irrelevant peptide (hemagglutinin [influenza A virus-derived]: 
negative control); 1µg/ml Con A (positive control) and 20µg/ml S. mansoni SEA (parasite control). 
Membrane-bound cytokines were detected using biotinylated IFN-γ /IL-2 secondary antibodies. Spots were 
developed using the Nova Red (Vector Laboratories, USA) substrate following manufacturer’s instructions. 
The number of spots was counted and analysed with a CTL ImmunoSpot analysing system (Cellular 
Technology Limited, USA). The average of triplicate counts of IFN-γ and IL-2 spot forming unit (SFU) was 
calculated for each stimulant and normalised to 106 splenocytes to give SFU/106 splenocytes. The results 
were reported as net IFN-γ or IL-2 SFU/106 splenocytes after subtracting the background SFU/106 
splenocytes obtained from cells stimulated with an irrelevant peptide (negative control). A cut-off value of 
2X background spots (responses in irrelevant peptide stimulation) plus 2X standard deviation (SD) was set 
to determine a positive response. Any response with an SFU/106 below the cut-off value was assigned a 




Table 2.1: Control and peptide stimulants used in the ELISpot, ICS and CBA assays 
Stimulant Source of stimulant  Description Peptide sequence 
Con A  Sigma-Aldrich, USA Non-specific polyclonal 
stimulus positive control 
N/A 
Env CD4 (Env 6) Bachem, Switzerland Env MHC class II-
restricted CD4 epitope 
-YGVPVWREAKTILFCA- 
Env CD8 (V3-CTL) 
peptide 
Bachem, Switzerland  Env H-2Dd-restricted 
CD8 peptide 
-RGPGRAFVTI- 
Gag CD4 (MRC13) 
peptide 
Bachem, Switzerland  Gag MHC class II-




Gag CD4 (MRC17) 
peptide 
Bachem, Switzerland  Gag MHC class II-




Gag CD8 peptide Bachem, Switzerland  Gag H-2Kd – restricted 




Irrelevant peptide  Bachem, Switzerland Negative peptide control -H-TXSTVASSL-OH- 
 
PMA/Ionomycin BD Biosciences, USA Leukocyte Activation 
cocktail containing  
PMA, Ionomycin and 
Brefeldin A: Positive 
control 
N/A 
RT CD4 peptide Bachem, Switzerland  MHC class II-restricted 
CD4 peptide 
-PKVKQWPLTEVKIKALTAI- 




SEA Theodore Bilharz 
Research Institute, 
Egypt 
Soluble Egg Antigen: 




2.2.7. Flow cytometry and ICS 
The frequency of IFN-γ, IL-2 and TNF-α secreting splenocytes in response to ex vivo stimulation with HIV 




protocol (Jongwe, 2015). Briefly, freshly isolated splenocytes (adjusted to 2 x 106 cells/ml) were stimulated 
with 2μg/ml of HIV Pol (RT CD4+ RT CD8) specific peptides; 20μg/ml of SEA (parasite-specific control) or 
with 2μl Leukocyte activation cocktail (phorbol 12-myristate 13-acetate + ionomycin [PMA/Ionomycin]) for 
2 hrs at 37°C, 5% CO2. Each group consisted of a negative control (unstimulated cells). Brefeldin A (BFA) 
(20μg/ml) was added to the splenocytes and incubated for an additional 4 hrs.  
 
Splenocytes were then dispensed into a V-bottomed 96-well plate and washed twice with 1x PBS (Gibco, 
Invitrogen) to remove any debris and proteins from the culture medium. This was achieved by spinning the 
plate in a centrifuge at 840 g for 3 minutes and discarding the supernatant from the wells. Cells were then 
blocked in 50μl blocking solution (0.12μl normal mouse serum, 0.12μl normal rat serum, 0.16μg CD16/32 
[BD Biosciences, USA]) for 15 minutes at 4˚C following re-suspending them in 1x PBS (150μl/well) and 
centrifuging as before. 
 
Cells were re-suspended in ViViD (50μl/well) (Invitrogen) at a pre-determined optimal concentration and 
the plate was incubated for 20 minutes at room temperature in the dark to stain for the live/ dead cells. 
Plates were then washed twice with FACS wash buffer and pelleted by centrifugation (840 g for 3 minutes), 
to remove unbound ViViD before surface staining. Cell surface molecules were stained with the 
fluorochrome-conjugated antibody (anti-CD3-Alexa 700, anti-CD4-PE-Cy7, anti-αCD8-APC-Cy7, anti-
CD62L-APC, and anti-CD44-FITC) diluted to 0.2µg in staining buffer (BD Biosciences, USA) and incubated 
at 4˚C for 20 minutes. Cells were washed and permeabilized with Cytofix/cytoperm and further stained with 
pooled PE-conjugated anti-TNF (0.2μg) anti-IL-2 (0.06μg) and anti-IFN-g (0.06μg) antibodies diluted in 
Perm/Wash buffer (BD Biosciences, USA). Cells were washed twice 200µl wash buffer before being re-
suspended in 100μl stain buffer and stored at 4˚C for until acquisition on a BD LSRII (BD Biosciences, 
USA). All the antibodies except anti-CD3-Alexa 700; anti-CD62L-APC and anti-CD44-FITC (eBioscience, 
USA) were obtained from BD Biosciences) (Table 2.2). 
 
Data was acquired using an LSRII flow cytometer running FACS Diva (BD Biosciences, USA) and analysed 
in FlowJo version 10 software (FlowJo LLC, USA). The gating strategy and representative plots are 
illustrated below (Fig 2.2). Responses to individual stimulants were considered positive for cytokine 
production if the frequency of cytokine-producing cells was ≥ 0.05% (with a minimum of 50 events). 
Cytokine-positive memory T cells (memory phenotypes of the cytokine positive cells determined by their 
relative expression of CD44 [effector] and CD62L [central]) were considered positive if >20 events were 
detected. Thus, any responses not meeting the set cutoff were assigned 0 (negative). One experiment was 






Figure 2.2: Gating strategy used for flow cytometry analysis of vaccine-specific CD8+ and CD4+ 
cytokine-producing cells. Splenocytes were stimulated with appropriate stimulant or left unstimulated 
(negative control). Time gates were plotted and used to exclude artefacts or aggregates (if any) (plot 1). 
Lymphocytes were gated based on the relative size and granularity of the cells and plotted as forward 
scatter (FSC) versus side scatter (SSC) (plot 2). Singlet gates based on forward scatter height (FSC-H) 
and forward scatter area (FSC-A) were used to exclude doublet cells (plot 3). Live CD3+cells were gated 
on ViViD negative populations (plot 4). CD4+ and CD8+ T cells populations were identified (plot 5 and plot 
6 respectively). Cytokine-producing CD4+ and CD8+ cells were identified (plot 5.1 and plot 6.1 
respectively) as well as, effector (TEM) and central (TCM) memory for both cytokine-producing CD4+ and 



















































Table 2.2: Antibodies used in Flow cytometry and ICS of this study modified from previously 
published thesis (Jongwe, 2015). 
Ab Working concentration  Manufacturer 
anti-CD3-Alexa 700 0.2µg eBioscience 
anti-CD4-PE-Cy7 0.2µg BD Biosciences 
anti-αCD8-APC-Cy7 0.2µg BD Biosciences 
anti-CD62L-APC 0.2µg eBioscience 
anti-CD44-FITC 0.2µg eBioscience 
anti-TNF-PE 0.2µg BD Biosciences 
anti-IL-2-PE 0.06μg BD Biosciences 
anti-IFN-g-PE 0.06μg BD Biosciences 
anti-CD19-Parc Blue 0.2µg BD Biosciences 
 
 
2.2.8. Quantification of secreted cytokines by CBA 
The cytometric bead array (CBA) assay (BD Biosciences, USA) is a powerful tool used for quantifying 
cytokine production in cells. Unlike ELISA assays, the CBA assay is cost effective and can measure multiple 
cytokines at a time while requiring less sample volume. The BD CBA mouse Th1/Th2/Th17 kit (BD 
Biosciences, USA) provides an affordable way to determine whether an immune response elicited is a Th1 
or Th2 biased, with IFN-γ, IL-2, and TNF-α being are associated with a Th1 response, while IL-4, IL-6, and 
IL-10 are associated with a Th2 response (Murphy and Weaver, 2016). Freshly isolated splenocytes pooled 
from 5-8 mice /group were adjusted to 15x106 cell/ml) with R10 medium. One hundred microlitres (100μl) 
of the splenocyte suspension (1.5x106 splenocytes) was added to each well in a 96 well round-bottom 
microtiter plate followed by the addition of 100μl of R10 medium (RPMI medium supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 15mM 2-mercaptoethanol, 100U penicillin per ml, and 100μg 
streptomycin), Con A / SEA or HIV peptides (described in Table 2.1). The Gag CD4 peptides comprised of 
MRC13 and MRC17 were pooled together. (The Env CD8 peptide (V3 CTL) was not used in the preliminary 
study but used in succeeding assays in Chapters 3 and 4). The plates were incubated at 37°C; 5% CO2 in 
a humidified air incubator for 48 hours. The cells were cultured in duplicate for each group of mice. The 
supernatants were carefully harvested (150μl) without disturbing the cell pellets and stored at -22˚C until 
the day of cytokine detection using a CBA mouse Th1/Th2/Th17 cytokine kit (BD Biosciences, USA) that 
measures Th1 (IFN-γ, TNF-α, IL-2) Th2 (IL-4, IL-6), Th17 (IL-17A) and non-classical Th2 (IL-10) cytokines. 
The CBA assay was carried out according to the manufacturer’s protocol. Briefly, lyophilized mouse 
Th1/Th2/Th17 standards were reconstituted in 2ml of assay diluent and allowed to equilibrate at room 
temperature for 15 minutes. Serial dilutions (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256) of the 




(negative control). Individual capture beads (A1-A7: IL-2, IL-4, IL-6, IFN-γ, TNF-α, IL-17A and IL-10 
respectively) were vortexed vigorously before being pooled together in a FACS tube (10μl of each type of 
capture bead per assay). Fifty microliters (50μl) of capture bead mixtures and 50μl of test sample 
supernatants were mixed in a FACS tube. Also, fifty microliters (50μl) of each standard dilution were added 
into allocated tubes. Fifty microliters (50μl) of PE detection reagent was then added into each of the tubes 
containing standards and test samples following which the tubes were incubated at room temperature for 
two hours in the dark. All the tubes were washed with 1ml wash buffer and each bead pellet was re-
suspended with 300μl of wash buffer. The samples were analysed using an LSRII flow cytometer running 
FACS Diva (BD Biosciences, USA). 
  
The average values of cytokine produced were calculated using FCAP array software (BD Biosciences, 
USA) and expressed as picogram per millilitre (pg/ml) of supernatant. Cytokine values were considered 
positive if they were greater than twice the background values (cytokine secreted by splenocytes in the 
presence of an irrelevant peptide per group). Furthermore, values below the cut-off (detection limit per 
cytokine described in Table 2.3) were set to zero. Th17 cytokine (IL-17A) was excluded from the final 
results. The sum of cytokine values obtained with the individual HIV peptide stimuli (cumulative cytokine 
response) for all vaccinated groups was plotted and expressed as pg/ml. The theoretical limit of detection 
of the CBA mouse Th1/Th2/Th17 Cytokine Kit (Table 2.3) is comparable to conventional ELISA. By applying 
the 4-parameter curve fit option, it was possible to extrapolate values for sample intensities not falling within 
the limits of the standard curve. All responses not meeting the set cut-off were assigned zero (negative). 
 
Table 2.3: Cytometric bead array (CBA) kit (BD Biosciences): Limit of cytokine detection  
Cytokine Limit of detection (pg/ml) 
IL-2  0.1 
IL-4  0.03 
IL-6  1.4 
IFN-γ  0.5 
TNF-α  0.9 
IL-17A  0.8 





2.2.9. Quantification of total and Env-gp140 specific antibody isotypes by ELISA assay  
2.2.9.1. Total IgG antibody ELISA 
Ninety-six-well MaxiSorp ELISA plates (Nunc, USA) were coated with goat anti-mouse IgG capture antibody 
(Sigma Aldrich, USA) at a concentration of 2.5μg/ml in coating buffer (PBS) and incubated at 4°C overnight. 
The wells were washed five times with 200μl washing buffer (PBS containing 0.05% Tween-20: Sigma 
Aldrich, USA), then blocked for 60min at room temperature with 200μl blocking buffer (PBS containing 5% 
skimmed milk). A standard dilution series for IgM; IgG1; IgG2a and IgG2b were prepared by serially diluting 
standards in dilution buffer (PBS containing 2.5% skimmed milk) and plated in duplicates. Samples to be 
tested were diluted (1:5000) and plated in duplicates for 2 hours at room temperature. Plates were washed 
five times with 200μl wash buffer following which matching secondary antibodies conjugated to horseradish 
peroxidase (HRP) (1:500) were added. The plates were incubated for 60min at room temperature in the 
dark. After incubation with appropriate secondary antibodies, plates were washed five times with washing 
buffer followed by developing with 100μl/well tetramethyl-benzidine substrate (TMB; KPL, USA). The 
reaction was stopped by addition of 100μl/well stop solution (1N H2SO4). Immediately after stopping the 
reaction, the optical density (OD) was measured at 450nm and a reference of 540nm with a microplate 
reader (Molecular Devices Corporation) running SOFTmax v6 software (Molecular Devices Corporation, 
USA). Curve fitting was approximated by a 4-parameter hyperbolic curve (SOFTmax PRO ver.6; Molecular 
Devices Corporation, USA) and data was presented as ng/ml.   
 
2.2.9.2. Env-gp140 specific antibody ELISA 
To measure the level of HIV gp140 Env-specific antibodies in mouse sera, a standardised ELISA assay 
was established according to the ELISA method by (Cheung et al., 2015). The method was based on 
assigning antibody units (at a fixed dilution) extrapolated from a standard curve of a reference sample. To 
prepare the reference sample to be used in the current study, sera from mice (previously vaccinated twice 
with HIV gp140 Env protein) selected for relatively high antibody titer to Env-gp140 were pooled and diluted 
1:100 with PBS. Diluted and aliquoted (50μl per aliquot) sera were stored at -22°C until required. To perform 
the standardized ELISA assay, flat-bottom 96-well ELISA plates (Nunc, USA) were coated with 0.5µg/ml of 
gp140 protein diluted in phosphate buffered saline (PBS) and incubated overnight at 4°C. Plates were 
blocked with 200 μl/well of blocking buffer for 2 hours at room temperature. Independent duplicates dilutions 
(1:1000) of each test mouse serum was prepared in dilution buffer (PBS containing 2.5% skimmed milk). 
Diluted test sera (1:1000) and 12 two-fold dilutions of reference sample were added to gp140-coated wells 
(100μl/well) and incubated for 2 hours at room temperature. Plates were washed five times with washing 
buffer (PBS containing 0.05% Tween-20: Sigma Aldrich, USA) using an automatic plate washer followed 
by addition of 100μl/well of the appropriate secondary antibody conjugated with horseradish 
peroxidase (HRP) for 2 hours at room temperature. The secondary antibodies included 3 anti-Mouse IgG 




antibody, plates were washed five times following developing with 100μl/well tetramethyl-benzidine 
substrate (TMB; KPL, USA). Plates were incubated at room temperature for 5-10 minutes in the dark. 
Reactions were terminated by adding 100μl/well of stopping buffer (1N H2SO4). Immediately after stopping 
the reaction, the optical density (OD) was measured at 450nm and a reference of 540 nm with a microplate 
reader (Molecular Devices, USA) running SOFTmax v6 (Molecular Devices Corporation, USA). 
To assign antibody units (AUs), first, one of the aliquots was serially diluted in two-fold steps from 1:100 to 
1:204, 800 (12 dilutions) with dilution buffer. Mouse sera from naïve (unvaccinated) animals were used as 
a negative control. Next, the ELISA steps were performed as described above. Based on the constants of 
the standard curve generated from the serially diluted reference sample, the reciprocal dilution giving an 
OD=1 (against gp140) was assigned 1000 antibody units and the negative control was assigned a 
reciprocal dilution of 0. Curve fitting was approximated by a 4-parameter hyperbolic curve (SOFTmax PRO 
ver.6; Molecular Devices Corporation, USA). This method was validated by comparing AUs derived from 
single dilutions versus multiple serial dilutions of the same test serum and confirming a positive correlation 
between reciprocal dilutions with OD=1 and calculated AUs. Thereafter, a reference sample was used on 
each ELISA plate to generate a standard curve from which the assigned antibody units were used to 
extrapolate for test samples at a fixed dilution of 1:1000. A cut-off value for positive antibody responses 
was set at 2 x the OD value of the negative control serum (naïve) and those below the cut of value were 
assigned an antibody unit of zero. 
 
2.2.10. Statistical analysis 
In order to measure the effect of schistosomiasis on the immunogenicity of the candidate HIV vaccine that 
induced antibody immune responses, statistical analyses were conducted to compare between the 
vaccinated groups that were either infected or uninfected. Results were analysed in Prism® version 5.0 
(GraphPad Software, USA), using two-tailed Student t-tests for significance. Statistical p values < 0.05 were 
considered to be significant. The false discovery rate (FDR) with Benjamini-Hochberg-adjusted P <0.05 
was performed as described by (McDonald, 2009). No statistical analysis was conducted for the cellular 





2.3.1. Cellular immune responses to the DNA+MVA and MVA+gp140 vaccine regimen in the 
background of Sm measured by ELISpot 
Cellular immune responses were evaluated using IFN-γ and IL-2 ELISpot assays to enumerate the 
magnitude of Gag; RT and Env-specific IFN-γ and IL-2 secreting CD8+ and CD4+ T cells in the spleen of 
mice vaccinated with either the DNA-MVA (DNA+MVA) (Fig 2.3) or MVA-protein (MVA+gp140) (Fig 2.4) 
vaccines.  
 
2.3.1.1. Vaccine-specific ELISpot responses to DNA+MVA vaccine regimen 
Vaccination with DNA+MVA induced high cumulative HIV-1 Gag, RT and Env-specific IFN-γ (3957 SFU/106 
splenocytes) (Fig 2.3 A) and IL-2 ELISpot (958 SFU/106 splenocytes) responses in Sm-free vaccinated 
mice (DNA+MVA). In contrast, vaccination in Sm-infected mice (Sm+DNA+MVA) induced a moderate 
magnitude of peptide-specific IFN-γ (2210 SFU/106 splenocytes) and a low magnitude of IL-2 (115 SFU/106 
splenocytes) ELISpot responses. The same was observed for IFN-γ (Fig 2.3 B) and IL-2 (Fig 2.3 D) ELISpot 
responses to individual Gag (CD4 or CD8); RT (CD4 or CD8) and Env (CD4) specific peptides. IFN-γ 
ELISpot responses to the RT CD8 peptide induced the highest magnitude of IFN-γ secreting CD8+ and 
CD4+ T cells (2228 SFU/106 splenocytes) in Sm-free mice. However, a lower magnitude of RT CD8-specific 
IFN-γ (1258 SFU/106 splenocytes) was observed in Sm-infected vaccinated mice. The same was observed 
for all the other peptides except for the Gag CD8 peptide which had slightly higher IFN-γ responses in Sm-
infected (649 SFU/106 splenocytes) compared to Sm-free vaccinated (538 SFU/106 splenocytes) group. 
 
The highest magnitude of IL-2 ELISpot responses was observed in Sm-free vaccinated mice splenocytes 
(352 SFU/106 splenocytes) stimulated with Env CD4 peptide, while in Sm-infected mice, IL-2 responses as 
low as (37 SFU/106 splenocytes) were observed. While all peptides (Gag CD8 and CD4; RT CD8 and RT 
CD4; and Env CD4) exhibited IL-2 ELISpot response in Sm-free vaccinated mice, they were reduced by 
almost a half in Sm-infected vaccinated mice. In fact, IL-2 ELISpot responses to the Gag CD8 and RT CD8 
peptides were undetectable in Sm-infected mice (Fig 2.3 D). 
 






Figure 2.3: IFN-γ and IL-2 ELISpot analysis of HIV-1 Gag; RT and Env-specific T cell responses 
induced in the spleen of Sm-infected and Sm-free mice vaccinated with the DNA+MVA vaccine 
regimen described in Fig 2.1. At sacrifice, splenocytes were pooled from 5-8 mice per group and 
stimulated with a control stimulant (irrelevant peptide) or HIV-1 (Gag; RT [CD4 and CD8] and Env CD4) 
peptides in an IFN-γ ELISpot (A and B) and IL-2 ELISpot (C and D) assays. Positive responses to the HIV 
peptides were considered to be those greater than twice the background response (response to irrelevant 
peptide stimulation) plus two times the standard deviation (SD) of this response. The magnitude of positive 
ELISpot responses is expressed as either net cumulative (A and C) or net individual peptides (B and D) 















































































































































































































2.3.1.2. Vaccine-specific ELISpot responses to MVA+gp140 vaccine regimen 
Vaccination with MVA+gp140 induced high cumulative HIV-1 Gag, RT and Env-specific IFN-γ (2347 
SFU/106 splenocytes) (Fig 2.4 A) and IL-2 ELISpot (306 SFU/106 splenocytes) (Fig 2.4 C) responses in Sm-
free vaccinated mice. Vaccinated Sm-infected groups had a low magnitude of HIV peptide-specific IFN-γ 
(900 SFU/106 splenocytes) and undetectable IL-2 (0 SFU/106 splenocytes) ELISpot responses. The same 
was observed for IFN-γ (Fig 2.3 B) and IL-2 (Fig 2.3 D) ELISpot responses to individual Gag (CD4 or CD8); 
RT (CD4 or CD8) and Env (CD4) specific peptides. IFN-γ ELISpot responses to the RT CD8 peptide 
induced the highest magnitude of IFN-γ secreting CD8+ and CD4+ T cells (1115 SFU/106 splenocytes) in 
Sm-free mice. However, a lower magnitude of RT CD8 specific IFN-γ (550 SFU/106 splenocytes) was 
observed in Sm-infected vaccinated mice. The same reduction was observed for all the other peptides. The 
highest magnitude of IL-2 ELISpot responses was observed in Sm-free vaccinated mice splenocytes (163 
SFU/106 splenocytes) stimulated with RT CD4 peptide followed by Gag CD4 (85 SFU/106 splenocytes) and 
Env CD4 (58 SFU/106 splenocytes). On the other hand, Sm-infected mice had IL-2 responses below 






Figure 2.4: IFN-γ and IL-2 ELISPOT analysis of HIV-1 Gag; RT and Env-specific T cell responses 
induced in the spleen of Sm-infected and Sm-free mice vaccinated with the MVA+gp140 vaccine 
regimen described in Fig 2.1. At sacrifice, splenocytes were pooled from 5-8 mice per group and 
stimulated with a control stimulant (irrelevant peptide) or HIV-1 (Gag; RT and Env [CD4 and CD8]) peptides 
in an IFN-γ ELISpot (A and B) and IL-2 ELISpot (C and D) assays. Positive responses to the HIV peptides 
were considered to be those greater than the background response (response to irrelevant peptide 
stimulation) plus two times the standard deviation (SD) of this response. The magnitude of positive ELISpot 
responses is expressed as either net cumulative (A and C) or net individual peptides (B and D) responses 






























































































































































































2.3.2. Th1 Th2 responses to non-specific stimulation (Con A) and parasite-specific (SEA) in mice 
vaccinated with MVA+gp140 and DNA+MVA vaccine regimens 
 
2.3.2.1. Cytokine responses to Con A and SEA 
The amount of Th1 and Th2 cytokines secreted by T cells after stimulation with Con A (non-specific 
stimulation) and SEA (parasite-specific stimulation) (Fig 2.5) were quantified for MVA+gp140 (A-G) and 
DNA+MVA (H-N) vaccinated mice using CBA. As shown in Fig 2.5 A-C, an increased skewing towards Th2 
of Sm-infected compared to Sm-free mice vaccinated with MVA+gp140 marked with IL-6 (418.77 pg/ml) 
and IL-10 (66.02 pg/ml) respectively in Sm-infected compared to Sm-free (IL-6=157.01 pg/ml) and IL-10 = 
36.56 pg/ml) but not IL-4 (10.5 vs 13.97 pg/ml) responses to Con A was observed. Furthermore, an increase 
in IL-4 (20.15 pg/ml); IL-6 (1115.56 pg/ml) and IL-10 (525.24 pg/ml) respectively in Sm-infected compared 
to Sm-free (IL-4 = 13.14 pg/ml) IL-6 (127.42 pg/ml) and IL-10 (4.66 pg/ml) in response to the parasite-
specific SEA was observed (Fig 2.5 A-C). 
However, drastic reduction of Th1 cytokines in Sm-infected compared to Sm-free vaccinated mice 
stimulated with Con A, marked by IFN-γ (29.93 vs 2257.03 pg/ml) IL-2 (6.94 vs 16.03 pg/ml) and TNF-α 
(24.94 vs 97.86 pg/ml) was observed. Sm-infected and Sm-free vaccinated mice produced close to similar 
levels of Th1 cytokines (IL-2 [9.54 vs 12.86 pg/ml] and TNF-α [34.34 vs 42.23 pg/ml]) except for IFN-γ [9.59 
vs 28.0 pg/ml] which was higher in Sm-free after stimulation with SEA (Fig 2.5 D-F). Skewing towards Th2 
marked by a decrease in the IFN-γ:IL-4 ratio following stimulation with Con A was observed in Sm-infected 
(2.85) compared to Sm-free (161.56) vaccinated mice (Fig. 2.5 G).   
In mice vaccinated with DNA+MVA, an increased Th2 cytokine production marked with IL-4 (20.0 vs 9.98 
pg/ml); IL-6 (516.93 vs 53.89 pg/ml) and IL-10 (259.79 vs 74.82 pg/ml) responses to Con A was observed 
in Sm-infected compared to Sm-free vaccinated mice (Fig 2.5 H-N). Also, an increase in IL-4 (10.3 vs 3.47 
pg/ml) IL-6 (624.35 vs 27.48 pg/ml) and IL-10 (473.80 vs 0 pg/ml) in response to the parasite-specific SEA 
was observed in Sm-infected mice compared to Sm-free vaccinated mice (Fig 2.5 H-J). 
Th1 cytokines were lower in Sm-infected compared to Sm-free mice vaccinated with DNA+MVA and 
stimulated with Con A marked by IFN-γ (508.69 vs 3967.68 pg/ml) IL-2 (10.85 vs 28.18 pg/ml) and TNF-α 
(49.34 vs 160.18 pg/ml). Similar to the mice vaccinated with MVA+gp140, Sm-infected and Sm-free 
vaccinated mice produced close to similar levels of Th1 cytokines (IL-2 [5.39 vs 6.85 pg/ml] and TNF-α 
[34.05 vs 36.87 pg/ml]) except for IFN-γ [11.37 vs 101.99 pg/ml] which was higher in Sm-free after 
stimulation with SEA (Fig 2.5 K-M). Th2 biasing marked by a decrease in the IFN-γ:IL-4 ratio upon 
stimulation with Con A was observed in Sm-infected (25.43) compared to Sm-free (397.56) vaccinated mice 





Figure 2.5: Cytokine production by Con A and SEA stimulation in Sm-free and Sm-infected mice 
vaccinated with MVA+gp140 or DNA+MVA regimen. Splenocytes were harvested from mice vaccinated 
with the indicated regimen described in Fig 2.1. They were then stimulated with an irrelevant peptide 
(negative control) or Con A or with SEA for 48 h. Culture supernatants were collected and the level of Th1 
and Th2 cytokines released into the medium for MVA+gp140 (A-C and D-F respectively) and DNA+MVA 
(H-J and K-M respectively) vaccinated mice was measured using a CBA and flow cytometric analysis. The 
individual bars represent the magnitude of the net positive cytokine levels in the medium of splenocytes of 
Sm-free and Sm-infected vaccinated mice. The level of cytokines in the culture medium was considered 
positive when the level is higher than the detection limit of the respective cytokine described in Table 2.3. 
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2.3.2.2. HIV-Specific cytokine production  
The amount of Th1 and Th2 cytokines secreted by HIV-specific T cells stimulated with HIV Gag (CD4; 
CD8); RT (CD8; CD4) and Env (CD4) was also quantified (Fig 2.6-2.9). Splenocytes harvested from mice 
vaccinated according to the regimens indicated in Fig 2.1 were incubated for 48 h with the HIV Gag (CD4; 
CD8); RT (CD8; CD4) and Env (CD4) T cell peptides or with Con A or SEA and the level of Th1 (IFN-γ; IL-
2; TNF-α) and Th2 (IL-6; IL-4; IL-10) cytokines released into the culture medium was quantified using a 
Cytometric Bead Array assay (BD Biosciences, USA) and flow cytometric analysis. 
2.3.2.3. Cytokine responses to DNA+MVA 
The cumulative positive cytokine levels produced in response to HIV peptides for the DNA+MVA 
vaccination regimen is shown in Fig 2.6. High levels of net Th1 cytokines: IFN-γ (4157.38 pg/ml); IL-2 
(102.59 pg/ml) and TNF-α (303.55 pg/ml) was released from T cells of Sm-free mice in response to a 
DNA+MVA vaccination regimen. However, splenocytes of mice infected with Sm produced lower Th1 
cytokine levels of IFN-γ (469.99 pg/ml); IL-2 (27.06 pg/ml) and TNF-α (71.71 pg/ml) (Fig 2.6 A; B and C 
respectively). Conversely, net Th2 cytokine levels in Sm-free vaccinated mice were lower compared to Sm-
infected vaccinated: IL-6 (301.67 vs 1007.16 pg/ml) and IL-10 (100.5 vs 169.13 pg/ml) with exception to IL-
4 which was similar between Sm-free (17.03 pg/ml) and Sm-infected (17.91 pg/ml) vaccinated mice (Fig 










Figure 2.6 Cumulative cytokines produced by HIV peptide-specific T cells of Sm-free and Sm-
















































































































































































































































































indicated regimen described in Fig 2.1. They were then stimulated with an irrelevant peptide (negative 
control) or with the individual HIV specific T cell peptides for 48 h. Culture supernatants were collected and 
the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines released into the medium was measured using 
CBA. The individual bars represent the magnitude of the cumulative positive cytokine levels in the medium 
of splenocytes of Sm-free and Sm-infected vaccinated mice, stimulated with individual HIV peptides, after 
subtracting the background (splenocytes stimulated with irrelevant peptide). The level of cytokines in the 
culture medium was considered positive when the level is higher than the detection limit of the respective 
cytokine described in Table 2.3. 
 
 
Despite high levels of net IFN-γ released from HIV peptide-specific T cells of Sm-free mice vaccinated with 
a DNA+MVA vaccine, 53% of the responses were attributed to the RT CD8 peptide-specific responses (Fig 
2.7 A). However, Sm-infected vaccinated groups had a drastic reduction of the net IFN-γ cytokine (95.37 
pg/ml) in response to RT CD8 peptide. The same was true for all peptides except for the Gag CD8, which 
was minimally reduced in Sm-infected (226.73 pg/ml) compared to Sm-free vaccinated mice (256.88 pg/ml). 
Levels of TNF-α were also drastically reduced in Sm-infected mice in response to all HIV peptides with 
exception to the Gag CD8 which produced almost similar TNF-α between the Sm-infected (26.8 pg/ml) and 
Sm-free vaccinated group (25.39 pg/ml) (Fig 2.7 C). The level of IL-2, on the other hand, was not detected 
in Sm-free mice (0 pg/ml) while they only reached 4.39 pg/ml in Sm-infected mice (Fig 2.7 B).   
 
On the contrary, Th2 cytokines were elevated in Sm-infected compared to Sm-free vaccinated mice. High 
levels of IL-6 were observed in all cultures of vaccinated Sm-infected cells stimulated with HIV peptides 
(Fig 2.7 E). Responses to the RT CD4 peptide were the highest (273.65 pg/ml) responses. The other 
peptides also induced higher levels of IL-6 in Sm-infected compared to Sm-free vaccinated mice.  
 
Higher levels of IL-4 were observed in Sm-free compared to Sm-infected vaccinated mice when stimulated 
with CD4-specific HIV peptides. On the other hand, stimulation with CD8-specific HIV peptides induced 
more Gag CD8 (3.47 pg/ml) and RT CD8 (2.53 pg/ml) in Sm-infected compared to Sm-free vaccinated 
mice, which produced less Gag CD8 (1.71 pg/ml) and no RT CD8 (0 pg/ml) (Fig 2.7 D).  
 
Sm-infected cells stimulated with HIV peptides produced high IL-10 levels compared to Sm-free vaccinated 
cells (Fig 2.7 F). This was only true for Gag CD8 (53.51 pg/ml vs 0 pg/ml); Gag CD4 (11.69 pg/ml vs 7.94 
pg/ml) and Env CD4 (57.76 pg/ml vs 39.5 pg/ml) responses in Sm-infected versus Sm-free vaccinated 
mice. Cytokine responses to the RT CD4 and CD8 peptide stimulation produced more IL-10 for Sm-free 
(37.91 and 15.5 pg/ml respectively) versus Sm-infected (33.92 and 12.25 pg/ml respectively) vaccinated 
mice (Fig 2.7 F).         





Figure 2.7: Cytokine produced by Gag (CD8 and CD4) RT (CD8 and CD4) and Env (CD4) specific 
peptides in Sm-free and Sm-infected mice vaccinated with DNA+MVA. Splenocytes were harvested 












































































































































































































































































































































































irrelevant peptide (negative control) or with the individual HIV-specific T cell peptides for 48 h. Culture 
supernatants were collected, and the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines released 
into the medium was measured using a Cytokine Bead Array assay and flow cytometric analysis. The 
individual bars represent the magnitude of the net positive cytokine levels in the medium of splenocytes of 
Sm-free and Sm-infected vaccinated mice, stimulated with individual HIV peptides, after subtracting the 
background (splenocytes stimulated with irrelevant peptide). The level of cytokines in the culture medium 
was considered positive when the level is higher than the detection limit of the respective cytokine described 
in Table 2.3. 
 
 
2.3.2.4. Cytokine responses to MVA+gp140 
The cumulative positive cytokine responses to the HIV peptides for the MVA+gp140 vaccination regimen 
are shown in Fig 2.8. High levels of net Th1 cytokines: IFN-γ (2165.44 pg/ml); IL-2 (138.88 pg/ml) and TNF-
α (217.29 pg/ml) was released from HIV peptide-specific T cells of Sm-free mice vaccinated with the 
MVA+gp140 vaccination regimen compared to Sm-infected vaccinated mice which produced lower Th1 
cytokine levels of IFN-γ (142.63 pg/ml); IL-2 (34.34 pg/ml) and TNF-α (78.2 pg/ml) (Fig 2.8 A; B and C 
respectively). Conversely, net Th2 cytokine levels in Sm-free vaccinated mice were lower compared to Sm-
infected vaccinated: IL-4 (35.82 vs 108.56 pg/ml) and IL-10 (58.63 vs 115.88 pg/ml) with exception to IL-6 
which was similar between Sm-free (928.4 pg/ml) and Sm-infected (891.15 pg/ml) vaccinated mice (Fig 2.8 






Figure 2.8: Cumulative cytokines produced by HIV peptide-specific T cells of Sm-free and Sm-






































































































































































































































































































indicated regimen described in Fig 2.1. They were then stimulated with an irrelevant peptide (negative 
control) or with the individual HIV specific T cell peptides for 48 h. Culture supernatants were collected and 
the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines released into the medium was measured using 
a Cytokine Bead Array assay and flow cytometric analysis. The individual bars represent the magnitude of 
the cumulative positive cytokine levels in the medium of splenocytes of Sm-free and Sm-infected vaccinated 
mice, stimulated with individual HIV peptides, after subtracting the background (splenocytes stimulated with 
irrelevant peptide). The level of cytokines in the culture medium was considered positive when the level is 
higher than the detection limit of the respective cytokine described in Table 2.3. 
 
Although Sm-free mice vaccinated with an MVA+gp140 vaccine produced high levels of net IFN-γ in 
response to the HIV peptides, 47% (1018.30 pg/ml) of the responses were attributed to the RT CD4 peptide-
specific responses (Fig 2.9 A). However, Sm-infected vaccinated groups had a drastic reduction of the net 
IFN-γ cytokine (61.77 pg/ml) in response to RT CD4 peptide. The drastic drop in IFN-γ cytokine was also 
observed for all peptides (Fig 2.9 A). Levels of TNF-α were also reduced by more than half in Sm-infected 
mice (15.04 vs 61.31 pg/ml) in response to the Gag CD8 peptide. This was true for all the other HIV peptides 
(Fig 2.9 C). Levels of IL-2 in Sm-infected mice were also drastically reduced by more than half compared 
to the Sm-free vaccinated mice (Fig 2.9 B). 
 
Th2 cytokines were higher in Sm-infected compared to Sm-free vaccinated mice particularly IL-4 and IL-10 
(Fig 2.9 D and F respectively). High levels of IL-4 were observed in all cultures of vaccinated Sm-infected 
cells compared to those of Sm-free stimulated with HIV peptides (Fig 2.9 E). Responses to the RT CD4 
peptide were the highest in Sm-infected (29.54 pg/ml) and reduced in Sm-free mice (6.67 pg/ml). The other 
peptides relatively stimulated more or less similar levels of IL-4 responses to other peptides (Gag CD8 
[26.86 pg/ml]; Gag CD4 [20.6 pg/ml]; RT CD8 [15 pg/ml] and Env CD4 [179.90 pg/ml] in Sm-infected mice 
was reduced in Sm-free vaccinated mice (Gag CD8 [7.01 pg/ml]; Gag CD4 [6.53 pg/ml]; RT CD8 [7.08 
pg/ml] and Env CD4 [8.53 pg/ml]. 
 
Increased IL-10 levels were observed in Sm-infected cells while being decreased in cells of Sm-free 
vaccinated mice (Fig 2.9 F). This was the case for responses to all peptide with exception to the Env CD4 
which was higher in Sm-free (14.69 pg/ml) versus Sm-infected (11.05 pg/ml) cultures. Cytokine responses 
to the RT CD4 peptide stimulation produced more IL-10 for Sm-infected (45.72 pg/ml) versus Sm-free 
(14.23 pg/ml) vaccinated mice. A minimal decrease in L-10 levels was observed in cultures of Sm-free (6.69 
pg/ml) versus Sm-infected (7.8 pg/ml) vaccinated.  
 
High levels of IL-6 were detected in both Sm-infected and Sm-free vaccinated group for all peptides (Fig 




mice compared to Sm-infected (192.41 pg/ml) vaccinated mice. The Gag CD8 peptide also stimulated 
higher levels of IL-6 in Sm-free mice (249.04 pg/ml) than in Sm-infected (164.74 pg/ml) vaccinated mice. 
Only in Gag CD4 (210.21 pg/ml); RT CD8 (152.57 pg/ml) and Env CD4 (171.22 pg/ml) stimulated cells did 
Sm-infected have higher cytokine production compared to Sm-free vaccinated: Gag CD4 (161.6 pg/ml); RT 






Figure 2.9: Cytokine produced by Gag (CD8 and CD4) RT (CD8 and CD4) and Env (CD4) specific 












































































































































































































































































































































































from mice vaccinated with the indicated regimen described in Fig 2.1. They were then stimulated with an 
irrelevant peptide (negative control) or with the individual HIV-specific T cell peptides for 48 h. Culture 
supernatants were collected and the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines released into 
the medium was measured using a Cytokine Bead Array assay and flow cytometric analysis. The individual 
bars represent the magnitude of the net positive cytokine levels in the medium of splenocytes of Sm-free 
and Sm-infected vaccinated mice, stimulated with individual HIV peptides, after subtracting the background 
(splenocytes stimulated with irrelevant peptide). The level of cytokines in the culture medium was 
considered positive when the level is higher than the detection limit of the respective cytokine described in 
Table 2.3. 
 
2.3.3. Cellular immune responses to the SAAVI DNA-C2 and SAAVI MVA-C vaccine regimen in the 
background of Schistosomiasis measured by ICS and FACS 
The proportions of cytokine (pool of IFN-γ, IL-2 and TNF-α) producing T cells in response to a non-specific 
stimulant (PMA/Ionomycin) were determined by ICS. In both MVA+gp140 (Fig 2.10 A and B) and 
DNA+MVA (Fig 2.10 C and D) vaccination regimen, a high number of cytokine-producing CD4+ and CD8+ 
T cells was observed in Sm-free mice whilst a decrease in a number of cytokine-producing CD4+ and CD8+ 
T cells was observed in Sm-infected mice (Fig 2.10). However, the proportion of CD4+ T cells producing 
cytokines was greater than that of CD8+ T cells in DNA+MVA and MVA+gp140.  
 
2.3.3.1. Cellular immune responses to PMA in MVA+gp140 vaccine regimen 
The frequency of cytokine-producing CD4+ T cells was higher in Sm-free mice (32.7%) compared to Sm-
infected (7.71%) vaccinated mice (Fig 2.10 A). The same was observed for Sm-free (34.9%) mice 
compared to Sm-infected (5.87%) mice without vaccination. A similar pattern was observed for cytokine-
producing CD8+ T cell (Fig 2.10 B). Cytokine-producing CD8+ T cells were high in Sm-free mice (24%) 
compared to Sm-infected vaccinated mice (8.05%). Unvaccinated Sm-free mice also had higher cytokine-
producing CD8+ T cells compared to Sm-infected mice (20.5% vs 6.3%).   
 
2.3.3.2. Cellular immune responses to PMA in DNA+MVA vaccine regimen 
The frequency of cytokine-producing CD4+ T cells was also higher in Sm-free mice (38.1%) compared to 
Sm-infected (17.6%) vaccinated mice (Fig 2.10 C). The same was observed for Sm-free (31.7%) mice 
compared to Sm-infected (14.6%) mice without vaccination. This was also true for cytokine-producing CD8+ 
T cell (Fig 2.10 D). Cytokine-producing CD8+ T cells were high in Sm-free mice (19.6%) compared to Sm-
infected vaccinated mice (3.21%). Unvaccinated Sm-free mice also had higher cytokine-producing CD8+ T 






Figure 2.10: Assessment of cytokine-producing T cells (CD4+ and CD8+) following stimulation with 
a Leukocyte Activation Cocktail (PMA/Ionomycin). (A and B) Total frequency of T cells (CD4+ and 
CD8+) producing cytokines (IFN-γ, IL-2, and TNF-α), in response to PMA/Ionomycin stimulation following 











































































































































































































cytokines (IFN-γ, IL-2, and TNF-α), in response to PMA/Ionomycin stimulation following vaccination with 
DNA+MVA regimen. Bars show positive responses above a cut-off value of 2x background, 50 events or 
0.05% cytokine-producing T cells.   
 
2.3.3.3. Vaccine-specific cellular responses to MVA+gp140 and DNA+MVA measured by ICS 
The proportions of cytokine (pool of IFN-γ, IL-2 and TNF-α) producing T cells in response to pooled HIV 
peptides (Pol: [RT CD4 + RT CD8]) were determined by ICS. In both MVA+gp140 (Fig 2.11 A) and 
DNA+MVA (Fig 2.11 B) vaccination regimen, a moderate number of cytokine-producing CD8+ T cells was 
observed in Sm-free mice and Sm-infected vaccinated mice (Fig 2.11). Cytokine-producing CD4+ T cells 
above the cutoff value were not detected in this experiment. In the MVA+gp140 vaccination regimen, the 
frequency of cytokine-producing CD8+ T cells slightly higher in Sm-infected mice (1.03%) compared to Sm-
free (0.92%) vaccinated mice (Fig 2.11 A). In the DNA+MVA vaccination regimen, the frequency of cytokine-
producing CD8+ T cells was almost similar in Sm-infected mice (1.53%) and Sm-free (1.46%) vaccinated 




Figure 2.11: Assessment of cytokine-producing T cells (CD8+) following stimulation with pooled 
HIV peptides (Pol: [RT CD4 + RT CD8]). (A) Total frequency of T cells CD8+ producing cytokines (IFN-γ, 
IL-2, and TNF-α), in response to Pol stimulation following vaccination with MVA+gp140 regimen. (B) Total 
frequency of T cells CD8+ producing cytokines (IFN-γ, IL-2, and TNF-α), in response to Pol stimulation 
following vaccination with DNA+MVA regimen. Bars show positive responses above a cut-off value of 2x 
background, 50 events or 0.05% cytokine-producing T cells.   
 





















































2.3.4. Assessing antibody responses in mice vaccinated with MVA+gp140 and with gp140 alone 
2.3.4.1. Total antibody responses  
Total IgG (IgG1; IgG2a; IgG2b and IgM) antibody isotypes in mice serum were measured using ELISA. For 
the MVA+gp140 regimen, Sm-free mice vaccinated with the MVA+gp140 vaccines induced significantly 
lower total IgG1 (41.25 ± 11.65 µg/ml) responses compared to Sm-infected vaccinated mice, which induced 
significantly higher total IgG1 (228.7 ± 12.39 µg/ml) responses (Fig 2.12 A). This was true in unvaccinated 
Sm-free controls. Total IgM in Sm-infected mice vaccinated with the MVA+gp140 was also significantly 
higher (300.1 ± 68.63 µg/ml) than in Sm-free (62.55 ± 6.220 µg/ml) vaccinated mice (Fig 2.12 B). This was 
also the case in unvaccinated controls. On the contrary, IgG2a was significantly elevated in Sm-free mice 
(256.6 ± 6.463 µg/ml) compared to Sm-infected mice (56.15 ± 7.613 µg/ml) vaccinated with MVA+gp140 
(Fig 2.12 C). This was true for unvaccinated controls. A significantly higher total IgG2b was observed in 
Sm-free (26.33 ± 3.596 µg/ml) vaccinated mice compared to Sm-infected (11.14 ± 0.5159 µg/ml) vaccinated 






Figure 2.12: Antibody responses in Sm-infected and Sm-free mice vaccinates with MVA+gp140.  
Serum samples were collected two weeks post last vaccination. Total serum IgG isotypes (IgG1 [A], IgM 
[B], IgG 2b [C] IgG2a [D],) were analysed by ELISA. Values are expressed as mean ± SEM. Statistical 
differences between the groups were calculated by unpaired t-test (two-tailed) followed by FDR for multiple 









































































































































































































For the gp140 regimen, Sm-free mice vaccinated with the gp140 vaccines induced lower total IgG1 (135.8 
± 37.94 µg/ml) responses compared to Sm-infected vaccinated mice, which induced higher total IgG1 
(228.7 ± 8.487 µg/ml) responses (Fig 2.13 A). However, the difference was not statistically significant. The 
same observation was true for unvaccinated controls. Total IgM in Sm-infected mice vaccinated with the 
gp140 was also significantly higher (181.9 ± 23.66 µg/ml) than in Sm-free (96.89 ± 4.742 µg/ml) vaccinated 
mice (Fig 2.13 B). This was also the case in unvaccinated controls. On the contrary, IgG2a was significantly 
higher in Sm-free mice (222.2 ± 5.450 µg/ml) compared to Sm-infected mice (51.01 ± 3.801 µg/ml) 
vaccinated with gp140 (Fig 2.13 C). This was true for unvaccinated controls. A significantly higher total 
IgG2b was observed in Sm-free (23.71 ± 2.248 µg/ml) vaccinated mice compared to Sm-infected (11.11 ± 






Figure 2.13: Antibody responses in Sm-infected and Sm-free mice vaccinates with gp140. Serum 
samples were collected two weeks post last vaccination. Total serum IgG isotypes (IgG1 [A], IgM [B], IgG 
2b [C] IgG2a [D],) were analysed by ELISA. Values are expressed as mean ± SEM. Statistical differences 
between the groups were calculated by unpaired t-test (two-tailed) followed by FDR for multiple 








































































































































































2.3.4.2. Env-gp140 specific antibody responses to MVA+gp140 and gp140 vaccine regimen 
ELISA determined antibody immunity in response to immunisation with either MVA+gp140 or gp140 is 
shown in Fig 2.4. In mice vaccinated the MVA+gp140, a significant amount gp140 specific-IgG antibody 
units were observed in Sm-free (170.2 ± 26.85) vs Sm-infected (55.33 ± 25.02) mice (Fig 2.14 A). Sm-free 
vaccinated mice (100.7 ± 34.70) also elicited a significant amount of IgG2a compared to Sm-infected mice 
(2.156 ± 1.508) (Fig 2.14 C). Levels of gp140 specific IgG1 and IgG2b were also higher in Sm-free 
vaccinated mice (189.2 ± 78.32 and 105.8 ± 56.12) compared to Sm-infected mice (38.27 ± 1.552 and 
6.878 ± 1.963). However, the difference was not significant (Fig 2.14 B and D respectively).   
Similarly, in mice vaccinated with gp140, higher levels of gp140 specific IgG was observed in Sm-free 
(234.4 ± 43.59) vs Sm-infected (45.99 ± 26.47) vaccinated mice (Fig 2.14 E). Sm-free vaccinated mice 
(115.3 ± 32.37) also elicited a significant amount of IgG2b compared to Sm-infected (2.614 ± 1.550) mice 
(Fig 2.14 H). Levels of gp140 specific IgG1 and IgG2a were also higher in Sm-free vaccinated mice (189.2 
± 78.32 and 30.47 ± 11.97) compared to Sm-infected mice (65.73 ± 41.51 and 6.426 ± 4.742). However, 





Figure 2.14: Humoral immune responses in mice immunised with MVA+gp140 and gp140. HIV-1 
gp140-specific IgG (A and E), IgG1 (B and F), IgG2a (C and G), and IgG2b (D and H) serum antibody 
responses two weeks after the last vaccination with either MVA+gp140 (A-D) or gp140 (E-H) analysed 
using ELISA. Values are plotted and expressed as mean antibody units (AUs) ± SEM for the 3-5 animals 
in each group. Statistical differences between the groups were calculated by unpaired t-test (two-tailed) 
followed by FDR for multiple comparisons, *P<0.05. 







































































































































































































































































































































































Helminthiasis and HIV infections are co-endemic in many regions of sub-Saharan Africa (SSA). Globally, 
soil-transmitted helminths (STH) and schistosome infections are estimated to infect over 1 billion people 
(Lustigman et al., 2012) with a third of STH infections and over 90% of schistosomiasis cases occurring in 
Africa (WHO, 2014). In addition, the geographical distribution of these infections vastly overlaps with 
regions with high HIV prevalence in SSA (Webb et al., 2012). Therefore, it is very likely that successful 
future HIV vaccines will be administered to people who already have ongoing helminthiasis or have been 
previously infected and treated. In animal models, schistosomiasis impairs responses to immunisation 
against hepatitis B (Chen et al., 2012), malaria (Su et al., 2006), mycobacterial infection and BCG 
immunisation (Elias et al., 2005b, Elias et al., 2005a). There is a lack of consistent scientific data to inform 
how candidate HIV vaccines would perform in the presence of ongoing helminthiasis given that helminthic 
infections have been shown to down-regulate Th1 immune responses which are expected to be an 
important component of successful HIV vaccines (Da'Dara et al., 2006). However, some studies have 
shown that this is not always true. Shollenberger et al., have demonstrated that the Listeria monocytogenes 
vaccine vector elicited robust and functional HIV-specific cellular immune responses in mice, despite the 
presence of a chronic helminth infection (Shollenberger et al., 2013a). Furthermore, recent studies have 
shown that S. mansoni egg antigen (responsible for biasing immune responses towards Th2) enhances 
vaccine-specific T cell responses to Listeria monocytogenes vector HIV-1 Vaccine (Beck et al., 2015). 
 
The present study presents immunological data from three experiments, which were conducted to test the 
impact of helminth infection on the immunogenicity of three candidate HIV vaccine regimens that elicit (1) 
predominantly cellular (SAAVI DNA-C2 + SAAVI MVA-C: DNA+MVA), (2) Predominantly antibody (Env-
gp140 protein) and, (3) Mixed cellular and antibody responses (SAAVI MVA-C + Env-gp140:  MVA+gp140). 
The primary aim of this study was to generate preliminary data that address the possible effect of helminth 
infection on unrelated antigen stimulation such as vaccine immunogens. The first objective of these 
experiments was to demonstrate if infection with live helminth infection, induces a predominantly Th2 
immune response. This was necessary to confirm if the type of helminth model (S. mansoni) was capable 
of inducing a type 2 response in BALB/c mice as well as to get an understanding of the time of Th2 onset 
in these mice. The second objective was to evaluate if this helminth-induced Th2 immune biasing negatively 
affects responses to candidate HIV vaccines. Therefore, three experiments comprising of 4 groups of mice 
were used. Two groups of mice were chronically infected with Sm, of which one group was subsequently 
vaccinated twice, 4 weeks apart with appropriate vaccination regimen. The control groups were those with 
either appropriate vaccine alone without Sm-infection or naïve. These experiments were conducted in 
BALB/c mice using S. mansoni (Sm) as a helminth prototype. The mouse model has been used extensively 
at the University of Cape Town for studying the Sm-associated disease (Ndlovu, 2013) as well as for initial 





2.4.1. Skewing of Th1/Th2 immune balance in chronic Sm infection 
 
Schistosomiasis in mice drives immune responses towards a predominant Th2-type characterized by the 
production of cytokines including IL-4, IL-5, IL-13, and IL-6. In addition to driving polarized Th2 responses, 
an increased production of the immunoregulatory cytokine IL-10 is common (MacDonald et al., 2002, 
Pearce and MacDonald, 2002). To test this in our mouse model, mice were chronically infected with Sm 
and systemic immune responses to Con A and SEA in Sm-infected and Sm-free vaccinated mice were 
analysed 16 weeks post-infection (wpi) to assess the induction of Th2 biasing using CBA assay (Fig 2.5). 
Parasite-specific Th2 cytokines (IL-4; IL-6 and IL-10) went on the rise in Sm-infected mice vaccinated with 
either an MVA+gp140 (Fig 2.5 A-C) or DNA+MVA (Fig 2.5 H-J) vaccine regimen in comparison with Sm-
free vaccinated mice. This was accompanied by a decrease in Th1 cytokines IFN-γ; IL-2 and TNF-α by 
almost 50% in Sm-infected mice vaccinated with MVA+gp140 (Fig 2.5 D-F) or DNA+MVA (Fig 2.5 K-M) 
compared to Sm-free vaccinated mice. Furthermore, a significant decrease of the IFN-γ:IL-4 ratio was 
observed in Sm-infected vaccinated mice when compared to Sm-free vaccinated mice (Fig 2.5 G and N), 
which is considered representative of a trend toward Th2 biasing and immunosuppression advocated by 
an increase in IL-10; IL-6 and antigen-specific IL-4 in helminth-infected mice (Shollenberger et al., 2013a). 
  
Cytokine data was further complimented with findings from ICS assay, which showed an overall reduction 
in the frequency of Th1 cytokine-producing CD4+ and CD8+ T cells in Sm-infected vaccinated mice 
stimulated with PMA/Ionomycin compared to Sm-free vaccinated (Fig 2.10). In Sm-free unvaccinated 
controls, the frequency of Th1 cytokine-producing CD4+ and CD8+ T cells was also higher compared to 
Sm-infected and Sm-infected vaccinated mice after stimulation with PMA/Ionomycin. Furthermore, total Ig 
antibodies were measured to further confirm skewing of host immune responses to Th2 biased. Infection 
with Sm resulted in increased Th2 Ig antibody markers (IgG1 and IgM) and a decrease in Th1 Ig antibody 
markers (IgG2a and IgG2b). The findings in the present study are consistent with the literature which reports 
that Sm infection increases total Th2 antibodies in Sm-infected compared to Sm-free individuals (Maizels 
and McSorley, 2016).The findings in this study also suggest that there is a correlation between the decrease 
of cytokine-producing CD8+ cells (Fig 2.10) and IgG2a and IgG2b (Fig 2.13) observed in Sm infected and 
Sm-infected and vaccinated mice. Previous studies have shown that cytokines produced by CD4+ and 
CD8+ T cells play an important role in the regulation of the humoral immune response and isotype switching 
(Kemeny et al., 1994, Burger et al., 1996, Snapper et al., 1997). Moreover, CD8+ depletion study conducted 
by Cano et al., showed that CD8+ T cells are necessary for optimal clearance of the fungus from tissues of 
mice infected with P. brasiliensis (Cano et al., 2000) which is dependent on IgG2a and IgG2b antibodies 
(Bueno et al., 2016). It is worth nothing that vaccines that induce antibody responses, may result in a slight 
reduction of non-specific total antibody responses (Fig 2.10) since more antibodies will become specific to 
epitopes presented by the vaccines. The immunological consequence of a predominant Th2 biasing 




previously suggested (Finkelman and Urban, 2001, Fincham et al., 2003, Thomas and Harn, 2004). 
Analysing both cellular responses and antibody responses eliminate ambiguity regarding Th2 dominance 
status during a chronic infection in the mouse model in the present study.  
 
2.4.2. Vaccine-specific T cell responses induced by the MVA+gp140 and DNA+MVA vaccine 
regimen in Sm infected mice 
The findings of the present study demonstrated that chronic helminth infection impairs Th1 cellular 
responses to HIV antigens, which are important for the induction of vaccine-specific cellular responses. 
Vaccination with the SAAVI-MVA + gp140 or SAAVI-DNA+MVA vaccine regimens induced strong T cell 
responses in Sm-free vaccinated mice measured by IFN-γ and IL-2 ELISpot (Fig 2.3 and 2.4) and CBA (Fig 
2.6 -2.9) as previously demonstrated (Burgers et al., 2006, Burgers et al., 2008, Shephard et al., 2008, 
Burgers et al., 2009). However, the mice with chronic Sm-infection failed to generate high vaccine-specific 
Th1 cellular responses measured by ELISpot (Fig 2.3 and 2.4) and CBA (Fig 2.6 -2.9) after vaccination with 
MVA+gp140 and DNA+MVA vaccine regimen. These results suggest that a chronic Sm-infection inhibited 
the immune responses to the vaccines against CD4+ and CD8+ specific HIV epitopes. Previous reports 
have linked the downregulation of vaccine-specific Th1 responses with a rise in helminth-induced Th2 
responses (Fallon et al., 1996, Urban et al., 1996, Urban et al., 2000, Remoué et al., 2000, Finkelman and 
Urban, 2001, Fincham et al., 2003, De Silva et al., 2003, Thomas and Harn, 2004). Thus, the results of the 
present study echo the findings by Da'Dara et al., which demonstrated that Sm infection suppressed T cell 
responses to a multi-epitope HIV-1 TD158 DNA vaccine (Da'Dara et al., 2006, Da'dara and Harn, 2010). 
However, Shollenberger et al, reported no negative impact on the Listeria induced CD8+ responses in Sm-
infected mice upon Gag stimulation (Shollenberger et al., 2013a). Although not substantial, a similar 
outcome was observed in the present study when splenocytes of Sm-infected mice vaccinated with 
DNA+MVA regimen induced higher ELISpot responses to Gag CD8 peptide (Fig 2.3B) compared to Sm-
free vaccinated mice. It can be hypothesised that interplay between parasite-induced cytokines may 
contribute to this upregulation of vaccines specific cellular responses. However, evaluating T cell responses 
to multiple vaccine immunogens as done in the current study, could give a much clearer picture compared 
to evaluating responses to only 2 peptides as previously done by Shollenberg et al., (Shollenberger et al., 
2013a). Nonetheless, our data along with other published observations shows that, helminth infection may 
attenuate vaccine-specific responses (Actor et al., 1993, Sabin et al., 1996, Cooper et al., 1999, Cooper et 
al., 2001, Elias et al., 2005a, Elias et al., 2008, Chen et al., 2012). The reduction of activated CD4+ and 
CD8+ cells due to infection reiterates the potential negative impact of helminth infection on the hosts T 
cells, and potentially the immunogenicity of future candidate HIV vaccines. Furthermore, cellular anergy or 
hyporesponsiveness that result from immunoregulatory cytokines (Prendergast et al., 2015) may be a 
huddle that may prevent mounting of vaccine-specific cellular responses in helminth-endemic areas. 
However, these findings do not address if the early phase of helminth infection could similarly impair cellular 




responses to in acutely infected groups compare to chronically infected groups since there is a paradigm 
shift of immune responses during these two phases. Surprisingly, slightly higher frequency of cytokine-
producing CD8+ T cells in response to stimulation with pol peptide pool (RT CD4 and RT CD8) in mice 
vaccinated with MVA+gp140 and DNA+MVA regimen were observed (Fig 2.11). However, it is not clear if 
an increased TNF-α production may attribute to this. A previous study by Magalhães et al., have shown 
that infection with schistosomiasis may be accompanied by high proportions of TNF-α secreting T cells and 
a low proportion of T cells secreting IFN-γ which is often associated with liver fibrosis (Magalhães et al., 
2004). In this study, it was not possible to confirm this because the ICS assay was designed to have IFN-
γ, IL-2 and TNF- monoclonal antibodies multiplexed on the same fluorochrome to analyse a pool of all the 
three cytokines rather than individual cytokines. It is, therefore, tempting to speculate that the slight increase 
in the frequency of cytokine-producing T cells may just be to other factors other than the vaccines 
themselves. 
 
2.4.3. Vaccine-specific antibody responses induced by the MVA+gp140 and gp140 vaccine 
regimen in Sm infected mice 
The implication of inhibited functionality of CD4+ T cells, translates to failure in B cell activation, hence 
failure in antibody production (Swain et al., 2012). We demonstrated this in chronically Sm-infected mice 
vaccinated with MVA+gp140 (Fig 2.14 A-D) and gp140 (Fig 2.14 E-F) vaccine regimens. A dramatic 
decrease in production of serum anti-gp140 antibodies levels of IgG and all subclasses of IgG (IgG1; IgG2a 
and IgG2b) was observed in Sm-infected compared to Sm-free vaccinated mice (Fig 2.14). A study by Chen 
et al., demonstrated similar results in mice infected with S. japonicum and vaccinated with an HBV vaccine 
(Chen et al., 2012). These results were attributed to a preexisting Th2-dominated immune profile in the 
infected host, which is associated with downregulation of anti-HBs antibodies and Th1 cytokines to 
vaccination (Chen et al., 2012). To our knowledge, there is no reported study evaluating HIV vaccine-
specific antibody responses to Env-gp140 in helminth setting. However, it may be hypothesised that 
because Th1 cellular responses can stimulate B cells into secreting IgG2a while inhibiting IgG1 (Deenick 
et al., 2005), their reduction may directly affect antibody responses. 
 
 
2.4.4. Conclusion and recommendations 
The results of this preliminary study were useful in validating successful reproducibility of the 




(i) Infection with Sm induces a predominantly Th2 biased response marked by increased Th2 
cytokines and decreased Th1 cytokines in mice. Also, infection with Sm increases type 2 
antibodies (IgG1 and IgM) with a decrease in type 2 total antibodies (IgG2a and IgG2b) in mice.   
(ii) Infection with Sm resulted in a decrease in cellular responses to SAAVI DNA and MVA vaccines 
in mice measured by ELISpot, CBA and ICS. 
(iii) Infection with Sm significantly reduced the production of env-gp140-specific antibodies in 
vaccinated mice. 
 
Although these results are preliminary, they suggest that the leading of host immune responses 
towards biased Th2 responses caused by helminth infections could potentially dampen the 
efficacy of the vaccine-induced immunity. These results justify further studies to investigate the 
impact of helminth infection on the immunogenicity of HIV vaccines and to investigate if these 
adverse effects can be overcome by the elimination of parasites through chemotherapy as 





CHAPTER 3  
3. Treatment moderately restores T cell responses but not antibody responses 
3.1. Introduction 
Schistosomiasis is one of the major neglected tropical diseases affecting more than 207 million people in 
tropical areas. It is well documented that infection with the parasite skews the immune response to a 
predominantly Th2 immune setting which is capable of dampening responses to unrelated antigens, 
particularly that of vaccine immunogens. In the preceding chapter, three experiments were conducted in 
order to identify whether T cell-mediated, antibody-mediated or both vaccine responses are affected by 
helminthiasis. Furthermore, the preceding chapter also aimed at confirming if the helminth mouse model 
using Schistosoma mansoni as a prototype helminth can be reproduced as previously shown (Ndlovu, 
2013).  
 
The outcomes of the preliminary study showed that chronic schistosomiasis could be successfully 
established in mice and it skewed the host immune system towards a predominantly Th2 profile. 
Interestingly, this skewing towards Th2, correlated with reduced vaccine-specific cellular responses, 
including upregulation of IL-10 (suppressive cytokine) which is not considered desirable for an effective HIV 
vaccine. Similarly, vaccine-specific antibody responses including IgG and all is isotypes (IgG1; IgG2a; 
IgG2b) were reduced in Sm-infected mice compared with Sm-free mice. This chapter serves as a follow up 
to the preliminary study further investigate the effect of parasite elimination on the immunogenicity of HIV 
vaccines. 
 
As reviewed in Chapter 1, section 1.5.3 parasitic helminth infections can be treated with chemotherapeutic 
drugs such as praziquantel (PZQ) for schistosomiasis (Shaheen et al., 1989, Utzinger and Keiser, 2004, 
Tallima and El Ridi, 2007) and ivermectin or mebendazole for geohelminths (Cañete et al., 2009, Churcher 
et al., 2009, Geary, 2012). However, reinfection is common and frequent in endemic populations (N'Goran 
et al., 2001). We hypothesise that the elimination of these parasites should result in the recovery of immune 
responsiveness as previously suggested (Bentwich et al., 1999, Cooper et al., 2000a, Borkow and 
Bentwich, 2006). 
  
Previous vaccine studies have shown in mice that certain candidate HIV vaccines failed in schistosome-
infected mice but were functional if the helminth infection was eliminated prior to vaccination (Shollenberger 
et al., 2013b). Another study by Cooper et al. has demonstrated that Ascaris lumbricoides infected patients 
had diminished Th1 response to cholera toxin B subunit (CT-B) vaccine, however, once treated with ALB, 
they showed partial recovery of vaccine-induced Th1 responses (Cooper et al., 2001). Similarly, a study by 
Elias et al. demonstrated that peripheral blood mononuclear cells from de-wormed (ALB treatment) 




infected individuals (Elias et al., 2008). These studies suggest that anthelminthic treatment may correct the 
overall immune balance in the host immune response, hence restore vaccine responses. However, it 
remains unclear whether complete restoration and immune balance are entirely achieved (Da'dara and 
Harn, 2010). The present chapter sought to investigate if vaccine-specific responses in chronically infected 
mice as shown in the previous chapter can be restored by anthelminthic chemotherapy. In addition, this 
chapter served as a validity and reproducibility experiment of the preliminary study.  
  
The immune responses of the hosts to chronic helminth infection are generally characterized by a skewed 
Th2-like response. Th2-type responses, commonly associated with chronic schistosomiasis, are typically 
characterized by increases in the levels of IL-4, IL-6 and IL- 13 (Yin et al., 2012). Parasite-induced Th2 
responses are protective to the host against excessive pathology, however, helminths have developed 
several means of escaping these immune responses, enabling them to persist in the host (McSorley and 
Maizels, 2012). Conversely, an effective HIV vaccine would be expected to induce high expression of Th1 
cytokines such as IFN-γ, IL-2 and TNF-α which in turn may inhibit the parasite-induced Th2 responses. 
This could result in exacerbation of the helminth-associated pathology, thus, making vaccination unsafe in 
helminth-infected recipients. This chapter further investigates if predominantly Th1 T cell responses 
induced by HIV vaccination will exacerbate helminth-induced pathology in chronically infected individuals.  
The primary markers of immunopathology of the helminth S. mansoni are characterized by enlarged 
granulomas and fibrosing inflammation around parasite eggs in the liver tissue. Thus, the present study 
was also designed to examine liver tissue of Sm-infected mice vaccinated with a predominantly Th1 







3.2. Materials and methods 
3.2.1. Parasites 
Infectious Schistosoma mansoni cercariae were prepared as described in chapter 2 (section 2.2.1).  
3.2.2. Vaccines 
Vaccines described in chapter 2 (section 2.2.2) (SAAVI DNA‐C2; SAAVI MVA‐C and HIV-1 gp140 Env 
protein were used for immunisation of mice. 
3.2.3. Alum adjuvant 
Imject Alum (Thermo Fisher Scientific, USA) was used as an adjuvant for the formulation of Env protein 
gp140 protein. 
3.2.4. Animals 
Female BALB/c mice (6–8 weeks old) were purchased from South African Vaccine Producers (SAVP) 
(Johannesburg, South Africa) and housed as described in chapter 2 (section 2.2.3).  
 
3.2.5. Experimental design 
3.2.5.1. Immunization schedule 
Two pre-clinical experiments comprising of 6 groups of mice were used. The first experiment was designed 
to induce a predominantly HIV-specific T cell response (DNA+MVA) whilst the second experiment was 
designed to induce a mixed T cell and humoral response (MVA+gp140). The immunogenicity of these 
vaccines was evaluated in a chronic schistosomiasis mouse model.  
Briefly, BALB/c mice were chronically infected with S. mansoni (Sm). Nine and a half weeks post infection; 
half of the infected mice were treated twice with PZQ (Sigma Aldrich, USA) and the other half remained 
untreated. The two doses of PZQ were administered by oral gavage two days apart. At week 10, half of the 
PZQ-treated, untreated Sm-infected and Sm-free mice were vaccinated with either MVA+gp140 vaccine 
regimen, two vaccinations 4 weeks apart (Experiment 1) or vaccinated once with DNA followed by MVA, 4 
weeks later (Experiment 2). Groups of Sm-infected but untreated, Sm-infected but PZQ-treated and Sm-
free (naïve) mice were left unvaccinated to serve as controls. Twelve days following last vaccination 
(week16), mice were euthanised and spleens, blood, and livers were collected and evaluated for HIV 





Figure 3.1: Infection, treatment and Immunization schedules: Groups of BALB/c mice (n=5-8) were 
chronically infected with S. mansoni (Sm) before vaccination with SAAVI MVA-C (107 pfu/mouse) 
concurrently with gp140 Env protein (10µg/mouse, formulated in Imject Alum [Thermo Fisher Scientific, 
USA]), 4 weeks apart (Experiment 1) or vaccinated once with DNA followed by MVA, 4 weeks apart 
(Experiment 2). These vaccinations were given with or without (control) prior anti-helminthic treatment with 
PZQ. Twelve days following last vaccination (week16), mice were euthanised and spleens, blood, and livers 
were collected and evaluated for HIV immune responses and helminth-induced pathology. A) 
Representation of infection and immunisation strategy. B) Schedule for infection, treatment, vaccination 
and experimental endpoint. 
 
3.2.5.2. Infection of mice with Sm-cercariae 
Infection of mice was performed as described in Chapter 2, section 2.2.4.2. 
3.2.5.3. Vaccination of mice with SAAVI DNA-C2; SAAVI MVA and HIV Env-gp140 
Vaccination of mice was performed as described in Chapter 2, section 2.2.4.3 with modifications to the 
gp140 formulation. Briefly, the Env-gp140 vaccine protein was administered at a dose of 10µg Env-gp140 
formulated in an equal volume of Imject® Alum adjuvant (Thermo Scientific, USA) and given at 100µl 
mixture per mouse. 
   
3.2.6. Preparation of splenocytes and serum  





3.2.7. Interferon (IFN)-γ and interleukin-2 (IL-2) ELISpot assay 
Splenocytes were stimulated with Gag (CD4 and CD8); RT (CD4 and CD8) and Env (CD4 and CD8) specific 
peptides. Interferon (IFN)-γ and IL-2 ELISpot was performed as previously described in chapter 2 (section 
2.2.6).  
 
3.2.8. Flow cytometry and ICS 
Splenocytes were stimulated with Gag (CD4 and CD8); RT (CD4 and CD8) and Env (CD4 and CD8) 
specific peptides. Flow cytometry and ICS analysis were performed as described in chapter 2 (section 
2.2.7).  
 
3.2.9. Quantification of secreted cytokines by CBA 
Splenocytes were stimulated with Gag (CD4 and CD8); RT (CD4 and CD8) and Env (CD4 and CD8) specific 
peptides. CBA was used to measure cytokine levels and was performed as described in previous chapter 
2 (section 2.2.8). 
 
3.2.10. Quantification of total and Env-gp140 specific antibody isotypes by ELISA assay 
Total and gp140 specific antibodies in mice serum were detected and quantified by an ELISA assay as 
previously described in chapter 2 (section 2.2.9). 
3.2.11. Liver and spleen weighing 
Spleens and livers were weighed prior to processing for immunological evaluation in the laboratory to 
determine if HIV vaccination worsens helminth-associated pathology.  
 
3.2.12. Histopathological examination 
After sacrifice of different groups of animals, part of the liver tissue was immediately fixed in 4% (v/v) 
buffered formalin solution. These were further processed in Groote Schuur Hospital for histopathological 
analysis. Briefly, samples were fixed in formaldehyde in phosphate buffered saline, embedded in wax and 
processed. Sections (5-7μm) were stained with hematoxylin and eosin (H&E) (Sigma Aldrich, USA) and 
Chromotrop-aniline blue solution (CAB) (Sigma Aldrich, USA) and counterstained with Weigert's 
hematoxylin (Sigma Aldrich, USA) for collagen staining. Micrographs of liver granuloma were captured 
using a Nikon 90i widefield microscope using a 5.0-megapixel colour digital camera running Nikon’s NIS-
Elements v. 4.30 software (Nikon Instruments Inc., USA). The area of each granuloma containing a single 




granulomas per slide per mouse were included in the analyses of all groups with liver granulomas. Data 
was presented as a mean area of each granuloma containing a single egg. 
 
3.2.13. Hydroxyproline content assay 
Hydroxyproline content, which is a direct measure of collagen content was determined using a modified 
protocol (Bergman and Loxley, 1963). Briefly, liver samples were weighed, hydrolyzed and added to a 40mg 
Dowex/Norit mixture (20g Dowex [200 to 400 mesh; Sigma Aldrich, USA] with 10g Norit-A [Thermo Fisher 
Scientific, USA]). The supernatants were neutralised with 1% phenolphthalein and titrated against 10 M 
NaOH. An aliquot was mixed with isopropanol and added to chloramine-T/citrate buffer solution (pH 6.5). 
Erlich’s reagent (95% ethanol containing dimethylaminobenzaldehyde (DMAB) and 
concentrated hydrochloric acid) was added and absorbance was read at 570 nm. Hydroxyproline levels 
were calculated using 4-hydroxy-L-proline (Sigma Aldrich, USA) as a standard, and results were expressed 
as μmoles hydroxyproline per weight of tissue that contained 104 eggs. The number of eggs per gram of 
liver was determined by counting individual eggs from hydrolysed liver under a microscope.   
 
3.2.14. Statistical analysis 
In order to determine the effect of schistosomiasis on the immunogenicity of the candidate HIV vaccine to 
induce cellular and humoral immune responses, statistical analyses were conducted to compare across 
experimental and control groups (vaccinated Sm-free groups with vaccinated Sm-infected groups).  To 
determine if treatment restores vaccine-specific responses, vaccinated Sm-infected-PZQ treated groups 
were compared with untreated-Sm-infected vaccinated groups. However, to determine if HIV vaccination 
worsened helminth-associated pathology, the pathology of vaccinated Sm-infected groups was compared 
with unvaccinated Sm-infected groups. Furthermore, Con A and SEA responses between Sm-free and Sm-
infected groups were compared to determine the skewing of Th1/Th2 balance. Statistical analysis was 
performed using Prism version 5.0 (GraphPad Software, USA). The t-test for independent unpaired non-
parametric comparisons was applied to assess the level of significance between means ±SEM of groups. 
Three independent experiments were conducted and all tests were two-tailed. P values <0.05 were 





3.3.1. Cellular immune responses to Con A in Sm-infected mice vaccinated with the DNA+MVA 
and MVA+gp140 vaccine regimen measured by ELISpot 
To evaluate the Th1-Th2 balance cellular immune responses were evaluated using IFN-γ and IL-2 ELISpot 
assays to enumerate the magnitude of Con A-stimulated IFN-γ or IL-2 secreting CD8+ and CD4+ T cells in 
the spleen of mice vaccinated with either the DNA vaccine (DNA+MVA) or MVA-protein (MVA+gp140) (Fig 
3.2). 
 
3.3.1.1. ELISpot responses to Con A in DNA+MVA vaccine regimen 
A significant number of IFN-γ secreting T cells was observed in Sm-free (1446 ± 59.07 SFU/106 
splenocytes) compared to Sm-infected vaccinated (925.3 ± 64.17 SFU/106 splenocytes) mice (p<0.01). 
Vaccinated Sm-infected-PZQ treated (925.3 ± 64.17 SFU/106 splenocytes) mice also had a significant 
number of IFN-γ secreting T cells compared to Sm-infected vaccinated mice (P<0.05), However, Sm-free 
vaccinated mice had a slightly higher number of IFN-γ secreting T cells compared to vaccinated Sm-
infected-PZQ treated mice, albeit insignificant (Fig 3.2 A). 
  
The same pattern was observed for IL-2 ELISpot responses. Vaccinated Sm-free (1017 ± 33.98 SFU/106 
splenocytes) and Sm-infected-PZQ treated (969.2 ± 44.31 SFU/106 splenocytes) vaccinated mice had a 
significantly higher number of IL-2 secreting T cells compared to Sm-infected (526.7 ± 60.77 SFU/106 
splenocytes) vaccinated mice (P<0.01). The difference between vaccinated Sm-free and vaccinated Sm-
infected-PZQ treated mice was insignificant (Fig 3.2 B).  
 
3.3.1.2. ELISpot responses to Con A in MVA+gp140 vaccine regimen 
A significant number of IFN-γ secreting T cells was observed in vaccinated Sm-free (1468 ± 66.94 SFU/106 
splenocytes) compared to Sm-infected vaccinated (1058 ± 9.292 SFU/106 splenocytes) mice (P<0.01). 
Vaccinated Sm-infected-PZQ treated (1241 ± 80.83 SFU/106 splenocytes) mice also had higher but not 
significant number of IFN-γ secreting T cells compared to Sm-infected vaccinated mice, Sm-free vaccinated 
mice also had a higher number of IFN-γ secreting T cells compared to vaccinated Sm-infected-PZQ treated 
mice, but the difference was not significant (Fig 3.2 B). 
  
The same pattern was observed for IL-2 ELISpot responses. Sm-free (1042 ± 64.30 SFU/106 splenocytes) 
and Sm-infected-PZQ treated (985.9 ± 85.26 SFU/106 splenocytes) vaccinated mice had a significantly 
higher number of IL-2 secreting T cells compared to Sm-infected (386.7 ± 88.04 SFU/106 splenocytes) 
vaccinated mice (P<0.01). The difference between vaccinated Sm-free and vaccinated Sm-infected-PZQ 






Figure 3.2: IFN-γ and IL-2 ELISpot analysis of Con A stimulated T cell responses in the spleen of 
Sm-free vaccinated; Sm-infected vaccinated and Sm-infected-PZQ treated mice vaccinated with 
DNA+MVA (A) or MVA+gp140 (B) vaccine regimen described in Fig 3.1. At sacrifice, splenocytes were 
pooled from 5-8 mice per group then stimulated with Con A and analysed in an IFN-γ and IL-2 ELISpot 
assays. Bars are the mean number of spots of triplicate reactions in the irrelevant peptide (background) or 
to an individual peptide for 106 splenocytes with indicated standard deviation (SD) of the mean. Positive 
responses to the Con A stimulation were considered to be those greater than the background response 
(response to irrelevant peptide stimulation) plus two times the standard deviation (SD) of this response. 
Results represent 3 independent experiments. Statistical analysis was performed using unpaired, two-tailed 
t-test analysis followed by FDR for multiple comparisons, *p<0.05, **p<0.01. 
 
3.3.2. HIV-specific cellular immune responses to the DNA+MVA and MVA+gp140 vaccine regimen 
in the background of Sm measured by ELISpot 
Cellular immune responses were evaluated using IFN-γ and IL-2 ELISpot assays to enumerate 
the number of Gag; RT and Env-specific IFN-γ or IL-2 secreting CD8+ and CD4+ T cells in the spleen of 
mice vaccinated with either the DNA vaccine (DNA+MVA) or MVA-protein (MVA+gp140) (Fig 3.3). 
 
3.3.2.1. Vaccine-specific ELISpot responses to DNA+MVA vaccine regimen 
Vaccination with DNA+MVA induced high cumulative HIV-1 Gag, RT and Env-specific IFN-γ (2014 ± 177.4 
SFU/106 splenocytes) (Fig 3.3 A) and IL-2 ELISpot (174.1 ± 71.13 SFU/106 splenocytes) (Fig 3.3 D) 
responses in Sm-free compared to Sm-infected vaccinated mice which had significantly reduced IFN-γ 
































































responses. Also, cumulative HIV-specific IFN-γ ELISpot responses in Sm-free were significantly higher 
(P<0.05) compared to Sm-infected-PZQ treated (1290 ± 146.4 SFU/106 splenocytes) vaccinated mice. 
However, cumulative HIV specific IL-2 ELISpot responses in vaccinated Sm-infected-PZQ treated (185.0 ± 
25.86 SFU/106 splenocytes) mice were slightly lower but not significant when compared with Sm-free 
vaccinated mice (Fig 3.3 D).   
 
The same was also true for IFN-γ (Fig 3.3 B) and IL-2 (Fig 3.3 E) ELISpot responses to individual Gag 
(CD4); RT (CD4 or CD8) and Env (CD4) specific peptides. IFN-γ ELISpot responses to the RT (CD8) 
peptide induced the highest number of IFN-γ secreting CD8+ and CD4+ T cells (1019 ± 217.3 SFU/106 
splenocytes) in Sm-free mice. However, reduced number of RT (CD8) specific IFN-γ was observed in 
vaccinated Sm-infected (686 SFU/106 splenocytes) and Sm-infected-PZQ treated vaccinated mice. The 
same was observed for all the other peptides except for the Gag CD8 peptide which had higher IFN-γ 
responses in Sm-infected (228 SFU/106 splenocytes) compared to Sm-free vaccinated (141 SFU/106 
splenocytes) and Sm-infected-PZQ treated vaccinated mice. Vaccinated Sm-infected-PZQ treated mice 
only had slightly higher response compared Sm-infected mice when stimulated with Gag CD4 (109 vs 53 
SFU/106 splenocytes); RT CD8 (731 vs 686 SFU/106 splenocytes) and Env CD4 (255 vs 203 SFU/106 
splenocytes) (Fig 3.3 B).  
 
The highest number of IL-2 ELISpot responses was observed in Sm-free (67 SFU/106 splenocytes) and 
Sm-infected-PZQ treated (69 SFU/106 splenocytes) vaccinated mice splenocytes stimulated with Env CD4 
peptide, while in Sm-infected mice, no IL-2 responses above cutoff were observed for all the peptides (0 
SFU/106 splenocytes). While Gag CD4; RT CD4; and Env CD8 exhibited IL-2 ELISpot response in Sm-free 
vaccinated mice, vaccinated Sm-infected-PZQ treated mice also exhibited IL-2 responses to these peptides 
except for the Env CD8 peptide (Fig 3.3 E). 
 
3.3.2.2. Vaccine-specific ELISpot responses to MVA+gp140 vaccine regimen 
Vaccination with MVA+gp140 also induced significantly high cumulative HIV-1 Gag, RT and Env-specific 
IFN-γ (1838 ± 173.3 SFU/106 splenocytes) (Fig 3.3 A) and IL-2 (197.7 ± 20.12 SFU/106 splenocytes) 
ELISpot responses in Sm-free compared to Sm-infected vaccinated mice which had significantly reduced 
IFN-γ (1166 ± 132.2 SFU/106 splenocytes) (Fig 3.3 A) and IL-2 ELISpot (11.89 ± 5.951 SFU/106 
splenocytes) (Fig 3.3 D) responses. Also, cumulative HIV-specific IFN-γ ELISpot responses in vaccinated 
Sm-infected-PZQ treated (1685 ± 251.3 SFU/106 splenocytes) mice were higher compared to Sm-infected 
vaccinated mice albeit insignificant (Fig 3.3 A). However, cumulative HIV-specific IL-2 ELISpot responses 
in vaccinated Sm-infected-PZQ treated (185.0 ± 25.86 SFU/106 splenocytes) mice were significantly higher 





The same was also true for IFN-γ (Fig 3.3 C) and IL-2 (Fig 3.3 D) ELISpot responses to individual Gag 
(CD4 and CD); RT (CD4 and CD8) and Env (CD4 and CD8) specific peptides. IFN-γ ELISpot responses to 
the Env (CD8) peptide induced the highest number of IFN-γ secreting CD8+ and CD4+ T cells (553.3 ± 
55.86 SFU/106 splenocytes) in Sm-free mice. However, significantly reduced the number of Env (CD8) 
specific IFN-γ was observed in Sm-infected (450.0 ± 25.53 SFU/106 splenocytes) vaccinated mice (Fig 3.3 
C). Vaccinated Sm-infected-PZQ treated (703 SFU/106 splenocytes) mice had higher IFN-γ ELISpot 
responses when compared to Sm-infected vaccinated mice but no significant difference was observed (Fig 
3.3 C). The number of IFN-γ secreting CD8+ and CD4+ T cells in response to all the peptides was reduced 
in Sm-infected mice, whilst been recovered back after treatment with PZQ (Sm-infected-PZQ treated mice). 
However, responses in vaccinated Sm-infected-PZQ treated were not higher than responses in Sm-free 






Figure 3.3: IFN-γ and IL-2 ELISpot analysis of HIV-1 Gag; RT and Env-specific CD8+ and CD4+ T cell 
responses induced in the spleen of Sm-infected; Sm-infected-PZQ treated and Sm-free mice 


























































































































































































































































































































































































































































































last vaccination) splenocytes were pooled from 5-8 mice per group then stimulated with an irrelevant 
peptide or stimulated with HIV-1 Gag; RT; Env CD8 and CD4 T cell peptides in IFN-γ and IL-2 ELISpot 
assays. Cumulative proportions of positive IFN-γ (A) and IL-2 (D) as well as individual positive IFN-γ and 
IL-2 ELISpot responses induced by the DNA+MVA (B and E respectively) and MVA+gp140 (C and F 
respectively) vaccination regimens as described in Fig 3.1. The individual sections of each bar indicate the 
average net SFU ±SD from triplicate wells for 106 splenocytes to an individual CD8 or CD4 peptide. Results 
represent 3 independent experiments after subtraction of background (irrelevant peptide responses) and 
at a minimum of 2X background SFU/106 splenocytes considered positive. Statistical analysis was 




3.3.3. Th1 and Th2 cytokine responses in MVA+gp140 and DNA+MVA vaccine regimen in Sm-
infected-PZQ treated mice measured by Cytometric Bead Array (CBA) 
To assess the skewing towards Th2 profile, the amount of Th1 and Th2 cytokines secreted by T cells after 
being stimulated with Con A (non-specific stimulation) and SEA (parasite-specific stimulation) (Fig 3.4) were 
quantified for MVA+gp140 (A-G) and DNA+MVA (H-N) vaccinated mice by CBA.  
3.3.3.1. Th1 and Th2 cytokines in MVA+gp140 vaccinated mice 
As shown in Fig 3.4 A-C, there was more skewing towards Th2 in Sm-infected compared to Sm-free mice 
vaccinated with MVA+gp140 marked with increased IL-4 (4.28 vs 2.15 pg/ml); IL-10 (54.11 vs 33.97 pg/ml) 
and IL-6 (350.57 vs 113.3 pg/ml) responses to Con A. Furthermore, an increase in IL-4 (5.1 vs 1.3 pg/ml); 
IL-6 (559.27 vs 49.76 pg/ml) and IL-10 (236.91 vs 1.3 pg/ml) was observed in Sm-infected mice compared 
to Sm-free vaccinated mice when stimulated with the parasite-specific SEA (Fig 3.4 A-C).  
Interestingly, vaccinated Sm-infected-PZQ treated mice also showed skewing towards a Th2 profile marked 
with a significant increase in IL-6 (308.48 pg/ml); IL-10 (56.62 pg/ml) and high IL-4 (9.15 pg/ml) compared 
to Sm-free mice in response to the Con A stimulation. Furthermore, vaccinated Sm-infected-PZQ treated 
mice also had a significant increase in IL-6 (619.43 pg/ml); IL-10 (402.5 pg/ml) and high IL-4 (5.86 pg/ml) 
responses to the parasite-specific SEA compared to Sm-free and Sm-infected mice (Fig 3.4 A-C). 
Expectedly, Th1 cytokines were drastically reduced in Sm-infected compared to Sm-free vaccinated mice 
stimulated with Con A marked by decreased IFN-γ (70.19 vs 2732 pg/ml); TNF-α (25.47 vs 75.58 pg/ml) 
and a significant decreased IL-2 (4.29 vs 13.79 pg/ml) cytokine production. The same pattern was observed 
when splenocytes were stimulated with SEA. Sm-infected vaccinated mice produced lower IFN-γ (10.17 vs 
53.8 pg/ml); IL-2 (4.98 vs 9.86 pg/ml) but higher TNF-α (18.44 vs 10.33 pg/ml) production, when compared 




Interestingly, in vaccinated Sm-infected-PZQ treated mice, Th1 cytokines levels were higher compared to 
untreated Sm-infected vaccinated groups despite elevated Th2 cytokines. Significantly higher levels of IFN-
γ (290.2 ± 47.74 pg/ml) and higher TNF-α (35.5 pg/ml) and IL-2 (9.1 pg/ml) when compared to Sm-infected 
vaccinated mice in responses to Con A. However, when stimulated with SEA, Th1 responses in Sm-
infected-PZQ treated mice were similar to responses in Sm-infected vaccinated mice (Fig 3.4 D-F).    
Th2 biasing marked by a significant decrease in the IFN-γ:IL-4 ratio upon Con A stimulation was observed 
in vaccinated Sm-infected (20.38 ± 8.11) and vaccinated Sm-infected-PZQ treated (44.41 ± 3.52) relative 
to Sm-free (648.1 ± 96.38) vaccinated mice. However, vaccinated Sm-infected-PZQ treated mice had 
higher IFN-γ:IL-4 ratio compared to Sm-infected vaccinated mice. No difference was observed in the IFN-
γ:IL-4 ratio when stimulated with SEA except for higher levels observed (Fig. 3.4 G). 
 
3.3.3.2. Th1 and Th2 cytokines in DNA+MVA vaccinated mice 
As shown in Fig 3.4 H-J, an increased Th2 biasing in Sm-infected compared to Sm-free mice vaccinated 
with DNA+MVA was marked with increased IL-4 (15.4 vs 7.9 pg/ml); IL-10 (178.05 vs 76.86 pg/ml) and 
significant increased IL-6 (450.54 vs 100.44 pg/ml) responses to Con A. Furthermore, a significant increase 
in IL-4 (6.803 ± 0.46 vs 2.09 ± 1.06 pg/ml); IL-6 (522.6 ± 52.36 vs 47.88 ± 19.07 pg/ml) and IL-10 (413.7 ± 
30.07 vs below detectable [0.3433 ± 0.3433] pg/ml) was observed in Sm-infected mice compared to Sm-
free vaccinated mice when stimulated with the parasite-specific SEA (Fig 3.4 H-J).  
Interestingly, vaccinated Sm-infected-PZQ treated mice had significantly increased Th2 biasing marked 
with a significant increase in IL-4 (18.95 ± 3.795 pg/ml); IL-10 (222.2 ± 38.13 pg/ml) and higher IL-6 (256.41 
pg/ml) when compared to Sm-free mice in response to the Con A stimulation. Furthermore, vaccinated Sm-
infected-PZQ treated mice also had a significant increase in IL-6 (278.3 ± 40.90 pg/ml); IL-10 (472.7 ± 76.94 
pg/ml) and IL-4 (6.803 ± 0.46 pg/ml) responses to the parasite-specific SEA compared to Sm-free 
vaccinated mice (Fig 3.4 H-J). 
Expectedly, Th1 cytokines were drastically reduced in Sm-infected compared to Sm-free vaccinated mice 
stimulated with Con A marked by significant decreased IFN-γ (214.5 ± 55.71 vs 4486 ± 221.0 pg/ml); TNF-
α (20.17 ± 3.343 vs 131.3 ± 12.50 pg/ml) and a decreased IL-2 (5.3 vs 48.9 pg/ml) cytokine production (Fig 
3.4 K-M). When splenocytes were stimulated with SEA, Sm-infected vaccinated mice produced lower IFN-
γ (8.66 vs 81.86 pg/ml); TNF-α (19.64 vs 31.3 pg/ml), when compared to Sm-free, vaccinated mice, but no 
IL-2 (0 pg/ml) was observed in both Sm-infected and Sm-free vaccinated mice (Fig 3.4 D-F). 
Interestingly, vaccinated Sm-infected-PZQ treated mice showed recovery of Th1 cytokines despite 
increased Th2 cytokines. Significantly higher levels of IFN-γ (2933 ± 261.8 pg/ml); TNF-α (62.14 ± 11.42 




observed. However, when stimulated with SEA, Th1 responses in vaccinated Sm-infected-PZQ treated 
mice were similar to responses in Sm-infected vaccinated mice except for IL-2 responses which where only 
detectable in vaccinated Sm-infected-PZQ treated (Fig 3.4 K-M). 
Th2 biasing marked by a significant decrease in the IFN-γ:IL-4 ratio upon Con A stimulation was observed 
in Sm-infected (21.53 ± 2.00) relative to Sm-free (745.6 ± 244.9) vaccinated mice (Fig. 3.4 N). Vaccinated 
Sm-infected-PZQ treated mice showed a recovery of IFN-γ:IL-4 ratio (177.2) when compared to Sm-
infected (21.53 ± 2.00). No difference was observed in the IFN-γ:IL-4 ratio, when stimulated with SEA 
except for higher levels observed in Sm-free mice compared to both Sm-infected and Sm-infected PZQ, 






Figure 3.4: Cytokine production by Con A and SEA stimulation in Sm-free and Sm-infected mice 
vaccinated with MVA+gp140 or DNA+MVA regimen. Splenocytes were harvested from mice vaccinated 
with the indicated regimen described in Fig 3.1. They were then stimulated with an irrelevant peptide 
(negative control) or Con A or with SEA for 48 h. Culture supernatants were collected and the level of Th1 
and Th2 cytokines released into the medium for MVA+gp140 (A-C and D-F respectively) and DNA+MVA 
(H-J and K-M respectively) vaccinated mice was measured using a Cytokine Bead Array assay. The 
individual bars represent the magnitude of the net positive cytokine levels in the medium of splenocyte of 
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mice. The level of cytokines in the culture medium was considered positive when the level is higher than 
the detection limit of the respective cytokine described in Table 2.3. Results represent 3 independent 
experiments and plotted as the mean + SEM, and cytokine levels were expressed as pg/ml. Statistical 
analysis was performed using unpaired, two-tailed t-test analysis followed by FDR for multiple comparisons, 
*p<0.05, **p<0.01, ***p<0.001. 
 
3.3.4. HIV-Specific cytokine production  
The amount of Th1 and Th2 cytokine secreted by the Gag; RT and Env-specific CD4+ and CD8+ T cells 
during culture with the HIV peptides was also quantified for DNA+MVA and MVA+gp140 vaccine regimen 
(Fig 3.5). Splenocytes harvested from mice vaccinated according to the regimens indicated in Fig 3.1 were 
incubated for 48h with the Gag; RT and Env- specific CD8+ and CD4+ T cell peptides and the cytokine 
level released into the culture medium was quantified using a Cytometric Bead Array assay (BD 
Pharmingen, USA). 
 
3.3.4.1. HIV-Specific cytokine production in DNA+MVA vaccine regimen 
The cumulative positive cytokine levels produced against the HIV peptides for the DNA+MVA vaccination 
regimen is shown in Fig 3.5. Significantly higher levels of net cumulative Th1 cytokines: IFN-γ (6523 ± 282.0 
pg/ml); IL-2 (84.86 ± 0.3147 pg/ml) and TNF-α (251.2 ± 30.33 pg/ml) was released from splenocytes of Sm-
free mice in response to a DNA+MVA vaccination regimen compared to lower Th1 cytokine levels of IFN-γ 
(1899 ± 244.6 pg/ml); IL-2 (23.55 ± 4.094 pg/ml) and TNF-α (122.9 ± 17.45 pg/ml) released in Sm-infected 
vaccinated mice (Fig 3.5 A-C).  
 
Conversely, net cumulative Th2 cytokine levels in Sm-free vaccinated mice were drastically lower compared 
to Sm-infected vaccinated mice: IL-6 (339.3 ± 37.56 vs 949.8 ± 156.2 pg/ml) and IL-10 (68.38 vs 121.1 
pg/ml) with exception to IL-4 which was surprisingly higher (though insignificant) in Sm-free (25.38 pg/ml) 
compared to Sm-infected (20.1 pg/ml) vaccinated mice (Fig 3.5 D-F).  
 
Expectedly, Th1 cytokine recovery was observed in Sm-infected-PZQ treated vaccinated mice marked with 
a significant increase in IFN-γ (4729 ± 673.5 pg/ml); IL-2 (51.49 ± 7.189 pg/ml) and higher TNF-α (158.4 
pg/ml) when compared to Sm-infected mice. However, Th1 cytokine levels were still lower than those of 
Sm-free vaccinated mice (Fig 3.5 A-C). Furthermore, Th2 cytokines were lower in vaccinated Sm-infected-
PZQ treated compared to Sm-infected vaccinated mice (Fig 3.5 D-F). 
 
3.3.4.2. HIV-Specific cytokine production in MVA+gp140 vaccine regimen 
The cumulative positive cytokine levels produced in response to the HIV peptides for the MVA+gp140 




(2416 pg/ml); IL-2 (63.79 pg/ml) and lower TNF-α (112.48 pg/ml) was released from HIV peptide-specific T 
cells of Sm-free mice in response to a MVA+gp140 vaccination regimen compared to lower Th1 cytokine 
levels of IFN-γ (789 pg/ml); IL-2 (4.0 pg/ml) and higher TNF-α (123.87 pg/ml) released in Sm-infected 
vaccinated mice (Fig 3.5 A-C).  
 
Conversely, net cumulative Th2 cytokine levels in Sm-free vaccinated mice were drastically lower compared 
to Sm-infected vaccinated mice: IL-6 (497.92 vs 1681.88 pg/ml); IL-10 (14.95 ± 2.250 vs 68.42 ± 4.710 
pg/ml) and IL-4 (22.87 vs 27.6 pg/ml) (Fig 3.5 D-F). Expectedly, Th1 cytokine recovery was observed in 
Sm-infected-PZQ treated vaccinated mice marked with a significant increase in IFN-γ (2513.61 pg/ml); IL-
2 (38.04 pg/ml) but lower TNF-α (96.14 pg/ml) when compared to Sm-infected mice. Of all the Th1 cytokine 
levels, only IL-2 was lower compared to Sm-infected vaccinated mice (Fig 3.5 A-C). Furthermore, Th2 
cytokines were lower in vaccinated Sm-infected-PZQ treated compared to Sm-infected vaccinated mice 





Figure 3.5: Cumulative cytokines produced by HIV peptide-specific T cells of Sm-free and Sm-













































































































































































































































































































































































































































































































































































vaccinated with the indicated regimen described in Fig 3.1. They were then stimulated with an irrelevant 
peptide (negative control) or with the individual HIV-specific T cell peptides for 48 h. Culture supernatants 
were collected, and the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines released into the medium 
was measured using a Cytokine Bead Array assay and flow cytometric analysis. The individual bars 
represent the magnitude of the cumulative positive cytokine levels in the medium of splenocytes of 
vaccinated Sm-free; vaccinated Sm-infected and Sm-infected-PZQ treated vaccinated mice, stimulated 
with individual HIV peptides, after subtracting the background (splenocytes stimulated with irrelevant 
peptide). The level of cytokines in the culture medium was considered positive when the level is higher than 
the detection limit of the respective cytokine described in Table 2.3. Results represent 3 independent 
experiments and plotted as the mean + SEM, and cytokine levels were expressed as pg/ml. Statistical 
analysis was performed using unpaired, two-tailed t-test analysis followed by FDR for multiple comparisons, 
*p<0.05, **p<0.01, ***p<0.001. 
 
3.3.5. Cytokine responses to individual HIV-1 peptides for the DNA+MVA regimen 
Sm-infected mice (1489.38 pg/ml) vaccinated with a DNA+MVA vaccine had lower levels of IFN-γ compared 
to Sm-free vaccinated mice (3704 pg/ml) in response to Env CD8 peptide stimulations (Fig 3.6 A). 
Furthermore, net IFN-γ cytokine responses to Gag CD4 peptides was significantly lower in Sm-infected 
(31.06 ± 7.58 pg/ml) compared to Sm-free (385.5 ± 52.60 pg/ml) vaccinated mice. Although lower IFN-γ 
responses to the other HIV peptides was observed in Sm-infected compared to Sm-free vaccinated mice, 
no significant difference was observed (Fig 3.6 A). 
 
Net IFN-γ cytokine responses in vaccinated Sm-infected-PZQ treated mice was significantly higher for the 
Env CD8 (3502 ± 216.1 pg/ml) compared to Sm-infected (1489 ± 213.8 pg/ml) but not Sm-free vaccinated 
mice. IFN-γ cytokine responses to the other HIV peptides were higher in vaccinated Sm-infected-PZQ 
treated mice compared to Sm-free, but not higher that IFN-γ cytokine in Sm-free vaccinated mice.    
 
Of all the HIV peptides, Env CD4 induced higher levels of IL-2 in Sm-free (23.57 ± 2.508 pg/ml) compared 
to Sm-infected (5.390 ± 0.5727 pg/ml). Furthermore, Significant levels of Gag CD4 (16.74 ± 1.212 vs 3.627 
± 1.476 pg/ml); RT CD4 (20.16 ± 0.3842 vs 6.243 ± 0.1683 pg/ml) and Env CD8 (9.287 ± 0.8467 vs 4.250 
± 1.027 pg/ml) specific responses were observed in Sm-free vs Sm-infected mice. The same trend for other 
peptides (Gag CD8 and RT CD8) was observed but the difference was not significant (Fig 3.6 B). 
Expectedly; vaccinated Sm-infected-PZQ treated mice had significantly higher IL-2 responses to the Gag 
CD8 (4.520 ± 0.7757 vs 1.140 ± 0.5828 pg/ml) and Env CD4 (11.65 ± 1.059 vs 5.390 ± 0.5727 pg/ml) when 
compared to Sm-infected vaccinated mice. Also, IL-2 responses to other peptides were higher in vaccinated 




Furthermore, IL-2 responses in vaccinated Sm-infected-PZQ mice were not higher than those of Sm-free 
vaccinated mice (Fig 3.6 B). 
 
Levels of TNF-α were also drastically reduced in Sm-infected mice in response to all HIV peptides. 
Responses to the Env CD8 peptide induced the highest responses in Sm-free (111.76 pg/ml) compared to 
Sm-infected (47.48 pg/ml) vaccinated mice. However, only responses to the Env CD4 were significant when 
compared with Sm-free vaccinated mice (24.25 ± 2.732 vs 11.15 ± 1.789 pg/ml).  Responses to the HIV 
peptides in vaccinated Sm-infected-PZQ treated mice were similar to those of Sm-infected with exception 
to the Env CD8 which had higher TNF-α responses when compared to Sm-infected vaccinated mice. 
However, none of the responses in vaccinated Sm-infected-PZQ treated mice were higher than responses 
in Sm-free vaccinated mice (Fig 3.6 C).   
 
Higher levels of IL-6 cytokines in all cultures of vaccinated Sm-infected cells stimulated with HIV peptides 
compared to Sm-free vaccinated mice was observed. However, a significant difference was only observed 
in response to the Env CD8 peptide (274.5 ± 30.67 vs 67.37 ± 20.32 pg/ml) (Fig 3.6 E). Responses in 
vaccinated Sm-infected-PZQ treated mice had similar responses to all peptides when compared to the 
response in Sm-free vaccinated mice.  
 
Surprisingly, IL-4 levels in response to Gag CD4 (4.590 ± 0.5372 vs 1.890 ± 0.7314 pg/ml) and RT CD4 
(6.127 ± 0.2270 pg/ml vs 4.523 ± 0.3696 pg/ml) was significantly higher in Sm-free compared to Sm-infected 
vaccinated mice. Responses to the RT CD8 (1.79 vs 1.6 pg/ml); Env CD4 (6.1 vs 4.0 pg/ml) and Env CD8 
(5.4 vs 4.3 pg/ml) peptides were similar in vaccinated Sm-free mice compared to the Sm-infected 
vaccinated mice (Fig 3.6 D). Levels of IL-4 in vaccinated Sm-infected-PZQ treated mice was relatively 
similar to those of Sm-infected with exception to the Gag CD8 which was slightly lower in vaccinated Sm-
infected-PZQ treated (0.9 pg/ml) mice compared to Sm-infected (3.68 pg/ml) vaccinated mice.  
 
Levels of IL-10 in response to the Gag CD8 (26.89 vs 0 pg/ml) and Env CD4 (34.81 vs 20.26 pg/ml) were 
higher in Sm-infected compared to Sm-free vaccinated mice, although not significant. IL-10 response to the 
RT CD4 (20.81 vs 21.87 pg/ml) and Gag CD4 (14.34 vs 22.06 pg/ml) was relatively similar in Sm-infected 
compared to Sm-free vaccinated mice (Fig 3.6 F). Levels IL-10 in response to the RT CD8, and Env CD8 
was below detectable range. Vaccinated Sm-infected-PZQ treated mice only had detectable levels of IL-10 
to the Gag CD8 (15.73 pg/ml) and Env CD4 (17.8 pg/ml) which was closely similar to that of Sm-free 






Figure 3.6: Cytokine produced by Gag (CD8 and CD4) RT (CD8 and CD4) and Env (CD 4) specific 
peptides in Sm-free; Sm-infected and Sm-infected-PZQ treated mice vaccinated with DNA+MVA. 


















































































































































































































































































































































































































































































were then stimulated with an irrelevant peptide (negative control) or with the individual HIV-specific T cell 
peptides for 48 h. Culture supernatants were collected and the level of Th1 (A, B and C) and Th2 (D, E and 
F) cytokines released into the medium was measured using a Cytokine Bead Array assay and flow 
cytometric analysis. The individual bars represent the magnitude of the net positive cytokine levels in the 
medium of splenocyte of Sm-free and Sm-infected vaccinated mice, stimulated with individual HIV peptides, 
after subtracting the background (splenocytes stimulated with irrelevant peptide). The level of cytokines in 
the culture medium was considered positive when the level is higher than the detection limit of the 
respective cytokine described in Table 2.3. Results represent 3 independent experiments and plotted as 
the mean + SEM, and cytokine levels were expressed as pg/ml. Statistical analysis was performed using 
unpaired, two-tailed t-test analysis followed by FDR for multiple comparisons, *p<0.05, **p<0.01, 
***p<0.001. 
 
3.3.6. Cytokine responses to individual HIV-1 peptides for the MVA+gp140 regimen 
Despite high levels of net IFN-γ released from HIV peptide-specific T cells of Sm-free mice vaccinated with 
a DNA+MVA vaccine, 43% (1047.59 pg/ml) of the responses are attributed to the Env CD8 peptide-specific 
responses while 39.8% (926.76 pg/ml) of the responses are attributed to the RTCD4 (Fig 3.7 A). However, 
Sm-infected vaccinated mice had a drastic reduction of the net IFN-γ cytokine (1489.38 pg/ml) in response 
to Env CD8 (461) and RT CD4 (169.79 pg/ml) peptide, albeit not significant. Furthermore, net IFN-γ cytokine 
responses to all peptides were lower in Sm-infected compared to Sm-free vaccinated mice (Fig 3.7 A). Net 
IFN-γ cytokine responses in vaccinated Sm-infected-PZQ treated mice were relatively similar to those of 
Sm-free vaccinated mice for all HIV peptides. However, no significant difference was observed (Fig 3.7 A).  
 
The highest levels of IL-2 were observed in responses to the RT CD4 peptides in Sm-free (29.38 pg/ml) 
compared to both the Sm-infected (4.0 pg/ml) and Sm-infected-PZQ treated (16.46 pg/ml) vaccinated mice. 
Of all the HIV peptides, only responses to the RT CD4 were detected in the Sm-infected vaccinate mice 
while other peptides did not induce a detectable IL-2 cytokine. Interestingly, vaccinated Sm-infected-PZQ 
treated mice had detectable IL-2 responses to the Gag CD8 (1.6 pg/ml); Gag CD8 (3.4 pg/ml); Env CD4 
(16.48) and Env CD8 (1.3 pg/ml), although they were lower than IL-2 responses induced in Sm-free 
vaccinated mice (Fig 3.7 B). 
 
Levels of TNF-α were significantly lower in Sm-infected (8.807 ± 3.092 pg/ml) mice in response to Gag CD4 
peptides compared to the Sm-free (31.60 ± 2.119 pg/ml) vaccinated mice (Fig 3.7 C). However, responses 
to the Gag CD8 (12.8 vs10.22 pg/ml) RT CD8 (25.64 vs16.75 pg/ml) RT CD4 (24.61 vs 19.13 pg/ml) and 
Env CD8 (38.17 vs 19.84 pg/ml) was lower in Sm-free compared to Sm-infected vaccinated mice although 




(33.83 pg/ml) compared to Sm-free (19.14 pg/ml) and Sm-infected (24.61 pg/ml) vaccinated mice. However, 
for all the peptides, the amount of cytokine produced was similar to that of the Sm-free mice (Fig 3.7 C). 
      
Higher levels of IL-6 cytokines in all cultures of vaccinated Sm-infected cells stimulated with all HIV peptides 
(Gag CD4 [202.79 vs 66.37 pg/ml]; Gag CD8 [214.84 vs 28.92 pg/ml]; RT CD4 [279.09 vs 120.8 pg/ml]; RT 
CD8 [264.81 vs 40.54 pg/ml]; Env CD4 [309.31 vs 122.19 pg/ml] and Env CD8 [411.02 vs 119.1 pg/ml]) 
when compared to Sm-free vaccinated mice was observed. In vaccinated Sm-infected-PZQ treated mice, 
the levels of IL-6 produced was similar to that of the Sm-free mice except when stimulated with CD4 (233.09 
pg/ml) which was quite higher compared to Sm-free mice although lower compared to Sm-infected 
vaccinated mice. Although cumulative levels of IL-10 in response to HIV peptides were quantified, no levels 
of IL-10 in response to individual peptides was above the limit of detection, hence considered not positive 







Figure 3.7: Cytokine produced by Gag (CD8 and CD4) RT (CD8 and CD4) and Env (CD 4) specific 
peptides in Sm-free; Sm-infected and Sm-infected-PZQ treated mice vaccinated with MVA+gp140. 







































































































































































































































































































































































































































































were then stimulated with an irrelevant peptide (negative control) or with the individual HIV specific T cell 
peptides for 48 h. Culture supernatants were collected and the level of Th1 (A, B and C) and Th2 (D, E and 
F) cytokines released into the medium was measured using a Cytokine Bead Array assay and flow 
cytometric analysis. The individual bars represent the magnitude of the net positive cytokine levels in the 
medium of splenocyte of Sm-free and Sm-infected vaccinated mice, stimulated with individual HIV peptides, 
after subtracting the background (splenocytes stimulated with irrelevant peptide). The level of cytokines in 
the culture medium was considered positive when the level is higher than the detection limit of the 
respective cytokine described in Table 2.3. Results represent 3 independent experiments and plotted as 
the mean + SEM, and cytokine levels were expressed as pg/ml. Statistical analysis was performed using 
unpaired, two-tailed t-test analysis, *p<0.05, **p<0.01. 
 
3.3.7. Cellular immune responses to PMA in DNA+MVA and MVA+gp140 vaccine regimens in the 
background of Schistosomiasis measured by ICS and Facs 
To evaluate the Th1/Th2 balance in Sm-infected and Sm-free mice, the frequencies of cytokine (IFN-γ, IL-
2 and TNF-α) producing T cells in response to a non-specific stimulant (PMA/Ionomycin) were determined 
by ICS in the DNA+MVA (Fig 3.8 A) and MVA+gp140 (Fig 3.8 B) vaccination regimen. A significantly higher 
frequency of cytokine-producing CD4+ (53.03 ± 6.459 vs 29.77 ± 4.924%) and CD8+ T (11.26 ± 2.823 vs 
2.82 ± 0.7903%) cells were observed in Sm-free mice compared to Sm-infected mice vaccinated with the 
DNA+MVA vaccine regimen (Fig 3.8 A). In vaccinated Sm-infected-PZQ treated mice, cytokine-producing 
CD4 cells were similar to that on Sm-infected mice and significantly lower (53.03 ± 6.459 vs 32.37 ± 3.474%) 
when compared to that of Sm-free mice. Cytokine-producing CD8 cells in vaccinated Sm-infected-PZQ 
treated mice were higher (7.19%) than those of Sm-infected (2.82%) mice, however, were lower than that 
of Sm-free mice (11.26%) (Fig 3.8 A).  
In mice vaccinated with the MVA+gp140 vaccine regimen, a significantly higher number of cytokine-
producing CD4+ (29.90 ± 1.823 vs 18.23 ± 2.895%) and CD8+ T (8.293 ± 0.2149 vs 3.103 ± 1.256%) cells 
were observed in Sm-free mice compared to Sm-infected mice vaccinated with the MVA+gp140 vaccine 
regimen (Fig 3.8 B). In vaccinated Sm-infected-PZQ treated mice, cytokine-producing CD4 cells were 
higher (27.8%) compared to vaccinated Sm-infected mice but not higher than that of vaccinated Sm-free 
mice. Cytokine-producing CD8 cells in vaccinated Sm-infected-PZQ treated mice were higher (8.39%) than 
those of Sm-infected (3.1%) mice as well as higher than that of Sm-free mice (8.29%). However, the 






Figure 3.8: Assessment of cytokine-producing T cells (CD8+ and CD4+) following stimulation with 
a Leukocyte Activation cocktail (PMA/Ionomycin) in mice vaccinated with DNA+MVA and 
MVA+gp140 vaccine regimen. (A) Total frequency of T cells (CD4+ and CD8+) producing cytokines (IFN-
γ, IL-2, and TNF-α), in response to PMA/Ionomycin stimulation following vaccination with DNA+MVA 
regimen. (B) Total frequency of T cells (CD4+ and CD8+) producing cytokines (IFN-γ, IL-2, and TNF-α), in 
response to PMA/Ionomycin stimulation following vaccination with MVA+gp140 regimen. Bars show 
positive responses above a cut-off value of 2x background, 50 events or 0.05% cytokine-producing T cells. 
Results represent 3 independent experiments and plotted as the mean + SEM. Statistical analysis was 
performed using unpaired followed by FDR for multiple comparisons, two-tailed t-test analysis, *p<0.05. 
 
3.3.7.1. Vaccine specific-cellular responses to MVA+gp140 measured by ICS 
The proportions of cytokine (IFN-γ, IL-2 and TNF-α) producing T cells in response to HIV peptides Pol: 
(combined RT CD4 and RT CD8 peptides); Env CD4 and Env CD8 were determined by ICS. In the 
MVA+gp140 vaccination regimen, a significantly higher percentage of cumulative cytokine producing CD8 
cells in response to the Pol and Env CD8 peptide stimulation was observed in Sm-free vaccinated (1.79 ± 
0.04%) compared to Sm-infected vaccinated (1.49 ± 0.06%) mice (Fig 3.9A). Sm-infected-PZQ treated 
(1.57%) vaccinated mice had similar cumulative cytokine producing CD8 as Sm-infected vaccinated mice 

































































responded only to Pol (RT CD4 + CD8 peptides) in which the frequency was significantly higher than those 
of Sm-free and Sm-infected-PZQ treated mice (Fig 3.9C)   In general, the majority of the CD8+ T cytokine 
positive cells belonged to the effector memory phenotype (>80%) but the Sm-infected-PZQ treated group 
had a lower frequency (75%) of effector memory phenotype (Fig 3.9 C: charts). On the other hand, Cytokine 
producing CD4 cells in response to Pol and Env CD4 peptide was similar in Sm-free vaccinated (0.6%) and 
vaccinated Sm-infected-PZQ treated (0.67%) mice while not detected in Sm-infected mice vaccinated mice 
(Fig 3.9 B). In general, CD4+ T cytokine positive cells belonged to the effector memory phenotype (>90%) 
for both Sm-free and Sm-infected-PZQ-treated mice (Fig 3.9 D charts). 
3.3.7.2. Vaccine-specific cellular responses to DNA+MVA measured by ICS 
In the DNA+MVA vaccination regimen, In the DNA+MVA vaccination regimen, no significant difference 
between cumulative cytokine producing CD8 cells in response to the Pol and Env CD8 peptide stimulation 
was observed in Sm-free vaccinated (1.2%); vaccinate Sm-infected-PZQ treated (1.0%) and Sm-infected 
vaccinated (1.3%) mice. However, Sm-infected vaccinated mice responded only to Pol (RT CD4 + CD8 
peptides) in which the frequency was higher than those of Sm-free and Sm-infected-PZQ treated mice 
albeit insignificant (Fig 3.9 E). The majority of the CD8+ T cytokine positive cells belonged to the effector 
memory phenotype (>90%) (Fig 3.9 E: charts). On the other hand, Cytokine producing CD4 cells in 
response to Pol and Env CD4 peptide was similar in Sm-free vaccinated and vaccinated Sm-infected-PZQ 
treated mice while not detected in Sm-infected mice vaccinated mice (Fig 3.9 B). In general, CD4+ T 
cytokine positive cells belonged to the effector memory phenotype (>90%) for Sm-free but the Sm-infected-
PZQ treated group had a noticeably lower frequency (84%) of effector memory phenotype and Sm-infected-







Figure 3.9: Assessment of cytokine-producing T cells (CD8+ and CD4+) following stimulation with 
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CD4+ (B) producing cytokines (IFN-γ, IL-2, and TNF-α) in response to Pol and Env CD8 stimulation 
following vaccination with MVA+gp140 and DNA+MVA regimen. (C) Total frequency of T cells (CD8+) 
producing cytokines (IFN-γ, IL-2, and TNF-α), in response to Pol and Env CD8 stimulation following 
vaccination with MVA+gp140 regimen. (D) Total frequency of T cells (CD4+) producing cytokines (IFN-γ, 
IL-2, and TNF-α), in response to Pol and Env CD4 stimulation following vaccination with MVA+gp140 
regimen. (E) Total frequency of T cells (CD8+) producing cytokines (IFN-γ, IL-2, and TNF-α), in response 
to Pol and Env CD8 stimulation following vaccination with DNA+MVA regimen. (F) Total frequency of T 
cells (CD4+) producing cytokines (IFN-γ, IL-2, and TNF-α), in response to Pol and Env CD4 stimulation 
following vaccination with DNA+MVA regimen. Bars show positive responses above a cut-off value of 2x 
background, 50 events or 0.05% cytokine-producing T cells. Pie charts above each corresponding bar per 
group represent cell phenotype (Central; TCM [clear] and effector; TEM [solid] memory) of responding cells 
to HIV peptides. Results represent 3 independent experiments and plotted as the mean + SEM. Statistical 
analysis was performed using unpaired, two-tailed t-test analysis followed by FDR for multiple comparisons, 
**p<0.01, ***p<0.001. 
 
3.3.8. Assessing antibody responses in mice vaccinated with MVA+gp140 and with gp140 alone 
3.3.8.1. Total antibody responses   
To assess the antibody Th1/Th2 profile in Sm-infected mice, total IgG (Th1: IgG2a and IgG2b; Th2: IgG1 
and IgM) antibody isotypes in serum of Sm-infected; Sm-free and Sm-infected-PZQ treated mice vaccinated 
with the MVA+gp140 regimen were measured using ELISA.  
Sm-free mice vaccinated with the MVA+gp140 vaccines had significantly lower total IgG1 (11.25 ± 
0.22µg/ml) antibodies compared to Sm-infected vaccinated mice (12.50 ± 0.16µg/ml) antibodies. Similarly, 
vaccinated Sm-infected-PZQ treated mice had significantly lower total IgG1 (11.55 ± 0.19µg/ml) antibodies 
compared to Sm-infected vaccinated mice. Also vaccinated Sm-free vaccinated mice had significantly lower 
(17.41 ± 0.92µg/ml) total IgM antibodies compared to vaccinated Sm-infected (23.30 ± 0.96µg/ml) and Sm-
infected-PZQ treated (24.58 ± 0.34 µg/ml) vaccinated mice. However, there was no difference between 
vaccinated Sm-infected and vaccinated Sm-infected-PZQ treated mice. Total IgG2a was significantly lower 
in both vaccinated Sm-infected (11.26 ± 1.52µg/ml) and Sm-infected-PZQ treated (11.92 ± 0.4878µg/ml) 
compared to Sm-free (21.26 ± 1.67µg/ml) vaccinated mice. However, there was no difference between 
vaccinated Sm-infected and vaccinated Sm-infected-PZQ treated mice. Similarly, Total IgG2b was 
significantly lower in both vaccinated Sm-infected (2.11 ± 0.19µg/ml) and vaccinated Sm-infected-PZQ 
treated (1.95 ± 0.21µg/ml) compared to Sm-free (5.20 ± 0.22µg/ml) vaccinated mice. However, there was 






Figure 3.10: Antibody responses in Sm-free; Sm-infected and Sm-infected-PZQ treated mice 
vaccinates with MVA+gp140. Serum samples were collected two weeks post last vaccination. Total serum 
IgG isotypes (IgG1, IgM, IgG2a and IgG2b) were analysed by ELISA. Values are expressed as 
mean ± SEM. Statistical differences between the groups were calculated by unpaired t-test (two-tailed) 
followed by FDR for multiple comparisons, **P<0.01; ***P<0.0001. 
 
3.3.9. Env-gp140 specific antibody responses to MVA+gp140 vaccine regimen 
Env-specific antibody immunity in response to immunisation with MVA+gp140 was determined by ELISA. 
The mean concentration of gp140 Env-specific serum IgG antibody isotypes (IgG1, IgG2a, IgG2b) was 
determined and compared across the groups (Sm-free vaccinated; Sm-infected vaccinated and Sm-
infected-PZQ treated vaccinated). Significantly higher amounts of gp140-specific IgG antibodies were 
observed in Sm-free vaccinated compared to Sm-infected vaccinated mice across all IgG isotypes 
(IgG1[1681 ± 373.9 vs 140.8 ± 29.42 AUs]; IgG2a[4746 ± 1154 vs 71.14 ± 15.98 AUs]; IgG2b[2247 ± 553.9 
vs 45.23 ± 12.65 AUs]). Also, significantly higher amounts of gp140-specific IgG antibodies were observed 
in Sm-free vaccinated compared to Sm-infected-PZQ treated vaccinated mice across all IgG isotypes 
(IgG1[287.0 ± 79.96 AUs], IgG2a[866.1 ± 514.3 AUs], IgG2b[126.3 ± 28.41 AUs]). Furthermore, Sm-
infected-PZQ treated vaccinated mice had a higher amount of antibodies compared to Sm-infected 
vaccinated mice for the IgGb isotype only (Fig 3.11). 
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Figure 3.11: Humoral immune responses in mice immunised with MVA+gp140. Serum samples were 
collected two weeks post last vaccination. HIV-1 gp140-specific IgG1, IgG2a and IgG2b serum antibodies 
were analysed by ELISA. Values are plotted and expressed as mean antibody units (AUs) ± SEM for the 
8-12 animals in each group. Statistical differences between the groups were calculated by unpaired t-test 
(two-tailed) followed by FDR for multiple comparisons, *P<0.05, **P<0.01; ***P<0.0001. 
 
3.3.10. Liver and spleen weights of Sm-infected mice vaccinated with DNA+MVA 
This study sought to investigate if DNA+MVA exacerbate helminth associated pathology in chronically 
infected individuals. The study also sought to establish if PZQ treatment prior to vaccination can result in 
less pathology. 
Sm-associated pathology was evaluated by measuring the weights and size of the spleen, livers, and 
granuloma size in unvaccinated Sm-infected; Sm-infected vaccinated, and Sm-infected-PZQ treated 
vaccinated mice. Naïve and Sm-free vaccinated groups were considered as negative controls as they were 
uninfected. As shown in Fig 3.12 A, vaccinated Sm-infected and unvaccinated Sm-infected mice had larger 
spleens compared to vaccinated Sm-free; naïve and vaccinated Sm-infected-PZQ treated mice. The 
weights of Sm-infected (0.6083 ± 0.04994g) and Sm-infected vaccinated (0.7250 ± 0.03718g) mice spleens 
were significantly higher compared to Sm-free (0.2083 ± 0.01930g), naïve (0.1g) and Sm-infected-PZQ 
(0.2417 ± 0.02289g) treated mice. Spleen weights of Sm-infected vaccinated mice were higher compared 



































Similarly, liver sizes and weights in Sm-infected vaccinated and unvaccinated mice were larger compared 
to Sm-free; naïve and Sm-infected-PZQ treated mice (Fig 3.12 C). The weights of Sm-infected (2.083 ± 
0.08424g) and Sm-infected vaccinated (2.467 ± 0.06999g) mice livers were significantly higher compared 
to Sm-free (1.375 ± 0.05522g), naïve (1.483 ± 0.03445g) and Sm-infected-PZQ (1.808 ± 0.04516g) treated 
mice (Fig 3.12 D). Liver weights of Sm-infected vaccinated mice were significantly higher compared to Sm-
infected alone (2.467 ± 0.06999g vs 2.083 ± 0.08424g). 
 






Figure 3.12: Analysis of liver and spleen weights of Naïve; Sm-infected; Sm-infected-PZQ treated mice vaccinated or unvaccinated with 
the DNA+MVA vaccine regimen. Groups of mice were infected with 30-35 Sm cercariae. Nine and a half weeks post infection; half of the infected 
mice were treated twice with PZQ and the other half remained untreated prior vaccination. Mice were euthanised 12 days after last vaccination and 
samples (liver and spleen) were collected and weighed for analysis. (A) Representations of freshly harvested spleen. B) Spleen weights measured 
during autopsy. C) Representation of harvested livers of different groups; D) Liver weights measured during autopsy. Results represent 3 
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independent experiments as the mean + SEM of weights in grams (g). Statistical analysis was performed using unpaired, two-tailed t-test analysis 
followed by FDR for multiple comparisons, **p<0.01, ***p<0.0001. 
 
3.3.11. Sm-induced granuloma size in mice vaccinated with DNA+MVA vaccine regimen  
Analysis of the H&E staining revealed that granuloma sizes in Sm-infected vaccinated mice were significantly larger compared to other groups of 
mice (Fig 3.13 upper panel). Also, Sm-infected vaccinated mice had more collagen staining as indicated by more CAB staining compared to other 
groups (Fig 3.13 lower panel). Furthermore, Sm-infected vaccinated had significantly larger (60.27 ± 2.368 mm2) granuloma area when compared 
to vaccinated Sm-infected-PZQ treated (41.29 ± 1.660 mm2); Sm-infected alone (40.79 ± 2.382 mm2) and Sm-infected-PZQ treated vaccinated 







Figure 3.13: Representative micrographs showing of liver granulomas viewed under the microscope. Groups of mice were infected with 30 
Sm for 10 weeks and a half were treated with PZQ 3 days prior vaccinating with DNA+MVA or left unvaccinated. Mice were euthanised 12 days 
after last vaccination and samples (Liver) were collected for histology. Upper panel: H&E stained, magnification: X100; Lower panel: CAB stained, 





Figure 3.14: DNA vaccine in Sm-infected groups result in large granuloma sizes: Groups of mice were infected with 30 Sm for 10 weeks and 
a half were treated with PZQ 3 days prior vaccinating with DNA+MVA or left unvaccinated. Mice were euthanised 12 days after last vaccination and 
samples (Liver) were collected for histology. Granuloma area surrounding eggs was quantified by microscopic analysis on H&E stained sections. 
The area of each granuloma containing a single egg was measured with the ImageJ 1.34 software. An average of 20 granulomas per mouse was 
included in the analyses. Data is representative of 3 independent experiments, student t-test followed by FDR for multiple comparisons. *P<0.05; 
**P<0.01; ***p< 0.0001. 
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3.3.12. Analysis of hydroxyproline content and egg burden in the liver of mice vaccinated with 
DNA+MVA  
Hepatic fibrosis is a key pathological change of schistosomiasis, and the elevated hydroxyproline content 
in the liver is an informative biomarker for hepatic fibrosis. Therefore, we assessed hepatic hydroxyproline 
content to examine liver pathology. We further evaluated the levels of collagen using hydroxyproline assay 
between groups: Sm-infected vaccinated; Sm-infected-PZQ treated vaccinated; Sm-infected-PZQ treated 
and Sm-infected mice. Surprisingly, high levels of hydroxyproline content were observed in unvaccinated 
Sm-infected-PZQ treated mice (52.79 ± 18.70 hydroxyproline µM/104 eggs) groups compared to Sm-
infected (11.64 ± 2.485 hydroxyproline µM/104 eggs); Sm-infected vaccinated (15.76 ± 3.581 
hydroxyproline µM/104 eggs) and Sm-infected-PZQ treated vaccinated (17.42 ± 6.405 hydroxyproline 
µM/104 eggs) (Fig 3.15 A). The number of eggs per gram of liver in Sm-infected mice (17610 ± 4161 eggs/g 
liver) was significantly higher compared to unvaccinated Sm-infected-PZQ treated (4585 ± 2265 eggs/g 
liver) and vaccinated Sm-infected-PZQ treated (7003 ± 1420 eggs/g liver) mice. Sm-infected vaccinated 
mice had a higher number of eggs (10100 ± 1540 eggs/g liver) which was not a significantly higher than 
the number in Sm-infected-PZQ treated and Sm-infected-PZQ treated vaccinated.  
 
  
Figure 3.15: Liver fibrosis measured by hydroxyproline assay. BALB/c mice were chronically infected 
with Schistosoma mansoni. At 9.5 weeks post-infection, some groups were treated twice with PZQ. At 10 
weeks post-infection, groups were primed and boosted with DNA and MVA vaccines 4 weeks apart. Mice 
were euthanised 12 days after last vaccination and livers were collected for hydroxyproline analysis. 
Hydroxyproline content (A) and a number of eggs per gram of liver (B) were analysed in 4 mice per group. 
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Data is representative of 2 independent experiments, student t-test followed by FDR for multiple 







Helminths are potent modulators of host immune responses that drive Th2-dependent pathways to mediate 
their protection from the host (Borkow and Bentwich, 2004, Anthony et al., 2007, Allen and Maizels, 2011). 
In chronically infected individuals, the Th2 biased profile is accompanied by an increase in 
immunoregulatory responses which have been associated with suppression of non-parasite antigens 
(Kullberg et al., 1992). Therefore, it is likely that helminth-infected vaccine recipients will have a problem in 
mounting optimal vaccine-specific immune responses (Finkelman and Urban, 2001, Fincham et al., 2003, 
Thomas and Harn, 2004). So far, several studies have reported that helminth infections impair the outcome 
of a variety of vaccines, including BCG (Buck et al., 1970, Kilian and Nielsen, 1989, Stewart et al., 1999, 
Elias et al., 2008), yellow fever (Buck et al., 1970), tetanus (Prost et al., 1983, Kilian and Nielsen, 1989, 
Sabin et al., 1996, Cooper et al., 1998), diptheria toxoid (Haseeb and Craig, 1997), live attenuated oral 
cholera (Cooper et al., 2000a), and HIV-1 vaccine candidates (Da'Dara et al., 2006). On the other hand, 
another study showed that HIV-specific responses generated in mice by an attenuated live L. 
monocytogenes expressing HIV-1 Gag were not statistically different between schistosome-free and 
chronically infected animals (Shollenberger et al., 2013b, Shollenberger et al., 2013a). Albeit each of the 
studies has empirical support and opposition, it remains unclear whether or not helminth infection will 
confound the immunogenicity and efficacy of future HIV vaccination. Moreover, the HIV vaccines tested in 
the above studies expressed only the HIV-1 gag gene whilst future successful HIV vaccines are most likely 
to comprise of multiple HIV-1 genes (de Souza Apostólico et al., 2017). 
Granting that there is no vaccine for helminth infections, chemotherapeutic drugs such as praziquantel 
(PZQ) for schistosomiasis (Shaheen et al., 1989, Utzinger and Keiser, 2004, Tallima and El Ridi, 2007) and 
ivermectin or mebendazole for geohelminths (Cañete et al., 2009, Churcher et al., 2009, Geary, 2012) are 
available alternatives that have been associated with recovery of immune responses to unrelated antigens 
(Piessens et al., 1981, Colley et al., 1986, Grogan et al., 1996, Elias et al., 2001, Abaitua et al., 2006, 
Ghosh et al., 2006, Da'dara and Harn, 2010, Chen et al., 2012). 
The findings from the preliminary study (Chapter 2) demonstrated the capacity to reproduce the BALB/c 
model of chronic schistosomiasis by using Sm infection to induce a dominant Th2 immune profile. The 
study also generated preliminary data that strongly suggested that the immune skewing towards Th2 was 
associated with HIV vaccine-specific Th1 cellular and antibody responses. However, no firm conclusions 
could be made as the experiments were repeated only once. Furthermore, it was found reasonable to 
further refine the experiments by introducing a treatment arm to investigate the effect of eliminating the 
parasite on the immunogenicity of the vaccines and vaccine safety. Therefore, the present study aimed to 
investigate the impact of chronic helminthic infections on the immunogenicity of HIV vaccines regimens that 
elicit predominantly cellular (DNA+MVA) and mixed cellular and antibody responses (MVA+gp140) using 




3.4.2. Skewing of Th1/Th2 profile 
To confirm that the vaccinated mice with chronic helminth infection also exhibited Th2 biased profile, the 
skewing of the host immune responses towards a Th2 (an archetypical feature of helminth infection) was 
determined using cytometric bead array. As seen in the preliminary study (Chapter, Section 2.4.1), 
vaccinated mice infected with Sm induced high levels of Th2 cytokines compared to Sm-free mice 
vaccinated with DNA+MVA or MVA+gp140 (Fig 3.4). Conversely, Sm-infected vaccinated mice had lower 
Th1 cytokine levels compared to Sm-free vaccinated mice. In addition, the reduction of the IFN-γ:IL-4 ratio 
accompanied with increase IL-10 levels in Sm-infected vaccinated mice further indicated that immune 
profile of Sm-infected vaccinated mice was skewed towards Th2 and most likely immune suppressed 
(Shollenberger et al., 2013a). These findings are in line with previous studies conducted on the immune 
system of humans, as well as animals (Nutman et al., 1987, Grzych et al., 1991, Araujo et al., 1994, Sartono 
et al., 1995, McKee and Pearce, 2004, Yin et al., 2012). However, compared to the preliminary study, the 
IFN-γ:IL-4 ratio of Sm-free vaccinated groups in this study was generally higher for both vaccination 
regimens (Fig 2.5 vs Fig 3.4).  
Furthermore, total immunoglobulin levels (non-specific antibody immune responses) in the mouse sera 
were evaluated in order to elucidate the Th1/Th2 bias of the different mouse groups. Antibody isotype of 
serum is useful in determining T-helper lymphocyte bias by virtue of the effects that certain cytokines have 
on immunoglobulin isotype selection in B cells (McSorley and Maizels, 2012). For example, a Th2 cytokine 
such as IL-4 is capable of inducing B cells to secrete IgG1, at the same time inhibiting IgG2a production 
(Deenick et al., 2005). On the other hand, a Th1 cytokine, IFN-γ can stimulate B cells into secreting IgG2a 
while inhibiting IgG1 (Deenick et al., 2005). Thus, the type of cytokine being produced can be extrapolated 
from the IgG isotype secreted. Therefore, total immunoglobulin isotypes were evaluated between Sm-
infected vaccinated and Sm-free vaccinated mice. It was found that IgG2a and IgG2b (Th1 antibodies 
markers) were significantly decreased in Sm-infected vaccinated groups compared to Sm-free vaccinated 
groups. On the contrary, IgG1 and IgM (Th2 antibodies markers) where significantly elevated in vaccinated 
Sm-infected compared to Sm-free vaccinated groups (Fig 3.10), indicative of a very strong chronic helminth-
induced Th2 immunity (Deenick et al., 2005, McSorley and Maizels, 2012). These findings confirm the 
results of the preliminary study and further demonstrated that Sm infected mice had immune responses 
skewed towards predominantly Th2, which can be attributed to chronic infection (Maizels and McSorley, 
2016). However, when compared to the preliminary study, the overall total antibody was lower (~3 fold) in 
study, particularly IgG1 and IgM (Fig 2.12 vs 3.10).  
To evaluate if whether PZQ treatment reduced the Th2 skewing or not, the quantity of Th1 cytokines (IFN-
γ; IL-2 and TNF-α) upon Con A stimulation were evaluated and found to be partially restored when mice 
were treated with PZQ compared to Sm-infected untreated vaccinated mice (Fig 3.4 D-F, and K-M. 
However, the Th2 (IL-4; IL-6 and IL-10) particularly parasite-specific IL-4 and IL-10 remain considerably 




MVA+gp140, albeit partially elevated in DNA+MVA groups (Fig 3.2 C). Because chemotherapy with PZQ 
only has effects on adult worm, the reduction of the adult worm will reduce the egg burden hence lowering 
the TH2 responses but only restoring TH1 responses partially since it is not a guaranteed that all adult 
worms were eliminated. This implies that even after treatment with PZQ, the Th2-biased profile may remain 
increased. The increase of IL-10 (immune suppressing cytokine) and IL-4 have been reported after 
treatment with PZQ in mice (Da'dara and Harn, 2010). These findings may further support and explain why 
IL-10 messenger RNA (mRNA) expression in a study by Helmy et al., was significantly increased in PZQ-
treated mice compared to infected mice (Helmy et al., 2009). 
  
3.4.3. Vaccine-induced Cellular responses in Sm-infected mice  
Because helminth infections are associated with immunological features that have the potential to impair 
non-parasite antigens, this raised a question of whether Sm infection could suppress cellular immune 
responses to the SAAVI candidate HIV vaccine regimens as demonstrated in other previous vaccine studies 
(Buck et al., 1970, Kilian and Nielsen, 1989, Actor et al., 1993, Sabin et al., 1996, Muniz-Junqueira et al., 
1996, Stewart et al., 1999, Cooper et al., 2000a, Da'Dara et al., 2006, Elias et al., 2008). Normally, 
vaccination with DNA+MVA or MVA+gp140 induces high magnitude Th1 cellular responses. These 
responses are associated with high cumulative Th1 cytokine production (Fig 3.5 A-C), a high number of 
responding T cells (Fig 3.3 A and D), and a high number of cytokine-producing CD8+ and CD4+ in response 
vaccine peptides (Fig 3.9) (Burgers et al., 2006, Burgers et al., 2008, Shephard et al., 2008, Burgers et al., 
2009). Cumulative ELISpot, cytokine and cytokine-producing T cell responses to HIV peptides were shown 
to be impaired in Sm infected mice.  
Vaccine-specific Th1 cytokines in Sm-infected mice 
As shown in Fig 3.5 A-C, vaccine-specific Th1 cumulative cytokines levels (IFN-γ, IL-2 and TNF-α) in 
response to HIV peptides was significantly reduced in vaccinated Sm-infected compared to Sm-free mice 
vaccinated with DNA+MVA, suggesting a suppression. Similarly, mice vaccinated with the MVA+gp140 
induced significantly lower cumulative IFN-γ and IL-2 cytokine responses in Sm-infected groups, with 
exception to TNF-α which was similar in both vaccinated Sm-infected and Sm-free, vaccinated mice (Fig 
3.5 A-C). These findings reflect observations in the preliminary study, except for IFN-γ which was much 
higher in this study compared to the preliminary study in DNA+MVA vaccinated groups. However, the 
vaccine-induced IL-2 and TNF-α in this study were slightly lower than in the preliminary study (Fig 2.6 vs 
Fig 3.5).  
Classical cytokines such as IFN-γ, IL-2 and TNF-α are important immune correlates of protection in HIV 
immunity (Tomaras and Plotkin, 2017) and good indications of polyfunctional CD4 T-cell responses (Lin et 




protective HIV-1 immunity. This is often attributed to its characteristics of inducing downmodulation of 
inflammatory responses (Pearce and MacDonald, 2002). As such Th1 cytokines such as IFN-γ, IL- 2 and 
TNF-α can be inhibited in Sm-infected vaccine recipients whilst an increase in the levels of IL-4, IL-6 and 
IL- 13 are observed (Yin et al., 2012).  
 
3.4.3.1. Vaccines-specific ELISpot responses in Sm infected mice 
Also, vaccine-specific cumulative IFN-γ and IL-2-producing T cell responses measured by ELISpot were 
significantly lower in Sm-infected vaccinated mice compared to Sm-free mice vaccinated with DNA+MVA 
and/or MVA+gp140 (Fig 3.3 A and B). These observations agree with a previous study by Actor et al., which 
suggested that the immune inability to mount specific responses in helminth-infected mice might prevent 
the mice from clearing viral infections (Actor et al., 1993). Another Sm-infection mouse study by Da’Dara 
et al., 2006, agreed with these findings reporting a significant decline in the number of IFN-γ secreting CD8+ 
T cells in Sm-infected mice compared to uninfected controls following immunization with DNA vaccine 
(Da'Dara et al., 2006). Apiwattanakul et al., also reported that that the effectiveness and immunogenicity of 
their pneumococcal vaccine were compromised in helminth-infected mice (Apiwattanakul et al., 2014). 
Recently, a human study conducted by Riner et al., also agree with the pattern of these findings and showed 
that Schistosoma mansoni infection can jeopardize the duration of protective levels of antibody responses 
to immunizations against Hepatitis B and Tetanus Toxoid (Riner et al., 2016). These studies alongside with 
others, conclude that the attenuation of Th1 responses, such as IFN-γ production, together with increased 
production of anti-inflammatory and Th2 cytokines in helminth-infected vaccine recipients correlate with 
impaired vaccine efficiency (Elias et al., 2001, Elias et al., 2005b, Elias et al., 2008, Da'dara and Harn, 
2010, Apiwattanakul et al., 2014). Interestingly, the DNA+MVA vaccination in the preliminary study induced 
double the ELISpot responses in Sm-free vaccinated groups compared to this study (Fig 2.3 vs Fig 3.3), 
while MVA+gp140 vaccination was consistent in both studies (Fig 2.4 vs Fig 3.3).   
 
3.4.3.2. Cytokine-producing CD4+/CD8+ T cells in Sm-infected mice 
Furthermore, the ability of the SAAVI HIV vaccines to induce cytokine-producing T cells as well as memory 
phenotype was determined by flow cytometry in Sm-infected vaccinated mice. As shown in Fig 3.9 A, a 
significantly higher cumulative cytokine-producing CD8+ cells in response was observed in Sm-free 
vaccinated compared to Sm-infected mice vaccinated with MVA+gp140 mice. However, no statistical 
difference between the percentages of cumulative cytokine-producing CD8+ cells was observed between 
Sm-free vaccinated and Sm-infected mice vaccinated with DNA+MVA. These findings were consistent with 
the finding in the preliminary study, except that in a preliminary study, no statistical difference could be 




HIV-1 risk and control of viral replication as observed in HIV-1 controllers (Appay et al., 2000, Hersperger 
et al., 2010, Walker and McMichael, 2012, Sáez‐Cirión and Pancino, 2013, Tomaras and Plotkin, 2017, 
Arcia et al., 2017). As such, future preventative HIV vaccines will aim to induce these immune responses 
(Walker and McMichael, 2012, Hanke, 2014). Therefore, our data alongside with others report the potential 
drawback helminth infection could cause (Actor et al., 1993, Elias et al., 2007, Elias et al., 2008, Da'dara 
and Harn, 2010, Chen et al., 2012). A study by Stelekati et al., demonstrated that bystander chronic infection 
negatively impacted the development of CD8+ T cells memory (Stelekati et al., 2014). Cumulative cytokine-
producing CD4+ cells were completely attenuated by Sm-infection in DNA+MVA and MVA+gp140 
vaccinated groups (Fig 3.9 B). Polyfunctional CD4+ T cells have been correlated with decreased HIV 
transmission (Lin et al., 2015, Tomaras and Plotkin, 2017). Furthermore, CD4+ T cells play a major role 
during HIV infection in that they stimulate the function of CD8 T cells and B cells (NIAID, 2013). Inhibition 
functionality of CD4+ T cells, translates to failure in B cell activation, thus, failure in antibody production 
may be expected (Swain et al., 2012). Taking into account the findings of this study, Sm infection may not 
only affect cellular responses but antibody responses to unrelated antigens.   
Furthermore, cytokine-producing T cells were further characterized into effector or central memory T cell 
populations. The two are similar in expression of many costimulatory molecules with differences mostly 
noted in their adhesion, and chemokine receptors function. These populations have different functions 
(Schenkel and Masopust, 2014). Effector memory cells act as the first line of defence at the sites of HIV-1 
infection. When effector memory T cells experience viral activation, they mature rapidly into effector cells 
that secrete large amounts of effector cytokines such as IFN-γ (Lefrançois, 2002, Murphy, 2011). Central 
memory T cells, on the other hand, take longer to differentiate into effector T cells and secrete lower 
amounts of cytokines compared to effector memory T cells upon viral activation; however, they serve as a 
backup for effector memory T cells replenishment (Lanzavecchia and Sallusto, 2005, McKinstry et al., 2010, 
Murphy, 2011). T cell memory phenotype of activated CD4+ T cells was not detected in Sm-infected 
vaccinated mice. Nevertheless, Sm-infected vaccinated mice had a slight but insignificant increase in 
central memory CD8+ T cells compared to Sm-free groups vaccinated with the MVA+gp140 regimen (Fig 
3.9 A charts). Mice vaccinated with the DNA+MVA exhibited comparable memory profiles of activated CD8+ 
T cells, which were similarly observed in a study by Shollenberger et al., showing that there were no 
difference between Sm-infected and Sm-free vaccinated with a Listeria vaccine (Shollenberger et al., 
2013b). It is not clear whether central memory would be favoured in Sm-infected vaccinated groups, 
however, further investigation in future may be necessary. 
 
3.4.4. Antibody responses   
The impairment of vaccine-specific cellular immune responses during a chronic helminth infection has been 




perform in the presence of helminth infections (Chen et al., 2012), thus, poorly understood. To our 
knowledge, no study has evaluated the impact of helminth infections on the antibody responses to HIV. 
Although the induction of cellular responses is central in vaccine design, correlation with protection for 
licensed vaccines include binding antibody responses, functional antibody responses and cellular immunity 
(Plotkin, 2010, Tomaras and Plotkin, 2017). In addition, the RV144 study demonstrated the importance of 
vaccine-generated Env antibodies in vaccine protection (Haynes et al., 2012). In this study, antibody 
responses to the Env gp140 protein in Sm-infected vaccinated and Sm-free vaccinated were evaluated 
using ELISA. The findings revealed that helminth infection significantly downregulated the production of 
Env gp140 specific binding antibodies in sera. The mean concentration of anti-gp140 antibodies in Sm-
infected mice vaccinated with MVA+gp140 was significantly lower than that in Sm-free vaccinated control 
for all IgG isotypes (IgG1; IgG2 and IgG2b) (Fig 3.11). An HBV vaccines study reported a reduction of anti-
HBV antibodies in mice infected with S. japonicum and vaccinated with an HBV vaccine (Chen et al., 2012). 
Another related study showed that helminth-infected cholera patients display decreased mucosal humoral 
immune responses to V. cholera protein antigen (Harris et al., 2009). Recently, other studies have 
associated duo parasite infections with an impaired ability to develop IgG antibody responses to key 
protective antigens of Hib and diphtheria in infants of mothers infected with malaria and/or helminths during 
pregnancy (Malhotra et al., 2015). Antibody responses to specific HIV antigens have been proposed to 
correlate with protection (Haynes et al., 2012, Tomaras and Plotkin, 2017). In this study, S. mansoni 
infection in mice was associated with decreased antibody immune responses to Env gp140, therefore, 
demonstrating a potential negative impact of helminthiasis on future antibody-based HIV vaccines. Unlike 
in the preliminary study which evaluated responses to gp140 protein, only MVA+gp140 vaccine was used 
evaluated in this study. However, the trend in the preliminary study reflected the observations made in this 
study.   
 
3.4.5. PZQ treatment and cellular responses 
Elimination of helminth parasites prior to immunization appears to restore normal vaccine T cell 
responsiveness (Elias et al., 2001, Abaitua et al., 2006, Ghosh et al., 2006, Da'dara and Harn, 2010). Thus, 
this study also aimed to investigate if the immunogenicity of these candidate vaccines (DNA+MVA and 
MVA+gp140) can be restored by the chemotherapeutic elimination of worms. For this, two experiments 
comprising of 6 groups of mice were used. Three groups of mice were chronically infected with Sm, of 
which two of these groups were further treated twice with PZQ nine and a half weeks post infection. One 
of the treated groups and the untreated group were subsequently vaccinated twice, 4 weeks apart with 
appropriate vaccination regimen. The control groups were those with either Sm-free vaccinated; 




This study hypothesised that treatment with PZQ would result in a restoration of cellular immune responses 
to normal as previously shown in other studies (Da'dara and Harn, 2010, Shollenberger et al., 2013b) by 
reducing predominating Th2 cytokines (IL-4, IL-6, and IL-10) while enhancing Th1 cytokines (IFN-γ; TNF-α 
and IL-2). Surprisingly, vaccine-specific cumulative IFN-γ ELISpot responses in DNA+MVA vaccinated 
groups infected with PZQ were not improved by PZQ treatment as anticipated, nevertheless, cumulative 
IFN-γ ELISpot responses in MVA+gp140 Sm-infected vaccinated groups were partially restored after PZQ 
treatment (Fig 3.3 A). Furthermore, a significant improvement in cumulative IL-2 ELISpot responses 
induced by DNA+MVA and MVA+gp140 vaccine regimen was observed in vaccinated Sm-infected-PZQ 
treated mice compared to Sm-infected vaccinated mice (Fig 3.3 D). These results agree with a study by 
Da'dara and Harn, which showed restored cellular immune responses to the HIV-1C T cell-based DNA 
vaccine in Sm-infected-PZQ treated vaccinated mice (Da'dara and Harn, 2010).    
A significant restoration in cumulative IFN-γ and IL-2 cytokines in response to HIV peptides was observed 
in PZQ treated groups vaccinated with DNA+MVA (Fig 3.5 A and B). However, cumulative TNF-α response 
to vaccine peptides in PZQ treated group was not different from the Sm-infected group (Fig 3.5 C). Similarly, 
in MVA+gp140 a vaccinated group, a significantly high cumulative IFN-γ and IL-2 cytokines in response to 
HIV peptides was observed after treatment with PZQ (Fig 3.5 A-B). This was with exception to cumulative 
TNF-α levels which were not different from the Sm-infected group (Fig 3.5 C). Cumulative vaccine specific 
Th2 cytokines (IL-4 IL-6 and IL-10) were also seen to decrease after treatment with PZQ in DNA+MVA and 
MVA+gp140 vaccinated group (Fig 3.5 D-F). However, these are not considered desirable for an effective 
HIV vaccine.  
The effect of treatment on the frequency of cytokine-producing CD4 and CD8 T cells was also evaluated 
using ICS. As shown in Fig 3.9 B, the cumulative cytokine-producing CD4+ T cells were completely restored 
to normal after PZQ treatment in MVA+gp140 and DNA+MVA vaccinated groups. On the other hand, there 
was no difference in cumulative cytokine-producing CD8+ T cells of Sm-infected compared to Sm-infected-
PZQ treated mice vaccinated with DNA+MVA or MVA+gp140. However, PZQ treated vaccinated groups 
had responses to all peptides compared to Sm-infected untreated vaccinated mice which did not have 
responses to Env CD8 peptide (Fig 3.9 A). Cytotoxic T lymphocytes (CD8+ T cells) play a vital role in 
clearing HIV infection while CD4+ cells serve as helpers (Sant and McMichael, 2012, Arcia et al., 2017, 
Tomaras and Plotkin, 2017). Thus, the inability to restore this form of vaccine responses raises potential 
challenges to future HIV vaccines. This suggests that vaccine responses to different peptides may not be 
equally restored by treatment. Nevertheless, this could be due to the length of time needed to clear 
schistosome antigens, and/or for immune cells to cease producing Th2-type cytokines (Da'dara and Harn, 
2010). 
Although no major difference in memory phenotype was observed between PZQ treated vaccinated mice 




CD8+ cells in MVA+gp140 vaccine regimen and central memory CD4+ in DNA+MVA vaccine regimen. The 
implications of these findings are not yet clear and justify a further future investigation. 
The potential of deworming to enhancing immune responses to vaccination has been demonstrated 
(Bentwich et al., 1999, Cooper et al., 2000a, Borkow and Bentwich, 2006). In this study, our results show 
that restoration of cellular immune responses is partial, rather than complete as observed in other studies 
(Da'dara and Harn, 2010). Results from this study are in line with those of Cooper et al., which demonstrated 
that Ascaris lumbricoides infected patients had diminished-Th1 response to cholera vaccine and only partial 
recovery following albendazole treatment was observed (Cooper et al., 2001). Taken together these 
findings, it can be concluded that treatment with PZQ may not be a guarantee of a complete restoration of 
vaccine-specific immune responses unless a longer recovery period after treatment is allowed. 
3.4.6. PZQ treatment and antibody responses 
The current study further demonstrated that in chronically Sm-infected mice vaccinated with MVA+gp140 
vaccine, production of serum anti-gp140 antibodies levels of subclass IgG1; IgG2a and IgG2b were 
significantly decrease compared to Sm-free vaccinated mice (Fig 3.11). To our knowledge, no study has 
evaluated the ability of anthelminthic treatment in the restoration of antibody responses to HIV. A mouse 
study by Chen and colleagues reported recovery of vaccine HBV- specific antibody responses in mice 
infected with S. japonicum following treatment with PZQ (Chen et al., 2012). Contrary to the proposition 
that treatment with anthelminthic chemotherapy is expected to restore host immune responses, treatment 
with PZQ did not recover levels of anti-gp140 antibodies in mice that were Sm-infected. The quantity of 
serum anti-gp140 antibodies levels of the subclasses IgG1 and IgG2a and IgG2b were significantly 
suppressed even after treatment with PZQ compared to uninfected vaccinated controls (Fig 3.11).  
Responses to vaccination following treatment of helminth infection have been shown to depend on the time 
given for clearance of helminth-induced responses in this mouse model. A study by Chen et al., showed a 
recovery of immune balance 16 weeks post-treatment (Chen et al., 2012). Also, findings from the studies 
conducted by Da’dara’s group and Shollenberger’s groups, demonstrated that normal immune responses 
can be achieved 2-10 weeks post-treatment(Da'dara and Harn, 2010, Shollenberger et al., 2013b). 
However, in this study, normal immune responses were not achieved even after four weeks post-treatment 
with PZQ. Nevertheless, the phenotype of the mice was restored, just as observed in previous mouse 
helminth studies (Da'dara and Harn, 2010, Shollenberger et al., 2013b).This study suggests that prior PZQ 
treatment may restore the phenotype but may not restore immune balance to normal, as such, not confer 
restoration to HIV vaccination responses. Perhaps, multiple doses and different treatment time points may 
be explored in future studies. Thus, the findings of this study validate the need to conduct more detailed 





3.4.7. Helminth-induced pathology  
In a mouse model, the literature describes schistosomiasis pathology in mice as being largely associated 
with granulomatous responses to parasite eggs that become lodged in the liver and intestinal tissue (Hams 
et al., 2013, Lundy and Lukacs, 2013). Therefore, the sizes and weights of the liver and spleen can be 
described as markers of exacerbation of schistosomiasis pathology, suggesting that groups with larger 
mean liver or spleen weights will have more severe pathology than those with lower mean weights. In this 
study, results suggest that immunization of Sm-infected mice with DNA+MVA vaccination resulted in 
marked exacerbation of the immunopathology in these mice. All Sm-infected vaccinated mice had larger 
and heavier spleens and livers compared to compared to unvaccinated Sm-infected groups, thus increased 
pathology (Fig 3.12 A-D).  
To further compare pathology between vaccinated and unvaccinated Sm-infected mice, areas of 
granulomatous responses to parasite eggs trapped in the liver are considered as primary markers for 
disease pathology in murine models (Pearce and MacDonald, 2002) humans (Gryseels et al., 2006, Colley 
et al., 2014). Therefore, granuloma areas of Sm-infected mice vaccinated with DNA+MVA were compared 
with granuloma areas of unvaccinated Sm-infected mice.   
Analysis of the H & E staining revealed that granuloma sizes in Sm-infected vaccinated group were 
significantly larger than in an unvaccinated Sm-infected group, implicating that vaccination with DNA+MVA 
worsens the pathology in Sm-infected groups (Fig 3.14). Furthermore, hydroxyproline and egg burden per 
gram of liver was analysed to further describe pathology between these groups. Hydroxyproline is an amino 
acid characteristic of collagen metabolism and used as an informative marker to express the extent of liver 
fibrosis (Souza et al., 2005). No significant difference in hydroxyproline content between unvaccinated Sm-
infected and vaccinated Sm-infected mice were observed. However, the number of eggs per gram of liver 
was higher in unvaccinated Sm-infected compared to Sm-infected vaccinated groups. This result suggests 
that egg deposition was severe in the unvaccinated Sm-infected group, but the pathology marked by 
granuloma size was severe in the presence of DNA+MVA vaccination. 
Expectedly, PZQ treatment restored liver and splenic sizes back to normal as shown in Fig 3.12, as well as 
a reduction in the area of liver granulomas (Fig 3.14). This finding entails that PZQ treatment restores and 
elevates tissue damage from schistosomiasis. Da’dara’s et al., have obtained similar results in their study 
were they showed that PZQ treatment significantly reduced splenomegaly in Sm-infected mice (Da'dara 
and Harn, 2010). 
Surprisingly, the amount of hydroxyproline content in PZQ treated Sm-free mice was significantly higher 
compared with unvaccinated Sm-infected groups, suggesting that PZQ treatment may contribute to 
increased fibrosis of the liver (Fig 3.15 A). A study by Brown et al., showed that treatment of S. mansoni 
infection with PZQ in adults coinfected with HIV-1 in Uganda resulted in a transient increase in viral 




experimental drug (Paeoniflorin) used for treating Schistosomiasis managed to control sclerosis better than 
PZQ (Abd El-Aal et al., 2017). This brings into question the ability of PZQ in controlling fibrosis in the livers 
of infected mice, hence, further studies could evaluate this research avenue. Nevertheless, PZQ treatment 
resulted in reduced egg per gram of liver when compared with Sm-infected untreated groups (Fig 3.15 B).  
 
3.4.8. Limitations of the study 
3.4.8.1. Mouse model limitations 
Although the BALB/c mice are a good model for first line of preliminary investigation, it does not provide full 
information. For example, The MHC of these animals is only limited to presenting few specific HIV peptides, 
rather than cumulative magnitude responses. Furthermore, Schistosoma mansoni kills mice just after 20 
weeks post-infection, while in human schistosomiasis, individuals can live longer with the infection, and 
thus the mouse model may be exaggerating the pathology.  
3.4.8.2. Vaccine immunogenicity 
Cytokine-producing T cells in vaccinated mice were detected using antibodies conjugated to the same 
fluorophore (PE) and thus making it difficult to determine the polyfunctionality of these candidate HIV 
vaccines in Sm-infection mouse model. Furthermore, cytotoxicity and T cell avidity were also not evaluated 
as part of this study in determining desirable immune readouts for a T cell-based vaccine in the Sm-infection 
mouse model. Cytokines and antibodies such as IL-13 and IL-12 and IgE could give valuable information 
concerning pathology and host immune switching.  
This study was unable to evaluate neutralizing and non-neutralizing antibodies such as ADCC-mediating 
antibodies elicited by the candidate HIV-1 vaccines standard TZM-bl assay (Barouch et al., 2013, 
Buchbinder et al., 2014, Goepfert et al., 2014) (Aasa-Chapman et al., 2005, Holl et al., 2006) (Pollara et 
al., 2011, Sarzotti-Kelsoe et al., 2014). Such antibodies have been associated with protection against HIV 
infection. These assays have not been established for the mouse model and thus, were unavailable. 
Nonetheless, this study provides concise empirical data on the impact of helminth infections in the 
immunogenicity of HIV vaccines as well the role of anthelminthic in restoring immune responses to 
vaccines. 
 
3.4.9. Conclusion and recommendations 
The findings of this study suggest that chronic helminth infections are capable of downregulating the 
immunogenicity of candidate HIV vaccines. Surprisingly, not only cellular responses are downregulated as 
previously reported (Da'Dara et al., 2006, Da'dara and Harn, 2010), but antibody responses to HIV Env 




responses to HIV vaccines, specifically to Env gp140, has not been previously reported. Praziquantel is a 
useful form of treatment available that has been reported to restore immune responses to other 
vaccinations. In this study, we demonstrated that partial restoration of cellular responses to HIV vaccination 
can be achieved; however, responses to antibody responses may not be achieved. Furthermore, this study 
suggests that vaccination with DNA+MVA candidate vaccines that elicit strong Th1 cellular responses may 
be detrimental to Sm-infected individuals in that they exacerbate helminth-induced pathology. This study 
contributes to the body of knowledge concerning the potential challenges helminth infection may pose to 
future successful candidate HIV vaccines.  
The overall study gives an informed report on the impact of helminth infection in HIV vaccines; however, 
not all immunological aspects could be elucidated. Thus, this study justifies further studies, probably using 
a nonhuman primate model such as baboons (immune system sequence is highly similar to humans) to 






CHAPTER 4  
4. Helminth eggs alone can drive Th2-dominant responses that can affect vaccine-induced 
responses 
4.1. Introduction 
In the preceding chapter, we demonstrated that the elimination of helminth worms by chemotherapy only 
partially restores cellular immune responses but not antibody responses. Although these results showed 
some improvement in vaccine immunogenicity after treatment, it was not clear if the remaining eggs that 
are trapped in tissue after treatment contributed to lack of full recovery by continuing to drive a Th2 immune 
response, capable of downregulating Th1 responses to vaccine antigens. Thus, the present chapter 
evaluated the effect of Schistosoma mansoni eggs (SmE) in the absence of adult Sm worms.  
As previously described in chapter 1, section 1.5.5, clinical and animal studies showed that chronic 
helminthic worm infections exert a predominant Th2 immune response as a parasite survival mechanism 
(Fincham et al, 2003; Urban et al, 1996). This is as a result of female schistosomes producing large 
numbers of eggs, many of which become lodged in the liver and intestine where they induce a 
granulomatous response, a major pathologic manifestation of the disease (Boros, 1989, La Flamme et al., 
2002, Caldas et al., 2008).      
No vaccines are available for schistosomiasis or other helminthic infections and although effective anti-
helminthic drugs are available (such as PZQ for schistosomiasis and ALB for STH), re-infections after 
successful treatments are also very common in endemic areas (N'Goran et al., 2001). Also, in the case of 
Schistosoma, antihelminth treatment using PZQ only eliminates live worms but not the eggs lodged and 
trapped in tissue such as liver (Shaheen et al., 1989, Utzinger and Keiser, 2004, Tallima and El Ridi, 2007).  
Mouse experiments have shown that Schistosoma eggs induce strong Th2 immune responses; however, 
this is only maintained for a short while before the immune response reverts to balanced Th1/Th2 (Wynn 
et al., 1993, Joyce et al., 2012). In fact, a study in mice showed that a challenge with Schistosoma mansoni 
eggs (SmE) induced a peak Th2 response at 2-3 weeks post challenge (Joyce et al., 2012). Murine studies 
have shown that following intraperitoneal (i.p) sensitization and intravenous (i.v) challenge, SmEs are 
transported to the lung via the pulmonary arteries where they are trapped within the lung parenchyma by 
granulomas composed of lymphocytes, eosinophils, and alternatively activated macrophages, thus, 
triggering a Th2 response (Sandler et al., 2003, Sandor et al., 2003, Perrigoue et al., 2007, Nair et al., 
2009). In the previous Chapter 3, livers from PZQ-treated mice had many Sm eggs (Fig 3.15 B) and the 
sizes of granulomas were almost the same as those in the livers from untreated Sm-infected mice (Fig 3.14) 
at least 6 weeks after treatment. In this Chapter, we attempt inform if Sm eggs left lodged in the tissues 
after PZQ treatment contributed to the incomplete restoration of the immune responses that were observed 
in the vaccinated Sm-infected PZQ-treated mice. Concurrently with this experiment, an additional control 




from the additional group would inform on the level of SmE induced Th2 responses at the time when the 
HIV vaccinations were given. 
 
 
4.2. Materials and methods 
4.2.1. Parasites eggs 
S. mansoni eggs (SmE) were purchased from the Theodor Bilharz Research Institute (Schistosome 
Biological Supply Center, Egypt). Upon arrival, the eggs were aliquoted in vials of 50 000 eggs/ml and 
stored at -80°C until use for inoculation. The integrity and viability of the eggs were determined using a light 
microscope prior to use.  
 
4.2.2. Vaccines 
Vaccines described in Chapter 3 (section 3.2.2 and 3.2.3) (SAAVI MVA‐C and HIV-1 gp140 Env protein) 
were used for immunisation of mice. 
4.2.3. Animals 
Female BALB/c mice (6–8 weeks old) were purchased from South African Vaccine Producers (SAVP) 
(Johannesburg, South Africa) and housed as described in Chapter 2 (section 2.2.3).  
 
4.2.4. Immunisation schedule and inoculation of mice with SmE 
 
Briefly, BALB/c mice were divided into 2 groups of 5 mice/group (SmE-free) and 2 groups of 5 mice/group 
(SmE-inoculated). Mice were inoculated with 2500 SmE given i.p to sensitise the immune system and 
challenged with 2500 SmE given i.v 14 days apart. After 7 days, one group of SmE-inoculated and one 
group of SmE-free was vaccinated with MVA+gp140 vaccine regimen. Mice were boosted 4 weeks later 
with the same vaccines to induce a mixed vaccine-specific T cell and antibody responses. Twelve days 
after the last vaccination, blood was collected via cardiac puncture under deep anaesthesia and euthanised 
by cervical dislocation followed by harvesting of spleen. Cellular and humoral responses were determined 
by using ELISpot, CBA; flow cytometry and antibody ELISA (Fig 4.1). In a concurrent experiment, a group 
of 20 mice (additional control group) were divided into 4 groups (5 mice/group). Two groups were sensitized 
and challenged with SmE in an identical manner (SmE-inoculated) as above while the other 2 groups were 
left as SmE-free. After 7 and 35 days (coinciding with the HIV vaccination times points), mice in one SmE-





 Briefly, BALB/c mice were divided into 2 groups of 5 mice/group (SmE-free) and 2 groups of 5 mice/group 
(SmE-inoculated). Mice were inoculated with 2500 SmE given i.p to sensitise the immune system and 
challenged with 2500 SmE given i.v 14 days apart. After 7 days, one group of SmE-inoculated and one 
group of SmE-free was vaccinated with MVA+gp140 vaccine regimen. Mice were boosted 4 weeks later 
with the same vaccines to induce a mixed vaccine-specific T cell and antibody responses. Twelve days 
after the last vaccination, blood was collected via cardiac puncture under deep anaesthesia and euthanised 
by cervical dislocation followed by harvesting of the spleen. Cellular and humoral responses were 
determined by using ELISpot, CBA; flow cytometry and antibody ELISA (Fig 4.1). In a concurrent 
experiment, a group of 20 mice (additional control group) were divided into 4 groups (5 mice/group). Two 
groups were sensitized and challenged with SmE in an identical manner (SmE-inoculated) as above while 
the other 2 groups were left as SmE-free. After 7 and 35 days (coinciding with the HIV vaccination times 
points), mice in one SmE-inoculated and one SmE-free groups were euthanized followed by harvesting of 
spleens for cellular immune assays. 
 
Figure 4.1: Immunisation schedules: Mice were inoculated with 2500 SmE given i.p to sensitise the 
immune system and challenged with 2500 SmE given i.v 14 days apart. After 7 days, one group of SmE-
inoculated and one group of SmE-free were vaccinated twice with MVA+gp140 vaccine regimen 4 weeks 
apart to induce a mixed vaccine-specific T cell and antibody responses. Twelve days after the last 
vaccination, mice were euthanised and blood and spleen were collected for analysis of cellular and humoral 
responses. Cellular and humoral responses were determined by using ELISpot, CBA; and antibody ELISA. 
Day -14                           0                          7                                35                          47









Groups: n=5 i.p. inoculation 
with 2500 SmE
i.v . inoculation 
with 2500 SmE
Immunisation 1 Immunisation 2 End point 
(Euthanise)
Day - -14 0 7 35 47
Experiment 3 MVA+Gp140 - -   
SmE+MVA+Gp140     
SmE   - - 
Naïve - - - - 
Additional control
group
SmE (a)   Euthanise
SmE (b)   - Euthanise
Naïve (a) - - Euthanise






A) Representation of SmE inoculation and immunisation strategy. B): experiment 3 (mixed cellular and 
antibody response vaccine regimen) and time point experiment without the vaccine. Three replicates of 
Experiment 3 and two replicates of control group experiments were conducted. 
 
4.2.5. Preparation of splenocytes and serum  
Splenocytes and serum were processed as previously described in Chapter 2 (section 2.2.5). 
4.2.6. Interferon (IFN)-γ and interleukin-2 (IL-2) ELISpot assay 
Interferon (IFN)-γ and IL-2 ELISpot was performed as previously described in Chapter 3 (section 3.2.7). 
 
4.2.7. Quantification of secreted cytokines by CBA 
CBA was used to measure cytokine levels and was performed as described in previous Chapter 3 (section 
3.2.9). 
4.2.8. Quantification of Env-gp140 specific antibody isotypes by ELISA assay 
Antibodies to gp140 in mice serum were detected and quantified using HIV-1 subtype C (strain TV1) gp140 
protein (Immune Technology, USA) in an ELISA assay as previously described in chapter 2 (section 2.2.9). 
 
4.2.9. Statistical analysis 
Statistical analysis was performed using Prism version 5.0 (GraphPad Software, San Diego, CA). The t-
test for independent unpaired non-parametric comparisons was applied to assess the level of significance 
between means ±SEM of groups. Three independent experiments were conducted and all tests were two-







4.3.1. Analysis of Th1/Th2 responses to non-specific stimulation (Con A) and Parasite-specific 
(SEA) in SmE-inoculated mice vaccinated/unvaccinated with MVA+gp140 vaccine regimen 
To determine if SmE alone drive Th2 responses strong enough to attenuate the immunogenicity of HIV 
vaccines, groups of mice were inoculated with 2500 SmE twice and euthanised at day 7 and day 35 post 
initial inoculation coinciding with vaccination time points. Data was useful for determining the Th1/Th2 
profile in SmE challenged mice. Furthermore, the study was aimed at determining the host immune 
response at the time of vaccination.  
The bias of the immunity to Th1/Th2-type was also evaluated by calculating the ratio of IFN-γ to IL-4 in 
response to stimulation with the Con A and SEA peptide. The full data on Th1 and Th2 cytokine profiles 
are shown in Appendix 1A-1F (Appendices section), which, in general, show secretion of more Th2 and 
less Th1 cytokines by splenocytes from SmE-inoculated compared to those of SmE-free mice.  
At day 7 post-challenge, the IFN-γ:IL-4 ratio was significantly lower in SmE-inoculated (80.44 ± 33.65 pg/ml) 
compared to SmE-free (1133 ± 52.68 pg/ml) mice after stimulation with Con A. Similarly, when stimulated 
with SEA, the IFN-γ:IL-4 ratio was lower in SmE-inoculated mice compared to SmE-free mice was lower. 
At 35 days post challenge, the IFN-γ:IL-4 ratio was also significantly lower in SmE-inoculated (95.27 ± 15.26 
pg/ml) compared to SmE-free (1853 ± 217.0 pg/ml) mice after stimulation with Con A. Similarly, when 
stimulated with SEA, the IFN-γ:IL-4 ratio was lower in SmE-inoculated mice compared to SmE-free mice. 
At day 47 post-challenge, the IFN-γ:IL-4 ratio was significantly lower in vaccinated SmE-inoculated (367.0 
± 38.34 pg/ml) compared to SmE-free (597.2 ± 72.93 pg/ml) vaccinated mice after stimulation with Con A. 
Similarly, when stimulated with SEA, the IFN-γ:IL-4 ratio was lower in SmE-inoculated mice compared to 








Figure 4.2: Cytokine production by Con A and SEA stimulation in SmE-inoculated and SmE-free 
mice. Splenocytes were harvested from mice vaccinated with the indicated regimen described in Fig 4.1. 
They were then stimulated with an irrelevant peptide (negative control) or Con A or with SEA for 48 h. 
Culture supernatants were collected and the level of Th1 and Th2 cytokines released into the medium for 
naïve and SmE challenged mice was measured using a Cytokine Bead Array assay. The individual bars 
represent the magnitude of the net positive cytokine levels in the medium of splenocytes of SmE-free (blue) 
and SmE-inoculated (red) mice. #: mice were vaccinated with the MVA+gp140 vaccine. The level of 
cytokines in the culture medium was considered positive when the level is higher than the detection limit of 
the respective cytokine described in Table 2.3. Results represent 2-3 independent experiments and plotted 
as the mean + SEM, and cytokine levels were expressed as pg/ml. Statistical analysis was performed using 
unpaired, two-tailed t-test analysis followed by FDR for multiple comparisons, *p<0.05, **p<0.01, 
***p<0.001. 
 
3.3.3. Cytokine responses to HIV-specific peptide stimulation in the background of SmE-inoculation 
The cumulative positive cytokine responses to the HIV peptides for the MVA+gp140 vaccination regimen 
are shown in Fig 4.3. Higher but not significant levels of net Th1 cytokines: IFN-γ (3332.96 pg/ml); IL-2 
(103.69 pg/ml) and TNF-α (135.55 pg/ml) was released from HIV peptide-specific T cells of SmE-free mice 
vaccinated with the MVA+gp140 vaccination regimen compared to SmE-inoculated vaccinated mice which 































Th1/Th2 cytokine in response to non-specific (Con A)




produced lower Th1 cytokine levels of IFN-γ (2544.24 pg/ml); IL-2 (62.81 pg/ml) and TNF-α (86.97 pg/ml) 
(Fig 4.3 A; B and C respectively). No noticeable difference was observed in levels of IL-10 (86.47 vs 87.88 
pg/ml) and IL-4 (15.43 vs 15.38 pg/ml) and slightly higher IL-6 in SmE-free (818.86 pg/ml) compared to 






Figure 4.3: Cumulative cytokines produced by HIV peptide-specific T cells of Sm-free and Sm-
infected mice vaccinated with MVA+gp140. Splenocytes were harvested from mice vaccinated with the 


















































































































































































































































































































control) or with the individual HIV-specific T cell peptides for 48 h. Culture supernatants were collected and 
the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines released into the medium was measured using 
a Cytokine Bead Array assay and flow cytometric analysis. The individual bars represent the magnitude of 
the cumulative positive cytokine levels in the medium of splenocytes of SmE-free and SmE-inoculated 
vaccinated mice, stimulated with individual HIV peptides, after subtracting the background (splenocytes 
stimulated with irrelevant peptide). The level of cytokines in the culture medium was considered positive 
when the level is higher than the detection limit of the respective cytokine described in Table 2.3. Results 
represent 3 independent experiments and plotted as the mean + SEM, and cytokine levels were expressed 
as pg/ml. Student t-test followed by FDR for multiple comparisons. 
  
4.3.2. Cytokine responses to individual peptides 
Despite high levels of net IFN-γ released from HIV peptide-specific T cells of SmE-free mice vaccinated 
with an MVA+gp140 vaccine, only 37% (1233.51 pg/ml) of the responses are attributed to the RT CD4 
peptide-specific responses (Fig 4.4 A). However, SmE-inoculated vaccinated mice had a drastic reduction 
of the net IFN-γ cytokine (850.9 pg/ml) in response to RT CD4 peptide. IFN-γ responses to Gag CD8 (242.2 
vs 36.47 pg/ml); Gag CD4 (147.78 vs 32.93 pg/ml); RT CD8 (278.01 vs 41.42 pg/ml) in SmE-free vaccinated 
mice were higher compared to responses in SmE-inoculated vaccinated mice with exception to responses 
to Env CD8 which were higher in SmE-free (1158.23 vs 1550.36 pg/ml) compared to SmE-inoculated 
vaccinated mice (Fig 4.4 A). IL-2 (Fig 4.4 B) and TNF-α (Fig 4.4 C) levels were higher in SmE-free mice 
compared to SmE-inoculated mice; however, the difference was not significant in response to all HIV 
peptides. No noticeable difference was observed in all Th2 (Fig 4.4 D-F) cytokine levels between SmE-






Figure 4.4: Cytokine-produced by Gag (CD8 and CD4) RT (CD8 and CD4) and Env (CD 4 and CD8) 
specific peptides in SmE-free and SmE-inoculated mice vaccinated with MVA+gp140. Splenocytes 
were harvested from mice vaccinated with the indicated regimen described in Fig 4.1. They were then 
stimulated with an irrelevant peptide (negative control) or with the individual HIV-specific T cell peptides for 
48 h. Culture supernatants were collected and the level of Th1 (A, B and C) and Th2 (D, E and F) cytokines 




































































































































































































































































































































































































































































The individual bars represent the magnitude of the net positive cytokine levels in the medium of splenocytes 
of Sm-free and Sm-infected vaccinated mice, stimulated with individual HIV peptides, after subtracting the 
background (splenocytes stimulated with irrelevant peptide). The level of cytokines in the culture medium 
was considered positive when the level is higher than the detection limit of the respective cytokine described 
in Table 2.3. Results represent 3 independent experiments and plotted as the mean + SEM, and cytokine 
levels were expressed as pg/ml. Student t-test followed by FDR for multiple comparisons 
 
4.3.3. Cellular immune responses to the MVA+gp140 regimen in the background of SmE 
inoculation measured by ELISpot 
Cellular immune responses were evaluated using IFN-γ and IL-2 ELISpot assays to enumerate 
the number of Gag; RT and Env-specific IFN-γ or IL-2 secreting CD8+ and CD4+ T cells in the spleen of 
mice vaccinated with MVA-protein (MVA+gp140) (Fig 4.5).  
 
Vaccination with MVA+gp140 induced higher but not significant cumulative HIV-1 Gag, RT and Env-specific 
IFN-γ (1778.78 SFU/106 splenocytes) (Fig 4.5 A) and IL-2 ELISpot (126.89 SFU/106 splenocytes) (Fig 4.5 
C) responses in SmE-free vaccinated mice. In contrast, vaccination in SmE-inoculated mice induced a 
lower number of peptide-specific IFN-γ (1343.56 SFU/106 splenocytes) and IL-2 (103.78 SFU/106 
splenocytes) ELISpot responses.  
 
Levels of IFN-γ ELISpot responses to individual peptides were also higher in SmE-free vaccinated 
compared to SmE-inoculated mice except for the ELISpot responses to the Gag CD8 peptide which was 
slightly higher in SmE-inoculated compared to SmE-free vaccinated mice (Fig 4.5 B). On the other hand, 
IL-2 ELISpot responses to individual peptides were only positive for Gag CD4; RT CD4 and Env CD4. There 
was no difference between SmE-free and SmE-inoculated vaccinated mice except for IL-2 ELISpot 
responses to the RT CD4 which were slightly more in SmE-free (53.67 SFU/106 splenocytes) compared to 








Figure 4.5: IFN-γ and IL-2 ELISpot analysis of HIV-1 Gag; RT and Env-specific T cell responses 
induced in the spleen of Sm-infected and Sm-free mice vaccinated with the MVA+gp140 vaccine 
regimen described in Fig 4.1. At sacrifice, splenocytes were pooled from 5 mice per group then stimulated 
with an irrelevant peptide (negative control) or stimulated with HIV-1 Gag (CD4 and CD8); RT (CD8 and 
CD4) and Env (CD4 and CD8) T cell peptides in an IFN-γ ELISpot (A and B) and IL-2 ELISpot (C and D) 
assays. Bars are the mean number of spots of triplicate reactions in the irrelevant peptide (background) or 
to an individual peptide for 106 splenocytes. Positive responses to the HIV peptides were considered to be 
those greater than the background response (response to irrelevant peptide stimulation) plus two times the 
standard deviation (SD) of this response. The magnitude of positive IFN-γ ELISpot responses is expressed 
as either net cumulative (A) or net individual (B) responses per 106 splenocytes. The magnitude of positive 
IL-2 ELISpot responses is expressed as either net cumulative (C) or net individual (D) responses per 106 
splenocytes. The bars indicate the average net SFU from triplicate wells for 106 splenocytes. Results 
represent 3 independent experiments and plotted as the mean + SEM, and cytokine levels were expressed 
as pg/ml. Statistical analysis was performed using unpaired, two-tailed t-test analysis followed by FDR for 
multiple comparisons, *p<0.05. 





































































































































































































































4.3.4. HIV gp140 specific ELISA antibody responses in MVA+gp140 regimen 
To investigate the impact of SmE on vaccine antibody responses, antibody immunity in response to 
immunisation with MVA+gp140 was determined by ELISA. Significantly higher amount gp140-specific IgG1 
antibody units were observed in SmE-free (1203 ± 152.0 AUs) compared to SmE-inoculated (656.8 ± 177.1 
AUs). Significantly higher amount gp140-specific IgG2a antibody units were observed in SmE-free (238.1 
± 34.33 AUs) compared to SmE-inoculated (71.14 ± 15.98 AUs) vaccinated mice. Similarly, significantly 
higher amount gp140-specific IgG2b antibody units were observed in SmE-free (218.3 ± 41.86 AUs) 
compared to Sm-infected (82.73 ± 18.20 AUs) vaccinated mice (Fig 4.6). 
 
 
Figure 4.6: Schistosoma mansoni eggs (SmE) significantly reduce gp140 specific antibody units. 
Mice were sensitised and challenged with 2500 SmE prior vaccination with an MVA-protein (MVA+gp140) 
HIV vaccine regimen. Blood was collected 12 days after last vaccination from 5 mice per group and 
analysed for gp140 Env-specific IgG isotypes (IgG1, IgG2a, IgG2b). Previously-generated mouse anti-sera 
(Gp140 Env-specific with high OD values) were pooled and used to generate a standard curve. Individual 
mouse sera were tested at a dilution of 1:5,000. A test sample with OD values less than a cut-off value of 
2X the OD value of the negative control serum (pooled from unvaccinated, uninfected normal mice) was 
assigned a zero antibody unit. Each square represents an individual mouse of naïve (blue) or SmE 






























is representative of 3 independent experiments, student t-test followed by FDR for multiple comparisons. 
*P<0.05; **P<0.01; ***P<0.0001. 
4.4. Discussion 
Chronic helminth infections are characterized by skewing host immune response towards a dominant Th2 
type, marked by induction of Th2 related cytokines such as IL-4, IL-5 and IL-13 that induce B lymphocytes 
to switch to IgE antibody production accompanied by expanded T regulatory cell populations and some 
level of immune suppression (Pearce et al., 1991, Bundy et al., 2000, Voehringer et al., 2004, van Riet et 
al., 2007, Colley et al., 2014, Lundie et al., 2015, Mulu et al., 2015). Previous studies reported that this 
immune modulation from Th1 to Th2 induced by chronic helminth infection impaired the specific immunity 
induced by vaccination (Actor et al., 1993, Sabin et al., 1996, Muniz-Junqueira et al., 1996, Da'Dara et al., 
2006, Elias et al., 2008, Da'dara and Harn, 2010, Chen et al., 2012). In schistosomiasis, eggs drive the Th2 
immune response (Pearce et al., 1991, Grzych et al., 1991). However, elimination of the worms by treatment 
has been associated with recovery of immune balance and response to vaccination (Da'dara and Harn, 
2010, Chen et al., 2012, Shollenberger et al., 2013b). It is not known if eggs (trapped in tissue) in the 
absence of an active infection can induce a Th2 immune biased capable of affecting vaccine responses. 
This study asked if helminth eggs alone can drive a Th2-dominant response that can affect vaccine-induced 
responses to a vaccine regimen that induces mixed cellular and antibody responses (SAAVI MVA-C + Env-
gp140: MVA+gp140). For this, two experiments comprising of 4 groups of mice were used. The objective 
of the first experiment was to conduct a time point study to determine the immune profile at different 
vaccination time points in BALB/c mice model inoculated with Sm eggs (SmE). The second experiment was 
to evaluate if SmE induced Th2 immune biasing negatively affects responses to candidate HIV vaccines.  
 
 
4.4.1. Skewing towards Th2 in SmE-inoculated mice 
Our findings demonstrated that SmE induced strong Th2 cytokine responses and downregulation of host 
Th1 cytokines. The decrease of IFN-γ:IL-4 ratio observed in SmE inoculation further demonstrated biasing 
of host immune system towards predominant Th2 type. These findings coincide with other studies that have 
shown that biasing immune responses towards Th2 concurs with SmE deposition during live infection 
(Pearce et al., 1991, Grzych et al., 1991). In the absence of a live Sm-infection, this model shows that the 
eggs on their own induce strong Th2 immune responses comparable to those induced by live infection 
(Cheever et al., 2002, Fu et al., 2012, Joyce et al., 2012). It appears that SmE-induced Th2 immune 
responses wane over time. As shown in Fig 4.4, Day 47 post first inoculation with SmE, Th2 immune 
responses begin to decrease, marked by an overall decrease of IFN-γ:IL-4 ratio. However, the kinetics of 
this parasite eggs induced immune responses are not well understood past 47 days post first inoculation, 




the IFN-γ:IL-4 ratio in the SmE experiment was much higher in SmE-free vaccinated group at early time 
points (day 7 and 35 post inoculation with SmE) and became similar at 47 days post-inoculation (Fig 3.4 vs 
Fig 4.2). This observation may suggest that younger mice, elicit higher responses to antigens due to their 
stronger immune system. Generally, too young mice or too old mice don’t mount best immune responses 
compared to middle-aged groups of mice. Perhaps, this strain of mice responds best at 35 days post 
inoculation. It would be interesting to evaluate how different vaccination timepoints in younger mice behave.   
First, this may be likely due to the number of eggs inducing these Th2 responses in the host. In a live 
infection, egg deposition is continuous, thus, maintaining strong helminth-induced Th2 (Hams et al., 2013, 
Colley et al., 2014). As seen in this chapter, SmE-inoculated mouse only received a fixed amount of eggs 
(+-5000 eggs per mouse) compared to (+-1000 SmE daily for 4weeks plus) found in livers of mice infected 
with live infection (Pearce, 2005). It can be concluded that the number of eggs correlates with the strength 
or intensity of Th2 biasing.  
In previous chapter 3, parasitic worms were eliminated using PZQ treatment which does not eliminate the 
eggs trapped in tissue, which are drivers of Th2 responses, thus only partial restoration of Th1 responses 
was observed while Th2 responses remained high. Da'dara and Harn reported increased IL-10 (suppressor 
cytokine following Th2 responses) levels in PZQ treated groups despite the restoration of Th1 responses 
to their DNA vaccines (Da'dara and Harn, 2010). However, little is known about the consequences of these 
residual Th2 cytokines.  
 
4.4.2. Vaccine-specific cellular response 
Cumulative vaccine-specific T cell responses in SmE inoculated mice were evaluated using ELISpot. SmE-
inoculated vaccinated mice induced slightly lower net IFN-γ and IL-2 ELISpot responses compare to SmE-
free vaccinated mice, albeit insignificant (Fig 4.7). These results suggest that SmE is downregulating 
vaccine responses though it may be to a low degree (Fig 4.7). These findings were comparable to the 
treatment experiment in chapter 3 when comparing SmE-free vaccinated and Sm-free vaccinated groups, 
except that SmE did not significantly reduce vaccine responses as observed with the live infection with Sm. 
These findings may explain why PZQ treatment only partially restored responses to vaccines. Because 
eggs where still trapped in tissue, they may be inducing responses that suppress vaccine-specific cellular 
responses as observed in this study. These findings are further supported by previous studies that point 
SmE as the culprit that drives vaccine-specific response suppression, likely due to hyporesponsiveness 
(Hams et al., 2013, Colley et al., 2014).  
The same was true for vaccine-specific cytokine responses measured by CBA. SmE inoculated vaccinated 
mice had lower cumulative vaccine specific Th1 cytokines IFN-γ; IL-2 and TNF-α compared to SmE-free 




insignificant (Fig 4.5 A-C). In previous Chapter 3, vaccinated Sm-infected-PZQ treated mice showed only 
partially restored cytokine levels, suggesting that because eggs were still in liver tissue, they induced Th2 
cytokines which are known to participate in the reduction of Th1 vaccine-specific responses. These findings 
further suggest that SmE may only partially reduce vaccine-specific responses rather that completely 
reducing them as observed in a live infection model.  
Conversely, Bui and colleagues showed that S. mansoni soluble egg antigens enhance the Listeria 
monocytogenes vector HIV-1 vaccine induction of cytotoxic T cells (Bui et al., 2014). As a follow-up study, 
Bui and colleagues recently demonstrated that SEA enhances T cell responses to a newly identified HIV-1 
Gag H-2b epitope (Bui et al., 2015). These findings suggest that there may be two sides of the coin 
concerning the impact of helminth products on HIV vaccination. 
It is worth noting that a considerable level of Th2 cytokines (IL-10; IL-6 and IL-4 were expressed in high 
levels even in SmE free groups. Even though Th1 are the classical markers for these vaccines. These 
findings may suggest that these vaccines may have the ability to induce Th2 cytokine responses particularly 
in younger mice (Fig 4.3). However, they still induce more Th1 cytokines when compared to Th2 despite 
the presence of SmE.    
 
4.4.3. Antibody responses in SmE-inoculated mice 
To evaluate if egg-induced Th2 responses affect vaccine-specific antibody responses, serum of SmE 
vaccinated was evaluated by ELISA. Surprisingly, antibody responses in SmE vaccinated groups were 
significantly reduced for all Env gp140 specific isotypes compared to SmE-free vaccinated mice (Fig 4.8). 
This was not anticipated since only partial reduction of cellular immune responses was observed. Thus, 
these findings may suggest that the SmE affect critical immune components responsible for antibody 
production, most likely, the major players in antibody activation and production (T helper B cells) (Swain et 
al., 2012). These findings may explain why PZQ treated mice remained with defected vaccine-specific 
antibody responses, while T helper cells were reduced to undetectable levels (Fig 3.9 B). Furthermore, 
even if there were 10-fold more eggs in PZQ treatment vaccinated compared to SmE mice, PZQ has been 
shown to increase Th2 responses, which may contribute greatly to the reduction of vaccine antibody 
responses. The overall findings of this study suggest that even in the absence of a live Sm-infection, SmE 
can still induce Th2 responses that can potentially affect vaccine-specific responses, particularly antibody 
responses. To our knowledge, this study is the first to demonstrate the ability of Sm eggs in negatively 
affecting vaccine specific HIV antibody responses. There was a big difference in vaccine-specific IgG2a 
and IgG2b between SmE-free experiments and Sm-free experiments. It is not clear why this could be, 
however, the difference in age may play a role in modifying how antibody responses behave in these mice. 




compared to younger mice, attributing this to increased autoantibody forming cells found in older mice 
(Zhao et al., 1995).       
Conversely, a vaccine study by Shollenberger and colleagues demonstrated that the Listeria vaccine vector 
induced enhanced antibody responses to HIV Gag in vaccinated mice infected with Sm (Shollenberger et 
al., 2013b). They attributed these enhancements in the vaccine responses to the soluble egg antigen (SEA) 
which is produced by Sm eggs. 
 
4.4.4. Limitations of the study 
The egg model does not reproduce S. mansoni infection model (characterised by continuous egg 
deposition) which is performed by infecting mice with infectious cercariae. However, the S. mansoni egg 
model provides a platform for evaluating a series of immunological concepts. In this study, lungs were 
collected with an aim of determining successful inoculation with the eggs which get trapped in the lungs. 
However, this was not achievable due to lack of time and resources. Furthermore, comparison of the two 
models (liver for live infection vs lungs for SmE model) would give information on the types of granulomas 
formed and estimating egg burden of different tissues. It would have been interesting to evaluate 
pathological characteristics such as mouse footpads of vaccinated mice compared to unvaccinated mice.   
     
 
4.4.5. Conclusion and recommendations 
The overall study demonstrates that S. mansoni egg (SmE) alone can drive Th2 responses capable of 
attenuating the immunogenicity of HIV vaccines, particularly humoral responses. These findings propose 
that Sm eggs left lodged in the tissues after PZQ treatment may be contributors to the incomplete restoration 
of the immune responses observed in the vaccinated Sm-infected PZQ-treated mice (Chapter 3). These 
findings further suggest that future mass antihelminthic treatment may not be the immediate solution to 
counteract the impact of helminth infections on the immunogenicity of HIV vaccines as previously 
suggested, thus, further investigations may be required to give clarity on method of restoring immune 
responses. Therefore, this study recommends the implementation of thorough evaluation of immune 
responses even after antihelminthic therapy to achieve optimal and effective vaccine responses to 
established and future Th1 based vaccines. This study also calls for HIV vaccine development programs 
to consider designing vaccines that can overcome helminth-induced immunity as shown by the likes of Bui 
and Shollenberger (Shollenberger et al., 2013b, Bui et al., 2014, Bui et al., 2015). This study is, however, 





CHAPTER 5  
 
5. General Discussion 
The development of successful HIV vaccines remains a high priority, particularly in the developing Sub-
Saharan Africa (SSA) (UNAIDS, 2015). These candidate vaccines are expected to elicit effective humoral 
and T cell-mediated responses against HIV (Haynes and McElrath, 2013, McMichael and Koff, 2014). T 
cell responses associated with a predominantly T-cell helper type 1 (Th1) immune response will control 
viral replication in the tissues and disease progression (Koup and Douek, 2011), while humoral responses 
associated with durable antibody production neutralise and block virus entry at the mucosal sites (Mascola 
and Montefiori, 2009). However, the success of these future vaccines may be threatened by the widespread 
infection with water and soil-transmitted parasitic helminths in SSA (Means et al., 2016, WHO, 2016). This 
is mainly because helminth infection has been shown to cause CD4+ Th2 immune biased response 
(Maizels and Yazdanbakhsh, 2003, Maizels et al., 2004, Moreau and Chauvin, 2010, Dauby et al., 2012, 
Yin et al., 2012), which in turn downregulates the CD4+ Th1 responses that are normally required for 
vaccine effectiveness (Maizels and Yazdanbakhsh, 2003, van Riet et al., 2007, Bourke et al., 2011). 
Whether vaccines currently in development for HIV and other diseases will function in populations that have 
a high prevalence of helminth infection is uncertain, and is something to worry about in the field of vaccine 
development. Especially with a growing literature showing that infection with helminth parasites causes 
immune suppression and a CD4+ Th2 skewing of the immune system, thereby impairing Th1-type vaccine 
efficacy (Buck et al., 1970, Prost et al., 1983, Kilian and Nielsen, 1989, Sabin et al., 1996, Haseeb and 
Craig, 1997, Cooper et al., 1998, Stewart et al., 1999, Cooper et al., 2000a, Elias et al., 2008, Chen et al., 
2012, Apiwattanakul et al., 2014, Bobat et al., 2014, Wajja et al., 2017). 
In this study, 3 major experiments were conducted to explore some of the unanswered questions regarding 
this idea.  
The first experiment sought to investigate the effect of helminth infection on the humoral and cellular 
immunogenicity of two candidate HIV vaccines previously shown to induce specific immune responses in 
a mouse model system. A preliminary study for the establishment and the validation of a suitable helminth-
HIV vaccines experiment was conducted in mice using Schistosoma mansoni (Sm) as a helminth model. 
In this experiment, Sm-infected mice elicited predominantly Th2 responses marked by increased levels of 
Th2 cytokine and a decreased Th1 cytokine profile. Furthermore, it was demonstrated in Figure 2.10 that 
cytokine producing CD8 and CD4 T cells are impaired during Sm-infection. This was accompanied by an 
increase in type 2 total antibodies in serum of Sm-infected mice compared to uninfected groups (Fig 2.12 
and 2.13). The phenotype of infected mice was characterized by enlarged spleens and liver. With the model 
established, infected mice were immunised with SAAVI candidate HIV vaccines, following which immune 
responses against HIV peptides and proteins were evaluated between Sm-infected vaccinated and Sm-




adequate vaccine-specific T cell responses. Furthermore, humoral responses to the gp140-env protein 
were significantly impaired in Sm-infected vaccinated mice (Fig 2.14). This was an interesting finding with 
far-reaching implications for vaccine development. This lead to asking if the removal of the worms by 
antihelminth chemotherapy could perhaps restore vaccine-specific responses.  
The second experiment sought to evaluate how previously infected mice will respond to vaccination after 
being treated with an antihelminth drug. The findings showed that treating mice prior vaccination could 
partially restore T cells responses, particularly IFN-γ and IL-2. Surprisingly, the partial recovery of these 
responses did not translate to the reduction of Th2 responses. Anti-inflammatory cytokine such as IL-10 
remained elevated despite treatment with antihelminth. Similar findings were reported in previous 
schistosome-mouse studies, were PZQ was a drug of choice (Da'dara and Harn, 2010, Shollenberger et 
al., 2013b).  
Even more surprising, findings revealed that antibody responses to the gp140-env protein in Sm-infected 
mice remained significantly low despite prior treatment with PZQ (Fig 3.11). The reason for such findings 
could be that there is a disruption of T cell-B cell interaction caused by Sm-associated elements. Livers and 
spleen evaluation revealed that after treatment, the normal phenotype can be achieved. However, histology 
showed that eggs remained trapped in tissue even after treatment. Treatment with PZQ has been shown 
to act upon adult worms, thus lowering the egg burden in treated subjects (Shaheen et al., 1989, Utzinger 
and Keiser, 2004, Tallima and El Ridi, 2007). Therefore, it can be anticipated that after treatment, the 
immune responses would return to normal. However, in this study, vaccine-specific cellular response in 
treated mice were not fully recovered. Instead, they still had eggs trapped in their livers. Because SmE 
drives the Th2 biasing induced by Sm, it can be concluded that the recovery of T cell responses can only 
be partial as a result of the helminth eggs trapped in tissue. This impairment of T cell responses, albeit 
minimal, may be the reason for significantly impaired vaccine-specific antibody responses observed in this 
study to vaccines despite treatment.  
This study went further to demonstrate that Th1 cellular responses elicited by DNA+MVA vaccines 
exacerbated helminth-induced pathology. Sm-infected mice which were vaccinated with DNA+MVA 
vaccines had significantly larger granuloma sizes (a marker for pathology in Schistosomiasis (Hams et al., 
2013, Lundy and Lukacs, 2013) as well as heavier spleen and livers compared to Sm-infected unvaccinated 
groups. Treatment significantly reduced the pathology, however, eggs were still present in the tissue. These 
findings highlighted the scientific challenges in the development of HIV vaccines for Africa, where parasitic 
helminthiasis is endemic. Furthermore, this raised a question if Sm eggs in the absence of a live infection 
could result in same downregulation of HIV vaccine-specific responses.  
The third experiment sought to further investigate the impact of the presence of helminth eggs alone on 
vaccine-induced immune responses. Following an established Sm-egg model (Joyce et al., 2012), mice 




showed that even in the absence of live worms, eggs could drive a considerable Th2 immune response 
shown by elevated Th2 cytokines. Surprisingly, this immune response only partially affects the T cell 
compartment. Although reduced, the decrease in vaccine-specific cellular responses observed in SmE 
inoculated mice was not significant. This may be because the number of eggs used for inoculation were 
low, hence the minimal downregulation observed. This can also explain why treated-vaccinated groups also 
induced partially reduced vaccine-specific responses, attributing the effect to be orchestrated by the 
schistosome eggs. Unexpectedly, antibody responses to HIV env-gp140 were significantly reduced in the 
presence of SmE. This again may explain why antibody responses in treated groups did not get restored. 
This finding further highlights another challenge, that even treatment of helminths would not be a definite 
solution as helminth eggs alone could still attenuate HIV vaccine-induced immune responses.  
In light of the findings, this study suggests that elimination of worms can offer an affordable and a simple 
means to partially restore immune responsiveness to T cell-based vaccines for HIV-1 and other infectious 
diseases in helminth endemic settings. However, it would be important to consider bacterial vector such as 
the Listeria delivering HIV vaccine, as these have been shown to elicit immune responses without being 
affected by the presence of helminth infections. Perhaps current and future therapeutic vaccines can benefit 
from the cooperative use of antihelminthic treatment together with HAART, as this will give the immune 
system a better chance to mount appropriate responses. The question of how acutely infected patients 
would respond to HIV vaccination is an avenue to explore, since few such cases may occur. Perhaps such 
patients could benefit from these drugs as does chronically infected patients.  
Furthermore, this study gives an informed report on the impact of helminth infection in HIV vaccines; 
however, not all immunological aspects could be elucidated. Thus, this study justifies further investigations 
with use of a nonhuman primate model such as baboons (immune system sequence is highly similar to 
humans) to obtain a comprehensive understanding of these immune responses. The findings of this study 
contribute to the body of knowledge concerning the potential challenges helminth infection may pose to 
future successful candidate HIV vaccines. To our knowledge, there is no reported study evaluating HIV 
vaccine-specific antibody responses to Env-gp140 in a helminth setting. Furthermore, this study is the first 







Appendix A: Supplementary data 
 
 
Appendix A: Th1 and Th2 profile induced by SmE in mice.  Splenocytes were harvested and stimulated with either con A or SEA for 72 hrs at 
5% CO2, 37°C. Supernatants were harvested and analysed for Th2 cytokines IL-4; IL-6; IL-10 (A-C respectively) and Th1 cytokines: IFN-γ; TNF-α 
IL-4












































































































































































and IL-2 (D-F respectively) measured by CBA. Red bars represent mice challenged with SmE and blue bars represent Naïve groups. Results 
represent 2-3 independent experiments and plotted as the mean + SEM, and cytokine levels were expressed as pg/ml. #:Groups that received 




Appendix B Reagents and solutions 
 
Chloramine T 
Dissolve 7 g of chloramine T in 100 ml deionized water. Store for 6 months in the dark at 4°C. 
 
Citrate-acetate buffer 
To 385 ml of isopropanol (2-propanol), add: 
57 g sodium acetate.3H2O 
37.5 g sodium citrate.2H2O 
5.5 g H3citrate. H2O 
Bring final volume to 1 liter with deionized water 
Store indefinitely at room temperature 
 
Dowex/Norit A mixture 
Mix 20 g Dowex (200 to 400 mesh; Sigma, USA) with 10 g Norit-A (Fisher Scientific, USA) in a large beaker. 
Add 200 ml of 6N HCl and mix well. Transfer mixture to a large Büchner funnel and filter. Wash two times 
with 6 N HCl. Wash with 95% ethanol and then with 100% ethanol two times. Let dry and store 12 months 
at room temperature. 
 
Phenolphthalein, 1% 
Add 1 g of phenolphthalein to 100 ml of absolute ethanol. Stable for up to 2 years at room temperature. 
 
 
Ehrlich's solution  
Dissolve 1g of Para-dimethylamino benzaldehyde in 95ml of 95% ethanol 




10x Lepple Buffer 
5.6 g CaCl2 
12.28 g MgSO4.7H2O 
0.43 g K2SO4 
4.2 g NaHCO3 
0.48 mL FeCl3.6H2O solution (2.5 g dissolve in 50 mL H20) 





Mix all reagents in 1 L distilled water, except the NaHCO3, and allowed to stand for 1 hour.  
Add NaHCO3 and make up a solution to 10 L with distilled water. 
To make a working stock of 1x Lepple buffer, add 1 part 10x Lepple buffer to 9 parts distilled water and add 







AASA-CHAPMAN, M. M., HOLUIGUE, S., AUBIN, K., WONG, M., JONES, N. A., CORNFORTH, D., 
PELLEGRINO, P., NEWTON, P., WILLIAMS, I. & BORROW, P. 2005. Detection of antibody-
dependent complement-mediated inactivation of both autologous and heterologous virus in primary 
human immunodeficiency virus type 1 infection. Journal of Virology, 79, 2823-2830. 
ABAITUA, F., RODRIGUEZ, J. R., GARZON, A., RODRIGUEZ, D. & ESTEBAN, M. 2006. Improving 
recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA 
and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Research, 116, 
11-20. 
ABD EL-AAL, N. F., HAMZA, R. S. & HARB, O. 2017. Paeoniflorin targets apoptosis and ameliorates 
fibrosis in murine schistosomiasis mansoni: A novel insight. Experimental Parasitology, 183, 23-
32. 
ACTOR, J. K., SHIRAI, M., KULLBERG, M. C., BULLER, R. M. L., SHER, A. & BERZOFSKY, J. A. 1993. 
Helminth Infection Results in Decreased Virus-Specific Cd8+ Cytotoxic T-Cell and Th1-Cytokine 
Responses as Well as Delayed Virus Clearance. Proceedings of the National Academy of Sciences 
of the United States of America, 90, 948-952. 
AKHIANI, A. A. 1996. Immunological studies of murine Schistosomiasis mansoni. Göteborgs 
universitet/University of Gothenburg. 
ALLEN, J. E. & MAIZELS, R. M. 2011. Diversity and dialogue in immunity to helminths. Nature Reviews 
Immunology, 11, 375-388. 
ALTFELD, M., KALIFE, E. T., QI, Y., STREECK, H., LICHTERFELD, M., JOHNSTON, M. N., BURGETT, 
N., SWARTZ, M. E., YANG, A. & ALTER, G. 2006. HLA alleles associated with delayed progression 
to AIDS contribute strongly to the initial CD8+ T cell response against HIV-1. PLoS Medicine, 3, 
e403. 
ALTFELD;, M., BEHRENS;, G., BERZOW;, D., BOESECKE;, C., BRAUN;, P., CAMP;, R., EGGERS;, C., 
ESSER;, S., FÄTKENHEUER;, G., HARRER;, T., HERZMANN;, C., HOFFMANN;, C. & 
CHRISTIAN HOFFMANN, E. A. 2015. HIV book, Hamburg, Germany. 
AMANNA, I. J. & SLIFKA, M. K. 2010. Mechanisms that determine plasma cell lifespan and the duration of 
humoral immunity. Immunological Reviews, 236, 125-138. 
ANDERSON, R. M., TRUSCOTT, J. E., PULLAN, R. L., BROOKER, S. J. & HOLLINGSWORTH, T. D. 
2013. How effective is school-based deworming for the community-wide control of soil-transmitted 
helminths? PLOS Neglected Tropical Disease, 7, e2027. 
ANTHONY, R. M., RUTITZKY, L. I., URBAN, J. F., STADECKER, M. J. & GAUSE, W. C. 2007. Protective 
immune mechanisms in helminth infection. Nature Reviews Immunology, 7, 975-987. 
APIWATTANAKUL, N., THOMAS, P. G., IVERSON, A. R. & MCCULLERS, J. A. 2014. Chronic helminth 
infections impair pneumococcal vaccine responses. Vaccine, 32, 5405-5410. 
APPAY, V., NIXON, D. F., DONAHOE, S. M., GILLESPIE, G. M., DONG, T., KING, A., OGG, G. S., 
SPIEGEL, H. M., CONLON, C. & SPINA, C. A. 2000. HIV-specific CD8+ T cells produce antiviral 
cytokines but are impaired in cytolytic function. Journal of Experimental Medicine, 192, 63-76. 
ARANZAMENDI, C., SOFRONIC-MILOSAVLJEVIC, L. & PINELLI, E. 2013. Helminths: immunoregulation 
and inflammatory diseases—which side are Trichinella spp. and Toxocara spp. on? Journal of 
parasitology research, 2013. 
ARAUJO, M., BACELLAR, O., RIBEIRO-DE-JESUS, A. & CARVALHO, E. 1994. The absence of gamma-
interferon production of S. mansoni antigens in patients with schistosomiasis. Brazilian journal of 
medical and biological research= Revista brasileira de pesquisas medicas e biologicas/Sociedade 
Brasileira de Biofisica...[et al.], 27, 1619-1625. 
ARCIA, D., ACEVEDO-SÁENZ, L., RUGELES, M. T. & VELILLA, P. A. 2017. Role of CD8+ T cells in the 
selection of HIV-1 immune escape mutations. Viral Immunology, 30, 3-12. 
AYINDE, D., CASARTELLI, N. & SCHWARTZ, O. 2012. Restricting HIV the SAMHD1 way: through 




BAETEN, J. M., DONNELL, D., NDASE, P., MUGO, N. R., CAMPBELL, J. D., WANGISI, J., TAPPERO, J. 
W., BUKUSI, E. A., COHEN, C. R. & KATABIRA, E. 2012. Antiretroviral prophylaxis for HIV 
prevention in heterosexual men and women. New England Journal of Medicine, 367, 399-410. 
BAROUCH, D. H., LIU, J., LI, H., MAXFIELD, L. F., ABBINK, P., LYNCH, D. M., IAMPIETRO, M. J., 
SANMIGUEL, A., SEAMAN, M. S. & FERRARI, G. 2012. Vaccine protection against acquisition of 
neutralization-resistant SIV challenges in rhesus monkeys. Nature, 482, 89. 
BAROUCH, D. H., STEPHENSON, K. E., BORDUCCHI, E. N., SMITH, K., STANLEY, K., MCNALLY, A. 
G., LIU, J., ABBINK, P., MAXFIELD, L. F. & SEAMAN, M. S. 2013. Protective efficacy of a global 
HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell, 155, 531-
539. 
BARRE-SINOUSSI, F., CHERMANN, J. C., REY, F., NUGEYRE, M. T., CHAMARET, S., GRUEST, J., 
DAUGUET, C., AXLER-BLIN, C., VEZINET-BRUN, F., ROUZIOUX, C., ROZENBAUM, W. & 
MONTAGNIER, L. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired 
immune deficiency syndrome (AIDS). Science, 220, 868-871. 
BARSOUM, R. S., ESMAT, G. & EL-BAZ, T. 2013. Human schistosomiasis: clinical perspective: review. 
Journal of advanced research, 4, 433-444. 
BARTLEY, P. B., RAMM, G. A., JONES, M. K., RUDDELL, R. G., LI, Y. & MCMANUS, D. P. 2006. A 
contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-
induced fibrosis. International Journal for Parasitology, 36, 993-1001. 
BECK, I., HOTOWY, A., SAWOSZ, E., GRODZIK, M., WIERZBICKI, M., KUTWIN, M., JAWORSKI, S. & 
CHWALIBOG, A. 2015. Effect of silver nanoparticles and hydroxyproline, administered in ovo, on 
the development of blood vessels and cartilage collagen structure in chicken embryos. Archives of 
Animal Nutrition, 69, 57-68. 
BENTLEY, A. G., DOUGHTY, B. L. & PHILLIPS, S. M. 1982. Ultrastructural analysis of the cellular response 
to Schistosoma mansoni. III. The in vitro granuloma. The American Journal of Tropical Medicine 
and Hygiene, 31, 1168-1180. 
BENTWICH, Z., KALINKOVICH, A., WEISMAN, Z., BORKOW, G., BEYERS, N. & BEYERS, A. D. 1999. 
Can eradication of helminthic infections change the face of AIDS and tuberculosis? Immunology 
Today, 20, 485-487. 
BERGES, B. K., AKKINA, S. R., FOLKVORD, J. M., CONNICK, E. & AKKINA, R. 2008. Mucosal 
transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2−/− 
γc−/−(RAG-hu) mice. Virology, 373, 342-351. 
BERGMAN, I. & LOXLEY, R. 1963. Two improved and simplified methods for the spectrophotometric 
determination of hydroxyproline. Analytical Chemistry, 35, 1961-1965. 
BERMAN, P. W., GREGORY, T. J., RIDDLE, L., NAKAMURA, G. R. & CHAMPE, M. A. 1990. Protection 
of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but 
not gp160. Nature, 345, 622. 
BERMAN, P. W., MURTHY, K. K., WRIN, T., VENNARI, J. C., COBB, E. K., EASTMAN, D. J., CHAMPE, 
M., NAKAMURA, G. R., DAVISON, D. & POWELL, M. F. 1996. Protection of MN-rgp120-
immunized chimpanzees from heterologous infection with a primary isolate of human 
immunodeficiency virus type 1. Journal of Infectious Diseases, 173, 52-59. 
BOBAT, S., DARBY, M., MRDJEN, D., COOK, C., LOGAN, E., AURET, J., JONES, E., SCHNOELLER, C., 
FLORES-LANGARICA, A., ROSS, E. A., VIRA, A., LOPEZ-MACIAS, C., HENDERSON, I. R., 
ALEXANDER, J., BROMBACHER, F., HORSNELL, W. G. & CUNNINGHAM, A. F. 2014. Natural 
and vaccine-mediated immunity to Salmonella Typhimurium is impaired by the helminth 
Nippostrongylus brasiliensis. PLoS neglected tropical diseases, 8, e3341. 
BONSIGNORI, M., POLLARA, J., MOODY, M. A., ALPERT, M. D., CHEN, X., HWANG, K.-K., GILBERT, 
P. B., HUANG, Y., GURLEY, T. C. & KOZINK, D. M. 2012. Antibody-dependent cellular cytotoxicity-
mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially 
use the VH1 gene family. Journal of virology, 86, 11521-11532. 
BOOTH, M., SHAW, M. A., CARPENTER, D., JOSEPH, S., KABATEREINE, N. B., KARIUKI, H. C., 
MWATHA, J. K., JONES, F. M., VENNERVALD, B. J. & OUMA, J. H. 2006. Carriage of DRB1* 13 
is associated with increased posttreatment IgE levels against Schistosoma mansoni antigens and 




BORKOW, G. & BENTWICH, Z. 2004. Chronic immune activation associated with chronic helminthic and 
human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clinical 
Microbiology Reviews, 17, 1012-1030. 
BORKOW, G. & BENTWICH, Z. 2006. HIV and helminth co-infection: is deworming necessary? Parasite 
Immunology, 28, 605-612. 
BORKOW, G. & BENTWICH, Z. 2008. Chronic parasite infections cause immune changes that could affect 
successful vaccination. Trends in Parasitology, 24, 243-245. 
BORKOW, G., LENG, Q., WEISMAN, Z., STEIN, M., GALAI, N., KALINKOVICH, A. & BENTWICH, Z. 2000. 
Chronic immune activation associated with intestinal helminth infections results in impaired signal 
transduction and anergy. Journal of Clinical Investigation, 106, 1053. 
BOROS, D. 1989. Immunopathology of Schistosoma mansoni infection. Clinical Microbiology Reviews, 2, 
250-269. 
BORROW, P., LEWICKI, H., HAHN, B. H., SHAW, G. M. & OLDSTONE, M. B. 1994. Virus-specific CD8+ 
cytotoxic T-lymphocyte activity associated with control of viremia in primary human 
immunodeficiency virus type 1 infection. Journal of Virology, 68, 6103-6110. 
BOTTIEAU, E., CLERINX, J., DE VEGA, M. R., VAN DEN ENDEN, E., COLEBUNDERS, R., VAN 
ESBROECK, M., VERVOORT, T., VAN GOMPEL, A. & VAN DEN ENDE, J. 2006. Imported 
Katayama fever: clinical and biological features at presentation and during treatment. Journal of 
Infection, 52, 339-345. 
BOURKE, C. D., MAIZELS, R. M. & MUTAPI, F. 2011. Acquired immune heterogeneity and its sources in 
human helminth infection. Parasitology, 138, 139-159. 
BRENCHLEY, J. M., PAIARDINI, M., KNOX, K. S., ASHER, A. I., CERVASI, B., ASHER, T. E., 
SCHEINBERG, P., PRICE, D. A., HAGE, C. A. & KHOLI, L. M. 2008. Differential Th17 CD4 T-cell 
depletion in pathogenic and nonpathogenic lentiviral infections. Blood, 112, 2826-2835. 
BRENCHLEY, J. M., PRICE, D. A. & DOUEK, D. C. 2006a. HIV disease: fallout from a mucosal 
catastrophe? Nature Immunology, 7, 235-239. 
BRENCHLEY, J. M., PRICE, D. A., SCHACKER, T. W., ASHER, T. E., SILVESTRI, G., RAO, S., KAZZAZ, 
Z., BORNSTEIN, E., LAMBOTTE, O. & ALTMANN, D. 2006b. Microbial translocation is a cause of 
systemic immune activation in chronic HIV infection. Nature Medicine, 12, 1365-1371. 
BROOKER, S., MIGUEL, E. A., MOULIN, S., LOUBA, A. I., BUNDY, D. A. & KREMER, M. 2000. 
Epidemiology of single and multiple species of helminth infections among school children in Busia 
District, Kenya. East African Medical Journal, 77. 
BROWN, M., MAWA, P. A., JOSEPH, S., BUKUSUBA, J., WATERA, C., WHITWORTH, J. A., DUNNE, D. 
W. & ELLIOTT, A. M. 2005. Treatment of Schistosoma mansoni infection increases helminth-
specific type 2 cytokine responses and HIV-1 loads in coinfected Ugandan adults. Journal of 
Infectious Diseases, 191, 1648-1657. 
BRUNET, L. R., FINKELMAN, F. D., CHEEVER, A. W., KOPF, M. A. & PEARCE, E. J. 1997. IL-4 protects 
against TNF-alpha-mediated cachexia and death during acute schistosomiasis. The Journal of 
Immunology, 159, 777-785. 
BUCHBINDER, S. P., HAY, C., GRUNENBERG, N., GOEPFERT, P., GEORGIA, T., SEATON, K., SATO, 
A., ELIZAGA, M., YU, X. & GILBERT, P. 2014. VLP-expressing DNA/MVA Vaccines: The Effect of 
Schedule and Regimen on Antibody Magnitude and Avidity. AIDS Research and Human 
Retroviruses, 30, A32-A32. 
BUCHBINDER, S. P., MEHROTRA, D. V., DUERR, A., FITZGERALD, D. W., MOGG, R., LI, D., GILBERT, 
P. B., LAMA, J. R., MARMOR, M. & DEL RIO, C. 2008. Efficacy assessment of a cell-mediated 
immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-
concept trial. The Lancet, 372, 1881-1893. 
BUCK, A. A., ANDERSON, R. I., SASAKI, T. T. & KAWATA, K. 1970. Health and disease in Chad. 
Epidemiology, culture, and environment in five villages. Health and disease in Chad. Epidemiology, 
culture, and environment in five villages. 
BUCKNER, C. M., MOIR, S., HO, J., WANG, W., POSADA, J. G., KARDAVA, L., FUNK, E. K., NELSON, 
A. K., LI, Y. & CHUN, T.-W. 2013. Characterization of plasmablasts in the blood of HIV-infected 
viremic individuals: evidence for nonspecific immune activation. Journal of virology, 87, 5800-5811. 
BUDEUS, B., DE REYNOSO, S. S., PRZEKOPOWITZ, M., HOFFMANN, D., SEIFERT, M. & KÜPPERS, 




clonal diversification in germinal centers. Proceedings of the National Academy of Sciences, 112, 
E5281-E5289. 
BUENO, R. A., THOMAZ, L., MUÑOZ, J. E., DA SILVA, C. J., NOSANCHUK, J. D., PINTO, M. R., 
TRAVASSOS, L. R. & TABORDA, C. P. 2016. Antibodies against glycolipids enhance antifungal 
activity of macrophages and reduce fungal burden after infection with Paracoccidioides brasiliensis. 
Frontiers in microbiology, 7. 
BUI, C. T., SHOLLENBERGER, L. M., PATERSON, Y. & HARN, D. A. 2014. Schistosoma mansoni Soluble 
Egg Antigens Enhance Listeria monocytogenes Vector HIV-1 Vaccine Induction of Cytotoxic T 
Cells. Clinical and Vaccine Immunology, 21, 1232-1239. 
BUI, C. T., SHOLLENBERGER, L. M., PATERSON, Y. & HARN, D. A. 2015. Schistosoma mansoni Soluble 
Egg Antigens Enhance T Cell Responses to a Newly Identified HIV-1 Gag H-2(b) Epitope. Clinical 
and Vaccine Immunology, 22, 193-199. 
BUNDY, D., SHER, A. & MICHAEL, E. 2000. Good worms or bad worms: do worm infections affect the 
epidemiological patterns of other diseases? Parasitology Today, 16, 273-274. 
BUONAGURO, L., TORNESELLO, M. L. & BUONAGURO, F. M. 2007. Human immunodeficiency virus 
type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. 
Journal of Virology, 81, 10209-10219. 
BURGER, E., VAZ, C. C., SANO, A., CALICH, V. L., SINGER-VERMES, L. M., XIDIEH, C. F., KASHINO, 
S. S., NISHIMURA, K. & MIYAJI, M. 1996. Paracoccidioides brasiliensis infection in nude mice: 
studies with isolates differing in virulence and definition of their T cell-dependent and T cell-
independent components. The American Journal of Tropical Medicine and Hygiene, 55, 391-398. 
BURGERS, W. A., CHEGE, G. K., MULLER, T. L., VAN HARMELEN, J. H., KHOURY, G., SHEPHARD, E. 
G., GRAY, C. M., WILLIAMSON, C. & WILLIAMSON, A. L. 2009. Broad, high-magnitude and 
multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara 
vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. Journal of 
General Virology, 90, 468-480. 
BURGERS, W. A., SHEPHARD, E., MONROE, J. E., GREENHALGH, T., BINDER, A., HURTER, E., VAN 
HARMELEN, J. H., WILLIAMSON, C. & WILLIAMSON, A. L. 2008. Construction, characterization, 
and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 
subtype C. AIDS Research and Human Retroviruses, 24, 195-206. 
BURGERS, W. A., VAN HARMELEN, J. H., SHEPHARD, E., ADAMS, C., MGWEBI, T., BOURN, W., 
HANKE, T., WILLIAMSON, A. L. & WILLIAMSON, C. 2006. Design and preclinical evaluation of a 
multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. Journal 
of General Virology, 87, 399-410. 
BURKE, M., JONES, M., GOBERT, G., LI, Y., ELLIS, M. & MCMANUS, D. 2009. Immunopathogenesis of 
human schistosomiasis. Parasite Immunology, 31, 163-176. 
BURTON, D. R. & MASCOLA, J. R. 2015. Antibody responses to envelope glycoproteins in HIV-1 infection. 
Nature Immunology, 16, 571-576. 
BUSTINDUY, A., KING, C., SCOTT, J., APPLETON, S., SOUSA-FIGUEIREDO, J. C., BETSON, M. & 
STOTHARD, J. R. 2014. HIV and schistosomiasis co-infection in African children. The Lancet 
Infectious Diseases, 14, 640-649. 
CALDAS, I. R., CAMPI-AZEVEDO, A. C., OLIVEIRA, L. F. A., SILVEIRA, A. M. S., OLIVEIRA, R. C. & 
GAZZINELLI, G. 2008. Human schistosomiasis mansoni: immune responses during acute and 
chronic phases of the infection. Acta Tropica, 108, 109-117. 
CAMPBELL-YESUFU, O. T. & GANDHI, R. T. 2011. Update on human immunodeficiency virus (HIV)-2 
infection. Clinical Infectious Diseases, 52, 780-787. 
CAÑETE, R., ESCOBEDO, A., ALMIRALL, P., GONZÁLEZ, M., BRITO, K. & CIMERMAN, S. 2009. 
Mebendazole in parasitic infections other than those caused by soil-transmitted helminths. 
Transactions of the Royal Society of Tropical Medicine and Hygiene, 103, 437-442. 
CANO, L. E., SINGER-VERMES, L. M., COSTA, T. A., MENGEL, J. O., XIDIEH, C. F., ARRUDA, C., 
ANDRÉ, D. C., VAZ, C. A., BURGER, E. & CALICH, V. L. 2000. Depletion of CD8+ T cells in vivo 
impairs host defense of mice resistant and susceptible to pulmonary paracoccidioidomycosis. 
Infection and Immunity, 68, 352-359. 
CARRINGTON, M. & O'BRIEN, S. J. 2003. The influence of HLA genotype on AIDS. Annual Review of 




CASIMIRO, D. R., TANG, A., PERRY, H. C., LONG, R. S., CHEN, M., HEIDECKER, G. J., DAVIES, M.-E., 
FREED, D. C., PERSAUD, N. V. & DUBEY, S. 2002. Vaccine-induced immune responses in 
rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol 
gene. Journal of virology, 76, 185-194. 
CDC. 2012. Parasites - Schistosomiasis [Online]. Available: 
https://www.cdc.gov/parasites/schistosomiasis/ [Accessed]. 
CHEEVER, A. W., HOFFMANN, K. F. & WYNN, T. A. 2000. Immunopathology of schistosomiasis mansoni 
in mice and men. Immunology Today, 21, 465-466. 
CHEEVER, A. W., LENZI, J. A., LENZI, H. L. & ANDRADE, Z. A. 2002. Experimental models of 
Schistosoma mansoni infection. Memorias do Instituto Oswaldo Cruz, 97, 917-940. 
CHEEVER, A. W., XU, Y. H., SHER, A. & MACEDONIA, J. G. 1991. Analysis of egg granuloma formation 
in Schistosoma japonicum-infected mice treated with antibodies to interleukin-5 and gamma 
interferon. Infection and Immunity, 59, 4071-4074. 
CHEGE, G. K., BURGERS, W. A., MÜLLER, T. L., GRAY, C. M., SHEPHARD, E. G., BARNETT, S. W., 
FERRARI, G., MONTEFIORI, D., WILLIAMSON, C. & WILLIAMSON, A.-L. 2017. DNA-MVA-
protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated 
lymph nodes and functional antibodies. Vaccine, 35, 929-937. 
CHEN, H., PIECHOCKA-TROCHA, A., MIURA, T., BROCKMAN, M. A., JULG, B. D., BAKER, B. M., 
ROTHCHILD, A. C., BLOCK, B. L., SCHNEIDEWIND, A. & KOIBUCHI, T. 2009. Differential 
neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-
specific cytotoxic T lymphocytes. Journal of Virology, 83, 3138-3149. 
CHEN, L., LIU, W. Q., LEI, J. H., GUAN, F., LI, M. J., SONG, W. J., LI, Y. L. & WANG, T. 2012. Chronic 
Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. 
PLoS One, 7, e51512. 
CHENINE, A.-L., BUCKLEY, K. A., LI, P.-L., RASMUSSEN, R. A., ONG, H., JIANG, S., WANG, T., 
AUGOSTINI, P., SECOR, W. E. & RUPRECHT, R. M. 2005. Schistosoma mansoni infection 
promotes SHIV clade C replication in rhesus macaques. AIDS, 19, 1793-1797. 
CHENSUE, S. & BOROS, D. 1979. Population dynamics of T and B lymphocytes in the lymphoid organs, 
circulation, and granulomas of mice infected with Schistosoma mansoni. The American Journal of 
Tropical Medicine and Hygiene, 28, 291-299. 
CHEUNG, Y. B., XU, Y., REMARQUE, E. J. & MILLIGAN, P. 2015. Statistical estimation of antibody 
concentration using multiple dilutions. Journal of Immunological Methods, 417, 115-123. 
CHHATBAR, C., MISHRA, R., KUMAR, A. & SINGH, S. K. 2011. HIV vaccine: hopes and hurdles. Drug 
Discovery Today, 16, 948-956. 
CHOWDHURY, A. & SILVESTRI, G. 2013. Host–pathogen interaction in HIV infection. Current Opinion in 
Immunology, 25, 463-469. 
CHRISTIAN, M. A. G. B. D. B. C. B. P. B. R. C. C. E. S. E. G. F. T. H. C. H. C. H. 2015. HIV book, Hamburg, 
Germany. 
CHUANG, I., SEDEGAH, M., CICATELLI, S., SPRING, M., POLHEMUS, M., TAMMINGA, C., 
PATTERSON, N., GUERRERO, M., BENNETT, J. W. & MCGRATH, S. 2013. DNA 
prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile 
protection associated with cell-mediated immunity. PloS one, 8, e55571. 
CHUNG, A. W., KUMAR, M. P., ARNOLD, K. B., YU, W. H., SCHOEN, M. K., DUNPHY, L. J., SUSCOVICH, 
T. J., FRAHM, N., LINDE, C. & MAHAN, A. E. 2015. Dissecting polyclonal vaccine-induced humoral 
immunity against HIV using systems serology. Cell, 163, 988-998. 
CHURCHER, T. S., PION, S. D., OSEI-ATWENEBOANA, M. Y., PRICHARD, R. K., AWADZI, K., 
BOUSSINESQ, M., COLLINS, R. C., WHITWORTH, J. A. & BASÁÑEZ, M.-G. 2009. Identifying 
sub-optimal responses to ivermectin in the treatment of River Blindness. Proceedings of the 
National Academy of Sciences, 106, 16716-16721. 
CHURCHYARD, G., MLISANA, K., KARUNA, S., WILLIAMSON, A.-L., WILLIAMSON, C., MORRIS, L., 
TOMARAS, G. D., DE ROSA, S. C., GILBERT, P. B. & GU, N. 2016. Sequential Immunization with 
gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected 
South African Participants. PloS one, 11, e0161753. 
CLAVEL, F., MANSINHO, K., CHAMARET, S., GUETARD, D., FAVIER, V., NINA, J., SANTOS-




virus type 2 infection associated with AIDS in West Africa. New England Journal of Medicine, 316, 
1180-1185. 
COFFIN, J. & SWANSTROM, R. 2013. HIV pathogenesis: dynamics and genetics of viral populations and 
infected cells. Cold Spring Harbor perspectives in medicine, 3, a012526. 
COHEN, M. S., CHEN, Y. Q., MCCAULEY, M., GAMBLE, T., HOSSEINIPOUR, M. C., KUMARASAMY, N., 
HAKIM, J. G., KUMWENDA, J., GRINSZTEJN, B. & PILOTTO, J. H. 2011a. Prevention of HIV-1 
infection with early antiretroviral therapy. New England Journal of Medicine, 365, 493-505. 
COHEN, M. S., SHAW, G. M., MCMICHAEL, A. J. & HAYNES, B. F. 2011b. Acute HIV-1 Infection. New 
England Journal of Medicine, 364, 1943-1954. 
COHEN, Y. Z. & DOLIN, R. 2013. Novel HIV vaccine strategies: overview and perspective. Therapeutic 
advances in vaccines, 1, 99-112. 
COLLEY, D. G., BUSTINDUY, A. L., SECOR, W. E. & KING, C. H. 2014. Human schistosomiasis. The 
Lancet, 383, 2253-2264. 
COLLEY, D. G., GARCIA, A. A., LAMBERTUCCI, J. R., PARRA, J. C., KATZ, N., ROCHA, R. S. & 
GAZZINELLI, G. 1986. Immune responses during human schistosomiasis. The American Journal 
of Tropical Medicine and Hygiene, 35, 793-802. 
CONNICK, E., MARR, D. G., ZHANG, X.-Q., CLARK, S. J., SAAG, M. S., SCHOOLEY, R. T. & CURIEL, 
T. J. 1996. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS 
Research and Human Retroviruses, 12, 1129-1140. 
COOPER, P., ESPINEL, I., PAREDES, W., GUDERIAN, R. & NUTMAN, T. 1998. Impaired tetanus-specific 
cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible 
role for interleukin-10. Journal of Infectious Diseases, 178, 1133-1138. 
COOPER, P. J., CHICO, M., SANDOVAL, C., ESPINEL, I., GUEVARA, A., LEVINE, M. M., GRIFFIN, G. 
E. & NUTMAN, T. B. 2001. Human infection with Ascaris lumbricoides is associated with 
suppression of the interleukin-2 response to recombinant cholera toxin B subunit following 
vaccination with the live oral cholera vaccine CVD 103-HgR. Infection and Immunity, 69, 1574-
1580. 
COOPER, P. J., CHICO, M. E., LOSONSKY, G., SANDOVAL, C., ESPINEL, I., SRIDHARA, R., AGUILAR, 
M., GUEVARA, A., GUDERIAN, R. H. & LEVINE, M. M. 2000a. Albendazole treatment of children 
with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera 
vaccine CVD 103-HgR. Journal of Infectious Diseases, 182, 1199-1206. 
COOPER, P. J., CHICO, M. E., SANDOVAL, C., ESPINEL, I., GUEVARA, A., KENNEDY, M. W., URBAN, 
J. F., GRIFFIN, G. E. & NUTMAN, T. B. 2000b. Human infection with Ascaris lumbricoides is 
associated with a polarized cytokine response. Journal of Infectious Diseases, 182, 1207-1213. 
COOPER, P. J., ESPINEL, I., WIESEMAN, M., PAREDES, W., ESPINEL, M., GUDERIAN, R. H. & 
NUTMAN, T. B. 1999. Human onchocerciasis and tetanus vaccination: impact on the 
postvaccination antitetanus antibody response. Infection and Immunity, 67, 5951-5957. 
COOPMAN, S. A., JOHNSON, R. A., PLATT, R. & STERN, R. S. 1993. Cutaneous disease and drug 
reactions in HIV infection. New England Journal of Medicine, 328, 1670-1674. 
DA'DARA, A. A. & HARN, D. A. 2010. Elimination of helminth infection restores HIV-1C vaccine-specific T 
cell responses independent of helminth-induced IL-10. Vaccine, 28, 1310-1317. 
DA'DARA, A. A., LAUTSCH, N., DUDEK, T., NOVITSKY, V., LEE, T. H., ESSEX, M. & HARN, D. A. 2006. 
Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. 
Vaccine, 24, 5211-5219. 
DA SILVA, F. A., LI, M., RATO, S., MAIA, S., MALHÓ, R., WARREN, K., HARRICH, D., CRAIGIE, R., 
BARBAS, C. & GONCALVES, J. 2012. Recombinant rabbit single‐chain antibodies bind to the 
catalytic and C‐terminal domains of HIV‐1 integrase protein and strongly inhibit HIV‐1 replication. 
Biotechnology and Applied Biochemistry, 59, 353-366. 
DAAR, E. S., LITTLE, S., PITT, J., SANTANGELO, J., HO, P., HARAWA, N., KERNDT, P., GLORGI, J. V., 
BAI, J., GAUT, P., RICHMAN, D. D., MANDEL, S. & NICHOLS, S. 2001. Diagnosis of primary HIV-
1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Annals of Internal 
Medicine, 134, 25-29. 
DAAR, E. S., PILCHER, C. D. & HECHT, F. M. 2008. Clinical presentation and diagnosis of primary HIV-1 
infection. Current Opinion HIV AIDS, 3, 10-15. 
DANDEKAR, S., GEORGE, M. D. & BÄUMLER, A. J. 2010. Th17 cells, HIV and the gut mucosal barrier. 




DANSO‐APPIAH, A., DE VLAS, S., BOSOMPEM, K. & HABBEMA, J. 2004. Determinants of health‐seeking 
behaviour for schistosomiasis‐related symptoms in the context of integrating schistosomiasis 
control within the regular health services in Ghana. Tropical medicine & international health, 9, 784-
794. 
DAUBY, N., GOETGHEBUER, T., KOLLMANN, T. R., LEVY, J. & MARCHANT, A. 2012. Uninfected but 
not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to 
postnatal infections. The Lancet infectious diseases, 12, 330-340. 
DE BOER, R. J., MOHRI, H., HO, D. D. & PERELSON, A. S. 2003. Turnover rates of B cells, T cells, and 
NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. The Journal 
of Immunology, 170, 2479-2487. 
DE SILVA, N. R., BROOKER, S., HOTEZ, P. J., MONTRESOR, A., ENGELS, D. & SAVIOLI, L. 2003. Soil-
transmitted helminth infections: updating the global picture. Trends in Parasitology, 19, 547-551. 
DE SILVA, T. I., COTTEN, M. & ROWLAND-JONES, S. L. 2008. HIV-2: the forgotten AIDS virus. Trends 
in Microbiology, 16, 588-595. 
DE SOUZA APOSTÓLICO, J., LUNARDELLI, V. A. S., YAMAMOTO, M. M., SOUZA, H. F. S., CUNHA-
NETO, E., BOSCARDIN, S. B. & ROSA, D. S. 2017. Dendritic cell Targeting effectively Boosts T 
cell responses elicited by an hiV Multiepitope Dna Vaccine. Frontiers in immunology, 8. 
DEEKS, S. G., LEWIN, S. R., ROSS, A. L., ANANWORANICH, J., BENKIRANE, M., CANNON, P., 
CHOMONT, N., DOUEK, D., LIFSON, J. D. & LO, Y.-R. 2016. International AIDS Society global 
scientific strategy: towards an HIV cure 2016. Nature Medicine. 
DEENICK, E. K., HASBOLD, J. & HODGKIN, P. D. 2005. Decision criteria for resolving isotype switching 
conflicts by B cells. European Journal of Immunology, 35, 2949-2955. 
DESIMMIE, B. A., DELVIKS-FRANKENBERRRY, K. A., BURDICK, R. C., QI, D., IZUMI, T. & PATHAK, V. 
K. 2014. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. Journal of 
Molecular Biology, 426, 1220-1245. 
DHAMANAGE, A., THAKAR, M. & PARANJAPE, R. 2017. Human immunodeficiency virus-1 impairs IFN-
alpha production induced by TLR-7 agonist in plasmacytoid dendritic cells. Viral Immunology, 30, 
28-34. 
DOBLECKI-LEWIS, S., COHEN, S. & LIU, A. 2015. Clinical treatment options infectious diseases: update 
on PrEP implementation, adherence, and advances in delivery. Current treatment options in 
infectious diseases, 7, 101-112. 
DOLO, H., COULIBALY, Y. I., DEMBELE, B., KONATE, S., COULIBALY, S. Y., DOUMBIA, S. S., DIALLO, 
A. A., SOUMAORO, L., COULIBALY, M. E. & DIAKITE, S. A. 2012. Filariasis attenuates anemia 
and proinflammatory responses associated with clinical malaria: a matched prospective study in 
children and young adults. PLOS Neglected Tropical Disease, 6, e1890. 
DORIA-ROSE, N. A., KLEIN, R. M., DANIELS, M. G., O'DELL, S., NASON, M., LAPEDES, A., 
BHATTACHARYA, T., MIGUELES, S. A., WYATT, R. T. & KORBER, B. T. 2010. Breadth of human 
immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association 
with clinical variables. Journal of Virology, 84, 1631-1636. 
DOUEK, D. C., ROEDERER, M. & KOUP, R. A. 2009. Emerging concepts in the immunopathogenesis of 
AIDS. Annual Review of Medicine, 60, 471-484. 
DOURADINHA, B. & DOOLAN, D. L. 2011. Harnessing immune responses against Plasmodium for rational 
vaccine design. Trends in Parasitology, 27, 274-283. 
DOWNS, J. A. & FITZGERALD, D. W. 2016. No more neglect of helminths and HIV. The Lancet, 388, 1857-
1859. 
DOWNS, J. A., VAN DAM, G. J., CHANGALUCHA, J. M., CORSTJENS, P. L., PECK, R. N., CLAUDIA, J., 
BANG, H., ANDREASEN, A., KALLUVYA, S. E. & VAN LIESHOUT, L. 2012. Association of 
Schistosomiasis and HIV infection in Tanzania. The American Journal of Tropical Medicine and 
Hygiene, 87, 868-873. 
DU PLESSIS, N., KLEYNHANS, L., THIART, L., VAN HELDEN, P. D., BROMBACHER, F., HORSNELL, 
W. G. & WALZL, G. 2013. Acute helminth infection enhances early macrophage mediated control 
of mycobacterial infection. Mucosal Immunology, 6, 931-941. 
DUNNE, D. W. & PEARCE, E. J. 1999. Immunology of hepatosplenic schistosomiasis mansoni: a human 




EL-AMAD, Z., MURTHY, K. K., HIGGINS, K., COBB, E. K., HAIGWOOD, N. L., LEVY, J. A. & STEIMER, 
K. S. 1995. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by 
HIV-1SF2. AIDS, 9, 1313-1322. 
EL KHOBY, T., GALAL, N. & FENWICK, A. 1998. The USAID/Government of Egypt's schistosomiasis 
research project (SRP). Parasitology Today, 14, 92-96. 
ELBAZ, T. & ESMAT, G. 2013. Hepatic and intestinal schistosomiasis: review. Journal of advanced 
research, 4, 445-452. 
ELIAS, D., AKUFFO, H., PAWLOWSKI, A., HAILE, M., SCHON, T. & BRITTON, S. 2005a. Schistosoma 
mansoni infection reduces the protective efficacy of BCG vaccination against virulent 
Mycobacterium tuberculosis. Vaccine, 23, 1326-1334. 
ELIAS, D., AKUFFO, H., THORS, C., PAWLOWSKI, A. & BRITTON, S. 2005b. Low dose chronic 
Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in 
mice. Clinical and Experimental Immunology, 139, 398-404. 
ELIAS, D., BRITTON, S., ASEFFA, A., ENGERS, H. & AKUFFO, H. 2008. Poor immunogenicity of BCG in 
helminth infected population is associated with increased in vitro TGF-beta production. Vaccine, 
26, 3897-3902. 
ELIAS, D., BRITTON, S., KASSU, A. & AKUFFO, H. 2007. Chronic helminth infections may negatively 
influence immunity against tuberculosis and other diseases of public health importance. Expert 
Review of Anti-infective Therapy, 5, 475-484. 
ELIAS, D., WOLDAY, D., AKUFFO, H., PETROS, B., BRONNER, U. & BRITTON, S. 2001. Effect of 
deworming on human T cell responses to mycobacterial antigens in helminth‐exposed individuals 
before and after bacille calmette–guérin (BCG) vaccination. Clinical & Experimental Immunology, 
123, 219-225. 
ELLIOTT, A. M., MAWA, P. A., JOSEPH, S., NAMUJJU, P. B., KIZZA, M., NAKIYINGI, J. S., WATERA, C., 
DUNNE, D. W. & WHITWORTH, J. A. 2003. Associations between helminth infection and CD4+ T 
cell count, viral load and cytokine responses in HIV-1-infected Ugandan adults. Transactions of the 
Royal Society of Tropical Medicine and Hygiene, 97, 103-108. 
ELLIOTT, D. E., RAGHEB, S., WELLHAUSEN, S. R. & BOROS, D. 1990. Interactions between adherent 
mononuclear cells and lymphocytes from granulomas of mice with schistosomiasis mansoni. 
Infection and Immunity, 58, 1577-1583. 
ENGELMAN, A. & CHEREPANOV, P. 2012. The structural biology of HIV-1: mechanistic and therapeutic 
insights. Nature Reviews Microbiology, 10, 279-290. 
EXCLER, J.-L., ROBB, M. L. & KIM, J. H. 2014. HIV-1 vaccines: Challenges and new perspectives. Human 
vaccines & immunotherapeutics, 10, 1734-1746. 
FALLON, P., FOOKES, R. & WHARTON, G. 1996. Temporal differences in praziquantel-and oxamniquine-
induced tegumental damage to adult Schistosoma mansoni: implications for drug-antibody 
synergy. Parasitology, 112, 47-58. 
FALLON, P. G. & DUNNE, D. W. 1999. Tolerization of mice to Schistosoma mansoni egg antigens causes 
elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute 
infection. The Journal of Immunology, 162, 4122-4132. 
FALLON, P. G., RICHARDSON, E. J., MCKENZIE, G. J. & MCKENZIE, A. N. J. 2000. Schistosome 
Infection of Transgenic Mice Defines Distinct and Contrasting Pathogenic Roles for IL-4 and IL-13: 
IL-13 Is a Profibrotic Agent. The Journal of Immunology, 164, 2585-2591. 
FAUCI, A. S. & MARSTON, H. D. 2014. Ending AIDS--is an HIV vaccine necessary? The New England 
Journal of Medicine, 370, 495. 
FECTEAU, J. F., CÔTÉ, G. & NÉRON, S. 2006. A new memory CD27− IgG+ B cell population in peripheral 
blood expressing VH genes with low frequency of somatic mutation. The Journal of Immunology, 
177, 3728-3736. 
FELLAY, J., SHIANNA, K. V., GE, D., COLOMBO, S., LEDERGERBER, B., WEALE, M., ZHANG, K., 
GUMBS, C., CASTAGNA, A. & COSSARIZZA, A. 2007. A whole-genome association study of 
major determinants for host control of HIV-1. Science, 317, 944-947. 
FENTON, A. 2013. Dances with worms: the ecological and evolutionary impacts of deworming on 
coinfecting pathogens. Parasitology, 140, 1119-1132. 
FIEBIG, E. W., WRIGHT, D. J., RAWAL, B. D., GARRETT, P. E., SCHUMACHER, R. T., PEDDADA, L., 




and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary 
HIV infection. AIDS, 17, 1871-1879. 
FINCHAM, J. E., MARKUS, M. B. & ADAMS, V. J. 2003. Could control of soil-transmitted helminthic 
infection influence the HIV/AIDS pandemic. Acta Tropica, 86, 315-333. 
FINK, K. 2012. Origin and function of circulating plasmablasts during acute viral infections. Frontiers in 
immunology, 3, 78. 
FINKELMAN, F. D. & URBAN, J. F., JR. 2001. The other side of the coin: the protective role of the TH2 
cytokines. The Journal of Allergy and Clinical Immunology, 107, 772-780. 
FINZI, D., BLANKSON, J., SILICIANO, J. D., MARGOLICK, J. B., CHADWICK, K., PIERSON, T., SMITH, 
K., LISZIEWICZ, J., LORI, F. & FLEXNER, C. 1999. Latent infection of CD4+ T cells provides a 
mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. 
Nature Medicine, 5, 512-517. 
FLYNN, N. M., FORTHAL, D. N., HARRO, C. D., JUDSON, F. N., MAYER, K. H. & PARA, M. F. 2005. 
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 
infection. Journal of Infectious Diseases, 191, 654-665. 
FOLEY, B., LEITNER, T., APETREI, C., HAHN, B., MIZRACHI, I., MULLINS, J., RAMBAUT, A., 
WOLINSKY, S. & KORBER, B. 2013. HIV sequence compendium 2013. Los Alamos National 
Laboratory, NM: Theoretical Biology and Biophysics Group. p, 448. 
FORTHAL, D. N., GILBERT, P. B., LANDUCCI, G. & PHAN, T. 2007. Recombinant gp120 vaccine-induced 
antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and 
correlate inversely with HIV infection rate. The Journal of Immunology, 178, 6596-6603. 
FORTHAL, D. N., LANDUCCI, G. & DAAR, E. S. 2001. Antibody from patients with acute human 
immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of 
natural-killer effector cells. Journal of Virology, 75, 6953-6961. 
FRANCHINI, G. & BOSCH, M. L. 1989. Genetic relatedness of the human immunodeficiency viruses type 
1 and 2 (HIV-1, HIV-2) and the simian immunodeficiency virus (SIV). Annals of the New York 
Academy of Sciences, 554, 81-87. 
FREED, E. O. 2001. HIV-1 replication. Somatic Cell and Molecular Genetics, 26, 13-33. 
FREED, E. O. & GALE, M., JR. 2014. Antiviral innate immunity: editorial overview. Journal of Molecular 
Biology, 426, 1129-1132. 
FU, C. L., ODEGAARD, J. I., HERBERT, D. R. & HSIEH, M. H. 2012. A novel mouse model of Schistosoma 
haematobium egg-induced immunopathology. PLoS Pathogens, 8, e1002605. 
GALLO, R. C., SALAHUDDIN, S. Z., POPOVIC, M., SHEARER, G. M., KAPLAN, M., HAYNES, B. F., 
PALKER, T. J., REDFIELD, R., OLESKE, J., SAFAI, B. & ET AL. 1984. Frequent detection and 
isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 
224, 500-503. 
GARNIER, R., BOULINIER, T. & GANDON, S. 2013. Evolution of the temporal persistence of immune 
protection. Biology Letters, 9, 20130017. 
GASCHEN, B., TAYLOR, J., YUSIM, K., FOLEY, B., GAO, F., LANG, D., NOVITSKY, V., HAYNES, B., 
HAHN, B. H. & BHATTACHARYA, T. 2002. Diversity considerations in HIV-1 vaccine selection. 
Science, 296, 2354-2360. 
GEARY, T. G. 2012. Are new anthelmintics needed to eliminate human helminthiases? Current Opinion in 
Infectious Diseases, 25, 709-717. 
GELDERBLOM, H. 1997. Fine structure of HIV and SIV. 
GHOSH, K., WU, W., ANTOINE, A. D., BOTTAZZI, M. E., VALENZUELA, J. G., HOTEZ, P. J. & MENDEZ, 
S. 2006. The impact of concurrent and treated Ancylostoma ceylanicum hookworm infections on 
the immunogenicity of a recombinant hookworm vaccine in hamsters. Journal of Infectious 
Diseases, 193, 155-162. 
GILBERT, P. B., PETERSON, M. L., FOLLMANN, D., HUDGENS, M. G., FRANCIS, D. P., GURWITH, M., 
HEYWARD, W. L., JOBES, D. V., POPOVIC, V. & SELF, S. G. 2005. Correlation between 
immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection 
in a phase 3 HIV-1 preventive vaccine trial. Journal of Infectious Diseases, 191, 666-677. 
GIORGI, J. V., HULTIN, L. E., MCKEATING, J. A., JOHNSON, T. D., OWENS, B., JACOBSON, L. P., 
SHIH, R., LEWIS, J., WILEY, D. J. & PHAIR, J. P. 1999. Shorter survival in advanced human 




than with plasma virus burden or virus chemokine coreceptor usage. Journal of Infectious 
Diseases, 179, 859-870. 
GIRARD, M. P., OSMANOV, S., ASSOSSOU, O. M. & KIENY, M.-P. 2011. Human immunodeficiency virus 
(HIV) immunopathogenesis and vaccine development: a review. Vaccine, 29, 6191-6218. 
GISBERT, J., VILLAGRASA, J., RODRÍGUEZ-NOGUEIRAS, A. & CHAPARRO, M. 2012. Efficacy of 
hepatitis B vaccination and revaccination and factors impacting on response in patients with 
inflammatory bowel disease. The American journal of gastroenterology, 107, 1460-1466. 
GOEPFERT, P. A., ELIZAGA, M. L., SEATON, K., TOMARAS, G. D., MONTEFIORI, D. C., SATO, A., 
HURAL, J., DEROSA, S. C., KALAMS, S. A. & MCELRATH, M. J. 2014. Specificity and 6-month 
durability of immune responses induced by DNA and recombinant modified vaccinia Ankara 
vaccines expressing HIV-1 virus-like particles. The Journal of infectious diseases, 210, 99-110. 
GÓMEZ-ROMÁN, V. R., PATTERSON, L. J., VENZON, D., LIEWEHR, D., ALDRICH, K., FLORESE, R. & 
ROBERT-GUROFF, M. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular 
cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with 
SIVmac251. The Journal of Immunology, 174, 2185-2189. 
GOOD, M. F. & DOOLAN, D. L. 2010. Malaria vaccine design: immunological considerations. Immunity, 
33, 555-566. 
GOPINATH, R., OSTROWSKI, M., JUSTEMENT, S. J., FAUCI, A. S. & NUTMAN, T. B. 2000. Filarial 
infections increase susceptibility to human immunodeficiency virus infection in peripheral blood 
mononuclear cells in vitro. Journal of Infectious Diseases, 182, 1804-1808. 
GRANICH, R., GUPTA, S., MONTANER, J., WILLIAMS, B. & ZUNIGA, J. M. 2015. Pattern, determinants, 
and impact of HIV spending on care and treatment in 38 high-burden low-and middle-income 
countries. Journal of the International Association of Providers of AIDS Care (JIAPAC), 
2325957415623261. 
GRANT, R. M., LAMA, J. R., ANDERSON, P. L., MCMAHAN, V., LIU, A. Y., VARGAS, L., GOICOCHEA, 
P., CASAPÍA, M., GUANIRA-CARRANZA, J. V. & RAMIREZ-CARDICH, M. E. 2010. Preexposure 
chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of 
Medicine, 2010, 2587-2599. 
GRAY, E., MOORE, P., CHOGE, I., DECKER, J., BIBOLLET-RUCHE, F., LI, H., LESEKA, N., 
TREURNICHT, F., MLISANA, K. & SHAW, G. 2007. Neutralizing antibody responses in acute 
human immunodeficiency virus type 1 subtype C infection. Journal of Virology, 81, 6187-6196. 
GRAY, E. S., MADIGA, M. C., HERMANUS, T., MOORE, P. L., WIBMER, C. K., TUMBA, N. L., WERNER, 
L., MLISANA, K., SIBEKO, S. & WILLIAMSON, C. 2011. The neutralization breadth of HIV-1 
develops incrementally over four years and is associated with CD4+ T cell decline and high viral 
load during acute infection. Journal of Virology, 85, 4828-4840. 
GRAY, G., BUCHBINDER, S. & DUERR, A. 2010. Overview of STEP and Phambili trial results: two phase 
IIb test of concept studies investigating the efficacy of MRK ad5 gag/pol/nef sub-type B HIV 
vaccine. Current Opinion HIV AIDS, 5, 357. 
GRAY, G. E., MAYER, K. H., ELIZAGA, M. L., BEKKER, L. G., ALLEN, M., MORRIS, L., MONTEFIORI, 
D., DE ROSA, S. C., SATO, A., GU, N., TOMARAS, G. D., TUCKER, T., BARNETT, S. W., 
MKHIZE, N. N., SHEN, X., DOWNING, K., WILLIAMSON, C., PENSIERO, M., COREY, L. & 
WILLIAMSON, A. L. 2016. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the 
South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year 
Gap. Clinical and Vaccine Immunology, 23, 496-506. 
GRAY, G. E., MOODIE, Z., METCH, B., GILBERT, P. B., BEKKER, L.-G., CHURCHYARD, G., 
NCHABELENG, M., MLISANA, K., LAHER, F. & ROUX, S. 2014. Recombinant adenovirus type 5 
HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 
503/Phambili study. The Lancet infectious diseases, 14, 388-396. 
GROGAN, J. L., KREMSNER, P. G., DEELDER, A. M. & YAZDANBAKHSH, M. 1996. Elevated proliferation 
and interleukin‐4 release from CD4+ cells after chemotherapy in human Schistosoma 
haematobium infection. European Journal of Immunology, 26, 1365-1370. 
GROOPMAN, J. E. 1984. Causation of AIDS revealed. Nature, 308, 769. 
GROSSMAN, Z., MEIER-SCHELLERSHEIM, M., PAUL, W. E. & PICKER, L. J. 2006. Pathogenesis of HIV 
infection: what the virus spares is as important as what it destroys. Nature Medicine, 12, 289-295. 
GRYSEELS, B. & NKULIKYINKA, L. 1988. The distribution of Schistosoma mansoni in the Rusizi plain 




GRYSEELS, B. & POLDERMAN, A. 1991. Morbidity, due to schistosomiasis mansoni, and its control in 
Subsaharan Africa. Parasitology Today, 7, 244-248. 
GRYSEELS, B., POLMAN, K., CLERINX, J. & KESTENS, L. 2006. Human schistosomiasis. The Lancet, 
368, 1106-1118. 
GRZYCH, J. M., PEARCE, E., CHEEVER, A., CAULADA, Z. A., CASPAR, P., HEINY, S., LEWIS, F. & 
SHER, A. 1991. Egg deposition is the major stimulus for the production of Th2 cytokines in murine 
schistosomiasis mansoni. Journal of Immunology, 146, 1322-1327. 
GUAN, F., HOU, X., NIE, G., XIAO, Y., ZHANG, Q., LIU, W.-Q., LI, Y.-L. & LEI, J.-H. 2013. Effect of 
Trichinella spiralis infection on the immune response to HBV vaccine in a mouse model. Foodborne 
pathogens and disease, 10, 882-887. 
GUPTA, R. K., HILL, A., SAWYER, A. W., COZZI-LEPRI, A., VON WYL, V., YERLY, S., LIMA, V. D., 
GÜNTHARD, H. F., GILKS, C. & PILLAY, D. 2009. Virological monitoring and resistance to first-
line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: 
a systematic review and meta-analysis. The Lancet Infectious Diseases, 9, 409-417. 
HAAS, A., ZIMMERMANN, K. & OXENIUS, A. 2011. Antigen-dependent and-independent mechanisms of 
T and B cell hyperactivation during chronic HIV-1 infection. Journal of Virology, 85, 12102-12113. 
HABEN, I., HARTMANN, W. & BRELOER, M. 2014. Nematode-induced interference with vaccination 
efficacy targets follicular T helper cell induction and is preserved after termination of infection. PLoS 
neglected tropical diseases, 8, e3170. 
HAGAN, P., BLUMENTHAL, U. J., DUNN, D., SIMPSON, A. J. & WILKINS, H. A. 1991. Human IgE, IgG4 
and resistance to reinfection with Schistosomahaematobium. Nature., 349:, 243-245. 
HAMMER, S. M., SOBIESZCZYK, M. E., JANES, H., KARUNA, S. T., MULLIGAN, M. J., GROVE, D., 
KOBLIN, B. A., BUCHBINDER, S. P., KEEFER, M. C. & TOMARAS, G. D. 2013. Efficacy trial of a 
DNA/rAd5 HIV-1 preventive vaccine. New England Journal of Medicine, 369, 2083-2092. 
HAMS, E., AVIELLO, G. & FALLON, P. G. 2013. The schistosoma granuloma: friend or foe? Front Immunol, 
4, 89. 
HANKE, T. 2014. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 
vaccines. Expert opinion on biological therapy, 14, 601-616. 
HANSEN, S. G., FORD, J. C., LEWIS, M. S., VENTURA, A. B., HUGHES, C. M., COYNE-JOHNSON, L., 
WHIZIN, N., OSWALD, K., SHOEMAKER, R. & SWANSON, T. 2011. Profound early control of 
highly pathogenic SIV by an effector memory T-cell vaccine. Nature, 473, 523-527. 
HARMS, G. & FELDMEIER, H. 2002. Review: HIV infection and tropical parasitic diseases–deleterious 
interactions in both directions? Tropical medicine & international health, 7, 479-488. 
HARNETT, W. & HARNETT, M. M. 2010. Helminth-derived immunomodulators: can understanding the 
worm produce the pill? Nature Reviews Immunology, 10, 278-284. 
HARRIS, J. B., PODOLSKY, M. J., BHUIYAN, T. R., CHOWDHURY, F., KHAN, A. I., LAROCQUE, R. C., 
LOGVINENKO, T., KENDALL, J., FARUQUE, A. S. & NAGLER, C. R. 2009. Immunologic 
responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh. PLOS 
Neglected Tropical Disease, 3, e403. 
HARTGERS, F. C., OBENG, B. B., KRUIZE, Y. C., DIJKHUIS, A., MCCALL, M., SAUERWEIN, R. W., 
LUTY, A. J., BOAKYE, D. A. & YAZDANBAKHSH, M. 2009. Responses to malarial antigens are 
altered in helminth-infected children. Journal of Infectious Diseases, 199, 1528-1535. 
HASEEB, M. & CRAIG, J. P. 1997. Suppression of the immune response to diphtheria toxoid in murine 
schistosomiasis. Vaccine, 15, 45-50. 
HAYNES, B. F. 2015. New approaches to HIV vaccine development. Current Opinion in Immunology, 35, 
39-47. 
HAYNES, B. F., GILBERT, P. B., MCELRATH, M. J., ZOLLA-PAZNER, S., TOMARAS, G. D., ALAM, S. 
M., EVANS, D. T., MONTEFIORI, D. C., KARNASUTA, C., SUTTHENT, R., LIAO, H. X., DEVICO, 
A. L., LEWIS, G. K., WILLIAMS, C., PINTER, A., FONG, Y., JANES, H., DECAMP, A., HUANG, 
Y., RAO, M., BILLINGS, E., KARASAVVAS, N., ROBB, M. L., NGAUY, V., DE SOUZA, M. S., 
PARIS, R., FERRARI, G., BAILER, R. T., SODERBERG, K. A., ANDREWS, C., BERMAN, P. W., 
FRAHM, N., DE ROSA, S. C., ALPERT, M. D., YATES, N. L., SHEN, X., KOUP, R. A., 
PITISUTTITHUM, P., KAEWKUNGWAL, J., NITAYAPHAN, S., RERKS-NGARM, S., MICHAEL, N. 
L. & KIM, J. H. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New 




HAYNES, B. F. & MCELRATH, M. J. 2013. Progress in HIV-1 vaccine development. Current Opinion HIV 
AIDS, 8, 326. 
HAZENBERG, M. D., OTTO, S. A., VAN BENTHEM, B. H., ROOS, M. T., COUTINHO, R. A., LANGE, J. 
M., HAMANN, D., PRINS, M. & MIEDEMA, F. 2003. Persistent immune activation in HIV-1 infection 
is associated with progression to AIDS. AIDS, 17, 1881-1888. 
HECHT, F. M., BUSCH, M. P., RAWAL, B., WEBB, M., ROSENBERG, E., SWANSON, M., CHESNEY, M., 
ANDERSON, J., LEVY, J. & KAHN, J. O. 2002. Use of laboratory tests and clinical symptoms for 
identification of primary HIV infection. AIDS, 16, 1119-1129. 
HELMY, M. M., MAHMOUD, S. S. & FAHMY, Z. H. 2009. Schistosoma mansoni: effect of dietary zinc 
supplement on egg granuloma in Swiss mice treated with praziqantel. Experimental Parasitology, 
122, 310-317. 
HEMELAAR, J., GOUWS, E., GHYS, P. D. & OSMANOV, S. 2011. Global trends in molecular epidemiology 
of HIV-1 during 2000-2007. AIDS, 25, 679-689. 
HERRMANN, A., HAPPEL, A.-U. & GRAMBERG, T. 2016. SAMHD1 in Retroviral Restriction and Innate 
Immune Sensing–Should We Leash the Hound? Current HIV Research, 14, 225-234. 
HERSPERGER, A. R., PEREYRA, F., NASON, M., DEMERS, K., SHETH, P., SHIN, L. Y., KOVACS, C. 
M., RODRIGUEZ, B., SIEG, S. F. & TEIXEIRA-JOHNSON, L. 2010. Perforin expression directly ex 
vivo by HIV-specific CD8+ T-cells is a correlate of HIV elite control. PLoS Pathogens, 6, e1000917. 
HIV/AIDS, J. U. N. P. O. 2016. Prevenfion Gap Report. Geneva, Switzerland: UNAIDS. 
HO, D. D., NEUMANN, A. U., PERELSON, A. S., CHEN, W., LEONARD, J. M. & MARKOWITZ, M. 1995. 
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126. 
HOENIGL, M., GREEN, N., CAMACHO, M., GIANELLA, S., MEHTA, S. R., SMITH, D. M. & LITTLE, S. J. 
2016. Signs or symptoms of acute HIV infection in a cohort undergoing community-based 
screening. Emerging Infectious Diseases, 22, 532. 
HOERAUF, A., SATOGUINA, J., SAEFTEL, M. & SPECHT, S. 2005. Immunomodulation by filarial 
nematodes. Parasite immunology, 27, 417-429. 
HOLL, V., PERESSIN, M., DECOVILLE, T., SCHMIDT, S., ZOLLA-PAZNER, S., AUBERTIN, A.-M. & 
MOOG, C. 2006. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 
1 replication in macrophages and immature dendritic cells. Journal of Virology, 80, 6177-6181. 
HOSSEINIPOUR, M. C., VAN OOSTERHOUT, J. J., WEIGEL, R., PHIRI, S., KAMWENDO, D., PARKIN, 
N., FISCUS, S. A., NELSON, J. A., ERON, J. J. & KUMWENDA, J. 2009. The public health 
approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase 
inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS (London, 
England), 23, 1127. 
HOTEZ, P. J., BRINDLEY, P. J., BETHONY, J. M., KING, C. H., PEARCE, E. J. & JACOBSON, J. 2008. 
Helminth infections: the great neglected tropical diseases. The Journal of clinical investigation, 118, 
1311-1321. 
HUANG, J., OFEK, G., LAUB, L., LOUDER, M. K., DORIA-ROSE, N. A., LONGO, N. S., IMAMICHI, H., 
BAILER, R. T., CHAKRABARTI, B. & SHARMA, S. K. 2012. Broad and potent neutralization of 
HIV-1 by a gp41-specific human antibody. Nature, 491, 406-412. 
HUNT, P. W. 2009. Natural control of HIV-1 replication and long-term nonprogression: overlapping but 
distinct phenotypes. The Journal of infectious diseases, 200, 1636-1638. 
IWASAKI, A. 2016. Exploiting mucosal immunity for antiviral vaccines. Annual Review of Immunology, 34, 
575-608. 
IWASAKI, A. & MEDZHITOV, R. 2010. Regulation of adaptive immunity by the innate immune system. 
Science, 327, 291-295. 
JIN, X., BAUER, D. E., TUTTLETON, S. E., LEWIN, S., GETTIE, A., BLANCHARD, J., IRWIN, C. E., 
SAFRIT, J. T., MITTLER, J. & WEINBERGER, L. 1999. Dramatic rise in plasma viremia after CD8+ 
T cell depletion in simian immunodeficiency virus–infected macaques. Journal of Experimental 
Medicine, 189, 991-998. 
JOGLEKAR, A., LAMOTHE, P. A., OUYANG, Y., LIU, Z., WALKER, B. D. & BALTIMORE, D. 2016. Role 
of T cell receptors in suppressing HIV infection in elite controllers. The Journal of Immunology, 196, 
79.10-79.10. 
JOHNSTON, M. I. & FAUCI, A. S. 2011. HIV vaccine development—improving on natural immunity. New 




JONES, R. B. & WALKER, B. D. 2016. HIV-specific CD8^ sup+^ T cells and HIV eradication. Journal of 
Clinical Investigation, 126, 455. 
JONGWE, T. I. 2015. Construction and evaluation of three candidate vaccines expressing HIV-1 subtype-
C mosaic Gag. University of Cape Town. 
JORDAN, P. & WEBBE, G. 1993. Human schistosomiasis. In: JORDAN P, W. G., STURROCK R, EDS 
(ed.) Epidemiology. Wallingford, UK: CAB International. 
JOSEPH, S., QUINN, K., GREENWOOD, A., COPE, A. V., MCKAY, P. F., HAYES, P. J., KOPYCINSKI, J. 
T., GILMOUR, J., MILLER, A. N. & GELDMACHER, C. 2017. A comparative phase I study of 
combination, homologous subtype-C DNA, MVA and Env gp140 protein/adjuvant HIV vaccines in 
two immunisation regimes. Frontiers in Immunology, 8, 149. 
JOYCE, K. L., MORGAN, W., GREENBERG, R. & NAIR, M. G. 2012. Using eggs from Schistosoma 
mansoni as an in vivo model of helminth-induced lung inflammation. JoVE (Journal of Visualized 
Experiments), e3905-e3905. 
KALLESTRUP, P., ZINYAMA, R., GOMO, E., BUTTERWORTH, A. E., VAN DAM, G. J., GERSTOFT, J., 
ERIKSTRUP, C. & ULLUM, H. 2006. Schistosomiasis and HIV in rural Zimbabwe: efficacy of 
treatment of schistosomiasis in individuals with HIV coinfection. Clinical Infectious Diseases, 42, 
1781-1789. 
KAMAL, S. & EL SAYED KHALIFA, K. 2006. Immune modulation by helminthic infections: worms and viral 
infections. Parasite Immunology, 28, 483-496. 
KARP, C. L. & AUWAERTER, P. G. 2007. Coinfection with HIV and tropical infectious diseases. II. 
Helminthic, fungal, bacterial, and viral pathogens. Clinical Infectious Diseases, 45, 1214-1220. 
KAUL, R., MCKINNON, L., GELMON, L., ARTHOS, J., BLOCK, K., NYANGA, B., KIMANI, J., HUIBNER, 
S., CHEGE, D. & IZULLA, P. 2011. Characterization of a human cervical CD4+ T cell subset 
coexpressing multiple markers of HIV susceptibility. The Journal of Immunology, 187, pp.6032-
6042. 
KEELE, B. F., GIORGI, E. E., SALAZAR-GONZALEZ, J. F., DECKER, J. M., PHAM, K. T., SALAZAR, M. 
G., SUN, C., GRAYSON, T., WANG, S. & LI, H. 2008. Identification and characterization of 
transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the 
National Academy of Sciences, 105, 7552-7557. 
KEELE, B. F., VAN HEUVERSWYN, F., LI, Y., BAILES, E., TAKEHISA, J., SANTIAGO, M. L., BIBOLLET-
RUCHE, F., CHEN, Y., WAIN, L. V., LIEGEOIS, F., LOUL, S., NGOLE, E. M., BIENVENUE, Y., 
DELAPORTE, E., BROOKFIELD, J. F., SHARP, P. M., SHAW, G. M., PEETERS, M. & HAHN, B. 
H. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science, 313, 523-526. 
KEMENY, D. M., NOBLE, A., HOLMES, B. J. & DIAZ-SANCHEZ, D. 1994. Immune regulation: a new role 
for the CD8+ T cell. Immunology Today, 15, 107-110. 
KILIAN, H. & NIELSEN, G. 1989. Cell-mediated and humoral immune responses to BCG and rubella 
vaccinations and to recall antigens in onchocerciasis patients. Tropical medicine and parasitology: 
official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur 
Technische Zusammenarbeit (GTZ), 40, 445-453. 
KILLIAN, M. S., JOHNSON, C., TEQUE, F., FUJIMURA, S. & LEVY, J. A. 2011. Natural suppression of 
human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. 
Journal of Virology, 85, 1696-1705. 
KILLIAN, M. S., TEQUE, F., WALKER, R. L., MELTZER, P. S. & KILLIAN, J. K. 2013. CD8+ Lymphocytes 
Suppress Human Immunodeficiency Virus 1 Replication by Secreting Type I Interferons. Journal of 
Interferon & Cytokine Research, 33, 632-645. 
KIM, C., NAZLI, A., ROJAS, O., CHEGE, D., ALIDINA, Z., HUIBNER, S., MUJIB, S., BENKO, E., KOVACS, 
C. & SHIN, L. 2012. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal 
immunopathogenesis. Mucosal Immunology, 5, 670-680. 
KIM, J. H., EXCLER, J.-L. & MICHAEL, N. L. 2015. Lessons from the RV144 Thai phase III HIV-1 vaccine 
trial and the search for correlates of protection. Annual review of medicine, 66, 423-437. 
KJETLAND, E. F., NDHLOVU, P. D., GOMO, E., MDULUZA, T., MIDZI, N., GWANZURA, L., MASON, P. 
R., SANDVIK, L., FRIIS, H. & GUNDERSEN, S. G. 2006. Association between genital 
schistosomiasis and HIV in rural Zimbabwean women. AIDS, 20, 593-600. 
KLEIN, M. R., VAN BAALEN, C. A., HOLWERDA, A. M., GARDE, S. K., BENDE, R., KEET, I., EEFTINCK-
SCHATTENKERK, J.-K., OSTERHAUS, A., SCHUITEMAKER, H. & MIEDEMA, F. 1995. Kinetics 




longitudinal analysis of rapid progressors and long-term asymptomatics. Journal of Experimental 
Medicine, 181, 1365-1372. 
KLEPPA, E., RAMSURAN, V., ZULU, S., KARLSEN, G. H., BERE, A., PASSMORE, J.-A. S., NDHLOVU, 
P., LILLEBØ, K., HOLMEN, S. D. & ONSRUD, M. 2014. Effect of female genital schistosomiasis 
and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female 
genital tract. PloS one, 9, e98593. 
KORBER, B., GASCHEN, B., YUSIM, K., THAKALLAPALLY, R., KESMIR, C. & DETOURS, V. 2001. 
Evolutionary and immunological implications of contemporary HIV-1 variation. British Medical 
Bulletin, 58, 19-42. 
KORBER, B., HRABER, P., WAGH, K. & HAHN, B. H. 2017. Polyvalent vaccine approaches to combat 
HIV‐1 diversity. Immunological Reviews, 275, 230-244. 
KOUP, R., SAFRIT, J. T., CAO, Y., ANDREWS, C. A., MCLEOD, G., BORKOWSKY, W., FARTHING, C. 
& HO, D. D. 1994. Temporal association of cellular immune responses with the initial control of 
viremia in primary human immunodeficiency virus type 1 syndrome. Journal of Virology, 68, 4650-
4655. 
KOUP, R. A. & DOUEK, D. C. 2011. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harbor 
perspectives in medicine, 1, a007252. 
KOYASU, S., MORO, K., TANABE, M. & TAKEUCHI, T. 2010. 2 Natural Helper Cells: A New Player in the 
Innate Immune Response against Helminth Infection. Advances in Immunology, 108, 21. 
KROIDL, I., SAATHOFF, E., MAGANGA, L., MAKUNDE, W. H., HOERAUF, A., GELDMACHER, C., 
CLOWES, P., MABOKO, L. & HOELSCHER, M. 2016. Effect of Wuchereria bancrofti infection on 
HIV incidence in southwest Tanzania: a prospective cohort study. The Lancet, 388, 1912-1920. 
KRZYCH, U., DALAI, S., ZARLING, S. N. & PICHUGIN, A. V. 2012. Memory CD8 T cells specific for 
plasmodia liver-stage antigens maintain protracted protection against malaria. Frontiers in 
immunology, 3, 370. 
KULLBERG, M. C., PEARCE, E., HIENY, S., SHER, A. & BERZOFSKY, J. 1992. Infection with 
Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. Journal of 
Immunology, 148, 3264-3270. 
KURITZKES, D. R., WALKER, B. D. 2007. HIV-1: Pathogenesis, Clinical Manifestations, and Treatment. 
In: D. M. KNIPE, H., P. M., GRIFFIN, D. E., LAMB, R. & A., M., M. A., ROIZMAN, B., STRAUS, S. 
E. (eds.) Fields Virology. 5 ed. Lippincott Williams & Wilkins, Philadelphia. 
LA FLAMME, A. C., SCOTT, P. & PEARCE, E. J. 2002. Schistosomiasis delays lesion resolution during 
Leishmania major infection by impairing parasite killing by macrophages. Parasite Immunology, 24, 
339-345. 
LABEAUD, A. D., MALHOTRA, I., KING, M. J., KING, C. L. & KING, C. H. 2009. Do antenatal parasite 
infections devalue childhood vaccination? PLoS neglected tropical diseases, 3, e442. 
LAM, V. C. & LANIER, L. L. 2017. NK cells in host responses to viral infections. Current Opinion in 
Immunology, 44, 43-51. 
LAMBERTUCCI, J. 1993. Acute schistosomiasis: clinical, diagnostic and therapeutic features. Revista do 
Instituto de Medicina Tropical de São Paulo, 35, 399-404. 
LANDAIS, E., HUANG, X., HAVENAR-DAUGHTON, C., MURRELL, B., PRICE, M. A., 
WICKRAMASINGHE, L., RAMOS, A., BIAN, C. B., SIMEK, M. & ALLEN, S. 2016. Broadly 
neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. 
PLoS Pathogens, 12, e1005369. 
LANE, H. C., MASUR, H., EDGAR, L. C., WHALEN, G., ROOK, A. H. & FAUCI, A. S. 1983. Abnormalities 
of B-cell activation and immunoregulation in patients with the acquired immunodeficiency 
syndrome. New England Journal of Medicine, 309, 453-458. 
LANKOWSKI, A. J., TSAI, A. C., KANYESIGYE, M., BWANA, M., HABERER, J. E., WENGER, M., 
MARTIN, J. N., BANGSBERG, D. R., HUNT, P. W. & SIEDNER, M. J. 2014. Empiric deworming 
and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy. PLOS Neglected 
Tropical Disease, 8, e3036. 
LANZAVECCHIA, A. & SALLUSTO, F. 2005. Understanding the generation and function of memory T cell 
subsets. Current Opinion in Immunology, 17, 326-332. 
LAWSON, J. R. & WILSON, R. 1980. The survival of the cercariae of Schistosoma mansoni in relation to 




LAYLAND, L. E., MAGES, J., LODDENKEMPER, C., HOERAUF, A., WAGNER, H., LANG, R. & DA 
COSTA, C. U. P. 2010. Pronounced phenotype in activated regulatory T cells during a chronic 
helminth infection. The Journal of Immunology, 184, 713-724. 
LAYLAND, L. E., WAGNER, H. & DA COSTA, C. U. 2005. Lack of antigen-specific Th1 response alters 
granuloma formation and composition in Schistosoma mansoni-infected MyD88-/- mice. European 
Journal of Immunology, 35, 3248-3257. 
LEFEBVRE, J. S. & HAYNES, L. 2013. Vaccine strategies to enhance immune responses in the aged. 
Current Opinion in Immunology, 25, 523-528. 
LEFRANÇOIS, L. 2002. Dual personality of memory T cells. Trends in Immunology, 23, 226-228. 
LEMPICKI, R. A., KOVACS, J. A., BASELER, M. W., ADELSBERGER, J. W., DEWAR, R. L., NATARAJAN, 
V., BOSCHE, M. C., METCALF, J. A., STEVENS, R. A. & LAMBERT, L. A. 2000. Impact of HIV-1 
infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover 
in HIV-infected patients. Proceedings of the National Academy of Sciences, 97, 13778-13783. 
LETVIN, N. L. 2006. Progress and obstacles in the development of an AIDS vaccine. Nature Reviews 
Immunology, 6, 930-939. 
LETVIN, N. L., RAO, S. S., MONTEFIORI, D. C., SEAMAN, M. S., SUN, Y., LIM, S.-Y., YEH, W. W., 
ASMAL, M., GELMAN, R. S. & SHEN, L. 2011. Immune and genetic correlates of vaccine protection 
against mucosal infection by SIV in monkeys. Science translational medicine, 3, 81ra36-81ra36. 
LEVESQUE, M. C., MOODY, M. A., HWANG, K.-K., MARSHALL, D. J., WHITESIDES, J. F., AMOS, J. D., 
GURLEY, T. C., ALLGOOD, S., HAYNES, B. B. & VANDERGRIFT, N. A. 2009. Polyclonal B cell 
differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 
infection. PLoS Med, 6, e1000107. 
LIAN, Y., SRIVASTAVA, I., GÓMEZ-ROMÁN, V. R., ZUR MEGEDE, J., SUN, Y., KAN, E., HILT, S., 
ENGELBRECHT, S., HIMATHONGKHAM, S. & LUCIW, P. A. 2005. Evaluation of envelope 
vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 
strain. Journal of Virology, 79, 13338-13349. 
LIAO, H.-X., CHEN, X., MUNSHAW, S., ZHANG, R., MARSHALL, D. J., VANDERGRIFT, N., 
WHITESIDES, J. F., LU, X., YU, J.-S. & HWANG, K.-K. 2011. Initial antibodies binding to HIV-1 
gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental 
Medicine, jem. 20110363. 
LICHTENBERG, F. 1964. Studies on granuloma formation: III. Antigen sequestration and destruction in the 
schistosome pseudotubercle. The American journal of pathology, 45, 75. 
LIN, L., FINAK, G., USHEY, K., SESHADRI, C., HAWN, T. R., FRAHM, N., SCRIBA, T. J., MAHOMED, H., 
HANEKOM, W. & BART, P.-A. 2015. COMPASS identifies T-cell subsets correlated with clinical 
outcomes. Nature Biotechnology, 33, 610-616. 
LIU, R., PAXTON, W. A., CHOE, S., CERADINI, D., MARTIN, S. R., HORUK, R., MACDONALD, M. E., 
STUHLMANN, H., KOUP, R. A. & LANDAU, N. R. 1996. Homozygous defect in HIV-1 coreceptor 
accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367-377. 
LÓPEZ, M., SORIANO, V., PERIS-PERTUSA, A., RALLÓN, N., RESTREPO, C. & BENITO, J. M. 2011. 
Elite controllers display higher activation on central memory CD8 T cells than HIV patients 
successfully on HAART. AIDS Research and Human Retroviruses, 27, 157-165. 
LOWERY, E. M., BRUBAKER, A. L., KUHLMANN, E. & KOVACS, E. J. 2013. The aging lung. Clinical 
interventions in aging, 8. 
LU, S. 2009. Heterologous prime–boost vaccination. Current Opinion in Immunology, 21, 346-351. 
LUNDIE, R. J., WEBB, L. M., MARLEY, A. K., PHYTHIAN-ADAMS, A. T., COOK, P. C., JACKSON-JONES, 
L. H., BROWN, S., MAIZELS, R. M., BOON, L., O'KEEFFE, M. & MACDONALD, A. S. 2015. A 
central role for hepatic conventional dendritic cells in supporting Th2 responses during helminth 
infection. Immunology and Cell Biology, 94, pp.400-410. 
LUNDY, S. K. & LUKACS, N. W. 2013. Chronic schistosome infection leads to modulation of granuloma 
formation and systemic immune suppression. Frontiers in immunology, 4. 
LUO, B., SUN, J., CAI, R., SHEN, Y., LIU, L., WANG, J., ZHANG, R., SHEN, J. & LU, H. 2016. Spectrum 
of Opportunistic Infections and Risk Factors for In-Hospital Mortality of Admitted AIDS Patients in 
Shanghai. Medicine, 95. 
LUSTIGMAN, S., PRICHARD, R. K., GAZZINELLI, A., GRANT, W. N., BOATIN, B. A., MCCARTHY, J. S. 
& BASANEZ, M. G. 2012. A research agenda for helminth diseases of humans: the problem of 




MAARTENS, G., CELUM, C. & LEWIN, S. R. 2014. HIV infection: epidemiology, pathogenesis, treatment, 
and prevention. The Lancet, 384, 258-271. 
MACDONALD, A. S., ARAUJO, M. I. & PEARCE, E. J. 2002. Immunology of parasitic helminth infections. 
Infection and Immunity, 70, 427-433. 
MACEDONIA, J. & MOSIMANN, J. 1994. Kinetics of egg production and egg excretion by Schistosoma 
mansoni and S. japonicum in mice infected with a single pair of worms. American Journal of 
Tropical Medicine and Hygiene, 50, 281. 
MAGALHÃES, A., MIRANDA, D. G., MIRANDA, R. G., ARAÚJO, M. I., JESUS, A. A. D., SILVA, A., 
SANTANA, L. B., PEARCE, E., CARVALHO, E. M. & JESUS, A. R. D. 2004. Cytokine profile 
associated with human chronic schistosomiasis mansoni. Memorias do Instituto Oswaldo Cruz, 99, 
21-26. 
MAIZELS, R. & YAZDANBAKHSH, M. 2008. T-cell regulation in helminth parasite infections: implications 
for inflammatory diseases. T Cell Regulation in Allergy, Asthma and Atopic Skin Diseases. Karger 
Publishers. 
MAIZELS, R. M., BALIC, A., GOMEZ‐ESCOBAR, N., NAIR, M., TAYLOR, M. D. & ALLEN, J. E. 2004. 
Helminth parasites–masters of regulation. Immunological Reviews, 201, 89-116. 
MAIZELS, R. M. & MCSORLEY, H. J. 2016. Regulation of the host immune system by helminth parasites. 
Journal of Allergy and Clinical Immunology, 138, 666-675. 
MAIZELS, R. M. & YAZDANBAKHSH, M. 2003. Immune regulation by helminth parasites: cellular and 
molecular mechanisms. Nature Reviews: Immunology, 3, 733-744. 
MALHOTRA, I., MCKIBBEN, M., MUNGAI, P., MCKIBBEN, E., WANG, X., SUTHERLAND, L. J., MUCHIRI, 
E. M., KING, C. H., KING, C. L. & LABEAUD, A. D. 2015. Effect of antenatal parasitic infections on 
anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya. PLOS Neglected 
Tropical Disease, 9, e0003466. 
MARCONI, V. C., SUNPATH, H., LU, Z., GORDON, M., KORANTENG-APEAGYEI, K., HAMPTON, J., 
CARPENTER, S., GIDDY, J., ROSS, D. & HOLST, H. 2008. Prevalence of HIV-1 drug resistance 
after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 
Clinical Infectious Diseases, 46, 1589-1597. 
MARLINK, R., KANKI, P., THIOR, I., TRAVERS, K., EISEN, G., SIBY, T., TRAORE, I., HSIEH, C. C., DIA, 
M. C., GUEYE, E. H. & ET AL. 1994. Reduced rate of disease development after HIV-2 infection 
as compared to HIV-1. Science, 265, 1587-1590. 
MASCOLA, J. R. & MONTEFIORI, D. C. 2009. The role of antibodies in HIV vaccines. Annual Review of 
Immunology, 28, 413-444. 
MASCOLA, J. R., STIEGLER, G., VANCOTT, T. C., KATINGER, H., CARPENTER, C. B., HANSON, C. E., 
BEARY, H., HAYES, D., FRANKEL, S. S. & BIRX, D. L. 2000. Protection of macaques against 
vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing 
antibodies. Nature Medicine, 6, 207-210. 
MATA, M. & PATERSON, Y. 1999. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria 
monocytogenes vaccine are similar to those induced by endogenous listerial antigens. The Journal 
of Immunology, 163, 1449-1456. 
MATA, M., TRAVERS, P. J., LIU, Q., FRANKEL, F. R. & PATERSON, Y. 1998. The MHC class I-restricted 
immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a 
predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and 
pocket D. The Journal of Immunology, 161, 2985-2993. 
MATA, M., YAO, Z.-J., ZUBAIR, A., SYRES, K. & PATERSON, Y. 2001. Evaluation of a recombinant 
Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge. 
Vaccine, 19, 1435-1445. 
MAYER, K. H., KARP, C. L. & AUWAERTER, P. G. 2007. Coinfection with HIV and tropical infectious 
diseases. II. Helminthic, fungal, bacterial, and viral pathogens. Clinical Infectious Diseases, 45, 
1214-1220. 
MBABAZI, P. S., ANDAN, O., FITZGERALD, D. W., CHITSULO, L., ENGELS, D. & DOWNS, J. A. 2011. 
Examining the relationship between urogenital schistosomiasis and HIV infection. PLOS Neglected 
Tropical Disease, 5, e1396. 
MCCUNE, J. M., HANLEY, M. B., CESAR, D., HALVORSEN, R., HOH, R., SCHMIDT, D., WIEDER, E., 
DEEKS, S., SILER, S. & NEESE, R. 2000. Factors influencing T-cell turnover in HIV-1–seropositive 




MCDONALD, J. H. 2009. Handbook of biological statistics, Sparky House Publishing Baltimore, MD. 
MCKEE, A. S. & PEARCE, E. J. 2004. CD25+CD4+ cells contribute to Th2 polarization during helminth 
infection by suppressing Th1 response development. Journal of Immunology, 173, 1224-1231. 
MCKINSTRY, K. K., STRUTT, T. M. & SWAIN, S. L. 2010. The potential of CD4 T‐cell memory. 
Immunology, 130, 1-9. 
MCMICHAEL, A. J., BORROW, P., TOMARAS, G. D., GOONETILLEKE, N. & HAYNES, B. F. 2010. The 
immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews 
Immunology, 10, 11-23. 
MCMICHAEL, A. J. & KOFF, W. C. 2014. Vaccines that stimulate T cell immunity to HIV-1: the next step. 
Nature Immunology, 15, 319-322. 
MCSORLEY, H. J. & MAIZELS, R. M. 2012. Helminth infections and host immune regulation. Clinical 
Microbiology Reviews, 25, 585-608. 
MEANS, A. R., BURNS, P., SINCLAIR, D. & WALSON, J. L. 2016. Antihelminthics in helminth‐endemic 
areas: effects on HIV disease progression. The Cochrane Library. 
MIKELL, I., SATHER, D. N., KALAMS, S. A., ALTFELD, M., ALTER, G. & STAMATATOS, L. 2011. 
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog, 7, 
e1001251. 
MISHRA, P., PALMA, M., BLEICH, D., LOKE, P. & GAUSE, W. 2014. Systemic impact of intestinal helminth 
infections. Mucosal Immunology, 7, 753-762. 
MITCHELL, G. 1990. Immunopathology of schistosomiasis. Reviews in Medical Microbiology, 1, 101-107. 
MIYAUCHI, K., KIM, Y., LATINOVIC, O., MOROZOV, V. & MELIKYAN, G. B. 2009. HIV enters cells via 
endocytosis and dynamin-dependent fusion with endosomes. Cell, 137, 433-444. 
MOHRI, H., BONHOEFFER, S., MONARD, S., PERELSON, A. S. & HO, D. D. 1998. Rapid turnover of T 
lymphocytes in SIV-infected rhesus macaques. Science, 279, 1223-1227. 
MOIR, S., CHUN, T.-W. & FAUCI, A. S. 2011. Pathogenic Mechanisms of HIV Disease*. Annual Review of 
Pathology: Mechanisms of Disease, 6, 223-248. 
MOIR, S. & FAUCI, A. S. 2017. B‐cell responses to HIV infection. Immunological Reviews, 275, 33-48. 
MONTEFIORI, D. C., KARNASUTA, C., HUANG, Y., AHMED, H., GILBERT, P., DE SOUZA, M. S., 
MCLINDEN, R., TOVANABUTRA, S., LAURENCE-CHENINE, A., SANDERS-BUELL, E., MOODY, 
M. A., BONSIGNORI, M., OCHSENBAUER, C., KAPPES, J., TANG, H., GREENE, K., GAO, H., 
LABRANCHE, C. C., ANDREWS, C., POLONIS, V. R., RERKS-NGARM, S., PITISUTTITHUM, P., 
NITAYAPHAN, S., KAEWKUNGWAL, J., SELF, S. G., BERMAN, P. W., FRANCIS, D., SINANGIL, 
F., LEE, C., TARTAGLIA, J., ROBB, M. L., HAYNES, B. F., MICHAEL, N. L. & KIM, J. H. 2012. 
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 
vaccine efficacy trials. Journal of Infectious Diseases, 206, 431-441. 
MOORE, R. D. & CHAISSON, R. E. 1996. Natural history of opportunistic disease in an HIV-infected urban 
clinical cohort. Annals of Internal Medicine, 124, 633-642. 
MOORTHY, V. S. & BALLOU, W. R. 2009. Immunological mechanisms underlying protection mediated by 
RTS, S: a review of the available data. Malaria journal, 8, 1. 
MOREAU, E. & CHAUVIN, A. 2010. Immunity against helminths: interactions with the host and the 
intercurrent infections. BioMed Research International, 2010. 
MOREIN, B., ABUSUGRA, I. & BLOMQVIST, G. 2002. Immunity in neonates. Veterinary Immunology and 
Immunopathology, 87, 207-213. 
MOREIN, B., BLOMQVIST, G. & HU, K. 2007. Immune responsiveness in the neonatal period. Journal of 
comparative pathology, 137, S27-S31. 
MUDD, P. A., MARTINS, M. A., ERICSEN, A. J., TULLY, D. C., POWER, K. A., BEAN, A. T., PIASKOWSKI, 
S. M., DUAN, L., SEESE, A. & GLADDEN, A. D. 2012. Vaccine-induced CD8+ T cells control AIDS 
virus replication. Nature, 491, 129-133. 
MULU, A., ANAGAW, B., GELAW, A., OTA, F., KASSU, A. & YIFRU, S. 2015. Effect of deworming on Th2 
immune response during HIV-helminths co-infection. Journal of translational medicine, 13, 236. 
MUNIZ-JUNQUEIRA, M. I., TAVARES-NETO, J., PRATA, A. & TOSTA, C. E. 1996. Antibody response to 
Salmonella typhi lw human Schistosomiasis mansoni. Revista da Sociedade Brasileira de Medicina 
Tropical, 29, 441-445. 
MURPHY, K. 2011. Aneway's Immunobiology (Immunobiology: The Immune System (Janeway)) 8th 
(eighth) Edition By Murphy. 




N'GORAN, E., UTZINGER, J., N'GUESSAN, A., MÜLLER, I., ZAMBLÉ, K., LOHOURIGNON, K., TRAORÉ, 
M., SOSTHÈNE, B., LENGELER, C. & TANNER, M. 2001. Reinfection with Schistosoma 
haematobium following school‐based chemotherapy with praziquantel in four highly endemic 
villages in Côte d’Ivoire. Tropical medicine & international health, 6, 817-825. 
NAHLEN, B. L., CHU, S. Y., NWANYANWU, O. C., BERKELMAN, R. L., MARTINEZ, S. A. & RULLAN, J. 
V. 1993. HIV wasting syndrome in the United States. AIDS, 7, 183-188. 
NAIR, M. G., DU, Y., PERRIGOUE, J. G., ZAPH, C., TAYLOR, J. J., GOLDSCHMIDT, M., SWAIN, G. P., 
YANCOPOULOS, G. D., VALENZUELA, D. M. & MURPHY, A. 2009. Alternatively activated 
macrophage-derived RELM-α is a negative regulator of type 2 inflammation in the lung. The Journal 
of experimental medicine, 206, 937-952. 
NDEFFO MBAH, M. L., POOLMAN, E. M., DRAIN, P. K., COFFEE, M. P., WERF, M. J. & GALVANI, A. P. 
2013. HIV and Schistosoma haematobium prevalences correlate in sub‐Saharan Africa. Tropical 
medicine & international health, 18, 1174-1179. 
NDHLOVU, Z. M., KAMYA, P., MEWALAL, N., KLØVERPRIS, H. N., NKOSI, T., PRETORIUS, K., LAHER, 
F., OGUNSHOLA, F., CHOPERA, D. & SHEKHAR, K. 2015. Magnitude and kinetics of CD8+ T cell 
activation during hyperacute HIV infection impact viral set point. Immunity, 43, 591-604. 
NDLOVU, H. H. 2013. Investigating the role of CD28 costimulation and IL-4/IL-13 responsive myeloid and 
lymphoid cells during helminth infections in mice. University of Cape Town. 
NIAID. 2012. HIV Overview [Online]. Available: http://www.niaid.nih.gov/ [Accessed 02 March 2017 2017]. 
NIAID. 2013. Mini-Summit on Adenovirus Platforms for HIV Vaccines [Online]. Available: 
https://www.niaid.nih.gov/diseases-conditions/hivaids [Accessed 04 July 2017 2017]. 
NITAYAPHAN, S., PITISUTTITHUM, P., KARNASUTA, C., EAMSILA, C., DE SOUZA, M., MORGAN, P., 
POLONIS, V., BENENSON, M., VANCOTT, T. & RATTO-KIM, S. 2004. Safety and immunogenicity 
of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. Journal 
of Infectious Diseases, 190, 702-706. 
NOEL, N., PEÑA, R., DAVID, A., AVETTAND-FENOEL, V., ERKIZIA, I., JIMENEZ, E., LECUROUX, C., 
ROUZIOUX, C., BOUFASSA, F. & PANCINO, G. 2016. Long-term spontaneous control of HIV-1 is 
related to low frequency of infected cells and inefficient viral reactivation. Journal of Virology, 90, 
6148-6158. 
NOTO, A. & PANTALEO, G. 2017. B-cell abnormalities and impact on antibody response in HIV infection. 
Current Opinion HIV AIDS. 
NUTMAN, T. B., KUMARASWAMI, V. & OTTESEN, E. A. 1987. Parasite-specific anergy in human filariasis. 
Insights after analysis of parasite antigen-driven lymphokine production. Journal of Clinical 
Investigation, 79, 1516. 
NYAKUNDI, R. K., NYAMONGO, O., MAAMUN, J., AKINYI, M., MULEI, I., FARAH, I. O., GRIMBERG, B., 
HAU, J., MALHOTRA, I. & OZWARA, H. 2016. Protective effect of chronic schistosomiasis in 
baboons coinfected with Schistosoma mansoni and Plasmodium knowlesi. Infection and immunity, 
84, 1320-1330. 
NYE, K. & PARKIN, J. 2003. HIV and AIDS, Garland Science. 
O'BRIEN, S. J. & NELSON, G. W. 2004. Human genes that limit AIDS. Nature Genetics, 36, 565-574. 
O'CONNELL, K. A., HEGARTY, R. W., SILICIANO, R. F. & BLANKSON, J. N. 2011. Viral suppression of 
multiple escape mutants by de novo CD8+ T cell responses in a human immunodeficiency virus-1 
infected elite suppressor. Retrovirology, 8, 1. 
OBUKU, A. E., ASIKI, G., ABAASA, A., SSONKO, I., HARARI, A., VAN DAM, G. J., CORSTJENS, P. L., 
JOLOBA, M., DING, S. & MPENDO, J. 2016. Effect of Schistosoma mansoni Infection on Innate 
and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk. AIDS 
Research and Human Retroviruses, 32, 668-675. 
OKOYE, A. A. & PICKER, L. J. 2013. CD4+ T‐cell depletion in HIV infection: mechanisms of immunological 
failure. Immunological Reviews, 254, 54-64. 
OLIVEIRA, R. F. & ANDRADE, Z. A. 2001. Worm load and septal fibrosis of the liver in Capillaria hepatica-
infected rats. Memorias do Instituto Oswaldo Cruz, 96, 1001-1003. 
ORGANIZATION, W. H. 2010. Antiretroviral therapy of HIV infection in infants and children: towards 
universal access: recommendations for a public health approach-2010 revision, World Health 
Organization. 
ORTIZ, M. R., SCHREIBER, F., BENITEZ, S., BRONCANO, N., CHICO, M. E., VACA, M., ALEXANDER, 




trichuriasis on cytokine production and gene expression in human blood: a cross-sectional study. 
PLOS Neglected Tropical Disease, 5, e1157. 
PANTALEO, G. & KOUP, R. A. 2004. Correlates of immune protection in HIV-1 infection: what we know, 
what we don't know, what we should know. Nature Medicine, 10, 806-810. 
PASTORET, P.-P. 2007. Challenges and issues of early life vaccination in animals and humans. Journal 
of comparative pathology, 137, S2-S3. 
PEARCE, E. 2005. Priming of the immune response by schistosome eggs. Parasite Immunology, 27, 265-
270. 
PEARCE, E. J. 2016. Th2 Cell Responses in Immunity and Inflammation Following Helminth Infection. The 
Th2 Type Immune Response in Health and Disease. Springer. 
PEARCE, E. J., CASPAR, P., GRZYCH, J. M., LEWIS, F. A. & SHER, A. 1991. Downregulation of Th1 
cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma 
mansoni. Journal of Experimental Medicine, 173, 159-166. 
PEARCE, E. J. & MACDONALD, A. S. 2002. The immunobiology of schistosomiasis. Nature Reviews: 
Immunology, 2, 499-511. 
PEETERS, M., COURGNAUD, V., ABELA, B., AUZEL, P., POURRUT, X., BIBOLLET-RUCHE, F., LOUL, 
S., LIEGEOIS, F., BUTEL, C., KOULAGNA, D., MPOUDI-NGOLE, E., SHAW, G. M., HAHN, B. H. 
& DELAPORTE, E. 2002. Risk to human health from a plethora of simian immunodeficiency viruses 
in primate bushmeat. Emerging Infectious Diseases, 8, 451-457. 
PERREAU, M., LEVY, Y. & PANTALEO, G. 2013. Immune response to HIV. Current Opinion HIV AIDS, 8, 
333-340. 
PERRIGOUE, J. G., LI, J., ZAPH, C., GOLDSCHMIDT, M., SCOTT, P., DE SAUVAGE, F. J., PEARCE, E. 
J., GHILARDI, N. & ARTIS, D. 2007. IL-31–IL-31R interactions negatively regulate type 2 
inflammation in the lung. The Journal of experimental medicine, 204, 481-487. 
PERRIN, P. & PHILLIPS, S. 1989. The molecular basis of granuloma formation in schistosomiasis. III. In 
vivo effects of a T cell-derived suppressor effector factor and IL-2 on granuloma formation. The 
Journal of Immunology, 143, 649-654. 
PIANTADOSI, A., PANTELEEFF, D., BLISH, C. A., BAETEN, J. M., JAOKO, W., MCCLELLAND, R. S. & 
OVERBAUGH, J. 2009. Breadth of neutralizing antibody response to human immunodeficiency 
virus type 1 is affected by factors early in infection but does not influence disease progression. 
Journal of Virology, 83, 10269-10274. 
PICHICHERO, M. E. 2014. Challenges in vaccination of neonates, infants and young children. Vaccine, 32, 
3886-3894. 
PIESSENS, W., RATIWAYANTO, S., PIESSENS, P., TUTI, S., MCGREEVY, P., DARWIS, F., PALMIERI, 
J., KOIMAN, I. & DENNIS, D. 1981. Effect of treatment with diethylcarbamazine on immune 
responses to filarial antigens in patients infected with Brugia malayi. Acta Tropica, 38, 227-234. 
PITISUTTITHUM, P., GILBERT, P., GURWITH, M., HEYWARD, W., MARTIN, M., VAN GRIENSVEN, F., 
HU, D. & TAPPERO, J. W. 2006. Randomized, double‐blind, placebo‐controlled efficacy trial of a 
bivalent recombinant glycoprotein 120 HIV‐1 vaccine among injection drug users in Bangkok, 
Thailand. Journal of Infectious Diseases, 194, 1661-1671. 
PLOTKIN, S. A. 2008. Correlates of vaccine-induced immunity. Clinical Infectious Diseases, 47, 401-409. 
PLOTKIN, S. A. 2010. Correlates of protection induced by vaccination. Clinical and Vaccine Immunology, 
17, 1055-1065. 
PLOTKIN, S. A. 2013. Complex correlates of protection after vaccination. Clinical Infectious Diseases, 56, 
1458-1465. 
POLLARA, J., BONSIGNORI, M., MOODY, M. A., LIU, P., ALAM, S. M., HWANG, K. K., GURLEY, T. C., 
KOZINK, D. M., ARMAND, L. C., MARSHALL, D. J., WHITESIDES, J. F., KAEWKUNGWAL, J., 
NITAYAPHAN, S., PITISUTTITHUM, P., RERKS-NGARM, S., ROBB, M. L., O'CONNELL, R. J., 
KIM, J. H., MICHAEL, N. L., MONTEFIORI, D. C., TOMARAS, G. D., LIAO, H. X., HAYNES, B. F. 
& FERRARI, G. 2014. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for 
increased antiviral activities. Journal of Virology, 88, 7715-7726. 
POLLARA, J., HART, L., BREWER, F., PICKERAL, J., PACKARD, B. Z., HOXIE, J. A., KOMORIYA, A., 
OCHSENBAUER, C., KAPPES, J. C. & ROEDERER, M. 2011. High‐throughput quantitative 





POPE, M. & HAASE, A. T. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent 
infection. Nature Medicine, 9, 847-852. 
POPPER, S. J., SARR, A. D., TRAVERS, K. U., GUEYE-NDIAYE, A., MBOUP, S., ESSEX, M. E. & KANKI, 
P. J. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in 
pathogenicity of HIV-1 and HIV-2. Journal of Infectious Diseases, 180, 1116-1121. 
PRENDERGAST, A., PRADO, J. G., KANG, Y.-H., CHEN, F., RIDDELL, L. A., LUZZI, G., GOULDER, P. 
& KLENERMAN, P. 2010. HIV-1 infection is characterized by profound depletion of CD161+ Th17 
cells and gradual decline in regulatory T cells. AIDS, 24, 491-502. 
PRENDERGAST, C. T., SANIN, D. E., COOK, P. C. & MOUNTFORD, A. P. 2015. CD4+ T cell 
hyporesponsiveness after repeated exposure to Schistosoma mansoni larvae is dependent upon 
interleukin-10. Infection and Immunity, 83, 1418-1430. 
PROST, A., SCHLUMBERGER, M. & FAYET, M. 1983. Response to tetanus immunization in 
onchocerciasis patients. Annals of Tropical Medicine & Parasitology, 77, 83-85. 
PULLAN, R. L., SMITH, J. L., JASRASARIA, R. & BROOKER, S. J. 2014. Global numbers of infection and 
disease burden of soil transmitted helminth infections in 2010. Parasit Vectors, 7, 37. 
QUILLAY, H., EL COSTA, H., DURIEZ, M., MARLIN, R., CANNOU, C., MADEC, Y., TRUCHIS, C., 
RAHMATI, M., BARRÉ-SINOUSSI, F. & NUGEYRE, M. 2016. NK cells control HIV‐1 infection of 
macrophages through soluble factors and cellular contacts in the human decidua. Retrovirology, 
13, 39. 
RAFFATELLU, M., SANTOS, R. L., VERHOEVEN, D. E., GEORGE, M. D., WILSON, R. P., WINTER, S. 
E., GODINEZ, I., SANKARAN, S., PAIXAO, T. A. & GORDON, M. A. 2008. Simian 
immunodeficiency virus–induced mucosal interleukin-17 deficiency promotes Salmonella 
dissemination from the gut. Nature Medicine, 14, 421-428. 
RANASINGHE, S., SOGHOIAN, D. Z., LINDQVIST, M., GHEBREMICHAEL, M., DONAGHEY, F., 
CARRINGTON, M., SEAMAN, M. S., KAUFMANN, D. E., WALKER, B. D. & PORICHIS, F. 2016. 
HIV-1 antibody neutralization breadth is associated with enhanced HIV-specific CD4+ T cell 
responses. Journal of Virology, 90, 2208-2220. 
RAPPUOLI, R. 2011. The challenge of developing universal vaccines. F1000 Med Rep, 3, 16. 
REEVES, J. D. & DOMS, R. W. 2002. Human immunodeficiency virus type 2. Journal of General Virology, 
83, 1253-1265. 
REHWINKEL, J. 2014. Mouse knockout models for HIV-1 restriction factors. Cellular and Molecular Life 
Sciences, 71, 3749-3766. 
REMOUÉ, F., ROGERIE, F., GALLISSOT, M.-C., GUYATT, H. L., NEYRINCK, J.-L., DIAKKHATE, M.-M., 
NIANG, M., BUTTERWORTH, A. E., AURIAULT, C. & CAPRON, A. 2000. Sex-dependent 
neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human 
populations. Journal of Infectious Diseases, 181, 1855-1859. 
RERKS-NGARM, S., PITISUTTITHUM, P., NITAYAPHAN, S., KAEWKUNGWAL, J., CHIU, J., PARIS, R., 
PREMSRI, N., NAMWAT, C., DE SOUZA, M. & ADAMS, E. 2009. Vaccination with ALVAC and 
AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 361, 2209-
2220. 
RICHMAN, D. D., WRIN, T., LITTLE, S. J. & PETROPOULOS, C. J. 2003. Rapid evolution of the 
neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of 
Sciences, 100, 4144-4149. 
RINER, D. K., NDOMBI, E. M., CARTER, J. M., OMONDI, A., KITTUR, N., KAVERE, E., KORIR, H. K., 
FLAHERTY, B., KARANJA, D. & COLLEY, D. G. 2016. Schistosoma mansoni Infection Can 
Jeopardize the Duration of Protective Levels of Antibody Responses to Immunizations against 
Hepatitis B and Tetanus Toxoid. PLoS neglected tropical diseases, 10, e0005180. 
ROBERTSON, D. L., ANDERSON, J. P., BRADAC, J. A., CARR, J. K., FOLEY, B., FUNKHOUSER, R. K., 
GAO, F., HAHN, B. H., KALISH, M. L., KUIKEN, C., LEARN, G. H., LEITNER, T., MCCUTCHAN, 
F., OSMANOV, S., PEETERS, M., PIENIAZEK, D., SALMINEN, M., SHARP, P. M., WOLINSKY, 
S. & KORBER, B. 2000. HIV-1 nomenclature proposal. Science, 288, 55-56. 
ROMIEU, I., MARLINK, R., KANKI, P., M'BOUP, S. & ESSEX, M. 1990. HIV-2 link to AIDS in West Africa. 
Journal of Acquired Immune Deficiency Syndromes, 3, 220-230. 
ROWLAND-JONES, S. L. & WHITTLE, H. C. 2007. Out of Africa: what can we learn from HIV-2 about 




ROYCE, R. A., SENA, A., CATES, W., JR. & COHEN, M. S. 1997. Sexual transmission of HIV. The New 
England Journal of Medicine, 336, 1072-1078. 
RUBBERT A, B. G., OSTROWSKI M. 2011. HIV Book In, Hamburg, Germany. 
RUMBLEY, C. A. & PHILLIPS, S. M. 1999. The schistosome granuloma: an immunoregulatory organelle. 
Microbes and Infection, 1, 499-504. 
RUSTAGI, A. & GALE, M. 2014. Innate antiviral immune signaling, viral evasion and modulation by HIV-1. 
Journal of Molecular Biology, 426, 1161-1177. 
RUTITZKY, L. I., HERNANDEZ, H. J. & STADECKER, M. J. 2001. Th1-polarizing immunization with egg 
antigens correlates with severe exacerbation of immunopathology and death in schistosome 
infection. Proceedings of the National Academy of Sciences, 98, 13243-13248. 
SABIN, E. A., ARAUJO, M. I., CARVALHO, E. M. & PEARCE, E. J. 1996. Impairment of tetanus toxoid-
specific Thl-like immune responses in humans infected with Schistosoma mansoni. Journal of 
Infectious Diseases, 173, 269-272. 
SAENZ, S. A., NOTI, M. & ARTIS, D. 2010. Innate immune cell populations function as initiators and 
effectors in Th2 cytokine responses. Trends in Immunology, 31, 407-413. 
SÁEZ‐CIRIÓN, A. & PANCINO, G. 2013. HIV controllers: a genetically determined or inducible phenotype? 
Immunological Reviews, 254, 281-294. 
SAFRIT, J. T., FAST, P. E., GIEBER, L., KUIPERS, H., DEAN, H. J. & KOFF, W. C. 2016. Status of vaccine 
research and development of vaccines for HIV-1. Vaccine, 34, 2921-2925. 
SAGAR, M. 2014. Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. Journal 
of Infectious Diseases, 210, S667-S673. 
SALGAME, P., YAP, G. S. & GAUSE, W. C. 2013. Effect of helminth-induced immunity on infections with 
microbial pathogens. Nature Immunology, 14, 1118-1126. 
SANDLER, N. G., MENTINK-KANE, M. M., CHEEVER, A. W. & WYNN, T. A. 2003. Global gene expression 
profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and 
Th2 responses in tissue repair. The Journal of Immunology, 171, 3655-3667. 
SANDOR, M., WEINSTOCK, J. V. & WYNN, T. A. 2003. Granulomas in schistosome and mycobacterial 
infections: a model of local immune responses. Trends in Immunology, 24, 44-52. 
SANT, A. J. & MCMICHAEL, A. 2012. Revealing the role of CD4+ T cells in viral immunity. Journal of 
Experimental Medicine, 209, 1391-1395. 
SANYA, R. E., MUHANGI, L., NAMPIJJA, M., NANNOZI, V., NAKAWUNGU, P. K., ABAYO, E., WEBB, E. 
L. & ELLIOTT, A. M. 2015. Schistosoma mansoni and HIV infection in a Ugandan population with 
high HIV and helminth prevalence. Tropical medicine & international health, 20, 1201-1208. 
SARTONO, E., KRUIZE, Y. C., KURNIAWAN, A., VAN DER MEIDE, P. H., PARTONO, F., MAIZELS, R. 
M. & YAZDANBAKHSH, M. 1995. Elevated cellular immune responses and interferon-γ release 
after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis. Journal of 
Infectious Diseases, 171, 1683-1687. 
SARZOTTI-KELSOE, M., BAILER, R. T., TURK, E., LIN, C.-L., BILSKA, M., GREENE, K. M., GAO, H., 
TODD, C. A., OZAKI, D. A. & SEAMAN, M. S. 2014. Optimization and validation of the TZM-bl 
assay for standardized assessments of neutralizing antibodies against HIV-1. Journal of 
Immunological Methods, 409, 131-146. 
SCHENKEL, J. M. & MASOPUST, D. 2014. Tissue-resident memory T cells. Immunity, 41, 886-897. 
SCHENTEN, D. & MEDZHITOV, R. 2011. 3 The Control of Adaptive Immune Responses by the Innate 
Immune System. Advances in Immunology, 109, 87. 
SCHIFFNER, T., SATTENTAU, Q. J. & DUNCAN, C. J. 2013. Cell-to-cell spread of HIV-1 and evasion of 
neutralizing antibodies. Vaccine, 31, 5789-5797. 
SCHMITZ, J. E., KURODA, M. J., SANTRA, S., SASSEVILLE, V. G., SIMON, M. A., LIFTON, M. A., RACZ, 
P., TENNER-RACZ, K., DALESANDRO, M. & SCALLON, B. J. 1999. Control of viremia in simian 
immunodeficiency virus infection by CD8+ lymphocytes. Science, 283, 857-860. 
SCHOLZ, J. L., DIAZ, A., RILEY, R. L., CANCRO, M. P. & FRASCA, D. 2013. A comparative review of 
aging and B cell function in mice and humans. Current Opinion in Immunology, 25, 504-510. 
SHAHEEN, A. A., EBEID, F. A. & FAHIM, A. 1989. Effect of praziquantel on some aspects of carbohydrate 
metabolism in mice infected with Schistosoma mansoni. Pharmacological Research, 21, 263-270. 
SHARP, P. M. & HAHN, B. H. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harbor 




SHAW, A. C., GOLDSTEIN, D. R. & MONTGOMERY, R. R. 2013. Age-dependent dysregulation of innate 
immunity. Nature Reviews Immunology, 13, 875-887. 
SHAW, G. M. & HUNTER, E. 2012. HIV transmission. Cold Spring Harbor perspectives in medicine, 2, 
a006965. 
SHEN, Y.-J. 2010. An investigation into the Use of Lumpy Skin Disease Virus as a Vaccine Vector for a 
Potential HIV-1 vaccine. 
SHEPHARD, E., BURGERS, W. A., VAN HARMELEN, J. H., MONROE, J. E., GREENHALGH, T., 
WILLIAMSON, C. & WILLIAMSON, A. L. 2008. A multigene HIV type 1 subtype C modified vaccinia 
Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS 
Research and Human Retroviruses, 24, 207-217. 
SHIVER, J. W., FU, T.-M., CHEN, L., CASIMIRO, D. R., DAVIES, M.-E., EVANS, R. K., ZHANG, Z.-Q., 
SIMON, A. J., TRIGONA, W. L. & DUBEY, S. A. 2002. Replication-incompetent adenoviral vaccine 
vector elicits effective anti-immunodeficiency-virus immunity. Nature, 415, 331-335. 
SHOLLENBERGER, L. M., BUI, C., PATERSON, Y., ALLEN, K. & HARN, D. 2013a. Successful vaccination 
of immune suppressed recipients using Listeria vector HIV-1 vaccines in helminth infected mice. 
Vaccine, 31, 2050-2056. 
SHOLLENBERGER, L. M., BUI, C. T., PATERSON, Y., NYHOFF, L. & HARN, D. A. 2013b. HIV-1 vaccine-
specific responses induced by Listeria vector vaccines are maintained in mice subsequently 
infected with a model helminth parasite, Schistosoma mansoni. Vaccine, 31, 5651-5658. 
SHUM, K.-T., ZHOU, J. & ROSSI, J. J. 2013. Aptamer-based therapeutics: new approaches to combat 
human viral diseases. Pharmaceuticals, 6, 1507-1542. 
SIEGEL, M. O. & SIMON, G. L. 2012. Is human immunodeficiency virus infection a risk factor for 
Strongyloides stercoralis hyperinfection and dissemination. PLOS Neglected Tropical Disease., 6, 
e1581. 
SIEGRIST, C.-A. 2007. The challenges of vaccine responses in early life: selected examples. Journal of 
comparative pathology, 137, S4-S9. 
SIGALOFF, K. C., HAMERS, R. L., WALLIS, C. L., KITYO, C., SIWALE, M., IVE, P., BOTES, M. E., 
MANDALIYA, K., WELLINGTON, M. & OSIBOGUN, A. 2011. Unnecessary antiretroviral treatment 
switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in 
Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58, 23-31. 
SILICIANO, J. D., KAJDAS, J., FINZI, D., QUINN, T. C., CHADWICK, K., MARGOLICK, J. B., KOVACS, 
C., GANGE, S. J. & SILICIANO, R. F. 2003. Long-term follow-up studies confirm the stability of the 
latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine, 9, 727-728. 
SILVA, L. M., FERNANDES, A. L., BARBOSA JR, A., OLIVEIRA, I. R. & ANDRADE, Z. A. 2000. 
Significance of schistosomal granuloma modulation. Memorias do Instituto Oswaldo Cruz, 95, 353-
361. 
SIMON, V., BLOCH, N. & LANDAU, N. R. 2015. Intrinsic host restrictions to HIV-1 and mechanisms of viral 
escape. Nature Immunology, 16, 546-553. 
SIMON, V., HO, D. D. & KARIM, Q. A. 2006. HIV/AIDS epidemiology, pathogenesis, prevention, and 
treatment. Lancet, 368, 489-504. 
SIMPSON, D. M. & TAGLIATI, M. 1994. Neurologic manifestations of HIV infection. Annals of Internal 
Medicine, 121, 769-785. 
SMALLS-MANTEY, A., DORIA-ROSE, N., KLEIN, R., PATAMAWENU, A., MIGUELES, S. A., KO, S.-Y., 
HALLAHAN, C. W., WONG, H., LIU, B. & YOU, L. 2012. Antibody-dependent cellular cytotoxicity 
against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG 
binding. Journal of virology, 86, 8672-8680. 
SNAPPER, C. M., MARCU, K. B. & ZELAZOWSKI, P. 1997. The immunoglobulin class switch: beyond 
“accessibility”. Immunity, 6, 217-223. 
SOUZA, A. L., ROFFÊ, E., PINHO, V., SOUZA, D. G., SILVA, A. F., RUSSO, R. C., GUABIRABA, R., 
PEREIRA, C. A., CARVALHO, F. M. & BARSANTE, M. M. 2005. Potential role of the chemokine 
macrophage inflammatory protein 1α in human and experimental schistosomiasis. Infection and 
Immunity, 73, 2515-2523. 
STANISIC, D. I., BARRY, A. E. & GOOD, M. F. 2013. Escaping the immune system: How the malaria 




STEINMANN, P., KEISER, J., BOS, R., TANNER, M. & UTZINGER, J. 2006. Schistosomiasis and water 
resources development: systematic review, meta-analysis, and estimates of people at risk. The 
Lancet infectious diseases, 6, 411-425. 
STELEKATI, E., SHIN, H., DOERING, T. A., DOLFI, D. V., ZIEGLER, C. G., BEITING, D. P., DAWSON, 
L., LIBOON, J., WOLSKI, D. & ALI, M.-A. A. 2014. Bystander chronic infection negatively impacts 
development of CD8+ T cell memory. Immunity, 40, 801-813. 
STEPHENSON, K. E., T D’COUTO, H. & BAROUCH, D. H. 2016. New concepts in HIV-1 vaccine 
development. Current Opinion in Immunology, 41, 39-46. 
STEWART, G., BOUSSINESQ, M., COULSON, T., ELSON, L., NUTMAN, T. & BRADLEY, J. 1999. 
Onchocerciasis modulates the immune response to mycobacterial antigens. Clinical and 
Experimental Immunology, 117, 517. 
STIEGLER, G., KUNERT, R., PURTSCHER, M., WOLBANK, S., VOGLAUER, R., STEINDL, F. & 
KATINGER, H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel 
epitope on gp41 of human immunodeficiency virus type 1. AIDS Research and Human 
Retroviruses, 17, 1757-1765. 
STOREY, H. L., SINGA, B., NAULIKHA, J., HORTON, H., RICHARDSON, B. A., JOHN-STEWART, G. & 
WALSON, J. L. 2017. Soil transmitted helminth infections are not associated with compromised 
antibody responses to previously administered measles and tetanus vaccines among HIV-1 
infected, ART naïve Kenyan adults. Parasite Epidemiology and Control. 
STURROCK, R. 1993. The parasites and their life cycles: Description of the adult schistosomes infecting 
man and other schistosomes which may parasitize man. In: JORDAN P, WEBBE G & STURROCK 
R, E. (eds.) Human schistosomiasis. Wallingford, UK: CAB 
International. 
SU, Z., SEGURA, M., MORGAN, K., LOREDO-OSTI, J. C. & STEVENSON, M. M. 2005. Impairment of 
protective immunity to blood-stage malaria by concurrent nematode infection. Infection and 
Immunity, 73, 3531-3539. 
SU, Z., SEGURA, M. & STEVENSON, M. M. 2006. Reduced protective efficacy of a blood-stage malaria 
vaccine by concurrent nematode infection. Infection and Immunity, 74, 2138-2144. 
SWAIN, S. L., MCKINSTRY, K. K. & STRUTT, T. M. 2012. Expanding roles for CD4+ T cells in immunity 
to viruses. Nature Reviews Immunology, 12, 136-148. 
TALLIMA, H. & EL RIDI, R. 2007. Praziquantel binds Schistosoma mansoni adult worm actin. International 
Journal of Antimicrobial Agents, 29, 570-575. 
TAYLOR-ROBINSON, A. W. 2002. Exoerythrocytic malaria vaccine development: understanding host–
parasite immunobiology underscores strategic success. Expert review of vaccines, 1, 317-340. 
THAKUR, A., PEDERSEN, L. E. & JUNGERSEN, G. 2012. Immune markers and correlates of protection 
for vaccine induced immune responses. Vaccine, 30, 4907-4920. 
THIÉBAUT, R., MATHERON, S., TAIEB, A., BRUN-VEZINET, F., CHÊNE, G., AUTRAN, B. & COHORT, 
I. G. O. T. A. C. H.-. 2011. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-
2 cohort. AIDS, 25, 865-867. 
THOMAS, P. G. & HARN, D. A. 2004. Immune biasing by helminth glycans. Cellular Microbiology, 6, 13-
22. 
TINDALL, B., BARKER, S., DONOVAN, B., BARNES, T., ROBERTS, J., KRONENBERG, C., GOLD, J., 
PENNY, R. & COOPER, D. 1988. Characterization of the acute clinical illness associated with 
human immunodeficiency virus infection. Arch Intern Med, 148, 945-949. 
TOMALKA, J., GHNEIM, K., BHATTACHARYYA, S., AID, M., BAROUCH, D. H., SEKALY, R. P. & 
RIBEIRO, S. P. 2016. The sooner the better: innate immunity as a path toward the HIV cure. 
Current Opinion in Virology, 19, 85-91. 
TOMARAS, G. D., BINLEY, J. M., GRAY, E. S., CROOKS, E. T., OSAWA, K., MOORE, P. L., TUMBA, N., 
TONG, T., SHEN, X. & YATES, N. L. 2011. Polyclonal B cell responses to conserved neutralization 
epitopes in a subset of HIV-1-infected individuals. Journal of Virology, 85, 11502-11519. 
TOMARAS, G. D. & PLOTKIN, S. A. 2017. Complex immune correlates of protection in HIV‐1 vaccine 
efficacy trials. Immunological Reviews, 275, 245-261. 
TOMARAS, G. D., YATES, N. L., LIU, P., QIN, L., FOUDA, G. G., CHAVEZ, L. L., DECAMP, A. C., PARKS, 
R. J., ASHLEY, V. C. & LUCAS, J. T. 2008. Initial B-cell responses to transmitted human 




by plasma anti-gp41 antibodies with ineffective control of initial viremia. Journal of Virology, 82, 
12449-12463. 
UNAIDS. 2014. The Gap Report [Online]. Available: 
http://www.unaids.org/en/resources/documents/2014/20140716_UNAIDS_gap_report [Accessed 
09 December 2016 2016]. 
UNAIDS. 2015. World AIDS Day 2015 Report - Fact Sheet [Online]. Available: 
http://www.unaids.org/en/resources/fact-sheet [Accessed 09 December 2016 2016]. 
UNAIDS. 2016. Global AIDS Update 2016 [Online]. Available: http://aidsinfo.unaids.org/ [Accessed 21 
February 2017]. 
UNICEF, U. & WHO 2011. Global HIV/AIDS response: epidemic update and health sector progress towards 
universal access: progress report 2011, World Health Organization. 
URBAN, J., FAYER, R., SULLIVAN, C., GOLDHILL, J., SHEA-DONOHUE, T., MADDEN, K., MORRIS, S., 
KATONA, I., GAUSE, W. & RUFF, M. 1996. Local TH1 and TH2 responses to parasitic infection in 
the intestine: regulation by IFN-gamma and IL-4. Veterinary Immunology and Immunopathology, 
54, 337-344. 
URBAN, J. F., SCHOPF, L., MORRIS, S. C., OREKHOVA, T., MADDEN, K. B., BETTS, C. J., GAMBLE, 
H. R., BYRD, C., DONALDSON, D. & ELSE, K. 2000. Stat6 signaling promotes protective immunity 
against Trichinella spiralis through a mast cell-and T cell-dependent mechanism. The Journal of 
Immunology, 164, 2046-2052. 
UTZINGER, J., BOOTH, M., N'GORAN, E., MÜLLER, I., TANNER, M. & LENGELER, C. 2001. Relative 
contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma 
mansoni before and after treatment with praziquantel. Parasitology, 122, 537-544. 
UTZINGER, J. & KEISER, J. 2004. Schistosomiasis and soil-transmitted helminthiasis: common drugs for 
treatment and control. Expert Opinion on Pharmacotherapy, 5, 263-285. 
VAN DEN BIGGELAAR, A. H., VAN REE, R., RODRIGUES, L. C., LELL, B., DEELDER, A. M., 
KREMSNER, P. G. & YAZDANBAKHSH, M. 2000. Decreased atopy in children infected with 
Schistosoma haematobium: a role for parasite-induced interleukin-10. The Lancet, 356, 1723-
1727. 
VAN DER WERF, M. J., DE VLAS, S. J., BROOKER, S., LOOMAN, C. W., NAGELKERKE, N. J., 
HABBEMA, J. D. F. & ENGELS, D. 2003. Quantification of clinical morbidity associated with 
schistosome infection in sub-Saharan Africa. Acta Tropica, 86, 125-139. 
VAN RIET, E., HARTGERS, F. C. & YAZDANBAKHSH, M. 2007. Chronic helminth infections induce 
immunomodulation: consequences and mechanisms. Immunobiology, 212, 475-490. 
VENNERVALD, B. J. & DUNNE, D. W. 2004. Morbidity in schistosomiasis: an update. Current Opinion in 
Infectious Diseases, 17, 439-447. 
VERKOCZY, L. & DIAZ, M. 2014. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for 
their function & induction by vaccination. Current Opinion HIV AIDS, 9, 224. 
VOEHRINGER, D., SHINKAI, K. & LOCKSLEY, R. M. 2004. Type 2 immunity reflects orchestrated 
recruitment of cells committed to IL-4 production. Immunity, 20, 267-277. 
VOSKOBOINIK, I., WHISSTOCK, J. C. & TRAPANI, J. A. 2015. Perforin and granzymes: function, 
dysfunction and human pathology. Nature Reviews Immunology, 15, 388-400. 
WAJJA, A., KIZITO, D., NASSANGA, B., NALWOGA, A., KABAGENYI, J., KIMUDA, S., GALIWANGO, R., 
MUTONYI, G., VERMAAK, S. & SATTI, I. 2017. The effect of current Schistosoma mansoni 
infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated 
adolescents: An open-label trial. PLOS Neglected Tropical Disease, 11, e0005440. 
WALGATE, R. 1986. AIDS research. New human retroviruses: one causes AIDS. Nature, 320, 385. 
WALKER, B. & MCMICHAEL, A. 2012. The T-cell response to HIV. Cold Spring Harb Perspect Med, 2. 
WALKER, L. M., SIMEK, M. D., PRIDDY, F., GACH, J. S., WAGNER, D., ZWICK, M. B., PHOGAT, S. K., 
POIGNARD, P. & BURTON, D. R. 2010. A limited number of antibody specificities mediate broad 
and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathogens, 6, 
e1001028. 
WALLIS, C. L., MELLORS, J. W., VENTER, W. D., SANNE, I. & STEVENS, W. 2010. Varied patterns of 
HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. JAIDS Journal of 
Acquired Immune Deficiency Syndromes, 53, 480-484. 
WALSON, J., SINGA, B., SANGARÉ, L., NAULIKHA, J., PIPER, B., RICHARDSON, B., OTIENO, P. A., 




disease progression in adults with HIV who are ineligible for initiation of antiretroviral treatment (the 
HEAT study): a multi-site, randomised trial. The Lancet infectious diseases, 12, 925-932. 
WALSON, J. L., HERRIN, B. R. & JOHN‐STEWART, G. 2009. Deworming helminth co‐infected individuals 
for delaying HIV disease progression. The Cochrane Library. 
WALSON, J. L., STEWART, B. T., SANGARE, L., MBOGO, L. W., OTIENO, P. A., PIPER, B. K., 
RICHARDSON, B. A. & JOHN-STEWART, G. 2010. Prevalence and correlates of helminth co-
infection in Kenyan HIV-1 infected adults. PLOS Neglected Tropical Disease, 4, e644. 
WAMMES, L. J., HAMID, F., WIRIA, A. E., DE GIER, B., SARTONO, E., MAIZELS, R. M., LUTY, A. J., 
FILLIÉ, Y., BRICE, G. T. & SUPALI, T. 2010. Regulatory T cells in human geohelminth infection 
suppress immune responses to BCG and Plasmodium falciparum. European Journal of 
Immunology, 40, 437-442. 
WANKE, C., SILVA, M., KNOX, T., FORRESTER, J., SPEIGELMAN, D. & GORBACH, S. 2000. Weight 
loss and wasting remain common complications in individuals infected with human 
immunodeficiency virus in the era of highly active antiretroviral therapy. Clinical Infectious 
Diseases, 31, 803-805. 
WEBB, E. L., EKII, A. O. & PALA, P. 2012. Epidemiology and immunology of helminth–HIV interactions. 
Current Opinion HIV AIDS, 7, 245-253. 
WEE, E. G., ONDONDO, B., BERGLUND, P., ARCHER, J., MCMICHAEL, A. J., BALTIMORE, D., TER 
MEULEN, J. H. & HANKE, T. 2017. HIV-1 Conserved Mosaics Delivered by Regimens with 
Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Molecular Therapy, 25. 
WEI, X., DECKER, J. M., WANG, S., HUI, H., KAPPES, J. C., WU, X., SALAZAR-GONZALEZ, J. F., 
SALAZAR, M. G., KILBY, J. M. & SAAG, M. S. 2003. Antibody neutralization and escape by HIV-
1. Nature, 422, 307-312. 
WEINSTOCK, J., SUMMERS, R. & ELLIOTT, D. 2004. Helminths and harmony. Gut, 53, 7-9. 
WHERRY, E. J. 2011. T cell exhaustion. Nature Immunology, 12, 492-499. 
WHO 2013. Global update on HIV treatment 2013: Results, impact and opportunities. Geneva, Switzerland. 
WHO. 2014. WHO Schistosomiasis: Fact Sheet No 115 [Online]. Available: 
http://www.who.int/mediacentre/factsheets/fs115/en/ [Accessed 15 May 2017 2017]. 
WHO. 2015. Factsheet [Online]. Available: http://www.who.int/mediacentre/factsheets/fs360/en/ [Accessed 
05 May 2016 2016]. 
WHO. 2016. Schistosomiasis Fact Sheet. [Online]. Available: 
http://www.who.int/mediacentre/factsheets/fs366/en/ [Accessed 16 Decemebr 2016 2017]. 
WHO & UNAIDS 2009. AIDS epidemic update: December 2009. WHO Regional Office Europe. 
WILLIAMSON, A. L., RYBIKI, E., SHEPHARD, E., GRAY, G., BEKKER, L. G., DOWNING, K. & 
WILLIAMSON, C. 2012. South African HIV-1 vaccine candidates - the journey from the bench to 
clinical trials. South African Medical Journal, 102, 452-455. 
WILSON, M. S., MENTINK-KANE, M. M., PESCE, J. T., RAMALINGAM, T. R., THOMPSON, R. & WYNN, 
T. A. 2007. Immunopathology of schistosomiasis. Immunology and Cell Biology, 85, 148-154. 
WIRTHS, S. & LANZAVECCHIA, A. 2005. ABCB1 transporter discriminates human resting naive B cells 
from cycling transitional and memory B cells. European Journal of Immunology, 35, 3433-3441. 
WONG, C. & GOLDSTEIN, D. R. 2013. Impact of aging on antigen presentation cell function of dendritic 
cells. Current Opinion in Immunology, 25, 535-541. 
WOROBEY, M., GEMMEL, M., TEUWEN, D. E., HASELKORN, T., KUNSTMAN, K., BUNCE, M., 
MUYEMBE, J. J., KABONGO, J. M., KALENGAYI, R. M., VAN MARCK, E., GILBERT, M. T. & 
WOLINSKY, S. M. 2008. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. 
Nature, 455, 661-664. 
WORRELL, C. M., WIEGAND, R. E., DAVIS, S. M., ODERO, K. O., BLACKSTOCK, A., CUÉLLAR, V. M., 
NJENGA, S. M., MONTGOMERY, J. M., ROY, S. L. & FOX, L. M. 2016. A cross-sectional study of 
water, sanitation, and hygiene-related risk factors for soil-transmitted helminth infection in urban 
school-and preschool-aged children in Kibera, Nairobi. PloS one, 11, e0150744. 
WYNN, T. A., ELTOUM, I., CHEEVER, A. W., LEWIS, F. A., GAUSE, W. C. & SHER, A. 1993. Analysis of 
cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma 
mansoni. Journal of Immunology, 151, 1430-1440. 
WYNN, T. A., ELTOUM, I., OSWALD, I. P., CHEEVER, A. W. & SHER, A. 1994. Endogenous interleukin 




IL-12 both inhibits and prophylactically immunizes against egg pathology. Journal of Experimental 
Medicine, 179, 1551-1561. 
WYNN, T. A., THOMPSON, R. W., CHEEVER, A. W. & MENTINK‐KANE, M. M. 2004. 
Immunopathogenesis of schistosomiasis. Immunological Reviews, 201, 156-167. 
XU, H., WANG, X. & VEAZEY, R. S. 2013. Mucosal immunology of HIV infection. Immunological Reviews, 
254, 10-33. 
YAN, J., SABBAJ, S., BANSAL, A., AMATYA, N., SHACKA, J. J., GOEPFERT, P. A. & HEATH, S. L. 2013. 
HIV-specific CD8+ T cells from elite controllers are primed for survival. Journal of Virology, 87, 
5170-5181. 
YANG, O. O., KALAMS, S. A., TROCHA, A., CAO, H., LUSTER, A., JOHNSON, R. P. & WALKER, B. D. 
1997. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence 
for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. Journal of Virology, 
71, 3120-3128. 
YATES, N. L., LIAO, H. X., FONG, Y., DECAMP, A., VANDERGRIFT, N. A., WILLIAMS, W. T., ALAM, S. 
M., FERRARI, G., YANG, Z. Y., SEATON, K. E., BERMAN, P. W., ALPERT, M. D., EVANS, D. T., 
O'CONNELL, R. J., FRANCIS, D., SINANGIL, F., LEE, C., NITAYAPHAN, S., RERKS-NGARM, 
S., KAEWKUNGWAL, J., PITISUTTITHUM, P., TARTAGLIA, J., PINTER, A., ZOLLA-PAZNER, S., 
GILBERT, P. B., NABEL, G. J., MICHAEL, N. L., KIM, J. H., MONTEFIORI, D. C., HAYNES, B. F. 
& TOMARAS, G. D. 2014. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection 
risk and declines soon after vaccination. Sci Transl Med, 6, 228ra239. 
YATES, N. L., LUCAS, J. T., NOLEN, T. L., VANDERGRIFT, N. A., SODERBERG, K. A., SEATON, K. E., 
DENNY, T. N., HAYNES, B. F., COHEN, M. S. & TOMARAS, G. D. 2011. Multiple HIV-1-specific 
IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. 
AIDS (London, England), 25, 2089. 
YIN, J., DAI, A., ARANGO, T., KASINATHAN, R. S., GREENBERG, R. M. & BOYER, J. D. 2012. IL-4 and 
IFN-gamma induced by human immunodeficiency virus vaccine in a schistosome infection model. 
Human vaccines & immunotherapeutics, 8, 1555-1563. 
ZACCONE, P., FEHERVARI, Z., PHILLIPS, J., DUNNE, D. & COOKE, A. 2006. Parasitic worms and 
inflammatory diseases. Parasite Immunology, 28, 515-523. 
ZARLING, S., BERENZON, D., DALAI, S., LIEPINSH, D., STEERS, N. & KRZYCH, U. 2013. The survival 
of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against 
malaria. The Journal of Immunology, 190, 5128-5141. 
ZHAO, K.-S., WANG, Y.-F., GUÉRET, R. & WEKSLER, M. E. 1995. Dysregulation of the humoral immune 
response in old mice. International Immunology, 7, 929-934. 
ZOLLA-PAZNER, S. 2014. A critical question for HIV vaccine development: Which antibodies to induce? 
Science, 345, 167-168. 
 
